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1. GENERAL  INTRODUCTION:  AETIOLOGY  OF  AD  
LZHEIMERS DISEASE is considered as a complex, progressive and 
irreversible neurodegenerative disease of the brain, and represents the most 
common form of dementia in the elderly population.  Emerging data 
demonstrate pivotal roles for brain insulin resistance and insulin deficiency as 
mediators of cognitive impairment and neurodegeneration, particularly AD.  In this 
context AD is increasingly being referred to as type of brain diabetes in which 
endogenous brain-specific impairments in insulin and Insulin like growth factor 
signalling account for the majority of AD-associated abnormalities. However, AD 
emerges from a complex background of genetic, psychological and environmental 
factors, all of which can influence its expression and development.  
 This introductory chapter has two principal aims.  The first is to set the general 
context by providing a review of the aetiology of AD, including its prevalence and 
incidence, genetics, clinical features, molecular pathology, diagnosis and treatment.  
When discussing the clinical manifestation of AD, special consideration will be given 
to examining the nature of memory loss in AD, as well as impairments related to 
behavioural disinhibition and anxiety as these form the context to specific experiments 
detailed in Chapter 3 of this thesis.  Indeed, understanding the memory deficits 
experienced by patients is essential to designing and assessing the efficacy of novel 
pharmaceuticals for the treatment of such impairments [1], one of the principal 
concerns addressed by this thesis.  Thus, the second aim is the take what may at first 
glance seem to be the jangling discords of AD aetiology, and relate them to the 
concept of AD as a metabolic disorder.  In this context, the focus of discussion revolves 
around recent attempts to use rosiglitazone (an insulin sensitizer) as a means of 
ameliorating cognitive (learning and memory) deficits, and similar deficits in 
preclinical animal models of select pathological components of AD. Indeed, of 
particular concern throughout this chapter is how the concept of AD as a metabolic 
disorder relates to the overproduction and aggregation of the amyloid-beta protein in 
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the context of the amyloid cascade hypothesis (ACH).  This is important because the 
ACH is still regarded as the dominant theory of AD causation, and as such, forms the 
basis for many preclinical treatments for AD, including the use of insulin sensitizers.  
In this way I hope to achieve a symphony of words that captures something of the 
immense and sprawling complexity that is AD.  I believe this to be the correct context 
within which to fully appreciate the specific experiments detailed in Chapters 3 and 4 
of this thesis.  These experiments test the hypothesis that rosiglitazone ameliorates 
specific behavioural and neuropathological deficits associated with a popular 
preclinical animal model of mutated Amyloid Precursor Protein, which is linked to a 
rare familial (inherited) form of AD in humans. Discussion of preclinical animal 
models in AD and the specific phenotypic alterations associated with the model used 
in experimental studies in this thesis is discussed in Chapter 2. Finally, Chapter 5 
provides a discussion of the main experimental findings from this thesis, and considers 
these in relation to the wider scientific literature. 
 
1.1 PREVALENCE  AND  INCIDENCE 
In 1906, the German physician Alois Alzheimer gave a seminal lecture to his peers in 
Tübingen, Germany on the first case of the neurodegenerative disease that Kraepelin 
some years later named Alzheimer’s disease (AD) [2, 3]. In this single case, Alzheimer 
described the results of his clinical observations and post-mortem studies on a 56-year-
old-female patient known as Auguste D, who at the age of 51 had been  admitted to the 
state asylum in Frankfurt suffering from memory and language deficits, auditory 
hallucinations, delusions, paranoia, and aggressive behaviour [4].  When Auguste D 
died in April 1906, her brain was sent to Alzheimer for examination where he duly 
observed an atrophic brain with striking neurofibrillary tangle (NFT) pathology, as well 
as the presence of unusual deposits in the cerebral cortex that were refractory to 
staining; now known as amyloid-beta plaques (Aβ-plaques).  In the following year, 
Alzheimer published his findings in a short paper that marked the start of our 
understanding of the disorder.  However, being exclusively associated with dementia 
before the age of 65 years (early-onset), a diagnosis of AD remained a relative rarity for 
many years after Alzheimer. In the early 1970’s the disorder was recognised as a major 
cause of dementia in those over the age of 60/65 years (late-onset), and  eventually, a 
diagnosis of AD was formally adopted in medical nomenclature to describe individuals, 
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of all ages who displayed a characteristic symptomatic pattern based on cognitive 
deficits typified by memory and language impairment [5].  Today this unitary concept 
of AD has fragmented into an increasing number of genetic and clinical subtypes.   
According to Alzheimer’s Disease International, nearly 36.5 million people 
worldwide had a form of dementia in 2010, with the overall predicted increase in 
prevalence over the next 30 decades estimated to reach approximately 66 million by 
2030, and then 115 million by 2050 [6].  Much of this increase is considered to reflect 
demographic ageing, a process that shows the successes of improved health care over 
the last century in many countries [7].  The fastest growth in the elderly population is 
taking place in low and middle income countries such as China, India, and their south 
Asian and western Pacific neighbours [7].  Because the prevalence of dementia doubles 
about every five years after age 65, and after age 85 the risk reaches nearly 50 %, it is 
estimated that there will be significant disparity in the regional prevalence of dementia 
by 2030, with developing regions showing a 40% increase, Europe, 63%, North 
America, between 77-146%, and in the different regions of Latin America, 107%, and 
Asia 111% increase [6].  Indeed, whilst approximately 58% of the world's dementia cases 
currently reside in these countries, by 2050, low and middle income countries are 
expected to account for 71% of the world’s prevalent dementia cases [6].  Currently the 
number of new dementia cases (i.e. its incidence), is estimated to be around 7.7 million 
annually [6], with this figure predicted to increase further as populations age.  About 
3.6 million (46%) of these new cases are expected to impact in Asia, 2.3 million (31%) in 
Europe, 1.2 million (16%) in the Americas, and 0.5 million (7%) in Africa [8, 9]. 
Although there are many different subtypes of dementia, AD is considered the most 
prevalent, accounting for between 60-80% or more of the total, with a greater 
proportion in the higher age ranges [10-12].  However, the pathological hallmarks 
belonging to more than one subtype can also be co-present within many patients, 
particularly those with advanced late-onset dementia, making mixed dementia fairly 
common in this population [13].  Most cases of mixed dementia still reflect the 
pathological hallmarks of AD together with vascular dementia [14].  Presently, the 
number of persons believed to have AD worldwide is approximately 26.6 million, with 
the overall prevalence of the condition predicted to quadruple in line with dementia 
generally, to 106.2 million by 2050 [15].  Currently, about 48% of all AD cases reside in 
low and middle income countries, most of which are set to see the largest increases in 
AD over the next several decades [6, 15].  Although AD is more common in women 
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than men in late-life, this is usually attributed to the longer lifespan of women 
compared to men [16]. Over 90% of AD cases are late-onset (LOAD), where the 
condition affects people over the age of 60-65 years [13]. Age appears to be the most 
influential risk factor for AD (and other dementias). The prevalence of AD increases 
exponentially with age, rising from 3% among those 65–74 years to almost 50% among 
those 85 years or older [17, 18].  
Less than 10% of cases AD are early-onset (EOAD), developing between the ages of 
30-60, or 65 years [19]. Approximately 60% of EOAD cases are classed as familial 
(EOFAD) [20].  Of these early-onset familial cases, approximately 13% are inherited in 
an autosomal dominant manner with at least three generations affected [21, 22]. 
Autosomal dominant AD is mostly associated with a number of single gene disorders 
involving specific point mutations or single base substitutions all of which are 
extremely rare and account for less than 1% of AD cases overall [23] (see section 1.1.2).  
Although there is evidence for genetic factors affecting disease risk in many 
Alzheimer’s cases [24], and first-degree relatives of patients with the late-onset disease 
have approximately twice the expected lifetime risk for developing AD, most cases are 
said to be of sporadic (SAD) origin because they are rarely consistent with a pattern of 
Mendelian transmission [25]. Rather, the risk of developing SAD appears to be 
modulated by an interaction between multiple risk factors, including age, 
susceptibility genes, and environmental factors [26, 27].   
 
1.2 GENETIC  DETERMINANTS  AND  RIS K  FAC TORS  
Three causative genes have been associated with autosomal dominant familial AD; the 
gene on chromosome 21 for the Amyloid Precursor Protein (APP) [28 , 29], and the 
genes on chromosome 14 and 1 for the Presenilin 1 and Presenilin 2 genes (PSEN1, and 
PSEN2 respectively)[30-32]. Within the APP gene there is a specific region which 
encodes the Aβ peptide, with mutations in this gene shown to alter the subsequent 
processing of Aβ or its propensity to undergo fibrillogenesis, leading to early 
deposition of the peptide and EOFAD  [29].  Mutations in the presenilin genes that 
cause EOFAD also lead to changes in Aβ processing and its deposition [29].  It has 
been hypothesised that presenilin protein comprises a key component of the catalytic 
site in γ-secretase [33], one of the protease enzymes involved in the production of Aβ, 
although this process is tightly gated by at least two other membrane proteins [34]. 
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Taken together these observations strongly support the hypothesis that the generation 
of Aβ is central to AD pathogenesis. Indeed, whilst the identification of specific genes 
related to autosomal dominant AD has only had a minimal impact clinically, in terms 
of basic research aimed at understanding underlying disease mechanisms, the 
identification of these mutations has had greater impact and led to the creation of the 
Amyloid Cascade Hypothesis (see section 1.6.1).  However, it should be said that 
kindreds with autosomal dominant AD have also been described with none of the 
point mutations associated with the above genes, indicating that other factors may be 
causally related to the disorder in some cases [35, 36].   There are also alternative 
theories of AD causation.  Thus, research has shown that familial APP mutations may 
confer a gain or loss of function that in the presence of trophic factor withdrawal, 
resulting in the amino-terminal fragment of APP (N-APP) binding to the Death 
Receptor-6 (DR6), the induction of caspase-6-dependent neuronal axon pruning,  
Wallerian degeneration and thus, neuron death [37]. Identification of mutated genes 
isolated from FAD kindreds has also enabled the development of various transgenic 
animal models [38-41].  Although none of the models fully replicates the full human 
disease [42], each has contributed significant insights into the pathophysiology of Aβ 
in AD, as well as the testing of pre-clinical therapies.   
 
1.2. 1 Production  and  Clear anc e  of  Aβ 
1.2.1.1 Production of Aβ 
Aβ derives from the Amyloid Precursor Protein (APP), a large transmembrane protein 
expressed in many tissues and concentrated in the synapses of neurons [43].  APP is 
found in most cell types, including neuronal and glial cells, and contains a large 
extracellular region, a single transmembrane domain, and a small cytoplasmic tail [44].  
Like other members of its protein family, APP can undergo regulated intra-membrane 
proteolysis by α, β and γ secretases to generate secreted and cytoplasmic fragments 
[43, 45].  However, only APP has a transmembrane Aβ forming region, allowing it to 
produce Aβ peptides [46].  APP is cleaved via two main pathways.  Cleavage of APP via 
α-secretase represents a non-amyloidogenic pathway, and involves APP being cleaved 
in the middle of its Aβ region to produce a soluble APP fragment (sAPPα) which has 
neuroprotective properties [47].  This process leaves a membrane-bound C-terminal 
fragment (C83), that can be further cleaved by the intra-membrane γ-secretase 
complex (of which the presenilins form key components to yield a 3-kDa Aβ fragment 
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(P3) [48].  Under normal circumstances this non-amyloidogenic pathway accounts for 
about 95% of APP processing [49].  In the amyloidogenic pathway, β-secretase 
provides the initial (potentially neurotoxic) cleavage of APP in its extracellular domain 
(N-terminus), which generates a non-amyloidogenic fragment (sAPPβ), and a 
membrane bound C-terminal fragment of 99 amino acids in length (C99). C99 is then 
susceptible to a second intra-membrane cleavage by γ-secretase, which generates the 
4-kDa Aβ peptide and an intracellular domain (AICD) product, both of which are 
released from the membrane into the cytosol [50, 51].  
In non-neuronal cells, α-secretase cleavage predominates whereas in neurons the β-
cleavage pathway predominates [52]. Depending on the point of cleavage by γ-
secretase, three principal forms of Aβ are produced that have a chain of 38, 40, or 42 
amino acid residues (Aβ38, Aβ40, and Aβ42, respectively).  This along with research 
showing that the production and release of Aβ into the extracellular space positively 
correlates with the level of neuronal and synaptic activity [53-56], suggests that brain 
Aβ may be largely neuronal in origin.  Furthermore, it has been suggested that synaptic 
vesicle recycling through coupled endoexocytosis may be the primary mechanism 
mediating the activity-dependent production and release of Aβ in the brain [54, 57].  
The relative amount of Aβ42 formed is noteworthy because it is far more prone than 
the more abundantly produced Aβ40 to aggregate, and form the insoluble amyloid 
protofibrils and fibrils common to some forms of senile plaque [58-60].  Aβ peptides 
are capable of aggregation and self-assemble into dimer, trimer and higher-order 
soluble oligomers [46, 60, 61] (also called ADLLs or "Aβ-derived diffusible ligands" 
[62]).  Soluble Aβ describes any form of Aβ that is soluble in aqueous buffer, and 
remains in solution following high speed centrifugation. Whilst the formation of Aβ 
oligomers has been extensively studied by using synthetic forms of Aβ, research 
relating to endogenous formation has been limited [60, 63-65].  Nevertheless, 
endogenous soluble Aβ is considered to have the same potential for forming different 
assembly species, which may be produced via different pathways [64, 66]. The 
mechanisms of formation may even differ between pathways [46].  If soluble 
aggregates are not degraded or cleared from the brain, they form the "seeds" from 
which Aβ-plaques develop [67, 68].  However, both APP and Aβ are normal 
constituents of many cells; they have been implicated in a number of important 
physiological roles in the periphery, and central nervous system (CNS). 
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Nominal  Funct ion of APP and Aβ 
APP functions as a receptor since its homologues bind both extracellular ligands and 
intracellular adaptor proteins [69].  Consequently, APP has been implicated as a 
regulator of synapse formation [70], a regulator of neural plasticity [71], and as a bona 
fide iron oxidase [72].  As a natural product of cellular metabolism, Aβ is present in the 
interstitial and cerebrospinal fluid (CSF) of humans throughout life [60], where its 
normal physiological role is uncertain.  However, several potential physiological 
activities have been suggested for Aβ, including the activation of kinase enzymes  
involved with phosphorylation processes [73, 74], (antioxidant) protection against 
oxidative stress [75, 76], regulation of cholesterol transport [77, 78], anti-microbial 
activity potentially associated with the peptides pro-inflammatory activity [79], and as 
a transcription factor for AD-associated genes [80], and apoptotic genes [81].  Although 
higher Aβ concentrations have been postulated to boost synaptic glutamate in the 
hippocampus [82, 83], it is not clear whether this effect can also occur at nominal 
physiological concentrations.  However, research suggests that in low concentrations, 
Aβ does enhance neuronal activity via its ability to act as a regulator of release 
probability at hippocampal synapses [84].  Indeed, research conducted in animals 
suggests that low doses of Aβ enhance memory retention in behavioural tasks (T-maze 
foot-shock avoidance), as well as the in vivo enhancement of acetylecholine 
production in the hippocampus [85].  Furthermore, at sub-nanomolar doses, Aβ 
markedly enhances Long Term Potentiation (LTP) in hippocampal slices [85, 86], with 
LTP being a cellular process that many consider to underpin memory consolidation 
[87].  However, higher concentrations of Aβ have the opposite effect; depressing LTP 
and promoting LTD or ‘Long Term Depression’ (see review, [50]).  
 
1.2.1.2 Clearance of Aβ 
At any given time the amount of Aβ in the brain is thought to be determined by the 
steady-state balance between its in vitro production and release, and its degradation 
and clearance [88].  The canonical view is that any chronic imbalance between its 
production and clearance will result in the accumulation of Aβ in the interstitial fluid 
(ISF) [89], and eventually its deposition in the brain parenchyma as senile plaques [49, 
88, 90, 91].  In terms of its in vitro degradation, several metallopeptidase protease 
enzymes have been implicated, the most important of which are probably neprilysin 
(NEP) [92], and insulin degrading enzyme (IDE) [92], both of which possess a zinc-
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binding motif.  NEP is the most dominant protease, and due to its presynaptic 
localization and extracellular position of its catalytic site [93, 94], may be the best 
candidate for regulating the amount of Aβ in the synaptic cleft.  NEP is capable of 
degrading monomeric and oligomeric forms of Aβ [95], and examination of human 
post-mortem tissue suggests that the expression of NEP is inversely related to the 
extent of AD pathology [96-98].   
IDE is the principle protease responsible for the clearance and inactivation of 
insulin, and as such is ubiquitously expressed in the body where it has a subcellular 
localization, being primarily located in the cytosol and peroxisomes [99-101].  The 
highest expression of IDE occurs in the liver, testes, muscle and brain [102], where in 
the latter it is found in multiple neurons, but particularly in neocortical pyramidal cells 
[103].  Structurally IDE is composed of four homologous domains which together 
resemble a clamshell-like arrangement enclosing a large central chamber for engulfing 
the substrate. Substrates must enter the chamber, and it is believed that a hinge-like 
conformational change allows substrate binding and product release [104]. IDE exists 
as an equilibrium mixture of monomers, dimers, and tetramers, with dimers thought 
to be the predominant and most active state [105, 106]. In addition to its central 
involvement in insulin metabolism, IDE degrades other small peptides, including 
glucagon [103], insulin-like growth factors I and II  (IGF1 and 2 respectively) [107], 
transforming growth factor alpha (TGF-α) [105], and in a non-selective manner, 
extracellular forms of monomeric Aβ [108, 109].  Nevertheless, IDE does not apparently 
metabolise Aβ dimers and trimers [109], and incubation of these secreted oligomeric 
species with the enzyme does not rescue the inhibition of synaptic plasticity [110].  
Furthermore, given its subcellular location, IDE would not appear to be appropriately 
placed to degrade monomeric Aβ.  However, a small but significant proportion of IDE 
is secreted from cells through an unconventional protein secretion pathway [111], and it 
is this component of IDE that is functional in relation to Aβ degradation where it 
appears to be routed via detergent-resistant membrane complexes into exosomes for 
secretion along with Aβ [112].  IDE is also unusual among zinc metallopeptidases in 
that it exhibits allosteric kinetic behaviour in which small peptide substrates such as 
Aβ may increase the activity of the enzyme toward the same or other small peptides 
[106].  Animal research has indicated that IDE expression responds to Aβ accumulation 
in the brain [113], and mice with a homozygous deletion of IDE have elevated 
endogenous brain Aβ [114, 115].  Indeed, in post-mortem tissue obtained from AD 
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patients, levels of neuronal IDE are reduced in the hippocampus [116, 117].  However, 
whilst in the cortex IDE protein levels normally diminish with of age, for unknown 
reasons, cortical IDE expression in AD is elevated [118].   
Aβ can be cleared from the brain parenchyma through the interstitial fluid and 
Virchow–Robin perivascular space, a space surrounding perforating arteries and veins 
that is considered to play the role of a lymphatic vessel [88] (see review [119]). Aβ also 
likely interacts with the low-density lipoprotein receptor-related protein (LRP) [119], or 
with P-glycoprotein [120] in order to cross the blood brain barrier (BBB).  There is also 
an efflux of Aβ from the blood into the cerebral parenchyma mediated by the receptor 
for advanced glycation end products (RAGE) [121].  In addition to these processes, glial 
cells may also have a role in clearing Aβ deposits from the brain (see section 1.5.4). 
 
1.2. 2 APP  Gene  Mutations  
Mutations within the APP gene on chromosome 21, account for 10-to-15% of EOFAD 
cases [35, 122], with several different missense mutations having been discovered in 
exons 16 and 17 [123]. All these mutations alter APP processing, Aβ production, or alter 
the propensity of Aβ to aggregate into β-sheet amyloid fibrils.  Missense mutations are 
often referred to as ‘point mutations’ because they involve a single nucleotide being 
changed, resulting in a codon that then codes for a different amino acid.  Examples of 
point mutations in the APP gene include the "Dutch" (E693Q) [124], London (V717I) 
[28], "Indiana" (V717F) [125], "Florida" (I716V) [126], "Iowa" (D694N) [127], "Arctic" 
(E693G) [128], and "Swedish" (K670N/M671L) mutations [129]. The Swedish mutation 
is located just outside the N-terminus of the Aβ domain of APP, it favours β-secretase 
cleavage in vitro [130], and is associated with an increased level and deposition of Aβ42 
in AD brains [131]. The Dutch and Iowa mutations are both located in the Aβ forming 
domain of APP, and accelerate Aβ40 fibril formation in vitro [132, 133].  Both these 
mutations are also associated with "cerebral amyloid angiopathy" (CAA), a condition 
associated with the deposition of Aβ in cerebral blood vessels and to a lesser extent, 
veins [134].  The Dutch APP mutation, in particular, is known to result in cerebral 
haemorrhages and dementia in patients with AD [124], whereas the Iowa mutation is 
associated with severe CAA and widespread NFT formation as well as an unusually 
extensive distribution of Aβ40 in Aβ-plaques in the AD brain [127]. The Arctic 
mutation is also located inside the Aβ domain, but makes APP less available to α-
secretase cleavage, and thus increases β-secretase processing of APP, favouring 
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intracellular Aβ production in vitro [135, 136]. Whilst this mutation is likewise 
associated with severe CAA, this is generally in the absence of cerebral haemorrhage, 
abundant parenchymal Aβ deposits, and NFTs [137].  The London mutation is located 
in the transmembrane domain of APP, altering γ-secretase cleavage to produce an 
increase in the level of Aβ42 and/or, the ratio of Aβ42/Aβ40 in vitro [138]. The London 
mutation is associated with extensive parenchymal Aβ deposition, moderate CAA, and 
abundant Aβ-plaques and NFTs in AD brain [139, 140].  Both the Indiana and Florida 
mutations are also located in the transmembrane domain of APP, with the former 
associated with mild CAA, and large numbers of NFT’s and Aβ-plaques in the AD brain 
[141], and the latter affecting γ-secretase cleavage causing an increased Aβ42 
concentration and Aβ42/Aβ40 ratio in vitro [126, 138].  In summary, mutations close to 
the β-secretase site enhance the production of both Aβ40 and Aβ42, whereas 
mutations close to the  α-secretase site result in impaired  α-secretase activity, an 
increase in γ-secretase activity, and thus, an increase in secreted Aβ [142]. Mutations 
next to the γ-secretase site lead to a selective increase in Aβ42 over the Aβ40.   
Additional evidence implicating the APP gene in the parthenogenesis of AD comes 
from the fact that nearly all those with Down syndrome (DS) develop the 
neuropathological hallmarks of AD after the age of 40 years, with more than half 
showing clinical evidence of cognitive decline [143].  The development of DS is caused 
by the presence of an extra copy of human chromosome 21 [144, 145], with the 
presumed association between DS and AD being the lifelong overexpression of the APP 
gene and thus the resultant overproduction of Aβ [20].  However, recent research 
suggests that people with DS are also trisomic (having three copies) for a gene that 
produces a protein called "Regulator of Calcineurin 1" (RCAN1), leading to excess 
production of this protein.  In DS this can initiate a chain reaction which results in the 
death of neurons in the hippocampus [146], leading to disrupted memory for events 
and autobiographical experiences, as well as impairments in spatial navigation [147-
149].  In addition to the loss of hippocampal neurons, RCAN1 also results in the loss of 
cortical neurones [146].  Despite only having the usual two copies of the RCAN1 gene, 
some AD patients also have elevated levels of the RCAN1 protein, perhaps in response 
to stroke or hypertension [150].  Although the mechanisms by which RCAN1 mediates 
its deleterious effects remain unclear, research has suggested a possible role in 
mitochondrial degradation [151].   
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1.2. 3 Presenilin  Gene  Mutations  
Over 176 different missense mutations in the PSEN1 gene have been identified in 
approximately 390 families with a familial history of AD [152], and represent the most 
common cause of EOFAD accounting for between 18 and 50% of all autosomal 
dominant cases [153]. Defects in the PSEN1 gene are known to cause the most severe 
forms of AD, with most mutations displaying complete penetrance and an age of onset 
around 30 years, but can be greater than 58 years [25].  By contrast, only 12 missense 
mutations have presently been identified in the PSEN2 gene [154], with these 
mutations being a rare cause of EOFAD [25].  Missense mutations in the PSEN2 gene 
may be of lower penetrance than those relating to PSEN1, with the former possibly 
being subject to the modifying action of additional genes or environmental influences 
[26, 155].  The clinical features of PSEN2-affected families appear to differ from the 
clinical features of PSEN1 in that the age of onset in PSEN2 family members is 
generally older than some family members with PSEN1 mutations, ranging from 45-to-
88 years [25].  Thus, a minority of late-onset cases appear to be associated with PSEN2 
mutations [156], a fact further supported by recent research showing that some genetic 
polymorphisms of the PSEN2 gene may confer an enhanced risk of sporadic AD [157]. 
PSEN genes are expressed mostly in neurones and glia; their exact function and role 
in AD is uncertain [25]. However, because both PSEN1 and PSEN2 genes encode for 
transmembrane presenilin proteins that form the major components of the atypical 
aspartyl protease complexes responsible for the γ-secretase cleavage of notch proteins 
and APP [158, 159], PSEN mutations are normally assumed to confer pathogenesis in 
AD by affecting the production of Aβ. For example, a gain of-function phenotype has 
been suggested with some PSEN1 mutations due to the observed increase in Aβ42 
production, accompanied or not, with reduced Aβ40 production, thereby leading to an 
increased Aβ42 vs. Aβ40 ratio in mice and humans  [160, 161].  Concordant with this, 
the deposition of Aβ42 in Aβ-plaques has been suggested to be an early preclinical 
event that occurs in PSEN1 mutation carriers [161].  However, it also appears that some 
disease-causing PSEN1 mutations do not increase production of Aβ42 or affect the 
production ratio of Aβ42/Aβ40 [162], suggesting that different PSEN1 mutations 
mediate pathological effects via Aβ-independent means.  Indeed, recent research using 
cell cultures has demonstrated that PSEN1 mutations associated with EOFAD can 
cause defective lysosomal proteolysis/autophagic function in fibroblasts  providing one 
possible mechanism by which the abnormal accumulation and deposition of proteins 
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can occur in the AD brain [163].  Additionally, PSEN1 mutation may introduce 
aberrations in the intracellular Ca2+ mobilization in astrocytes [164], possibly 
contributing to aberrant neural-glial communication in AD.  PSEN2 is expressed in a 
variety of tissues; in the brain, is expressed primarily in neurons [165]. The cause of 
pathogenesis in PSEN2 mutations is less clear, particularly since this presenilin protein 
is a less efficient producer of Aβ than PSEN1 [166].  However, although not well 
understood, PSEN2 mutations linked to EOFAD have been reported to modify the way 
in which γ-secretase processes APP, with some mutations having been linked to an 
increase in the rate of Aβ production [167].  Nevertheless, a truncated version of the 
PSEN2 protein derived from differentially spliced mRNA exons does not apparently 
affect the ratio of Aβ peptides produced [168].   
 
1.3 RI SK FACTORS  RELATE D TO SAD  
Although advancing age is the most significant risk-factor for SAD, the relationship 
between aging and disease risk remains unclear. Physiological function declines with 
aging, even among the most robust sectors of the older population, although the 
degree to which this decline is attributable to true biological factors or social or 
lifestyle factors that accompany older age is not entirely clear [169].  However, it is 
certainly true that there is substantial heterogeneity in patterns of aging [170].  That is, 
while many older people continue to show expected patterns of decline in health and 
functional ability with advancing age, others appear more resilient to various 
physiological (e.g., infection, neuropathology), emotional (e.g., bereavement), or 
environmental challenges [169].  Thus, in relation to dementia, it may not simply be 
the number of years lived that matters most, but rather a person’s resiliency in the face 
of various challenges or perturbations that act to bring about the dementia state 
sooner rather than later.  Indeed, the resilience argument seems to make sense of the 
perplexing observation that in aged individuals neuropathological examination has 
detected those in whom the microscopic features typically associated with AD are 
present, and yet a clinical history of dementia is absent.  In 2010 the U.S. National 
Institutes of Health (NIH) published an independent state-of-the-science conference 
report [171], which was aimed at providing healthcare providers, patients, and the 
public with an assessment of currently available data on prevention of AD and 
cognitive decline with age.  Amongst other things, this report included a systematic 
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review of the risk factors associated with cognitive decline and AD, with one of the 
main summary points being that that firm conclusions cannot be drawn about the 
association of any modifiable risk factor with cognitive decline or AD [171]. Current 
epidemiological views of AD regard age, family history of AD, and specific inheritable 
genetic factors as non-modifiable risk factors for dementia, whereas potentially 
modifiable factors include those related to cardiovascular disease (smoking, 
hypertension, diabetes, and obesity), lifestyle and psychosocial factors (depression, 
physical activity and alcohol consumption), and cognitive reserve (education and 
occupational attainment).  It is clear that mild cognitive impairment (MCI) also 
represents a risk factor for dementia, although the degree to which this entity 
represents a non-modifiable/modifiable risk factor is uncertain. 
 
1.3. 1 Genes  Associated  with  SAD  
In comparison with EOFAD, the genetic basis of LOAD appears more complex; 
probably because the aetiology of these cases depends on genetic susceptibility at 
multiple gene levels, as well as the interaction between these and the various non-
genetic risk factors already discussed (see reviews, [25, 26, 172]). Recently, genome-
wide association studies (GWAS) have had considerable successes in identifying a 
number of gene variants with single nucleotide polymorphisms (SNPs) that may 
increase the risk of developing LOAD. These include specific gene loci relating to 
"Clusterin" (CLU), "Phosphatidylinositol-binding clathrin assembly protein" 
(PICALM), and "Complement receptor 1" (CR1) [173, 174], as well as "bridging integrator 
1" (BIN1) [175].  All of these genes have been independently replicated by subsequent 
research confirming their status as risk modifier genes for LOAD [176-178].  However, 
all SNPs associated with these genes in the above studies have had small estimated 
effect sizes, with odds ratios reported in the range of 1.1 to 1.5 (with little overlap 
among studies).  Nevertheless, such odds ratios are likely to be inaccurate, and the true 
effects may be much smaller [179].  How the contributions of CLU, CR1 and PICALM 
loci potentially add up to AD in late life remains to be clarified, although current 
research supports existing hypotheses about the roles of Aβ, lipid, chaperone and 
chronic inflammatory pathways in AD pathogenesis (see review, [180]).  It is evident 
that scientists still know very little about the roles of many of these genes, including 
how they relate to AD.  For example, whilst BIN1 and PICALM have been implicated in 
APP processing and Aβ toxicity [180, 181], other studies have suggested a link with 
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tauopathy [182], although a recent study of biomarkers related to cerebrospinal fluid 
(CSF) Aβ42 fragments, and phospho-tau (the pathological state of tau), has failed to 
find a correlation with these biomarkers and gene variants [183].   
 
1.3.1.1 Apolipoprotein E Gene Polymorphisms 
Despite the continued successes of GWAS, only one gene, "apolipoprotein E" (APOE) 
on chromosome 19, has the unequivocal status of a "susceptibility" gene for LOAD in 
multiple patient populations [184-186].  APOE exists in three different isoforms 
(epsilon; 2, 3 and 4), with the frequencies of these three alleles being highly variable in 
different populations [187-189]. Carrying the APOEε4 allele is a risk factor for AD [190], 
and in particular LOAD [191-194], whereas the APOEε2 allele is associated with 
decreased risk [195].  Indeed, even within in the GWAS studies reported above, the 
association between APOEɛ4 and AD dominates the results [26].  Furthermore, even 
SNPs near the APOE gene had larger effect sizes in these studies compared to CLU, 
PICALM and CR1. Nevertheless, APOEɛ4 has incomplete lifetime penetrance, even in 
the highest-risk APOE genotypes [196], and the fraction of genetic variance for risk in 
LOAD attributed to APOE is estimated to be only 10 to 20% [197, 198].  Given that 
oligogenic segregation analyses (i.e. the prioritizing for whole-exome sequencing 
studies to identify families more likely to harbour rare variants), support the presence 
of at least 4 to 6 additional major genes [199, 200], it is likely that additional risk loci 
remain to be discovered.   
APOEε4 acts in a dose-dependent manner: carriers of two APOEε4 alleles have a 
higher risk and earlier onset of AD compared to heterozygous subjects [184, 186, 201, 
202]. However, whilst these studies help to explain some of the variation in the age at 
which AD develops, how APOE ε4 confers this risk is not known. APOE is one member 
of a family of proteins that help carry cholesterol and other types of fat in the 
bloodstream. Prevailing evidence suggests that the differential effects of APOE 
isoforms on the brain in AD are multifactorial, containing Aβ dependent, and 
independent effects (see review, [203]).  For example, it is evident that Aβ aggregation 
and clearance play the major role in AD pathogenesis. APOE colocalizes with 
parenchymal (brain) and vascular Aβ deposits, with numerous studies having 
demonstrated that it can physically interact with Aβ peptides in an isoform-specific 
manner, affecting the physical/conformational properties of Aβ and thus potentially 
enhancing plaque formation [204, 205].  Alternatively, the physical interaction 
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between APOE and Aβ likely affects the efficiency of Aβ clearance from the brain, 
either across the BBB [206], or by modulating cellular uptake through receptor-
mediated endocytosis [207].  Indeed, in vivo studies using functional neuroimaging 
methods such positron emission tomography (PET) in conjunction with amyloid (Aβ) 
tracers such as 11C-Pittsburgh Compound B (PiB), have shown an APOEɛ4 dose-
dependent increase in fibrillar Aβ burden in cognitively healthy individuals [208].  
Subsequent research has also found that Aβ burden measured using PiB-PET correlates 
with a family history of LOAD, perhaps accounting for the known increased risk [209]. 
It is unclear whether increased Aβ deposition is an early initiating event in LOAD 
[210], although longitudinal studies of those with MCI suggest an increase fibrillar Aβ 
burden is predictive for future conversion to AD [211-213].   
APOE likely modulates disease risk for AD through pathways not directly linked to 
Aβ. As the major apolipoprotein of the brain, APOE is important for cholesterol 
homeostasis by serving as a ligand in receptor-mediated endocytosis of cholesterol-
containing lipoprotein particles (see review, [214]). Cholesterol is a major constituent 
of the neuronal membrane and the synapse, and impaired redistribution of lipids and 
cholesterol might affect neuronal plasticity [180].  There is increasing evidence that 
abnormal cholesterol metabolism may be a key component of a pathological cascade 
leading to AD [215]. Moreover, APP processing through γ-secretase takes place in the 
cholesterol-rich membrane, with high intracellular cholesterol favouring the 
amyloidogenic processing pathway of APP [180]; the degree of lipidation of APOE 
seems to affect the clearance rate of Aβ [206].  Taken together this suggests that 
APOEε4 likely contributes to AD pathogenesis by modulating the metabolism and 
aggregation of Aβ by directly regulating brain lipid metabolism and synaptic functions 
through APOE receptors (see, [216]).  APOE is also associated with circulating levels of 
cholesterol as well as atherosclerosis, and might serve as a common convergence point 
with other risk factors such as diabetes through a vascular component [215].  However, 
since recent research in elderly individuals has reported  high APOE concentrations in 
the blood irrespective of allele type indicate an increased risk of death from 
cardiovascular disease [217], it is difficult to see how APOEε4 may confer a differential 
impact on increased risk of AD in this singular regard.   
APOE has also been implicated in neural injury and repair processes long before its 
association with AD [214].  In this regard, transgenic animal studies of native murine 
APOE knockout mice which express similar levels of human APOEε3 or APOEε4 in the 
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brain, has shown that expression of APOEε3, but not of APOEε4, was protective 
against age-related excitotoxic-induced neuronal damage [218] (but see, [219]).  This 
may possibly explain the long-standing association between APOEε4 and poor 
outcome after brain to injury in humans [220].  Indeed, following brain injury, the 
expression of APOE is increased in both neurons and glial cells [219], and in clinical 
studies possession of an APOEε4 allele is associated with poorer outcome after head 
injury [221], as well as after acute stroke (see review, [222]). Interestingly, recent 
research has shown that even in healthy elderly adults, cortical thickness is associated 
with different APOE genotypes with significantly greater cortical thickness associated 
with  APOEε2 carriers [223].  Indeed, one could speculate that part of the protective 
role of APOEε2 may be mediated by greater brain reserve.  Cytokine and nitric oxide 
(NO) mediated neuroinflammation is also a significant pathological component of AD 
(1.7.4), and in cell culture and animal experiments APOE has been shown to be capable 
of suppressing pro inflammatory cytokine and NO production via a hithero unknown 
pathway [224].  This may represent another means by which different APOE alleles 
may modulate disease risk in Alzheimer’s [203], and may be particularly relevant given 
that cardiovascular disease and diabetes are associated with chronic low-grade 
inflammation [225, 226].  Taken in aggregate, APOE clearly mediates its effects on AD 
risk via a range of mechanisms, none of which may be mutually exclusive. 
 
1.3.1.2 Cardiovascular Risk Factors 
Several reports in the literature suggest that cardiovascular risk factors predispose 
individuals to developing dementia, and more specifically AD, and vascular dementia 
(see review, [227]). Recent reviews of cohort studies suggest that smoking increases the 
risk for developing all forms of dementia, including AD [228-231]. However, recent 
reviews of the associations between dementia and hypertension [229, 232, 233], 
cholesterol [234], and obesity [229, 235, 236] reveal complex relationships, because 
although hypertension, increased cholesterol, and obesity in midlife all increase the 
risk for late-onset of dementia, blood pressure levels, cholesterol and body mass index 
decrease progressively before disease onset [237]. Thus, people with dementia often 
have lower blood pressure levels, cholesterol and body mass compared to non-
demented persons at diagnosis.  Although early primary prevention may be the most 
effective intervention with respect to these risk factors, it is clear from recent Cochrane 
reviews that neither statins [238] nor antihypertensive treatment [239] lower the 
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incidence of late-life dementia, although long-term trials from midlife onwards are 
lacking.  Indeed, a recent Cochrane review has provoked controversy by concluding 
that there is insufficient evidence to recommend the widespread use of statins in the 
primary prevention of heart disease [240], although this is disputed by others [241]. 
 
1.3.1.3 Diabetes and Dementia 
Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting 
from defects in insulin secretion, insulin action, or both [242]. The majority of diabetes 
cases fall into two broad categories.  Type 1 diabetes (T1D) is the uncommon form, and 
results from autoimmune destruction of insulin-producing pancreatic islets [243].  T1D 
usually appears before the age of 40, and accounts for around 10% of all people with 
diabetes [244].  Type 2 Diabetes (T2D) is the most common form; it results from 
peripheral insulin resistance — a condition in which peripheral tissues such as muscle, 
liver, and the pancreas become resistant to the physiological actions of insulin [242].  
Insulin resistance is central to metabolic syndrome, a cluster of high adiposity, 
abnormal glucose level, dyslipidaemia, hypertension, and high inflammation, which in 
the long-term is associated with poor health outcomes, including heart disease, stroke, 
and cancer [242, 245].  In most cases insulin resistance is linked to being overweight 
and morbidly obese (i.e. body mass index or increased abdominal obesity) [242, 243]. 
T2D usually appears in people over the age of 40, though South Asian people have a 
particular vulnerability in relation to developing insulin resistance where it often 
appears after the age of 25 [242, 244]. Both insulin resistance and diabetes result in 
primary hyperglycemia.  Although insulin resistance in the absence of diabetes may 
not generate clinical symptoms, it is still often sufficient to cause pathologic and 
functional changes in various target tissues [242]. If increased insulin secretion (i.e. 
hyperinsulinemia), cannot overcome the insulin resistance, pre-diabetes or T2D 
usually ensues [242]. Acute life-threatening consequences of uncontrolled diabetes are 
hyperglycemia with ketoacidosis or the non-ketotic hyperosmolar syndrome [242].  
Long-term complications include retinopathy, renal failure, peripheral neuropathy, 
sexual dysfunction, autonomic neuropathy and cardiovascular disease [242].  In the 
advanced stages of T2D there may also be damage to pancreatic islets leading to 
insulin deficiency and T1D. A number of prospective observational studies have 
reported an age-related association between T2D and dementia, showing that diabetes 
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increases the risk of late-onset dementia 1.3-to-3.4 fold (see, [229, 232, 246-248]).  
However, not all studies have confirmed the link between AD and diabetes [249].  
 
1.3. 2 Other  Risk  Facto rs  Associated  With  SAD  
1.3.2.1 Lifestyle and Psychosocial Factors 
In Western countries lower socioeconomic status (SES) tends to correlate with lifestyle 
choices typically associated with the development of cardiovascular disease and 
metabolic impairment, including behaviours such as smoking, larger food portions, 
reduced physical activity, and increased alcohol consumption [250, 251].  However, in 
Asia, Latin America and Africa, chronic conditions such as cardiovascular disease, 
obesity and metabolic disorders such as T2D are all more likely to be associated with 
higher SES [252, 253].  For example, whilst in China medical services and economic 
prosperity have improved life expectancy, people are not necessarily healthier as 
improved SES in China is associated with a shift toward an unhealthy diet 
characterized by higher fat levels and greater amounts of added sugar as well as less 
exercise [254, 255].  In addition, some Asian and other ethnic populations have an 
increased susceptibility for developing metabolic disorders with age [256-259], 
although the basis for this remains unclear. Worldwide, the number of persons 
diagnosed with diabetes and in particular T2D, is on the increase, particularly in those 
low-to-middle income countries such as Asia, Latin America, and Africa which are also 
predicted to see the largest increases in the number of AD cases [6, 253].  Indeed, apart 
from demographic aging, the increase in diabetes may provide additional support for 
concerns regarding the projected rates of AD in these countries over the next several 
decades. There is also evidence to suggest that dietary intake of homocysteine-related 
vitamins (vitamin B12 and folic acid); antioxidants such as vitamin C and E; 
unsaturated fatty acids; and also moderate alcohol intake (especially wine) —could 
reduce the risk of AD [260, 261].  However, on the basis of the current data, it is not 
possible to make any general dietary recommendations [262].   Several cohort studies 
suggest that physical activity has a strong protective effect against dementia [229, 263, 
264].  Making positive life-style changes (eating a healthy diet; engaging in regular 
exercise) may be the most effective way of protecting against age-related cognitive 
decline and dementia [27, 262, 265-267]. These likely reduce other risk factors 
associated with cardiovascular disease and stroke [268-270], as well as T2D [270-274]. 
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1.3.2.2 The Metabolic Reserve Hypothesis 
The metabolic reserve hypothesis (MRH), has been proposed in which a high 
metabolic brain reserve characterized by the presence of neuronal circuits which 
respond adaptively to perturbations in cellular and somatic energy metabolism, is 
posited to protect against declining cognition [275].  Lifestyle determinants of 
increased metabolic reserve are generally the same factors which protect against the 
development of metabolic disorders and cardiovascular disease (e.g. exercise, reduced 
caloric intake, and intake of specific dietary components that can promote 
neuroprotection).  However, sedentary lifestyles and the effects of excessive caloric 
intake are well known in relation to the development of these disorders, and dementia 
[276] and decrease metabolic reserve in the brain [275]. The MRH postulates that the 
bidirectional relationship between metabolism and cognition is primarily mediated by 
alterations in central insulin and neurotropic factor signalling as well as central 
glucose metabolism, with downstream consequences for accumulation of 
neurohistologic lesions such as Aβ-plaques and NFTs [275].  MRH is supported by a 
range of epidemiological findings as well as the spectrum of individual cognitive 
trajectories during aging, with additional data from animal models identifying 
potential mechanisms for this relationship [275]. Identification of biomarkers for 
metabolic reserve may assist in generating a predictive model for the likelihood of 
cognitive decline with aging [275, 277].  Indeed, assessment of regional cerebral 
glucose metabolism via the radioactive labelled tracer (18F)Fluorodeoxyglucose (FDG) 
for use with PET (FDG-PET), has revealed that  impaired cerebral glucose metabolism 
in temporoparietal association cortices is a reliable predictor of rapid progression to 
dementia in patients who show above expected levels of cognitive decline in aging (i.e. 
mild cognitive impairment), and could serve as a biomarker for the diagnosis of pre-
symptomatic AD [278].  Frontal and temporoparietal metabolic impairment are also 
closely related to the progression of cognitive impairment in longitudinal studies; 
multi-centre studies suggest its use as an outcome parameter to increase the efficiency 
of therapeutic trials [275, 278]. 
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1.4 CLINIC AL  PROGRESSION  
Although the biological correlates of variability in relation to temporal progression 
have been investigated by many groups, including in relation to genetics [279-282], 
vascular factors [283, 284] and cerebrovascular disease [285-287], as well as MRI 
volumetric analysis of cortical atrophy [288-293], metabolic function [294, 295], and 
other factors [296, 297],  the underlying reasons for such variations remain largely 
uncertain. This variability poses difficulties in relation to the treatment and assessment 
of patients over the duration of AD, although it can still be useful to consider its 
progression in terms of generalised stages. Currently the 7 stage Global Deterioration 
Scale (GDS) is the most popular means of charting the progressive decline of people 
with AD since it measures the cognitive, behavioural, and functional impairments of 
patients [298, 299].  GDS stages 1-2 do not deal with dementia, but deal with normal 
cognition, and normal aged forgetfulness respectively.  Current diagnostic guidelines 
indicate that a portion of people at these stages will have prodromal dementia marked 
by the presence of abnormal biomarker patterns in the brain (e.g. those related to CSF 
levels of Aβ and phospo-tau), which may occur decades before more insidious 
symptoms appear [300].  Since there are no established diagnostic criteria currently in 
use for these biomarkers, these stages are not considered further here. GDS stage 3 
represents the clinical construct known as Mild Cognitive Impairment (MCI) 
introduced by Flicker and colleagues [301] and the Mayo Clinic group [302-304], as a 
clinical adjunct for an intermediate stage of impairment between successful ageing and 
dementia [305].  MCI is briefly summarised here because many consider the particular 
animal model used in experiments in Chapters 3 and 4 of this thesis to most closely 
model the overproduction of Aβ in the very earliest stages of AD related, and thus, 
aspects of aMCI.  Stages 4-7 then chart the general clinical progression of full blown 
AD.  These are referred here as Mild (early), Moderate (mid), and Advanced (late) 
stage-AD, and are not considered in depth (see, [306]), although these stages are  
referred to when considering the nature of  memory deficits and other affective and 
behavioural impairments in AD.  
 
1 .4.1  Mild Co gnitive  Impairm ent 
According to popular guidelines by the Mayo Clinic, MCI can be divided into two 
broad subtypes: amnestic MCI (aMCI), and non-amnestic MCI (nMCI). As the most 
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common subtype, aMCI patients predominantly display impaired recall for recent 
events in relation to personal facts and autobiographical incidents in their spatio-
temporal (i.e. episodic memory) [307].  The second (less common) subtype is non-
amnestic MCI (nMCI), where instead of memory deficits the dominant impairment is 
in a non-memory domain such as attentional-executive function [302-304]. Both 
categories of MCI can be further subdivided into single and multi-domain.  For 
example, patients could present with impairment in a single cognitive domain such as 
memory, but also have impairments in language and/or attentional-executive function. 
Whilst persons diagnosed with MCI have an increased risk of developing dementia 
compared to those without the condition [301, 304, 308], it is those with aMCI who are 
generally considered to be at highest risk of developing AD [308-310], whereas those 
diagnosed with nMCI are at risk of developing other forms of dementia [311].  Patients 
with objective memory loss (as verified via a psychological test), and/or impairments 
in multiple cognitive domains, have been shown to have less chance of improvement 
overall and thus a greater propensity to progress to AD within an assessment period 
[301, 302, 304, 308-310, 312, 313].  However, it remains unclear whether some nMCI 
cases may represent the early stages of atypical AD, where there is a slowly progressing 
focal syndrome characterised by impairment in one or more non-memory domains.   
Consideration of MCI as a clinical adjunct for an intermediate dementia remains a 
controversial topic [314]. There are several definitions of MCI that are now used in the 
literature, many of which require rigorous field testing [303, 314]. Consequently, the 
frequency of MCI in the population has been found to vary considerably, both between 
and within definitions [315].  A more fundamental issue is the fact that numerous 
studies have now reported findings consistent with the view that most instances of 
MCI likely do not represent very early-stage dementia since most patients diagnosed 
with MCI either stay stable (i.e. non-progressers) or revert to baseline on follow-up 
assessment (e.g., [308, 312, 313, 316, 317]).  However, in studies showing a return to 
baseline levels of cognition, the assessment of cognition has sometimes been limited to 
only a few domains.  It could also be argued that the reason why so many MCI patients 
stay stable, is that some have mild disease and/or a higher cognitive/metabolic reserve, 
and thus, may take longer to transition from MCI to dementia [275, 318, 319].  It is also 
unclear in those MCI patients who do recover, whether or not the condition is 
intermittent, with essentially normal function interspersed with multiple relapses. 
Only longer assessment periods of two decades or more with incremental assessment 
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will likely resolve these issues.  The pathologic substrate of MCI is not completely 
understood (see review, [311]).  Nevertheless, it is generally accepted that many 
dementia patients do pass through a very early stage of the disorder marked by 
symptoms similar to those of MCI.  
 
1.4. 2 C linical  Syndrome  o f  AD 
1.4.2.1 Diagnosis and General Symptomology 
More than 30 years have passed since the National Institute of Neurological and 
Communicative Disorders and Stroke, and the Alzheimer’s disease and Related 
Disorders Association (now called the Alzheimer’s Association), established the most 
common criteria for AD [320]. Recently, expert international workgroups convened by 
the Alzheimer's Association and the National Institute on Aging (NIA), an agency of 
the U.S. National Institutes of Health (NIH), jointly issued four new criteria and 
guidelines for clinicians and researchers in relation to the diagnosis of AD [321]. These 
new criteria update, refine and broaden previous widely used guidelines so that they 
remain in line with research findings, particularly neuroimaging studies and studies 
relating to new biomarker patterns [300, 322-325].  Three of the new guidelines focus 
on the major stages of AD whilst the fourth updates the criteria for documenting and 
reporting Alzheimer's-related histopathological changes observed during an autopsy 
[326, 327].  Although these guidelines are expected to have a significant impact on AD 
research and clinical practice making a diagnosis, they have been criticised for being 
biased in favour of a specific theory of the pathophysiological origins of AD [328, 329].  
The diagnosis of AD remains a difficult process that necessarily involves a number of 
different assessments, including  a clinical review of the patient’s medical history, 
physical examination, neuropsychological testing (i.e. via Mini-Mental State Exam), as 
well as nowadays, structural and functional neuroimaging [330].  Clinical assessment 
may take place in the home, in an outpatients department, in a day hospital over 
several weeks, or as a hospital inpatient.   
In general people with AD experience two different categories of symptoms. The 
first are referred to as cognitive symptoms, and commonly disrupt memory, language 
and attentional-executive function [331]. In its common presentation, cognitive 
symptoms in AD relate to progressive amnesia followed by various combinations of 
focal cortical deficits such as such as aphasia, apraxia, agnosia, and impaired executive 
function [332].  The above pattern of neuropsychological changes largely reflects the 
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current view regarding the progression of NFT pathology in AD, which in most cases is 
symmetrical and initially thought to involve regions of the MTL, starting with the 
perirhinal cortex (also called the transentorhinal cortex), before spreading into the 
entorhinal cortex, hippocampus, amygdala, and thereafter the rest of the temporal 
lobes and basal forebrain structures (including all cortical association areas) [333-337]. 
The second are experienced by many but not all AD patients, and relate to 
"behavioural and neuropsychiatric symptoms" (BPS) [338]. Symptoms belonging to this 
latter category are diverse and variable between patients, but often involve apathy, 
agitation, anxiety, irritability, depression, and aberrant motor behaviour, disinhibition, 
delusions and hallucinations [339, 340].  The category of BPS is only considered in 
general terms here (see review, [341]), although reference is made to specific symptoms 
throughout this thesis.  However, because behavioural disinhibition and non-
conditioned anxiety are the most directly relevant to specific experiments detailed in 
this thesis, these symptoms are discussed further in section 1.6. Many people with AD 
and their families find BPS to be the most challenging and distressing effects of the 
disease.  BPS is often a determining factor in a family’s decision to place a loved one in 
residential care [338], and within long-term care facilities BPS continues to impact on 
the care and quality of life patients [338, 342].   
  Activit ies of  Daily  Living 
Both cognitive symptoms and BPS impact on the activities of daily living (ADL) in 
dementia patients.  Indeed, the impact on ADL is often used as a major criterion for 
the differentiation between MCI and early-stage dementia. There are two categories of 
ADL [343].  Basic ADL includes activities such as eating, bathing, dressing, toileting, 
volitional movement, and continence, and are usually intact in the early stages of AD. 
Complex (instrumental) ADL is dependent on intact memory, including attentional-
executive functions (a major component of short-term working memory), and is 
associated with abilities that allow a person to live independently, including with 
respect to food preparation, housekeeping and laundry, managing financial matters, 
shopping, and using public transport. Instrumental ADL are typically impaired in the 
early stages of AD, with the impairment forming part of the very definition of the 
dementia syndrome [344, 345].   Whilst in general MCI is associated with intact ADL 
and thus, independent living [303, 304], recent research suggests that like early-stage 
AD, complex ADL is affected [346-349].  Furthermore, in MCI and AD there is also a 
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significant positive correlation between the presence and degree of BPS and ADL 
impairment [341, 350-355].  However, despite the disruption of instrumental ADL in 
MCI and early stage AD, most patients usually manage to live independently [356].  In 
the moderate dementia stage supervision is needed for most ADL when other cognitive 
domains are affected in a more obvious manner, and BPS symptoms where present, 
put increasing stress on care givers [306, 356].  Complete dependence of the patients, 
who by this time have also frequently developed neurological disturbances and 
incontinence, is typical of the late-stage of illness [356], with patients usually requiring 
a high level of care equivalent to that of a nursing home [306].  Overall, most AD 
patients are expected to survive for between 8 and 10 years with the condition after 
diagnosis, although the actual duration can range from 2 to 25 years [20].  However, 
the temporal progression of AD shows a pattern of high variability, with patients 
reported to transit the stages of the disease with time-courses ranging from months to 
decades [279, 357].  This has been supported by recent research demonstrating that the 
mean duration of the various stages of AD is comparable with their standard deviation 
(i.e. that  that individual courses of progression may differ considerably between 
people, and from ‘textbook’ mean values [358]).  The cause of death in AD is often the 
result of pneumonia or general inanition [20].   
 
 
1.5 THE  NATURE  OF  MEMORY  LOSS  IN  AD  
Although once thought to be a simple concept, memory is now considered to be a 
collection of cognitive abilities, many of which are mediated by different systems and 
anatomical components within the brain. Memory research that began with 
neuropsychological studies of patients with focal brain lesions today also includes 
functional neuroimaging techniques such as PET, functional magnetic resonance 
imaging (fMRI), structural imaging methods such as MRI, as well as non-invasive 
electrophysiology techniques such as event-related potentials (ERPs) (see reviews, 
[359, 360]).  In aggregate studies using these techniques have provided the rationale 
for the division memory phenomena into the specific categories outlined below [359]. 
In short these relate to Long-Term Memory (LTM), and Short-Term memory/Working 
Memory (STM, WM respectively). Since progressive impairment of LTM is often seen 
as the primary hallmark of AD, most of the focus of discussion in this section will be 
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on components of LTM. However, most types of memory are implicated in the primary 
amnesia common to AD, although not all forms are affected at the same time or to the 
same degree across the various stages of the disorder.  Indeed, a large and growing 
body of research indicates that some components of WM are impaired in MCI as well 
as the early-stages of AD (see, [361, 362]), although the biological basis of these deficits 
remains poorly understood.  Whilst the WM system is not covered in depth here (see, 
[363]), some components may be of relevance to the interpretation of specific 
behavioural experiments detailed in chapter 3 of this thesis.  Thus, a short summary of 
WM in AD is provided following a discussion of LTM.   
 
1.5. 1 L ong-Term Memo ry  
LTM can be divided into two broad categories: Declarative memory for conscious 
(explicit) forms of recollection, and nondeclarative memory for unconscious (implicit) 
recall of information from previous experiences [364, 365].  Declarative memory can be 
further subdivided into episodic memory for autobiographical events in their spatio-
temporal context (i.e. "What", "When" and "Where"), and semantic memory for factual 
knowledge devoid of its context of acquisition (i.e. landmark dates or personal 
semantics such as the date of ones birthday) [366, 367].  Both of these systems are 
compromised early on in AD. It widely accepted that declarative memory is critically 
dependent on the integrity of the MTL structures [368-371], although other cortical 
and subcortical structures are also important [372, 373].  Nonetheless, in humans 
bilateral damage limited to the hippocampus (dentate gyrus, CA fields and subiculum), 
and/or adjacent cortical regions is sufficient to produce severe anterograde amnesia, as 
well as temporally graded retrograde amnesia stretching back as much as 25 years [365, 
374]. Two special types of declarative memory are also impaired in AD: spatial memory 
and recognition memory; both of these memory systems are discussed after episodic 
and semantic memory.  The major subdivisions of LTM are summarised in Figure 1.1 
 
1.5.1.1 Episodic Memory Impairments 
The ability to encode and retrieve episodic memories, is supported by the circuitry of 
the MTL, including temporal-limbic structures such as the parahippocampal region 
(perirhinal cortex, and parahippocampal cortex or postrhinal cortex in rats, and 
entorhinal cortex), and hippocampus, the latter of which interacts extensively with a 
number of specific distributed cortical and subcortical structures [372].  Neocortical 
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structures forming part of this memory network include the prefrontal cortex and 
other areas that mediate working memory, effortful retrieval, source monitoring, and 
other processing functions essential to conscious recollection [375-378], as well as the 
parietal and temporal cortex —both of which are involved in complex perceptual 
processing essential to contents of recollection [379].  Other structures that appear to 
be involved in episodic memory include the fornix [380], mammillary bodies and 
mammillo-thalamic tract [381, 382], anterior dorsomedial nuclei of the thalamus [383], 
basal ganglia [384, 385], and retrosplenial cortex [386].  In both animals and humans, 
evidence from anatomical, neuropsychological, and physiological studies indicates that 
cortical components of this system have key functions in several aspects of perception 
and cognition, whereas the MTL structures have a central role in mediating the 
organization and persistence of the network of memories whose details are likely 
stored in those cortical areas [372].  However, accumulating evidence also implicates 
the hippocampus and  perirhinal cortex in the process of perceptual binding as 
amnesic patients with damage to these structures have been shown to be impaired on 
perceptual tasks when discriminating between objects, faces and scenes with 
overlapping features [387, 388].  Nevertheless, the canonical view is that  structures 
within the MTL, and in particular the hippocampus, have distinct functions in 
combining information from multiple cortical streams supporting the ability to encode 
and retrieve the details comprising episodic memories in humans [368], and similar 
episodic-like memories in other animal species [389, 390].  Conversely, selective 
damage in the hippocampus, MTL, and other structures of this large-scale memory 
system, or deterioration of these areas in AD compromises episodic memory [372].   
Anterograde amnesia defined by the loss of recent episodic memory, is one of the 
earliest and most prominent symptoms experienced by most patients with AD [391].  
Numerous studies have shown that patients with AD are impaired on episodic memory 
tests that use a variety of cognitive procedures (e.g., free recall, recognition, paired-
associate learning) across virtually all sensory modalities (see review, [392]).  However, 
the use of supra-span word lists (e.g. those which exceed working memory span) in 
multiple learning trials, and the delayed recall of these material have been shown to be 
particularly sensitive for detecting early changes in patients with respect to verbal 
episodic memory (see review, [393]).  Evidence from many of these studies suggests 
that the episodic memory deficit of AD patients is due in large part, to ineffective 
consolidation or storage of new information [331, 393].  Episodic memory continues to 
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decline throughout the mid-stages of AD, and by the latter-stages of the disorder a 
profound retrograde amnesia for distant episodic memories is also evident [331].   In 
AD, the perirhinal cortex and entorhinal cortex are both bilateral anatomical sites 
associated with the most severe NFT deposition in the early-stages of the disorder 
[394-396].  Indeed, NFT accumulation has been shown to correlate with the degree of 
neuronal cell loss in AD [394, 397], as well as the loss of synapses [398], with the 
entorhinal cortex in particular considered to be most heavily damaged cortex in AD 
[336].  Since as part of the parahippocampal region, both the perirhinal and entorhinal 
cortex provide the main source of bidirectional connectivity between the neocortex 
and hippocampus [372, 399], the destruction of these areas likely plays a significant 
role in the memory deficits that often herald the onset of AD, and which likely 
characterize its continued deterioration throughout its clinical course [336, 400].  
However, whether NFTs are causative in this respect remains uncertain, as the degree 
of neuronal apoptosis in AD has been shown to exceed NFT load suggesting the 
influence of additional factors [401].  Indeed, research from mice expressing wild-type 
human tau suggest that both neuronal and synaptic lesions can occur independently of 
fibular NFT formation, and may correlate best with the accumulation of pre-fibrillar 
oligomeric tau [402, 403].  However, in humans [404-406], and transgenic animal 
species (see reviews, [65, 407]), soluble Aβ species also correlate strongly with the 
extent of synaptic loss. Indeed, mounting evidence from human and animal studies 
suggests both the dysfunction and subsequent loss of synapses occur prior to frank 
neuronal degeneration [408],  and that this is primarily mediated by diffusible soluble 
oligomers deriving from Aβ [60, 62-65, 408, 409] and phospo-tau [402, 403], making 
both types of aggregate attractive therapeutic targets in AD [410-412].  However, since 
the particular animal model used in the experiments detailed in Chapters 2 and 3 of 
this thesis expresses only the APPSWE mutation, the primary focus in this thesis is on 
the role of Aβ isoforms in mediating the dysfunction and subsequent loss of synapses, 
and thus, the role of rosiglitazone in slowing down or reversing these changes and 
associated impairments in learning and memory.  
Although fibrillar amyloid pathology presages the onset of symptoms in AD by 
years [413-419], it is not abundant in MTL in the early-stages of the disease, but is 
instead, more evident in the cortical regions comprising the “default mode network” 
[420, 421]. The default mode network (DMN) is comprised of a set of functionally 
interconnected cortical areas (posterior cingulate, inferior parietal lobule, lateral 
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temporal neocortex, ventromedial and dorsomedial prefrontal cortex) that project 
heavily to MTL structures [420], with abnormalities in this network associated with Aβ 
deposition [421, 422].  Ultimately the gradual degeneration and loss of synapses and 
neurons in AD results in the gross symmetrical atrophy of the cerebral cortex seen in 
end stage post-mortem brain tissue, something that can be detected and studied 
longitudinally by structural MRI [423, 424]. Additional mechanisms contributing to 
episodic memory impairment in AD stem from working memory and executive 
dysfunction deficits [425, 426], the latter of which may lead to increased sensitivity to 
interference due to decreased inhibitory processes, and thus, intrusion errors [427-
429].  Since the frontal cortex plays an important role in the initial acquisition and 
encoding retrieval of episodic information in the absence of contextual cues, the 
recollection of source information (i.e. context), and assessment of the temporal 
sequence and recency of events [430-432], dysfunction of the frontal lobes can also 
contribute to episodic memory impairment [433, 434].  The recollection of source 
information will be explored further in Chapter 3 in relation to object place memory.  
In addition to these mechanisms, defective use of semantic information to bolster 
encoding may also be a factor [435-437]. 
 
1.5.1.2 Defective Semantic Memory 
Although this thesis does not explicitly investigate semantic processing is a defining 
feature of human behaviour, central not only to language but also the capacity to 
access acquired knowledge in reasoning, planning, and problem solving tasks [438].  
Semantic memory comprises a rich store of general knowledge about the world, 
including our understanding of words, pictures, objects, sounds, faces and events 
without connection to time and place [438]. Although semantic knowledge is acquired 
from specific experiences it is thought to be abstracted from the engram and 
generalised to a variety of different contexts.  Cognitive neuroscientists have proposed 
many conceptual and mechanistic models for semantic memory storage and retrieval 
over the years, including those based on modality-specific components, attribute-
specific components, and category-specific or meaning-specific components [439].  
Most of these models have been informed by lesion/deficit observations and/or 
functional imaging studies, and less frequently by electrophysiology studies [440]. 
Each has focused on particular aspects of long-term semantic memory storage and 
retrieval; some detail multiple semantic memory subsystems (see, [441]).   
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Recent neuroimaging and neuropsychological studies are consistent with the view 
that modality-specific components of conceptual knowledge are likely involves a wide 
network of brain regions.  For example, it seems that most of the actual content of 
semantic memory for objects is represented in neural systems that overlap with (or 
even correspond to), brain regions necessary for perceiving and using those objects 
[442-444].  Thus, current theoretical models of semantic memory tend to converge on 
the likelihood that it closely relates to perception and action, and that it is represented 
in the brain regions which overlap with (or possibly even correspond to), the regions 
responsible for perceiving and acting [444].  According to this view, the knowledge of 
what a cat sounds like would be stored in the auditory cortex, whilst an ability to 
recognize and imagine the visual features of a cat likely resides in the visual cortex.  In 
support of a distributed network for semantic memory, a recent meta-analysis of 
functional neuroimaging studies by Binder et al., has suggested that long-term storage 
and recall of semantic information in the brain depends on the orchestration of a 
distributed but predominantly left-lateralized network of cortical areas, including 
posterior inferior parietal lobe, middle temporal gyrus, fusiform and parahippocampal 
gyri, dorsomedial prefrontal cortex, inferior frontal gyrus, ventromedial prefrontal 
cortex, and posterior cingulate gyrus, [445].  However, whilst specific features of 
conceptual knowledge are likely represented within a distributed network of brain 
regions, the ability to receive information in one modality and express it in another, to 
generalize across conceptually similar entities that differ in almost every specific 
modality, and to differentiate between entities that resemble each other in many 
modalities (all semantic abilities) — seem to depend on the anterior temporal lobe 
(ATL) [444].   Indeed, the ATL likely provides a major common convergence zone for 
many different types of semantic information [444]. However, recent research has also 
shown that patients with bilateral damage thought to be restricted primarily to the 
hippocampal region, acquired less factual knowledge than controls patients as well as 
exhibiting a temporally limited retrograde amnesia for factual information from the 
several years preceding the onset of memory impairment [446]. These results show 
that the hippocampus may also support semantic memory with its role in the 
acquisition and storage of semantic knowledge being time limited [446]. 
Impairments of semantic processing figure in a variety of brain disorders, including 
AD, semantic dementia, fluent aphasia, schizophrenia, and autism. In semantic 
dementia, clinicopathological studies consistently show that anterior and inferior 
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temporal regions bear the brunt of the damage across histopathological subtypes [447].  
However, the neural correlates of semantic failure in other disorders are less clear.  In 
AD, language impairment often occurs early in the course of the disorder, and 
deteriorates with progression of the illness to cause significant disability [331]. The 
impairment initially affects verbal fluency and naming (both of which require integrity 
of semantic concepts), prior to the breakdown in other facets of language [448]. Little 
is known about the underlying neuropathology of language impairments in AD.  
Semantic memory is progressively disrupted in AD, and is generally considered to 
reflect progression of neuropathology into the temporal, frontal, and parietal 
association cortices in which such semantic memories are thought to be diffusely 
stored.  However, a recent review of functional neuroimaging studies by Verma and 
colleagues [448], has reported that semantic memory loss may occur in AD several 
years prior to diagnosis, and may reflect an altered state of cortical connectivity with 
respect to language networks possibly providing the structural basis for subsequent 
failure of semantic memory.  Dysfunction of the right superior temporal cortex has also 
been implicated in AD, and may contribute to early semantic deficits [449].  Given that 
cognitively normal individuals with the APOEƐ2 allele have been reported to have 
specific thicker cortical volumes in the superior temporal cortex compared to those 
persons with the Ɛ4 allele [223], one wonders perhaps, if those persons with the Ɛ4 
allele would show a dose dependent vulnerability to early decline of semantic memory 
due to reduced cortical thickness in this region.   
Recent research has shown that patients with bilateral damage thought to be 
restricted primarily to the hippocampal region, acquired less factual knowledge than 
controls patients as well as exhibiting a temporally limited retrograde amnesia for 
factual information from the several years preceding the onset of memory impairment 
[446]. These results are interesting because they show that in addition to episodic 
memory, the hippocampus may also support semantic memory with its role in the 
acquisition and storage of semantic knowledge being time limited [446]. This probably 
explains why semantic memory deficits reportedly overlap with episodic memory 
impairments.  Indeed, Leyhe et al. [307], have recently shown that in early-stage AD, 
both personal semantics (semantic information as it relates to autobiographical 
experiences [450]), and recall of autobiographical memory have a temporal gradient in 
patients with better preservation of childhood memories compared to early adulthood 
and recent life.   
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1.5.1.3 Spatial memory 
How do we know where we are? Orientation in space and by implication, “spatial 
memory”, is a key facet of our day-to-day existence as we follow familiar routes and 
navigate to a previous location, as well as explore and new environments [147]. The 
term “spatial” is somewhat ambiguous however, as it has different meanings and has 
been considered in numerous ways. For example, ‘spatial competence’ is associated 
with the processing of geometric (or metric) properties, including those related to 
distance and size, as well as dynamic properties such as velocity and strength. Clearly, 
the ability to navigate in the environment requires an understanding of all these 
properties, thus linking intuitive geometry with that of an intuitive physics [451].  In 
addition to navigation, spatial memory also forms a fundamental building block in 
relation to the psychological mechanisms supporting episodic memory and recognition 
memory processes [452].  As mobile organisms, humans must recognise objects despite 
updating their relative positions and orientations in the surrounding environment in 
order to efficiently interact with the world.  Indeed, as the consequences of getting lost 
or poor recognition are potentially fatal, the ecological validity of spatial memory is 
highly conserved across species.  Spatial memory impairment is particularly important 
in the context of this thesis because it forms one of the key phenotypic alterations 
associated with the particular animal model used as a vehicle in Experiments 1 and 4 of 
Chapter 3 in relation to the evaluation of the therapeutic impact of rosiglitazone in 
relation to learning and memory. 
Spatial memory is supported by multiple parallel representations, including 
egocentric (body-centred) and allocentric (world-centred) representations, and those 
which update to accommodate self-motion [453].  Egocentric navigation fixates on the 
traversed direction with respect to own body (e.g. ‘go straight ahead’ or ‘turn left’), and 
involves a self-to-object representational system. A fundamental aspect of egocentric 
navigation relates to “path integration”, a form of  “online” navigational strategy that 
involves an animal (including humans) starting at a fixed point, visiting several 
locations, and then returning directly to the original start point by processing self-
movement information generated along the way [454]. However, as an individual 
moves through an environment, the positions of surrounding objects relative to the 
body constantly change. Thus, the concept of spatial updating is used to refer to the 
automatic cognitive process whereby the brain continuously computes the spatial 
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relationships between an individual and their surrounding environment as they move 
based on perceptual information about their own movements [455].   
Spatial updating contributes to object and scene recognition by predicting the 
appearance of objects or scenes from novel vantage points, so that an individual can 
easily recognize them as they move [456].  However, observer movement does not 
necessarily automatically update representations of spatial layouts of scenes in small-
scale (room-sized) environments [456, 457], raising questions about the effects of 
encoding points of view on the automatic spatial updating of representations of scenes.  
A form of viewpoint-independent spatial updating also occurs in humans (see, [458]), 
and may have a role in maintaining perceptual stability [459], as well encoding the 
spatial representations of object layouts [459, 460].  However, this may involve a fixed 
reference direction independent of the body [459], and may be an implicit learning 
process [461].  The updating of egocentric representations of location in order to 
accommodate self-motion (called path integration when the location in question is the 
start of the path), falls prey to cumulative error after relatively short paths, 
necessitating the incorporation of corrections from landmarks or celestial cues in long-
distance orientation (e.g. [462, 463]).  Allocentric navigation requires an object-to-
object representational system that encodes information about the location of one 
object (or its parts) with respect to other objects in the environment [453]. This type of 
strategy is considered most useful in large and/or unfamiliar environments, and 
involves forming a mental representation of visible cues and landmarks when encoding 
the layout of a novel environment [464]. Current research indicates complementary 
roles for both egocentric and allocentric representations, with the former being most 
useful when allocentric representations are not of high fidelity [460].  In addition,  
both types of representations likely combine across learning and navigational 
situations, particularly since environments differ in respect of their familiarity, 
intrinsic structure, loco-motor demands, and the number and size of objects they 
contain [465]. 
 Neu ral  correl ate s of  spat ial  and object-plac e m emor y 
The hippocampus has long been implicated as a key neural correlate of spatial memory 
in both humans and animals [453], particularly since hippocampal lesions in many 
species have been shown to affect spatial recognition and memory for recently 
acquired allocentric representations [464, 466-469], as well as some allocentric 
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representations of places learned long ago (see review, [470]). At a cellular level, spatial 
recognition and spatial learning of position is supported by a subpopulation pyramidal 
cells within the hippocampus and entorhinal cortex, both of which contain a number 
of electrophysiological properties consistent with their role in forming allocentric 
representations of space, including head-direction,  place and grid cells [466, 471]. In 
the 36 years since their discovery in rats [472], place cells have been documented in 
monkeys and humans [149, 473, 474].  In the hippocampus, place cells place cells fire 
when an animal is at specific locations in an environment (the cell’s ‘place field’) [475, 
476], and as the animal explores an open environment the ensemble of cells provides a 
stable representation of the animal’s location that is independent of its orientation 
[477]. Thus, the pattern of place cell firing does not simply reflect direct sensory input 
because many of the cells continue to fire within their given place field irrespective of 
an animal changing the direction in which it is facing [478], or when the lights are 
tuned out [472].  Furthermore, the pattern of place cell firing has also been found to 
correlate with behavioural responses in some spatial memory tasks [466]. These and 
other studies show that place cells are encoding the more abstract concept of a place, 
in other words, a mental representation of where the rat “thinks” it is (see 
review,[147]).  Although speculative, such representations are likely needed for mental 
imagery [147, 464].  Nevertheless, many studies have shown that place cells form part 
of a much broader circuit for dynamic representation of self-location in the brain (see 
review, [147, 466]).  A key component of this network is the entorhinal grid cells, the 
activity of which is related to that of hippocampal place cells [479], and by virtue of 
their tessellating firing fields, may provide the neural elements of a path integration-
based strategy [466].  However, the presence of grid (like) cells in a network of brain 
regions implicated in spatial cognition and episodic memory in both humans [480] and 
rats, [481], likely reflects a wider role for these cells in memory function [480].  
Nevertheless, these two mesial temporal lobe regions have strong bidirectional 
interactions, probably explaining why they have a critical role in spatial and other 
forms of memory as well as their relation with the amygdala [482].  In summary, 
current research supports the role of the hippocampus in forming allocentric 
representations of space, whilst the entorhinal cortex likely mediates a path 
integration-based neural representation of the environment (see reviews, [464, 466]). 
In addition to location representation at the single cell level, locations are also 
represented by distinct neural assemblies [373], with studies in both humans and rats 
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having identified patterns of neuronal firing within the hippocampus that represent 
specific goal locations in both real [483] and virtual spatial environments [484].  
Consistent with the link between spatial and episodic memory, distinct patterns of 
hippocampal activation that are stable over time are have been suggested to represent   
specific episodic memories [485], although a thorough discussion of the results form 
experiments forming the basis for this are outside the bounds of this thesis.  The 
presence of neural representations of the spatial environment is also not in itself, likely 
to be sufficient for successful place learning as rats, as rats with lesions of the 
intermediate hippocampus are unable to learn new spatial locations rapidly within a 
familiar environment despite the persistence of intact spatial representations and 
neuronal plasticity in the septal hippocampus [486].  This addresses an important 
distinction between forming accurate spatial representations and the subsequent 
translation of these into behavioural actions, such as navigation [373], the latter of 
which requires the intermediate hippocampus [486].  Indeed, whilst a thorough review 
of the lesion data supporting the conclusion that the hippocampus plays a pivotal role 
in aspects of recognition memory is outside the bounds of this thesis, the net 
conclusion from such studies is that the hippocampus is required whenever such 
memory involves remembering that a particular stimulus occurred in a particular place 
or when the memory contains a temporal or object recency component (e.g. [487, 
488], but see, [489, 490]).  Indeed, such processes are of relevance to the interpretation 
of Experiment 4 in Chapter 3 which deals with object-place memory.   
Neuroimaging and other integrative methods in neuroscience now mean that it is 
possible to investigate how specific cells ‘learn’ about specific object–place or object–
context associations [373].  Indeed, there is growing evidence from animal studies for 
the automatic encoding of object–context associations within the hippocampus from 
both lesion studies [491], and studies looking at the expression of immediate-early 
genes following task performance [492].  This suggests that learning about specific 
object–place or object–context associations may not always reflect a conscious 
declarative process. Although more speculative, two recent reviews of the 
neuropsychological literature have also suggested that the hippocampus may also 
mediate multiple cognitive processes through the process of relational binding and 
comparison in the presence or absence of conscious awareness (see reviews, [493, 
494]).  Of particular interest is the fact that associative representations in the 
hippocampus are thought to be built on previously formed representations of both the 
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space and context within which learning takes place [495], further bringing together 
models of hippocampal function that emphasise the structures role in either spatial 
[453] or relational memory processes [496]. 
Finally, many modern studies of spatial and recognition memory processes have 
shifted the focus away from the more traditional approach of studying the brain in 
terms of modular brain regions, to a more integrated approach whereby the emphasis 
is on the interactions between multiple cortical regions [373].  In this paradigm, 
functional disconnections of brain regions, using crossed unilateral lesions or 
temporary in-activations, have been particularly informative for addressing these 
issues.  For example, using this approach it has been possible to determine that the 
perirhinal cortex interacts extensively with both the hippocampus [497], and medial 
prefrontal cortex to support learning about object–place associations [498].  Indeed, 
whilst the perirhinal cortex is known to play an important role in recognition memory 
generally [373, 499-501], it is worth pointing out that both the perirhinal and prefrontal 
cortex have been implicated in working memory processes [502-504], including 
executive functions in humans [505-507]  and similar processes in non-human animals 
[508, 509].  Thus, it appears that the hippocampus, perirhinal cortex and prefrontal  
cortex form part of a neural system that supports memory for items and the contexts in 
which they occur [373].  These structures may perform this role irrespective of whether 
long-term or short-term memory processes are engaged [510]. 
 Spatial  mem ory defi cits in A D 
Visual impairment is a common symptom of AD and thus, considered to be one of the 
contributing factors to performance deficits in many visually mediated tasks (see, 
[511]). However, whilst, in general, research has shown that static visual acuity, stereo-
acuity, dynamic visual acuity and motion direction discrimination are relatively intact, 
AD patients tend to perform significantly worse on tests of static spatial contrast 
sensitivity, visual attention, shape-from-motion, colour, visuospatial construction and 
visual memory [512].  Crucially, all these deficits are thought to be related to wider 
impairments in visuospatial memory in AD [513, 514], although recent neuroimaging 
research suggests that the loss of retinal ganglion cells, nerve fibre layer loss, and 
glaucoma may also play an important role mediating visual deficits in patients [511].   
Individuals with AD exhibit deficits in a wide range of spatial, visuospatial, and 
visuoconstructual memory tasks, both in respect of immediate and long-term duration 
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(see reviews, [331, 361]).  Visuospatial difficulties in AD are often characterized as 
showing more a rapid forgetting of information in serial position tasks, with the deficit 
in serial recall often attributed to more rapid decay and proactive interference between 
items [514].  Indeed, proactive interference is a particular issue in visuospatial working 
memory tasks even in those who are cognitively intact [515]. However, defective 
monitoring of STM and LTM, has also been shown to influence performance in short 
and long-term serial recall tasks [516], a function that has been associated with 
executive function [508, 517].  Nevertheless, consistent with the notion of largely intact 
implicit function, AD patients seem to do well on tasks involving priming (e.g. 
increased sensitivity to certain stimuli as a result of inconsequential prior exposure), 
although performance may depend on whether a given task requires perceptual or 
conceptual processing resources [518]. Interestingly, although semantic 
autobiographical memory is often preserved in AD until the moderate stages, semantic 
priming studies have yielded contradictory results [519].  Patients diagnosed with aMCI 
and early-stage AD exhibit a number of visuospatial difficulties in their day-to-day life, 
including topographical disorientation (e.g. getting lost whilst navigating in familiar or 
unfamiliar environments) [331, 520]. Recent research using a novel test of spatial 
memory (the four mountains test) in aMCI patients and those with early-stage AD, 
indicates that the core spatial memory deficit in both patient populations relates to an 
inability to represent topographical layout (even for very short durations) within the 
context of more general LTM impairments [521].  Indeed, performance on the four 
mountains test also differentiates AD from frontotemporal dementia (FTD) [521], a 
finding that has parallels with MCI research in that impairments in the allocentric 
component of spatial memory may be an accurate predictor of progression to AD [522, 
523]. Taken together these findings suggest that topographical representation may be 
sensitive to the early pathological changes in AD and aMCI [514, 523]), and may be a 
consequence of MTL atrophy [521]. Together these findings suggest that evaluation of 
visuospatial processes may be a promising approach to finding predictive markers of 
AD in clinical populations.   
As discussed already, object-place memory is also sensitive to the effects of 
hippocampal damage in humans and other mammalian species such as rodents [373, 
524, 525], and in most cases this type of memory is also disrupted in early-stage AD 
with object-place deficits revealed via visuospatial tasks in which patients are asked to 
recall the spatial position of a target item [331].  This type of task is able to discriminate 
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between the cognitive deficits shown by patients with AD and those with depression 
[526], questionable dementia, and FTD [527]. Indeed, at least three MCI subgroups 
have been distinguished using visuospatial tasks of this nature [523].  Interestingly, the 
acquisition of these types of associations has been shown to require cholinergic 
modulation of perirhinal-prefrontal network interactions [528].  In addition, recent 
data with a transgenic mouse model exhibiting a selective elimination of the vesicular 
acetylcholine transporter in the hippocampus (which interferes with synaptic storage 
and release of acetylcholine), results in significant deficits in hippocampal LTP, as well 
as and selective deficits in a spatial memory task [529].  Indeed, since disruption of 
cholinergic signalling is known to be an early pathological change in AD due to the 
profound loss of the acetylcholine synthesis enzyme choline acetyltransferase and 
neurons in the forebrain’s nucleus basalis of Meynert (the origin of major cortical 
cholinergic projections) [530], this potentially provides a basis for understanding the 
spatial memory deficits in the early-stages of AD. 
 
Figure 1.1:  Major Divisions of Long Term Memory. Adapted from Squire, L.R. (2004). 
Memory systems of the brain: a brief history and current perspective. Neurobiology of 
Learning and Memory, 82(3), 171-7. 
 
1.5.1.4 Recognition Memory 
Recognition commonly refers to the cognitive process whereby something is identified 
as having been previously encountered (heard, seen, known, or felt) [531], but may also 
refer to a perception of truth, or the acknowledgment of something [532]. As such, 
recognition memory relates to the cognitive process of recognition, and is considered a 
subcategory of declarative memory (see review, [500]). Recognition memory can be 
subdivided into two component processes: delayed recollection (or retrieval) of the 
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details associated with the previously experienced/encountered event, object or person 
(episodic information), and an immediate familiarity for the feeling that a stimulus was 
previously experienced without explicit recollection [500]. These two processes are 
sometimes respectively referred to as "remembering" and "knowing".   
Converging lines of evidence from research conducted with humans and animals 
suggests that recognition memory depends on the integrity of structures in the MTL 
[453, 464, 466, 477, 500, 501, 533-539], although there is uncertainty as to how these 
structures may differentially contribute to recollection memory processes [535, 540].  
Currently, two different models (dual process verses single process models) potentially 
describe how recognition memory is organized across different senses.  According to 
the dual process view, recollection and familiarity are supported by different 
anatomical substrates [500, 524, 541, 542]. In line with its role in episodic memory, 
recollection is thought to be hippocampal-dependent, and to support recognition of 
specific stimuli together with the contextual features of the learning event (i.e. where), 
whilst familiarity does not require the hippocampus and can support context-
independent recognition of individual stimuli via the perirhinal cortex [500, 543-551].  
However, the single process theory denies the independence of the two processes 
within recognition memory. In this theory, both familiarity and recollection are a 
continuous process, where the former is primarily thought of as a weak memory, and 
the latter is considered to be a type of strong memory [501].  The single process theory 
of recognition also has also accumulated experimental support in its favour, (see 
review, [501]), although it cannot fully explain some data obtained from lesion studies, 
particularly in rodents [546, 551-553]. 
 Imp airment s in AD 
There is considerable evidence that visual recognition memory is impaired in AD [331]. 
Aside from the potential impact of spatial and visuospatial memory deficits already 
discussed, these recognition deficits might concern defective strategies in relation to 
the forming, maintaining, and matching of the memory representation of the visual 
stimulus, especially when long inter-item lags occur [554].  Often this will involve a 
delayed matching to sample (DMS) recognition test.  Basically, patients are first shown 
a study list of items to memorize (sample phase), then after a delay, the individuals are 
tested on their ability to discriminate familiar target items from those which are novel 
(test phase).  Thus, the objective in DMS for the person to indicate via a simple yes/no, 
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whether or not the item was on the study list.  Alternatives to DMS relate to delayed 
non-matching to sample (DNMS) paradigms where participants have to indicate which 
of the list of items are novel rather than familiar, and immediate matching to sample 
tasks in which sample and test phases are continuous with no delay.  
 In yes/no MS and DMS tasks, patient responses fall into four classes: hits, misses, 
false alarms, and correct rejections [555].   Based on counts of these responses, persons 
with AD and those with dementia of the Lewy body type (DLBT) generally show 
impaired memory performance for test items relative to controls, although  DLBT 
patients exhibit a significant impairment relative to AD patients when DMS is used 
[556].  Indeed, further research using these and other cognitive tests in patient 
populations have shown that compared to AD, perception, attention, and working 
memory (WM: see section 1.5.3) are all disproportionately impaired in DLBT [557].  
Recently, Viggiano, et al have used an elegant experimental paradigm to study the 
effects of repetition lag in AD [558].  In this paradigm, pictures were presented to mild- 
and moderate-AD patients and normal age matched controls at different levels of 
spatial filtering, allowing for the measurement of the amount of physical information 
required for identification of stimuli as a function of prior exposure and repetition lag. 
Viggiano, et al have shown that in the elderly, the magnitude of repetition priming did 
not differ as a function of inter-item lag, but instead, repetition-lag effects interacted 
with dementia severity, with the capacity for retaining memory traces over longer 
intervals worsening as the disease progresses [558].  Indeed, Viggiano, et al suggest 
that suggest that severe cortical degeneration may render AD patients unable to 
maintain their perceptual memories, and that dementia severity is a critical variable in 
the visual recognition memory assessment [558].   
 
1.5. 2 No ndeclarative  Me mory  
Nondeclarative memory represents the second major division of LTM in mammals, 
and refers to the unconscious (implicit) recall of information from previous 
experiences.  Nondeclarative memory phenomena mostly relate to forms of procedural 
memory for performing cognitive and sensorimotor skills (e.g. riding a bicycle), as well 
as habits, priming, simple associative learning (e.g. operant and classical conditioning), 
and non-associative learning (e.g. habituation and sensitization) [559]. Whilst early 
studies of memory-impaired patients with MTL damage led to the view that this brain 
region is critically involved in declarative memory [374], they also showed that 
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nondeclarative memory, immediate STM and WM processes, —were all relatively 
intact in these patients [359].  This fostered the prevailing view that these types of 
memory are largely independent of MTL function, depending instead upon on an  
array of distributed cortical and subcortical structures that includes regions of the pre-
frontal cortex, cerebellum, and striatum [560, 561].  However, alternative formulations 
of memory systems exist which do not divide memory on the basis of consciousness 
(see, [562, 563]).  Specific MTL structures such as the hippocampus may also mediate 
some forms of implicit learning [494], as well as under some circumstances STM [510, 
564], particularly if the material to be learned exceeds the capacity of immediate 
memory, is difficult to rehearse, or if attention is diverted (see review, [510]).   
Numerous neuropsychological studies have reported that many aspects of 
procedural memory are left intact in most AD patients [565],  at least until the latter 
phases of the  neurodegenerative process (see reviews, [518, 566]).  For example, whilst 
explicit recognition of familiar or unfamiliar melodies is typically impaired in 
moderate-stage patients consistent with episodic memory impairment, implicit 
procedural memory for playing a musical instrument can be spared in musicians with 
AD [567].  Furthermore, unlike depressed patients, people with moderate AD can still 
develop a positive affective bias of judgment for previously heard melodies [568]. 
However, research has also revealed deficits in some domains, including amygdala-
dependent fear conditioning and eye-blink conditioning that may be supported by 
inputs from the entorhinal cortex to the hippocampus [569, 570].  In addition as stated 
earlier, studies of priming have reported mixed findings in AD patients [518, 571-573] 
but see, [573].  Some variability across studies reflects differences in methodology, 
where some tests may involve a greater or lesser degree of competition between 
explicit and implicit memory systems, with the final effect of learning being better 
when all of the implicit memory capacity is engaged in the learning process [566]. AD 
patients also show impairments in conceptual implicit memory [574].  Since 
conceptual implicit memory tests do not require word production [574], deficits in 
these tasks may be related to MTL damage [575].   
  
1.5. 3 Working  Memory  Defi cits  
The basis for the current view regarding the anatomical subdivision of LT and ST 
memory originates from Milner (1966), who showed that whilst patients with MTL 
damage displayed declarative memory impairment, they also showed intact non-
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declarative memory, and immediate STM, [374].  Indeed, this fostered the prevailing 
view that non-declarative and STM processes are largely independent of MTL function, 
depending instead on a wide array of cortical and subcortical structures which include 
amongst others, regions of the pre-frontal cortex, cortical association areas, cerebellum 
and  striatum (see reviews, [359, 360].  However, it is important to point out that 
alternative taxonomies of these systems exist which do not divide LTM on the basis of 
consciousness (see reviews, [562, 563]).   
STM is usually conceptualised in terms of WM, a model first proposed by Baddeley 
and Hitch (1974) as a response to the accumulation of experimental 
neuropsychological evidence that did not fit the previous Atkinson and Shiffrin model 
of STM [576].  Essentially WM is the system that actively holds multiple pieces of 
transitory information in the mind for a short period of time, where they can be 
manipulated in the course of completing various verbal and nonverbal tasks, and/or 
made available for further information-processing [577].  Thus, WM forms the basis for 
many day-to-day tasks, including retrieving from LTM, a familiar telephone number 
and then holding this information in mind whilst it is dialled (i.e. the initiation of a 
motor programme).  Because WM requires the active manipulation of information or 
behaviours (i.e. "monitoring") as part of completing goal-directed actions, it is not 
exactly the same concept as STM.  Nevertheless, correlational studies have not been 
able to consistently separate both constructs; there is evidence for a large or even 
complete overlap [578].  Thus, they probably refer to the system. In the original 
Baddeley and Hitch (1974) model [576], WM is comprised of  three components: the 
central executive which functions as an attentional system that monitors on-going 
mental processes, and its two slave systems: the phonological loop and visuo-spatial 
sketchpad.  These represent STM stores for phonological information and visuospatial 
information respectively  [576].  More recently Baddeley has added a third slave 
system, the ‘episodic buffer’, which is considered to be a short-term multidimensional 
store for the temporary binding of episodic information; it forms an important 
interface between the subsystems of WM, LTM and the central executive [579].   
 
1.5.3.1 Executive Dysfunction in AD  
The central executive is probably the least understood but most complex component 
of WM and is unlikely to reflect a single unitary process [363].  Putative functions of 
the central executive include the control and monitoring of WM (e.g. [517]), cognitive 
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flexibility, multi-tasking and attentional control despite distractions and changing 
demands (e.g. [580, 581]), strategic planning, execution, and evaluation of a sequence 
of thoughts/actions to achieve a desired goal (e.g. [582, 583]); inhibition of 
inappropriate responses and capacity for self-regulation (e.g. [584, 585]); ‘on-line’ 
active construction of an theory of mind [586]; rule discovery such as sorting cards 
based on specific rules and fluid intelligence (e.g. [587, 588] and concept generation 
(e.g. [589, 590]).  Perhaps, then, it is unsurprising that various neuropsychology and 
neuroimaging studies of executive processes have revealed links between many 
different brain areas, indicating a dynamic and flexible neural substrate for executive 
functions (see, [591]).  However, strong consensus exists in the literature with respect 
to the importance of the frontal regions and more specifically, regions of the prefrontal 
cortex in a range of WM and executive functions [577, 592-596]. Several studies have 
examined the role of executive function in MCI and early-stage AD, and found a 
number of disruptions in executive processes [348, 426, 516, 581, 597-624],  including in 
tasks related to response inhibition and task switching [625-627].  Indeed, multi-
domain executive impairments may be predictive for conversion to dementia [628].  
Defective self-monitoring [629], and control of attention [630] may well be predictive 
for which MCI patients will decline as opposed to stay stable across the assessment 
period. Furthermore, individual differences in executive function related to monitoring 
have been linked with memory accuracy in those over the age of 65 [517]. Deficits in 
WM [631] and in particular visuospatial executive function [632] may also distinguish 
those with MCI from persons exhibiting normal age related changes in cognition. 
Longitudinal studies investigating pre-diagnostic symptomatology and staging of AD 
also report that executive dysfunction is often present before diagnosis, with more 
rapid decline occurring 2-to-3 years before diagnosis [606, 612].  This evidence has led 
some to suggest that executive function may be the core underlying dysfunction 
associated with AD [606, 612]; others have proposed that there may be a subgroup of 
AD patients with a specific dysexecutive pattern of impairments (e.g. [599]).     
Thus, it would appear that a significant proportion of people with AD and MCI have 
discernible executive deficits which cause significant impairment in many aspects of 
day-to-day living [614, 622].  Although overt atrophy of the frontal cortex is usually not 
an early-stage pathological change in AD, executive dysfunction in patients has often 
been ascribed to brain damage of vascular origin, including white matter changes [633, 
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634]. However, recent research suggests that hippocampal atrophy may be the root 
cause of impaired executive function in early-stage AD [635, 636].   
 
1.5.3.2 Phonological Loop and Visuospatial Sketchpad in AD 
A variety of data from psychological and neuroimaging studies have converged on the 
suggestion that phonological loop function is largely intact at the preclinical and early 
stages of AD, becoming more impaired as the disease progresses (see review, [361]).  
Since phonological loop function is not central to the behavioural experiments in mice 
detailed in Chapter 3 of this thesis, this component of WM is not considered further 
here.  However, the visuospatial sketchpad may be important when considering the ST 
retention of visuospatial information in mice, particularly in Experiment 1 in relation 
to an assessment of rodent spatial WM.  Indeed, in mild AD it is commonly accepted 
that memory impairment is often apparent in patients when visuospatial function is 
assessed. However, as visuospatial tasks also require processing by the central 
executive system [363], it is difficult to know the degree to which this slave system is 
compromised [361, 637].  Additionally, the damage to MTL structures involved with 
spatial and episodic memory in the early stages of AD may also partly explain some 
deficits in visuospatial WM in AD, particularly in circumstances where the material to 
be learned has exceeded WM capacity, if the material was difficult to rehearse, or if 
attention was diverted (i.e. [510]). 
 
1.5.3.3 Episodic Buffer in AD 
The episodic buffer is considered to be a multidimensional store that forms an 
interface between the subsystems of WM, LTM and the central executive [638]. As a 
multidimensional buffer, it allows a range of different subsystems to interact, despite 
their being based on different modes, with a major function of the buffer being to 
“bind together” different sources of visual, spatial, and verbal information with time 
sequencing information into integrated chunks or ‘episodes’ [639, 640] —a process 
once assumed to depend upon executive resources [638, 641].  The episodic buffer 
shares conceptual overlap with Tulving's original concept of episodic memory [366], 
although it differs from the latter in that it represents a temporary time-limited store 
for such information [640]. Here there is agreement with Cowan that the number of 
episodes or chunks that it can hold is somewhere in the region of four [642], with 
capacity differing from one individual to another as reflected by individual differences 
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in working memory span [363].  The episodic buffer has not been extensively studied in 
AD; suitable tasks need to be developed and validated (see review, [361]).  However, 
experimental evidence indicates that both LT and ST memory binding deficits are 
evident in early-stage AD across a range of modalities [643-645].  Indeed, AD 
functional neuroimaging studies reveal large-scale functional abnormalities in brain 
networks which likely underpin deficits in relational binding [646]. 
 
Figure 1.2:  Major Divisions of Working Memory. Adapted from Baddeley, A. D., Eysenck, 
M., and Anderson, M. C. (2009). Memory. Hove: Psychology Press. 
 
1.6 ANXIE TY  AND BEHAVIOURAL  DISINHIB ITION  
Among the components of the limbic system, the amygdala is a fascinating structure 
that is involved in the processes of liking and disliking, and in the ways in which 
emotions drive actions (i.e. predicting which stimuli generate aversive events) and 
affect the salience of memories [647].  For example, the amygdala is central to the 
acquisition, storage, and expression of conditioned fear memory (i.e. Pavlovian fear 
conditioning) [648], a process that is widely accepted as dependent on LTP [649].  
Indeed, when the normal function of the amygdala is disrupted it can often manifest as 
post-traumatic stress disorder, or as an anxiety disorder [650], the latter of which are 
amongst the most prevalent of all psychiatric disorders in that about 17 % of people 
will suffer from an anxiety disorder at some point in their lives [650, 651].  Besides AD, 
amygdala function is also adversely affected in several additional neurodegenerative 
disorders which compromise the structural integrity of the MTL, the most common of 
which is AD. 
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1.6. 1 C ircu itry  and  Function  
The amygdalae are a group of nuclei (the amygdaloid complex) which are located deep 
within the rostro-medial part of each the temporal lobe in front of the HPC and 
underneath the uncus of the entorhinal cortex [652].  As such therefore, the amygdala 
has close interconnections with both cortical and subcortical areas [650], including the 
temporal cortex (perirhinal and entorhinal cortex), frontal lobe, insular, and cingulate 
association areas, with subcortical areas including the brainstem, hypothalamus, 
thalamus, hippocampus, and claustrum [653, 654]. The many components of the 
amygdaloid complex can be grouped into three principal divisions: the basolateral, 
cortical, and centro-medial nuclear groups. The largest part of the amygdala is the 
basolateral nuclear group and is reciprocally connected to many cortical areas in the 
per-frontal cortex, temporal, insular, and occipital regions [655].  Together with its 
close relations with the thalamus and projections to the striatum, the connectivity of 
the basolateral amygdalae likely belies its role in modulating memory, particularly for 
arousing or emotional events, during post-training periods of consolidation [656]. In 
particular, amygdala-pre-frontal cortex and amygdala-hippocampal circuitry has been 
broadly implicated in the processing of threatening-stimuli in humans [657], and 
conditioned fear responses in experimental mice (see review, [658].  Indeed, in 
primates the basolateral amygdalae nuclei are thought to be involved primarily in 
evaluating the emotional significance or context-dependent relevance of all stimuli, 
including social signals such as facial expressions [659].  Furthermore, recent evidence 
from electrophysiological recordings in rats has also suggested that the basolateral 
amygdalae is responsible for strengthening memories whose substrates are considered 
to be stored remotely in structures such as the hippocampus, striatum and cerebral 
cortex [652, 656].  Although there is insufficient space here to cover this topic in detail, 
recent research in rats has also supported the notion that the basolateral amygdalae 
likely plays a role in strengthening memories by increasing the number of neurons that 
come to best represent that event, and thus their cortical representations [660]. 
Furthermore, that traumatic, intrusive memories common to post traumatic stress 
disorder, might reflect abnormally extensive representational networks due to hyper-
activity of the basolateral amygdalae consequent to the release of excessive amounts of 
stress hormones [660]. The cortical amygdala receives olfactory input directly from the 
olfactory bulb and indirectly from the olfactory cortex, with the cortical amygdala in 
turn projecting to the centro-medial amygdala and the hypothalamus [650].  This 
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amygdala -olfactory circuitry has been implicated in social buffering in male rats [661, 
662], as well as odour recognition memory [663].  The centro-medial amygdala 
provides the main outputs for the basolateral complexes, and receives direct input 
from the cerebral cortex (largely restricted to fibers from the hippocampus, insula, and 
orbitofrontal cortex) [650].  However, because the amygdala is a bidirectional pathway 
that can relay information between association cortices and subcortical structures, it is 
in an optimal position to simultaneously influence the excitability of numerous brain 
regions at any given time [650].  Research has suggested that the centro-medial 
amygdala nuclei may be involved in allocating attention to stimuli of high significance 
as well as the initiation of situation-appropriate autonomic responses [659]. However, 
given the overlap in physiological and electrophysiological properties of the centro-
medial amygdala and basolateral amygdalae neurons, it is more likely that processing 
is distributed across both nuclear groups with differences reflecting processing bias 
rather than a hallmark of mutually exclusive functions [659].  
 
1.6. 2 Behaviou ral  Disin hibition  and  Anxiety  in  AD  
Anxiety and behavioural disinhibition are both emotional components typically 
associated with BPS in AD [341, 664].  Behavioural disinhibition refers to the loss of 
control or restraint over social behaviours, aggression, hyperactivity, self-destructive 
behaviour and sexual disinhibition [665].  In addition, behavioural dysfunction in AD 
patients can also present as “cognitive disinhibition” on tasks of attention and memory 
[666, 667].  Anxiety is generally considered as a psychological and physiological state 
characterized by somatic, emotional, cognitive, and behavioural components linked 
with the unpleasant feeling of fear and concern [344].  Whilst anxiety is reported to be 
increased in up to 70% of AD patients [664], research into its time-course has revealed 
that patients generally display greater levels of anxiety at an early stage of the disease 
when cognitive function is more intact, followed by a progressive pattern of decreased 
anxiety in the presence of decreased cognitive function [668].  Anxiety in AD patients 
is usually diagnosed by assessing neuropsychiatric symptoms of excessive worry, 
restlessness, irritability, muscle tension, fear behaviour, and respiratory symptoms 
[669].  However, diagnosis of anxiety is often complicated by its comorbid 
presentation with depression and apathy [341, 670]. 
In mammals, anxiety and behavioural disinhibition are both components of 
emotion typically attributed to the neural circuitry supporting the amygdala and 
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prefrontal cortex (including sub-regions of the orbitofrontal cortex) (see reviews, [664, 
671, 672]).  In a recent study spanning several neurodegenerative diseases, behavioural 
disinhibition was most significantly associated with atrophy in the orbitofrontal cortex, 
anterior cingulate, and temporal lobes [673]. In addition, damage to the orbitofrontal 
cortex has also been linked to deficits in WM, and in particular executive function 
[506].  Amygdala atrophy is prominent feature in AD (see review, [664]), particularly in 
the early stages of the disorder where it relates to symptom severity [674].  Anxiety has 
also been linked to the differential effects of human APOE isoforms as well as and 
molecular changes within the amygdala nuclei [675, 676].  Furthermore, ApoE-/- mice 
expressing ApoE ε4 have been shown to demonstrate an age-dependent increase in 
anxiety on the elevated plus maze, and had significantly lower levels of microtubule-
associated protein (MAP) 2-positive neuronal dendrites in the central nucleus of the 
amygdala [677].  AD pathology compromising the integrity of the amygdala and frontal 
regions has also been suggested as the root cause of patients inability to process fearful 
stimuli [678], as well as impairment in displaying enhanced emotional memory for 
negatively-valenced stimuli [569].  However, although severe amygdala dysfunction 
often manifests as components of Kluver-Bucy syndrome in humans and other 
primates [679] (including visual agnosia, hyperorality, hypermetamorphosis, blunting 
of fear or rage, and hypersexuality), pathological changes affecting the amygdala in AD 
rarely result in Kluver-Bucy syndrome [680].  The reasons for this are unclear although 
it is thought that the progressive functional disconnection hypothesised to occur 
between the MTL and other brain regions as AD [681, 682] may be sufficient to 
prohibit many of these abnormal behaviours from emerging in most AD patients [664].  
It is interesting that recent findings support a theory of FTD as essentially a disorder of 
frontolimbic disconnection leading to unconstrained prefrontal connectivity [683], 
whereas  AD is associated with frontal lobe hypometabolism [684], the latter of which 
has also been associated with impaired insight [684], and thus danger [685].  
Although the role of the prefrontal cortex and amygdala in anxiety and behavioural 
disinhibition are widely acknowledged, it is less commonly understood that lesions of 
the ventral hippocampus can also produce behavioural disinhibition and, interestingly, 
reduced anxiety [686, 687]. Indeed, the role of the hippocampus in emotional 
responses is further supported by lesion studies in rodents, which show that lesions to 
the ventral-medial hippocampus result in behavioural disinhibition and anxiolytic 
behaviour on unconditioned tests of anxiety, including a version of the elevated plus 
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maze [686, 687, #9410, 688-690].  Thus, whilst the amygdala and prefrontal regions are 
increasingly implicated in a range of various antisocial, violent, and psychopathic 
behaviours [691-693], the hippocampus is also likely to be complicit in mediating many 
of these behaviours.  Indeed, structural MRI has linked atypical anterior hippocampus 
asymmetries with those considered to be “unsuccessful psychopaths” (i.e. those who 
become institutionalized due to their poor behavioural control and aggressive 
tendencies) [694].  Hippocampal asymmetries in these individuals may reflect an 
underlying neurodevelopmental abnormality that disrupts hippocampal-prefrontal 
circuitry, resulting in affect dysregulation, poor contextual fear conditioning, and 
insensitivity to cues predicting capture by the ‘long arm of the law’[694].  Taken 
together these findings implicate the neural circuitry supporting the amygdala, 
hippocampus and pre-frontal cortex in a range of maladaptive outcomes associated 
with anti-social and aggressive behaviours, as well as the unconditioned expression of 
anxiety and conditioned expression of fear.  In this respect the pathological alterations 
observed in hippocampal-prefrontal circuitry in AD likely explain why affect 
behavioural dysregulation, poor contextual fear conditioning, and behavioural 
disinhibition, are all symptoms commonly experienced by AD patients. 
 
1.7 MOLECULAR  PATHOLOGY 
At the microscopic level, AD is primarily defined by the presence of large numbers of 
diagnostic Aβ-Plaques and NFTs, both lesions of which are fairly robust and easy to 
detect [88].  Plaques and tangles are further associated with a diffuse loss of synapses 
and neurons (losses), as well as neuroinflammation and deficits in insulin signalling, 
the latter of which is considered separately (see section 1.9). 
 
1.7. 1 Amyloidosis  and  Aβ-Plaques   
Amyloidosis refers to the physiological conditions wherein amyloid proteins and 
protein peptides aggregate to form plaque deposits in various organs and tissues.  
Many of these deposits contain amyloid fibrils formed from normally soluble proteins 
that have assembled into fibres dominated by a predominantly β-sheet conformation 
of their polypeptide backbone [695, 696].  Although amyloid is a naturally occurring 
protein, it is often associated with the pathological states common to ‘amyloid 
diseases’, including AD, T2D, and spongiform encephalopathies [697].  Amino acid 
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composition and sequence analysis of the proteins comprising a range of ex-vivo 
amyloid fibrils have revealed each amyloid disorder is associated with a particular 
protein or peptide [698]; AD is primarily associated with aggregation of the Aβ 
peptide.  Like other amyloid-associated proteins Aβ has the ability to self-associate 
into varied assembly forms ranging from individual monomers to large insoluble 
amyloid fibrils found in some Aβ-plaques.  Aβ can also form small intermediates 
known as soluble oligomers of varying molecular weights and sizes [46].  In addition, 
Aβ can also be deposited on the walls of cerebral blood vessels and veins during CAA 
[134].  CAA is found in approximately 25 to 90+ % of autopsied AD brains [699, 700], 
although its role in the progression of AD is not known.  However, since CAA is 
associated with an increased risk of intracerebral haemorrhage, ischemic micro-
infarcts, as well as non-haemorrhagic (white matter) lesions in the brain, it may induce 
a stepwise decline in cognition characteristic of vascular dementia [134]. 
 
1.7.1.1 Aβ-plaques and Their Topographical Distribution 
In AD, the Aβ peptide is deposited as extracellular plaques although other proteins 
such as ubiquitin and metal ions such as Zink and iron have also been localised to 
these types of brain lesion [90]. The predilection site for the deposition of amyloid as 
Aβ-plaques is the cerebral cortex, in particular the isocortex which consists of the grey 
matter, or neuronal cell bodies and un-myelinated fibres [88]. Generally speaking, Aβ-
plaques are not specific to AD, and are also found in other neurodegenerative 
disorders such as dementia with Lewy bodies, and dementia related to Down 
syndrome [49, 88, 90] as well as some persons with MCI, and aged persons evaluated 
as cognitively normal.   Aβ-plaques are commonly, classified into diffuse and dense-
cored plaques (neuritic plaques) based on their morphology and positive or negative 
staining with Thioflavin-S or Congo Red. Post-mortem identification and 
quantification of Aβ-plaques mostly relies on immunohistochemical staining methods 
utilising anti-Aβ antibody reagents [701].   
 Diffuse and Neu rit ic  Plaq ues  
Diffuse plaques are large 10-to-100μm areas of poorly defined Aβ deposition 
(principally shorter length Aβ isoforms such as those with 40 amino acids in length i.e. 
Aβ40) which tend to lack the fibrillar amyloid more commonly found in neuritic 
plaques [49, 90].  Due to defuse plaques being poorly immunoreactive, their number in 
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the brain depends on the quality of the immunohistochemistry, although in some 
brain regions they are the only type of Aβ deposit found  [88].  Diffuse plaques do 
generally affect the structure of the surrounding neuropil tissue  and consequently are 
not usually considered directly toxic [49].  This view is further supported by the fact 
that diffuse deposits can be found in large numbers in subjects whose intellectual 
status has been evaluated as normal [702, 703].  However, since diffuse plaques are 
often considered as pre-neuritic [704], the clinical status of these cases remains 
uncertain.  Some consider persons with large numbers of diffuse plaques but whose 
intellectual status is normal —to be pre-symptomatic for full-blown AD [88, 327], 
although this view is not universally accepted [705].  Whilst it not known how long 
diffuse plaques may remain uncomplicated in the brain prior to conversion, some 
individuals are thought to have better cognitive reserve which may mask the 
subsequent signs of early dementia [88]. 
Neuritic plaques are larger (50–200μm) “focal” deposits of Aβ deposition that 
consist of a dense amyloid core with radiating fibrils that are often (although not 
exclusively), surrounded by a corona of dystrophic neuritic and glial cell processes 
together with reactive microglia and astrocytes [49].  Neuritic processes often contain 
paired helical filaments of hyperphosphorylated protein tau.  The fibrillar amyloid 
contained in neuritic plaques is often identified via the Congo red or thioflavin S 
positive methods of detection [88].  In addition to the extracellular deposition of Aβ a 
growing body of evidence also suggests that Aβ-oligomers can accumulate 
intracellularly in AD, particularly in the neuronal cell body [88].  However, this 
“intracellular pool of Aβ” is controversial [88, 706], and it remains possible that it 
results from neurons internalizing extracellular Aβ deposits [707].  Nevertheless, the 
accumulation of intracellular Aβ via the uptake of extracellular peptides may provide a 
link between Aβ generation and synaptic dysfunction in AD [708]. Neuritic plaques are 
found mostly in layers II and III of the isocortex [709], the areal topography of which is 
non-random and dependent upon on the stage of the disease.  Progression of amyloid 
pathology in the brain generally proceeds in a particular manner, which depending on 
the brain regions affected, can be classified into specific stages referred to as Braak 
stages (A-C) [710].  At Stage A, low densities of amyloid deposits are found in the 
isocortex, particularly in the basal portions of the frontal, temporal and occipital lobe. 
Very little amyloid found in the MTL and associated structures at this stage. Stage B 
shows an increase in amyloid deposits in almost all isocortical association areas with 
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only the primary sensory areas and primary motor field remaining almost devoid of 
deposits [88]. Here there is a mild involvement of the hippocampus as well as the 
entorhinal cortex. In stage C virtually all isocortical areas are affected, while deposits in 
the hippocampus generally show the same pattern as stage B although there is usually 
a sparing of the subcortical grey matter [88].   
Until recently, cerebral Aβ burden could only be measured at autopsy and it is 
possible that in some of these clinicopathological studies there may have been a time 
lag between the last cognitive assessment and autopsy.  Nowadays the build-up of 
amyloid in the brain in AD patients, those believed to be pre-symptomatic for AD, and 
in normal aged controls can be studied non-invasively by using tracers such as PiB-PET 
[711, 712].  However, whilst PiB- (negative amyloid scans) using this tracer indicate 
absence of AD with a high level of accuracy, positive amyloid scans in 10-to-30 % of 
healthy elderly volunteers (PiB+) make their predictive value less clear [713, 714].  
Overall post-mortem studies have consistently shown that the distribution and density 
of Aβ-plaques (that is both diffuse and neuritic plaques), do not correlate well with the 
local extent of neuron death, synaptic loss, nor the degree of cognitive impairment in 
AD [715, 716], although as mentioned earlier, this is likely not the case for soluble 
oligomers of  Aβ [60, 65].  Overall, the distribution of Aβ-plaques in AD does not 
correlate with that of neurofibrillary pathology [49], suggesting that these two types of 
protinaceous lesion may occur independently.   
 
1.7. 2 Neurofibrillary  Tangl es  
Although this thesis does not involve research focusing on NFTs, they are an essential 
lesion in AD, and are therefore included here for completeness.  In the CNS, tau 
proteins are best known for their ability to bind and help stabilize microtubules where 
they form vital components of the cell's cytoskeleton [717].  Axoplasmic transport (also 
called axonal transport) is a vital cellular process that involves the movement of 
mitochondria, lipids, synaptic vesicles, proteins, and other cell parts (i.e. organelles) to 
and from a neuron's cell body through the cytoplasm of its axon (i.e. axoplasm) [718]. 
In healthy neurons, microtubules guide the bi-directional transport tracts for nutrients 
and other molecules from the cell body down to the ends of the axon (anterograde 
transport), as well as from the terminals to the cell body (retrograde transport). Under 
normal circumstances tau stabilise microtubules. However, in AD individuals, tau 
molecules become hyperphosphorylated (phospo-tau) via a variety of intracellular 
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kinases, leading to their disassociation from microtubules [88]. Indeed, tangle-bearing 
neurons are said to be devoid of normal microtubules [88].  Due to malfunctions in 
axonal transport, this disrupts communication between neurons [561], and likely leads 
to the neuronal apoptosis and thus the development of dementia [41].  Like Aβ, 
dislocated phospo-tau is able to polymerize into a variety of assemblies, including 
small soluble tau oligomers [719, 720], which upon aggregation form paired bundles of 
helical filaments [717], the latter of which are the primary constituents of NFTs found 
inside the cell body (soma) of neurons, as well as in distal dendrites as neuropil 
threads [721].  However, other proteins such as actin and ubiquitin have also been 
localised to these lesions [88, 722]. A variety of silver impregnation staining 
techniques, have been typically employed to visualize NFTs, including the modified 
Bielschowski or Gallyas technique, or the fluorochrome dye thioflavin S technique. In 
addition to these, a number of immunohistochemical approaches have also been used 
to visualise NFTs, most of employing antibodies directed against fibular tau [88].   
The topographical distribution of NFT pathology uses the Braak and Braak scheme 
of staging stages I to VI, with the spatial pattern being mostly predictable [334].  In the 
early stages of AD, NFT degeneration typically originates in the perirhinal cortex 
(particularly layer II neurons), and progresses through the hippocampus and 
amygdala.  Eventually NFT pathology progresses to the association cortices, and 
finally, the deeper layers of the primary cortices [88]. However, variability in the 
staging of NFT pathology can be found in neuroimaging and neuropathological studies 
of AD patients [394, 723-726], and may reflect atypical presentations of the disorder 
[332, 727].  Although NFTs are usually conceptualised as intraneuronal lesions, when 
tangle-bearing neurons die the NFTs they contain become the extra-neuronal “ghost” 
tangles seen in the brains of individuals with advanced AD [728].  Unlike their 
intracellular counterparts, ghost tangles are glial fibrillary acidic protein (GFAP) and 
Aβ immunoreactive [729], and also contain significant amounts of blood proteins such 
as amyloid-P [730], and ubiquitin [722].  As discussed earlier, the staging pattern of tau 
pathology in most cases of AD likely helps to explain the correlation between the 
degree of amnesia and NFT burden early on in the disorder [394, 397].   
 
1.7. 3 L oss  of  Cells  and  Synapses   
In the cortex the large and middle-sized pyramidal neurons are the most vulnerable in 
AD, whereas the very large Betz cells and the small granule cells are relatively spared 
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[88].  However,  by using appropriately controlled methods with post-mortem tissue, it 
has been found that neuronal loss in AD is primarily “focal” with the global number of 
cortical neurons lost being generally insufficient to override the very high inter-
individual variation [88, 731].  Focally, however, severe neuronal loss has been 
documented in a number of cortical regions, including layer II of the entorhinal cortex 
where the loss may reach 90 % of the normal neuronal population in the most 
advanced cases [732], in both CA1 and CA3 regions of the hippocampus [733, 734], in 
the superior temporal gyrus [401], and in the supra-marginal gyrus [735].  The loss of 
neurons is considered to be less extensive in the parietal and occipital lobes in AD, 
with cell loss predominantly found in cortical layers II and III [735].  There is also a 
substantial loss of neurons in the deep grey matter in AD, including the nucleus basalis 
of Meynert (innervating the isocortex in acetylcholine), substantia nigra in the 
midbrain (involved with dopamine production), locus coeruleus in the pons (main 
source of noradrenaline in the forebrain), and the raphe nuclei of the brainstem 
(innervating the isocortex in serotonin) [49, 88, 90].  It is no surprise then that the loss 
of neurones in AD is closely paralleled by widespread neurochemical changes, 
including disturbances in the cholinergic, glutamatergic, serotonergic and 
noradrenergic systems [530].  The reason for the focal loss of neurons in AD is still 
unclear [736], although as mentioned earlier it does correlate with the distribution of 
tangle-bearing cells [88, 332].   
Dendritic spines are tiny protrusions along neuronal dendrites that constitute the 
major postsynaptic sites for excitatory synaptic transmission. These spines are highly 
motile and can undergo remodelling even in the adult nervous system [737].  
Experiments conducted in animals suggest that the extent of spine remodelling is 
correlated with behavioural improvement after learning, implicating a crucial role of 
synaptic structural plasticity in memory formation [738-742].  Furthermore, recent 
research also suggests that a small fraction of new spines induced by novel experience 
together with most spines formed early during development and surviving experience-
dependent elimination, are preserved in order to provide a structural basis for memory 
retention throughout the entire life of an animal [739, 741-743].  A loss or alteration of 
these structures has been described in patients with neurodegenerative disorders , 
including  AD, and is considered to be a much better correlate of cognitive impairment 
in AD patient than Aβ-plaque burden (see reviews, [408, 744, 745]).  As discussed 
earlier, mounting evidence from human and animal studies suggests both the 
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dysfunction and subsequent loss synapses is likely mediated by diffusible soluble 
oligomers deriving from Aβ [60, 62-65, 408, 409] and phospo-tau [402, 403], making 
both species of aggregate attractive therapeutic targets in AD [410-412].   
 
1.7. 4 Reactive  Processes  and  Neuroinflammation  
In the normal brain microglia and astrocytes have a highly characteristic morphology 
comprised of a small cell soma and thin, straight processes [746, 747]. Microglia are the 
main innate resident immunological surveillance and macrophagic cells of the CNS, 
and like peripheral macrophages comprise heterogeneous populations with distinct 
immunological and functional characteristics [748-750]. Under physiological 
conditions resting microglia poses a resting ramified morphology that does not occur 
in any other tissue related population of macrophages [747].   
The inflammatory response is an early, non-specific immune reaction to tissue 
damage or pathogen invasion. Inflammation of the CNS is characterized by increased 
glial activation (both astrocytes and microglia), and concordant with pro-inflammatory 
cytokine concentration, blood-brain-barrier permeability (and thus, leukocyte invasion 
from the periphery), and recruitment of the complement system [751].  One key player 
that is believed to drive this neuroinflammatory process is interleukin-1-beta (ILβ), a 
pro-inflammatory cytokine that is known to be up-regulated in several 
neurodegenerative disorders, including Parkinson's disease, multiple sclerosis, and AD 
[752].  ILβ signals through the type I IL-1 receptor/IL-1 accessory protein complex, 
leading to nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) 
dependent transcription of pro-inflammatory cytokines.  This then leads to the 
activation of tumour necrosis factor-alpha (TNFα), IL-6, interferons, and the 
neutrophil-recruiting chemokines (CXCL1 and CXCL2) in glia [753].  Ultimately,  ILβ 
signalling leads to the generation of reactive oxygen and nitrogen species (ROS), and 
thus, oxidative stress [754].  However, many of these processes are not inherently 
pathological since they are often form elements of the brains response to dealing with 
infection, damage, and thus recovery and repair. For example, some cytokines released 
form astrocytes have a role in restricting inflammation; protecting neurons and 
oligodendrocytes thereby helping to limit tissue degeneration and preserve function 
after CNS injury [755, 756]. Furthermore, the systemic inflammatory response 
represents a coordinated set of physiologic actions that serves to fight infection, heal 
wounds, and promote recovery from various external stressors by inducing sickness 
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behaviours (see review,[757]). Nevertheless, under certain conditions, such as in major 
trauma and neurodegenerative disease, an excessive pro-inflammatory response can 
auto-modulate glial phenotype with potentially disastrous consequences that can 
worsen prognosis and damage the surrounding neural tissue; including the loss of 
neurones and synapses (see review, [758]).  Indeed, prolonged and widespread 
activation of microglia and astrocytes are apparent in AD brain, in which the severity 
of glial activation correlates with the extent of brain atrophy [759], and cognitive 
decline [760]. The majority of transgenic rodent models of AD also exhibit substantial 
reactive gliosis and accumulation of activated astrocytes in affected brain regions (see 
reviews, [761, 762]). These features are often observed before the appearance of 
plaques, and in those models which display NFTs and associated apoptosis of neurons, 
tangle pathology [763, 764], and neuronal death [764, 765]. 
 
1.7. 5 C urrent  Treatmen t  
To date, only symptomatic treatments exist for AD, all of which attempt to 
counterbalance the neurotransmitter disturbance. Three cholinesterase inhibitors 
(CIs) are currently available and have been approved for the treatment of mild to 
moderate AD. A further therapeutic option available for moderate to severe AD is 
memantine, an N-methyl-D-aspartate receptor (NMDR) non-competitive antagonist 
[766]. Common treatments for BPS in AD include the use of many second-generation 
(atypical) antipsychotic drugs, and most at best only lead to a small-modest overall 
effect over placebo [341].  Indeed, many of the treatments for BPS in widespread use 
are associated with a number of adverse side-effects that present notable risks for 
people using these medications [767, 768].  The dementia antipsychotic withdrawal 
trial has also found no significant efficacy for drug versus placebo, thereby suggesting 
that people do not need to be maintained on antipsychotics [769].  Nevertheless, the 
usage of these medications is fairly widespread in many nursing homes, where the 
over-prescription of antipsychotic medications have raised concerns over their use as a 
‘chemical cosh’ for placating difficult patients [768].  Treatments capable of stopping 
or at least effectively modifying the course of AD (referred to as 'disease-modifying' 
drugs), are still under extensive research or in phase I-III clinical trials. To block the 
progression of the disease these compounds have to interfere with the pathogenic 
steps responsible for the clinical symptoms, including most commonly, the deposition 
of extracellular Aβ-plaques and NFTs, inflammation, oxidative damage, iron 
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deregulation and cholesterol metabolism and metabolic dysfunction [412]. A 
comprehensive review of each of these lies outside the bounds of this thesis (see 
reviews, [412, 766, 770, 771]).  However, a few salient points on anti-inflammatory 
therapies, anti-Aβ immunotherapies, and therapies related to insulin sensitizing drugs 
will be covered in the next section.  Most of these therapies are heavily biased towards 
cases of ‘pure’ pathology, and instances of mixed dementia are likely to pose significant 
challenges to the treatment of dementia.  Both plaque and tangle pathologies may 
themselves may represent a host response to a (as of yet) undetermined upstream 
pathophysiologic process in most cases of AD [772]. As such, the therapeutic targeting 
of these lesions, including their supposedly neurotoxic oligemeric intermediates may 
only succeed when the host response is directly deleterious [773]. 
 
1.8 PATHOGENESIS  OF  AD 
During the past 20 years or so the Amyloid Cascade Hypothesis (ACH) has largely 
dominated academic and pharmaceutical led research, and today remains the lead 
hypothesis of AD causation.  In short, the ACH which proposed that the aggregation of 
Aβ was the initial pathological event in AD that leads to the formation of Aβ-plaques 
and the subsequent induction of a deleterious biochemical cascade that initiates 
secondary pathologies such as inflammation, neurofibrillary pathology, and the death 
of synapses and neurons that ultimately results in dementia [774, 775].  This 
hypothesis is not reviewed in depth here (see, [776-782]).  However, a few salient 
points are considered below. 
 
1.8. 1 The  Amyloid  Cascad e  Hypothesis 
The identification of Aβ as the main constituent of diffuse and neuritic plaques [783], 
and genetic studies that identified mutations in the APP [28, 29], and presenilin genes 
[32, 155], leading to the accumulation of Aβ and early-onset FAD [28, 32, 784], were all 
critical findings that led to the articulation of the ACH.  As discussed earlier, the 
mutations in these three genes all share a common effect of abnormally processing 
APP, with an average age of dementia onset at 50 years for APP mutations, 45 years for 
PS1 mutations and 52 years for PS2 mutations [785].  Although several hundred 
families with EOFAD carry at least one of the mutations mentioned above, it should be 
said that in the patient populations so far studied, no mutations have ever been found 
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in the "microtubule-associated protein tau" gene on chromosome 17 (MAPT-17), which 
encodes the tau protein [25].   For this reason the ACH considers the aggregation of 
tau and the formation of NFT pathology to be a downstream consequence of Aβ 
accumulation in the brain.  Nevertheless, other neurodegenerative dementias do 
exhibit a pathological aggregation of tau (i.e. "tauopathies"), related to MAPT-17 
mutation, most notably frontotemporal dementia with parkinsonism-17 (FTDP-17) 
[786].  Indeed, FTDP-17 has been associated with more than 40 mutations in the 
MAPT-17 gene [787].  Except for the age of onset and family history, no other 
pathological features appear to distinguish FAD from SAD [788, 789], and both are 
considered to share neuropathologic features that include Aβ-plaques and NFT 
pathology as well as the associated neuroinflammation [88, 790].  Although both types 
of AD may differ clinically (largely considered a result of variations in the staging of 
pathological lesions), the ACH tends lump both together as deriving from essentially 
the same pathogenic cascade.  However, the steady state of monomeric Aβ in the brain 
is the result of a tightly controlled balance between production and removal, and SAD 
is considered to reflect defects in the clearance mechanisms for Aβ rather than in the 
enhanced synthesis which commonly occurs in EOFAD cases [782]. Indeed, it was 
recently demonstrated that the kinetics of Aβ production are similar between control 
and late-onset AD patients, the latter group of which were shown to have an 
impairment in the clearance of Aβ compared to controls, indicating that Aβ clearance 
mechanisms may be critically important in AD [791].  Among these mechanisms, 
interaction of Aβ with ApoE, decreased catabolism via reduced proteolysis, impaired 
transport across the BBB, and impaired CSF transport, all deserve special attention in 
the context of therapeutic intervention [779].  However, the ACH is not without its 
critics (see reviews, [780, 792-794]). 
 
1.8.1.1 The Soluble Aβ Cascade Hypothesis 
Over time, the ACH has undergone various alterations with respect to the description 
of the nature of Aβ as a means of initiating the deleterious events that underpin AD. 
The original idea that the plaques were pathogenic has currently fallen out of favour 
for several reasons.  First, as indicated earlier, post-mortem studies have consistently 
shown that the distribution and density of Aβ-plaques does not correlate well with the 
local extent of neuron death, synaptic loss, nor the degree of cognitive impairment in 
AD [715, 716], and many AD patients with severely impaired memory show no plaques 
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at post mortem analysis. Second, many of the mouse models that contain mutated APP 
isolated from human FAD sufferers show memory deficits long before the plaques are 
observed in the brain [795].  Third, the distribution of Aβ-plaques in AD also does not 
appear to correlate closely with that of NFT pathology [88], and in most transgenic 
mouse models deriving form FAD kindreds, the overproduction/accumulation of Aβ 
does not lead to NFT formation or overt cell loss [42].  Forth, and perhaps most 
importantly, several therapeutics that were purported to reduce amyloid-β production 
or involve delivering antibodies targeting its aggregation into plaques, (i.e. plaque 
busting drugs), have failed in Phase III clinical testing, although many others are in 
various stages of development (see review, [778, 780]).  In addition, recent advances in 
neuroimaging techniques in vivo (such as 11C-PiB retention) have shown the presence 
of robust plaques in otherwise cognitively normal people ([796, 797].  Although it is 
possible that some of these individuals may as stated be pre-symptomatic with better 
cognitive reserve, at a minimum these findings show that the presence of plaques does 
not necessarily equate with memory deficits. These observations have led to thinking 
that perhaps the insoluble plaques do not trigger the pathological events, and may be 
benign or even protective in nature [798].  However, since plaques affect the function 
of the DMN even in elderly persons who are healthy [799], and the failure to fully 
disengage this network during goal-orientated explicit memory tasks can impact on 
performance [800, 801], it remains possible that Aβ-plaques exert an effect on memory 
via this mechanism. 
Thus, the ACH has been  modified, and now suggests that synaptic toxicity and Aβ 
neurotoxicity and may be mediated by soluble species of Aβ that have self-assembled 
into dimer, trimer and higher-order oligomers [110, 802, 803] }, or the equivalent term 
of  Aβ-derived diffusible ligands (ADDLs) [62] (see review, [407].  These oligomers are 
relatively long-lived, not converting into amyloid protein over periods of several days 
[64], and many groups have now identified a number of poorly characterized, but 
biochemically distinct forms of Aβ oligomers from brain tissue derived from transgenic 
mouse models related to FAD [804], and from human AD post-mortem brain tissue 
[805].  Studies have revealed high correlations between soluble Aβ levels and cognitive 
deficits in human AD patients [404, 405, 728, 806-809], as well as in transgenic mice 
containing  one or more of the APP mutations related to FAD [810-813].  Indeed, 
species of Aβ oligomer have been found to impair memory in transgenic APP mice in 
the absence of plaques [804].  Furthermore, it has also been shown that these 
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transgenic mice have normal memory function only when behavioural testing co-
insides with an episode of reduced Aβ oligomer formation [795].  The mechanism of 
the toxicity has been studied extensively from both the experimental and theoretical 
perspectives (see review, [65]), and include: the activation of inflammatory effects by 
interacting directly with the cell membrane [814]; induction of oxidative stress [815] 
through the formation of metal-Aβ complex [816, 817]; disruption of membrane 
receptors’ function by intimate binding [818]; formation of membrane pore [819-822] 
and alteration of ionic homeostasis across the membrane [823, 824] and modification 
of the structure of deoxyribonucleic acid (DNA) by the process of attachment [825].  
Aβ oligomers have been found to bind to synapses and exhibit significant toxicity in 
vitro and in vivo model systems (see reviews, [63-65]).  More generalized neuronal 
impacts of Aβ oligomers include mitochondrial damage, proteasome inhibition, tau 
accumulation and hyperphosphorylation, impairment of fast axonal transport, 
endoplasmic reticulum  stress, cell cycle re-entry and ultimately, cell death [65, 407].  
In addition, the ability of synthetic Aβ oligomers to mimic the structure and activity of 
brain-derived species in many if not all of these components [58, 65, 185] validates 
their use for experimentation [60].  Some of these points are considered below in 
relation to impaired synaptic plasticity and synaptic loss. 
 Aβ ol igomer s and  Imp airment s in fun ct iona l  synaptic pla st icity  
Once bound to synapses, Aβ oligomers have been found to instigate a variety of 
pathological processes, including by interfering with functional synaptic plasticity 
processes in the hippocampus [782]. At picomolar concentrations naturally secreted 
soluble Aβ oligomers can disrupt hippocampal LTP in acute brain slices and in vivo 
they can also impair the memory of a complex learned behaviour in rats [50].  
Inhibition of LTP in acute hippocampal brain slices occurs within minutes of their 
application [62], a finding that has since been confirmed by other studies [826-828].  
As a functional form of synaptic plasticity in the hippocampus, LTP is considered by 
many to underpin the process of memory consolidation [87].  Thus, the abolition of 
LTP has long been associated with memory impairment in various animal models [87, 
829].  However, since astrocytes have been also been found to support hippocampal-
dependent memory and LTP via interleukin-1 signalling [830], it is possible that 
reactive gliosis may also disrupt LTP.  Disruption of functional plasticity by Aβ 
oligomers has been shown to include Long-term depression (LTD) of synapses, which 
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is promoted rather than inhibited [805, 831].  This is important because LTD is 
generally considered to reflect an activity-dependent reduction in the efficacy of 
neuronal synapses that can last hours or longer, following a long patterned stimulus.  
Thus, the overall impact of oligomers is depressed synaptic output.   
At a morphological level, LTP is associated with dendritic spine growth, whereas 
LTD can induce the removal of postsynaptic 2-amino-3-(3-hydroxy-5-methyl-isoxazol-
4-yl) propanoic acid  (AMPA) receptors and loss of spines (i.e. synapse pruning; see 
reviews, [832, 833]).  Thus, under normal physiological conditions synaptic 
development, maintenance, and plasticity are frequently associated with changes in 
the morphology and number of dendritic spines (see reviews, [834, 835]).  Indeed, 
dendritic spines are the major postsynaptic sites for excitatory synaptic transmission in 
the CNS, and spine re-modelling and the formation of new synapses are activity-
dependent processes that provide a structural basis for memory formation [737, 836, 
837].  Since a loss or alteration of these structures is well established in AD patients 
and forms a better indicator for cognitive impairment than Aβ-plaque burden [408, 
744, 745], it was predicted that there should be a link between Aβ oligomers and 
synaptic loss in humans as well as in mouse models related to FAD kindreds [408, 831, 
838].  This prediction has been confirmed [839], as have predictions that Aβ oligomers 
cause dysfunctional trafficking of ionotropic glutamate receptors and metabotropic 
glutamate receptors [839, 840].  The concentration of soluble Aβ oligomers has also 
been shown to predict synaptic change in AD [404], and oligomers accumulate with 
age in all the transgenic models examined so far, including mouse, rat, and 
Caenorhabditis elegans [841-844].  However, what promotes oligomer accumulation in 
SAD remains uncertain.  In addition, since numerous transgenic mouse models 
overexpressing human APP FAD mutations (sometimes in combination with FAD-
linked PSEN1 mutations), do not generally display NFT pathology or neuronal cell loss, 
the relevance of these in vitro experimental paradigms has been questioned [779].  
Nevertheless, the Aβ oligomer hypothesis remains an attractive concept because it 
resolves the issues regarding the lack of correlation among deposited plaques, tau 
pathology and neuronal loss.  However, many issues of which require clarification. 
 
1.8.1.2 Aging, Senescence and Neuroinflammation 
Aging is associated with a number of functional changes in the CNS, including 
“microglial priming”, the process whereby microglial cells undergo a status change that 
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involves a dysregulated immune response to peripheral immune activation that results 
in an increased inflammatory profile of the CNS [845, 846]).  In this context, microglial 
activation is often amplified and prolonged in the aged brain compared to adults, with 
the cause considered to reflect impairments in several key regulatory systems with age 
that make it more difficult to resolve microglial activation [846]. This impaired 
regulation and microglial hyper-activation following peripheral immune challenge has 
consequences, including exaggerated systemic neuroinflammation, sickness behaviour, 
depressive-like behaviour and cognitive deficits [846-849]. This probably explains why 
elderly patients exhibiting the signs of cognitive dysfunction are routinely screened for 
bladder infections, and it is also interesting that elderly patients suffering from 
pneumonia often present symptoms consistent with delirium.  Work in rodents 
suggests that aged microglia are subject to replicative senescence (loss of mitotic 
ability after repeated rounds of replication), raising the possibility that old age, and 
perhaps other factors adversely affect viability and self-renewal capacity of microglia, 
resulting in the generation of senescent and/or dysfunctional cells (see review [850].  
This may suggest that in some species at least, the brain's immune system may have a 
‘best before’ date [850].  This priming may be particularly important in the context of 
Aβ accumulation in the brain since it can exacerbate the pathological mechanisms 
associated with AD (see reviews, [851, 852]. One possibility is that microglial 
senescence may drive an over-reaction to the presence of fibular Aβ in the cellular 
environment.  Indeed, it may be the non-senescent microglia that exhibit the more 
neuroprotective side of these types of glial cell by releasing neurotropic factors and 
helping to metabolise Aβ and facilitate its removal from the brain [853, 854]. 
Aging is also associated with increased oxidative stress, something that can trigger a 
senescence program in astrocytes when faced with multiple types of stress.  Astrocytic 
senescence is characterised in vivo by the expression of Cyclin-dependent kinase 
inhibitor 2A, (CDKN2A, p16INK4A), and matrix metalloproteinase-1 (MMP-1). In order 
to determine whether senescent astrocytes appear in vivo, a recent study by Bhat et al., 
used brain tissue from aged individuals, which was then examined for the presence of 
senescent astrocytes using INK4a and MMP-1 expression as markers [855]. Compared 
with foetal tissue samples, this study also reported a significant increase in p16(INK4a)-
positive astrocytes in subjects aged between 35 to 90 years.  Furthermore, the frontal 
cortex of AD patients harboured a significantly greater burden of p16(INK4a)-positive 
astrocytes compared with either non-AD adult control subjects of similar ages or foetal 
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controls, with the p16(INK4a)-positive astrocytes correlated with increased MMP-1 p16 
[855].  However, perhaps the most exciting findings were that vitro Aβ42 triggered the 
senescence of astrocytes, driving the expression of p16(INK4a) and senescence-
associated β-galactosidase [855]. Furthermore, that these senescent astrocytes 
produced a number of inflammatory cytokines, including interleukin-6 (IL-6), which 
seemed to be regulated by p38MAPK (a mitogen-activated protein kinase that is 
responsive to stress stimuli [855].  Although astrocytes have been previously shown to 
be key players in the inflammatory response in AD by releasing pro-inflammatory 
factors, Bhat et al., have been the first to link this to astrocyte senescence and have 
proposed that an accumulation of p16(INK4a)-positive senescent astrocytes may be the 
link between increased age and risk for sporadic AD [855].  However, for this to be 
more compelling it would have to be shown that astrocyte senescence precedes the 
accumulation of brain Aβ rather than just being a consequence of it.  Furthermore, in 
aged persons who are cognitively normal but who have significant amyloid load in the 
brain it would be interesting to determine the degree of astrocytic senescence.  Given 
that cellular senescence seems to be a more general facet of aging related to 
autonomous suppression of tumorigenesis as well as a means to mobilize the systemic 
and local tissue milieu for repair [856], it is also possible that the accumulation of Aβ 
in some elderly persons increases the chances of this becoming a runaway process that 
induces a neuroinflammatory cascade that ultimately results in neuronal cell death 
and dementia. Interestingly, although patients with comorbid cancer and dementia are 
more likely to die [857], limited research suggests that dementia is associated with a 
lower rate of cancer [858].  One could speculate that in AD this may be one sign of a 
possible senescence program in overdrive.  
 
1.8.1.3 Oxidative Stress 
Although reactive oxygen species (ROS) such as peroxides and free radicals are usually 
categorized as neurotoxic molecules, and typically exert their detrimental effects via 
the oxidation of essential macromolecules such as enzymes and cytoskeletal proteins, 
they are a natural by-product of cellular oxidative metabolism, and are generated in 
the mitochondria as molecules with unpaired electrons during the process of oxidative 
phosphorylation [772]. Since the brain is a metabolically active organ exhibiting high 
oxygen consumption, it has a robust production ROS such as superoxide (O2−) [859, 
860].  Indeed, in normal physiological concentrations, ROS are known to be involved 
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in the functional changes necessary for synaptic plasticity and hence, for normal 
cognitive function [860]. Under normal physiological circumstances the amount of 
ROS produced are kept in check by an elaborate network of antioxidants [860].  
However, these defensive mechanisms can fail, leading to neuronal oxidative stress.  
Thus, the detection of cellular damage to proteins, lipids, and DNA resulting from ROS 
is by definition, indicative of oxidative stress, with indirect evidence relating to the 
increased expression of (antioxidant) molecules involved in oxidant defence, including 
heme oxygenase, superoxide dismutases, glutathione transferases and catalase [859].  
However, it is important to note that neurons displaying signs of oxidative stress may 
not necessarily be succumbing to oxidative stress, but rather, may be adapting by way 
of their oxidant defences [772]. Thus, in neurodegenerative disorders such as AD where 
oxidative stress is postulated to play a causal role, the associated mechanisms may be 
involved with maintaining a balance between oxidative stress and adaptation to this 
stress, ultimately reflecting the ability of living systems to dynamically regulate their 
defence mechanisms in response to oxidants [772].   
Oxidative stress plays a major role in a number of pathological states, and has been 
clearly established as a contributor to disease and death in ischaemia-reperfusion 
injury, as well as several neurodegenerative diseases that include AD [859].  Since the 
aging process is also associated with an increase in the adventitious production of 
ROS, together with a concurrent decrease in the ability to defend against such ROS, it 
is not surprising that many studies have established oxidative stress and its associated 
cellular damage as significant contributors to neurohistologic lesions in AD, as well as 
mediators of early-neuronal vulnerabilities that place cells at risk of death [861].  
However, in AD, there may be a number of contributory sources which further add to 
the background level of age-related ROS production and reduced defence.  Most types 
of oxidative damage noted in AD (including glycation, protein oxidation, lipid 
peroxidation, and nucleic acid oxidation), result directly or indirectly from metal-
catalysed hydroxyl radical formation. Therefore, it is not surprising that the loss of 
homeostasis of iron, copper and zinc in the brain, is accompanied by severe 
neurological consequences characterized with increased oxidative damage (see 
reviews, [862, 863]). Transition metals, such as iron and copper, can facilitate the 
generation of free radicals in vivo [864], as can manganese, zinc, and aluminium [865].  
Indeed, the altered concentrations and distributions of these metals in the AD brain is 
likely suggestive of their importance in disease pathogenesis [866].  For example, Aβ 
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has an unusually high affinity for transition metal ions, which can accelerate Aβ40 and 
Aβ42 aggregation in vitro thereby contributing to their toxicity [867-869], although 
the oxidant effects of Aβ are now considered to be mediated via its interaction with 
redox-active metals such as iron and copper because chelation of Aβ significantly 
attenuates Aβ toxicity [870].  The relevance of this mechanism to disease pathogenesis 
is usually highlighted by the association of redox active metals with Aβ-plaques in AD, 
many of which contain relatively high amounts of Fe, Cu, and Zn [794, 863, 871], as 
well as iron-storage proteins such as ferritin [872].  In addition, soluble Aβ species have 
also been found to attach with specificity to particular synapses to cause oxidative 
stress, which occurs via a mechanism involving NMDAR activation and resultant 
calcium flux [873].  However, although Aβ may initiate oxidative stress at micromolar 
doses and reduce the antioxidant defence system, there is also evidence that oxidative 
stress increases the concentration of APP and thus, potentially the formation of Aβ 
peptides [874], although not all studies confirm this [875].  Indeed, it has been 
suggested that neurons respond to oxidative stress by increasing Aβ production [876], 
an increase that is associated with a consequent reduction in oxidative stress [877, 
878].  In this context, Aβ has been shown to act as a potent antioxidant similar to 
superoxide dismutase [879, 880], effectively blunting oxidative stress in vivo [878, 881].  
In addition, nanomolar concentrations of Aβ are known to block neuronal apoptosis 
following trophic factor withdrawal [75].  These and other studies (see review, [792]), 
have reported results consistent with the view that normal physiological 
concentrations of endogenous Aβ may have a neuroprotective role.  Therefore, AD 
cases with APP mutations may lose effective antioxidant capacity due to mutation-
driven protein dysfunction, while the Aβ deposits may reflect a host response to 
oxidative imbalance and an oxidative stress [772, 794, 882].  This is consistent with Aβ 
deposits beginning to appear around the age of 40 years in FAD [878].   
Viewing endogenous Aβ as a protective response element provides a heuristically 
valid mechanism for why it is that the brains of elderly individuals when redox 
alterations are first manifest [878], can contain Aβ-deposits at loads comparable to 
most AD patients and yet remain cognitively intact [883].  Thus, while the production 
and deposition of Aβ may enable these individuals to starve off age-related redox 
imbalance, the presence of a profound and chronic redox imbalance in AD [859] may 
mean that even high levels Aβ are insufficient to negate the oxidative damage [793].  
The cause of redox imbalance in AD remains unclear [862].  However, it is interesting 
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that studies of primary neuron cultures indicate a ferroxidase activity of APP, noting 
its up-regulation in response to increased iron stores [72].  Indeed, APP seems to 
facilitate the export of iron from cells likely in an attempt to minimize potential ROS 
generation by the presence of reactive iron [884].  APP has also been reported to 
prevent the release of iron (II) from heme further reducing the toxic accumulation of 
redox-active iron [885], and exogenous iron load reportedly promotes the α-secretase 
cleavage of APP, which generates a soluble, potentially neuroprotective Aβ peptide 
[862].  Thus, in addition to a less potent antioxidant effect of Aβ, it is possible that AD 
cases with APP mutations may also lose some functional ability with respect to the 
ability of APP to reduce the toxic accumulation of redox-active iron, leading to its 
accumulation in the brain and thus the generation of ROS.  Also, it has not been 
determined whether in vivo Aβ species have differential effects on mitigating such 
oxidation (i.e. intracellular vs. extracellular), or if some FAD mutations may favour the 
production of species perhaps less adept at this antioxidant function.  
Thus, from the studies summarised above, it is evident that whether or not Aβ 
levels become detrimental in the long-term, may well depend on multiple factors, 
including the production of ROS [853], and the degree of systemic neuroinflammation 
[851]. Indeed, glial cell senescence may be a key factor in this [850, 853, 855], as high 
concentrations of soluble Aβ have been shown to be sufficient to trigger a program of 
glial senescence in some individuals [855] — a process that is further associated with 
increased pro-inflammatory signalling [855], as well as further ROS production [886, 
887].  Indeed, this could form a positive feedback loop as ROS are also known to 
trigger senescence in a wide range of cell types [888], including potentially astrocytes, 
as these cells are known to be highly sensitive to oxidative stress and develop 
senescence when faced with multiple types of stress [855].  However, it is also worth 
remembering that AD may develop even in those without significant Aβ deposition 
[705], suggesting the presence of additional Aβ–independent pathological roads to AD.  
Indeed, multiple "hits" from a variety of pathological mechanisms may be required 
before AD develops [889]. This also suggests that there may be more 
clinicopathological subtypes of AD that is currently recognised.   
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1.9 CONVERGENCE:  AD  AS  A  METABOLIC  DISORDER  
Accumulating evidence now suggests that may in many ways AD may represent a 
metabolic disorder, with pivotal roles for both brain insulin resistance and insulin 
deficiency, as mediators of cognitive impairment and neurodegeneration (see reviews, 
[890-893]).  In this respect insulin resistance and insulin deficiency may both represent 
convergent age-related factors with other co-morbid health conditions such as 
metabolic syndrome and T2D, both of which are recognised as substantial risk factors 
of developing AD [890].  This final section briefly considers the roles of insulin 
resistance and insulin deficiency in the pathogenesis of AD. 
 
1.9. 1 Insulin  Signalling in  the Periphery  and  Brain   
Insulin is nearly exclusively produced by the beta Islet cells (β-cells) of the pancreas, 
where it primarily acts as a metabolic regulatory hormone to stimulate the uptake of 
glucose by liver, muscle, and adipose tissue [242].  However, in order to achieve these 
effects, insulin and its trophic IGF, must firstly bind to their respective receptors, a 
process which results in phosphorylation and activation of intrinsic receptor tyrosine 
kinases, with the interactions between the phosphorylated receptors and insulin 
receptor substrate molecules then promoting the transmission of downstream signals 
which then affect physiological function[894].  Within most tissues glucose is stored as 
glycogen, although in adipocytes it is stored as triglycerides.  The release of insulin 
from pancreatic β-cells occurs in response to peripheral blood glucose levels detected 
through the glucose transporter-2 (GLUT-2), although GLUT-2 is not itself stimulated 
or regulated by insulin [894].  From the close links that occur among insulin receptor 
sensitivity, pancreatic β-cell activity, blood glucose levels, and glucose use by insulin-
sensitive tissues, under normal physiological conditions a classic negative feedback 
loop is formed [894].  In brief, insulin secreted by pancreatic β-cells induces a 
signalling cascade which results in the insulin-sensitive glucose transporter -4 (GLUT-
4) being translocated from the intracellular vesicles inside muscle and fat cells, to the 
plasma membrane where they become available for absorbing glucose down its 
concentration gradient into muscle and fat cells fostering the lowering of blood 
glucose levels [895].  The subsequent detection of lower levels of glucose by the β-cells 
(via insulin-insensitive GLUT-2) then results in a decreased secretion of insulin [894].  
The loss of pancreatic β-cells as in T1D or in animals treated with streptozotocin, 
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results in no or deficient insulin secretion and loss of blood glucose control 
(hypoinsulinemic, hyperglycemia) [894].  However, insulin levels are also indirectly 
affected when resistance to the normal physiological actions of insulin occurs as in 
metabolic syndrome, obesity and T2D [242].  In these scenarios, insulin is inefficient in 
activating its receptors controlling the uptake of glucose by muscle and other insulin 
sensitive tissues [894].  Although the molecular basis for this is still debated, research 
has implicated the down regulation of GLUT-4 in adipose tissue and skeletal tissue, a 
process known to cause impairments in glucose transport [894, 895].  Consequently 
therefore, blood glucose levels rise, causing the pancreatic β-cells to release more 
insulin until either glucose levels return to normal, or pancreatic insulin output 
reaches its maximum [894]. However, as mentioned earlier, if increased insulin 
secretion by the pancreas cannot overcome the insulin resistance, pre-diabetes or T2D 
usually ensues [242].  Furthermore, in chronic circumstances the near maximal output 
of insulin from pancreatic β-cells can lead to their loss, and thus, an absolute insulin 
deficiency that may require insulin replacement therapy [242]. 
Insulin and IGF enter the CNS by means of a saturable transport system at the BBB 
[896], where via the same phosphorylated-receptor cascades they subserve a variety of 
important functions, including feeding behaviour, inhibition of apoptosis, stimulation 
of neurogenesis and cell survival, metabolism, and regulation of the synaptic plasticity 
activities required for learning and memory (see reviews, [894, 897]).  Insulin and IGF-
1 receptors are widely expressed throughout the mammalian brain, and are expressed 
at particularly high levels in the hypothalamus, cerebellum, hippocampus, and cortex 
[898, 899], as well as in different cell types, including glial and neuronal cells [900]. 
Thus, signalling through insulin/IGF receptors is impaired, the structural and 
functional integrity of the CNS is compromised [894]. 
 
1.9. 2 AD  as  a  ‘Type  3  Diabetes’   
Insulin and IGF signalling pathways regulate glucose utilization, metabolism, and the 
adenosine triphosphate (ATP) synthesis needed for cellular homeostasis and dynamic 
modulation of a broad range of functions in the CNS [890].  Indeed, the first step to 
understanding AD as a metabolic disorder came with the realisation that the condition 
was associated with significant impairments in cerebral glucose hypometabolism [901-
906], which worsens as the disorder progresses [907-910], and seem to represent a 
reliable marker of disease status [800, 903, 911-915].  These findings lend strong 
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credence to the view that impairments in insulin signalling likely have important roles 
in the pathogenesis of AD [916].  Indeed, a large body of evidence now indicates that 
insulin/IGF resistance [917-922], along with impaired brain energy utilization [923-926] 
are present in AD, and in particular AD brain tissue [916, 927, 928], and likely reflect 
fundamental components of AD since they can occur in early-stage AD patients even 
in the absence of T2D [897, 929].  Insulin and IGF polypeptides along with their 
associated receptor genes are all expressed in neurons [930-932], and glial cells [933-
936], in brain regions considered to play critical roles in regulating and maintaining 
many aspects of cognitive function [894].  The highest levels of CNS expression of 
insulin and IGF polypeptides are found in the frontal cortex, hippocampus and 
hypothalamus —all structures known to be targeted by the pathological progression of 
AD [937, 938].   
Insulin resistance and insulin deficiency in AD are also associated with significant 
disruption to signalling pathways regulating neuronal survival, energy production, and 
neuroplasticity [890], as well as abnormalities in the expression of genes and activation 
of kinases regulated by insulin IGF signalling [916, 924, 927, 939, 940].  For example,  
insulin and IGF regulated genes such as choline acetyltransferase, tau, and 
glyceraldehyde-3-phosphate dehydrogenase, which mediate cholinergic/cognitive, 
neuronal cytoskeletal, and metabolic functions, were all found to be suppressed in the 
AD brain in line with Braak Stage, whereas APP, GFAP, and microglial messenger 
ribonucleic acid (mRNA) transcripts all exhibited increasing expression with  Braak 
Stage [940].  Insulin resistance mediated impairments in energy metabolism also lead 
to oxidative stress in AD, and subsequently the generation of ROS, DNA damage, and 
mitochondrial dysfunction —all of which drive pro-apoptosis, pro-inflammatory, and 
pro-APP and Aβ cascades [897].  The above effects are supported by research 
conducted with experimental animals in which brain insulin receptor expression and 
function were suppressed by intra-cerebroventricular injections of streptozotocin, 
leading to cognitive impairment and neurodegeneration with features that overlap 
with AD [941-947].  In essence, AD may be the manifestation of “Type 3 diabetes” [916, 
940] with elements of insulin resistance and insulin deficiency [897].  In AD brains, 
deficits in insulin/IGF signalling are due to the combined effects of insulin/IGF 
resistance and deficiency [948].  The insulin/IGF resistance is manifested as by reduced 
levels of insulin/IGF receptor binding and decreased responsiveness to insulin/IGF 
stimulation, while the trophic factor deficiency is associated with reduced levels of 
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insulin polypeptide and gene expression in brain and cerebrospinal fluid [890, 916, 930, 
939-941, 944].  This hypothesis is not covered in depth here as several critical reviews 
have recently been published on this topic and the reader is directed to these for 
detailed discussion [891, 948-950].  A few salient points are considered below. 
 
1.9. 3 Neuromet abolic  Coupling 
Glucose metabolism fulfils important functions in adult brain related to 
neuroenergetics, neurotransmission, energy storage, biosynthesis and oxidative 
defence [894].  Indeed, compared to the rest of the body, the brain is the most energy 
demanding organ as it requires almost double the amount of energy in order to 
function correctly [894].  However, in contrast to the periphery, glucose transport into 
the CNS and the use of glucose by the majority of cells within the brain appears to be 
largely independent of insulin action in humans [894]. Insulin-insensitive GLUT-1 is 
the primary means by which glucose enters the brain across the BBB; it conveys about 
50 times more glucose into the CNS than would otherwise enter [951].  However, 
glucose transport across the BBB is saturable but not active (i.e. is not energy 
dependant), rather, GLUT-1 is a facilitated diffusion system that bi-directionally 
transports glucose from the region of highest concentration to the region of lowest 
concentration [894].  Under normal physiological conditions glucose levels are roughly 
twice as high in blood as in brain interstitial and cerebrospinal fluids, thus driving 
glucose into the brain from the blood plasma [894].  In studies in which glucose levels 
are raised in the CNS (or isotopes of glucose are introduced into the CNS), the brain-
to-blood efflux of glucose (which also occurs via GLUT1) can be demonstrated by the 
fact that any glucose not used by the CNS is returned to the blood [952].  For this 
reason glucose accumulation in the brain matches glucose use by the brain. Thus, the 
uptake, retention, and metabolism of glucose are nearly synonymous measures of CNS 
metabolic rate when glucose probes such as FDG-PET are taken up by the brain [894].  
Glycogen synthase is the only enzyme able to synthesize glycogen (the main storage 
form of glucose in the body). Muscle glycogen synthase (MGS) is expressed in most 
tissues including brain tissue [953], and phosphorylation by several kinases, including 
glycogen synthase kinase 3 (GSK3) induces the inactivation of the enzyme [954]. 
Glucose 6-phosphatase (G6Pase) is an enzyme that hydrolyses glucose-6-phosphate 
resulting in the creation of a phosphate group and free glucose.  In the periphery high 
levels of G6P allosterically activate MGS even when the enzyme is phosphorylated, this 
 70 
 
being the primary mechanism by which insulin promotes glycogen accumulation in 
skeletal muscle [955].  However, due to the neuronal version of MGS being kept in an 
inactive state only astrocytes are able to store glucose in the form of glycogen in the 
healthy CNS [956].  This is important because only astrocytes can metabolise glycogen 
via aerobic glycolysis into lactate [956-958], the latter of which is believed to be the 
principal oxidative energy substrate used by cortical neurons to sustain their activity 
[959, 960], although this has been hotly debated [961, 962].  According to the 
Astrocyte-Neuron Lactate Shuttle hypothesis, glutamate overspill at tripartite synapses 
stimulates the process of aerobic glycolysis in astrocytes via the sodium-coupled 
reuptake of glutamate and ensuing activation of the Na+/K(+)-ATPase which triggers 
the uptake of glucose via GLUT1 [963], and the subsequent production and release of 
lactate (see reviews, [964, 965]). The main source of glucose for glycolysis is 
extracellular [959], although endogenous glycogen may serve as a transient source of 
glucose [965].  Lactate is exported to neurons where it is taken up by the proton-linked 
membrane carrier monocarboxylate transporter 4 (MCT4) [966], and subsequently 
used to generate the ATP necessary for synaptic activity [957, 967].   
Measures of glucose levels in extracellular fluid in the rat hippocampus during 
memory tests reveal that glucose levels are dynamic, decreasing in response to memory 
tasks and loads; exogenous glucose blocks these decreases and enhances memory (as  
reviewed in [968]).  Indeed, neural-glia metabolic coupling is known to undergo 
various plastic adaptations in parallel with the adaptive mechanisms that characterize 
synaptic plasticity. Spatial learning and working memory in rats increases the number 
of astrocytes [969, 970], and distinct sub-regions of the hippocampus are metabolically 
active at different time points during spatial learning tasks, suggesting that a type of 
metabolic plasticity (involving by definition, neuron-glia coupling), occurs during 
learning [971].  New learning initiates a cascade of events in the brain that can lead to 
short-term and long-term memories [972]. While short-term memories require post-
translational modifications to existing proteins, the consolidation of long-term 
memories depends upon the activation of a gene cascade and downstream structural 
modifications in neurons that enable them to store the acquired information [973-975].  
This includes the activation of cyclic adenosine monophosphate (cAMP) response 
element binding protein” (CREB) [972, 974, 976] as well as the translation at activated 
synapses of the immediate early gene activity-regulated cytoskeletal protein (ARC) 
[977-981].  ARC is believed to play a key role in actin cytoskeletal dynamics as well as 
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regulation of the membrane excitability via expression of AMPA receptors (see review, 
[982]).  Furthermore, LTP and memory are also accompanied by synaptic structural 
changes associated with the phosphorylation of the p21-activated kinase-cofilin 
cascade involved in F-actin dynamics in dendritic spines [983-985], as well as the 
promotion of cytoskeleton assembly, and regulation of spine morphology [985-987].  
Thus, LTM formation would appear to have a high metabolic demand within the 
underlying active neuronal network, much of which is critically dependent on the 
import of lactate into neurons [988].  Indeed, the organization of astrocytes in non-
overlapping spatial domains indicates that they are uniquely positioned to shape the 
spatial distribution of the vascular responses that are evoked by neural activity (see 
review, [989]), and thus define the local availability of energy substrates by co-
ordinating local blood flow with neuronal activity [990],  a process that helps support 
neuronal functions [991].  However, this process also requires glucose and lactate to 
reach distal brain regions, a process accomplished via the astrocytic uptake of these 
energy substrates and their subsequent distribution and release through the astrocytic 
network via gap junctions (proteins CX30 and CX43) [992].  This process appears to be 
modulated by glutamatergic synaptic activity and AMPA receptors [992].  Indeed, the 
transfer of these energy substrates via this mechanism is able to sustain synaptic 
activity in the absence of extracellular glucose [992], suggesting an activity-dependent 
intracellular pathway for the delivery of energetic metabolites from blood vessels to 
distal neurons (see review, [968]).  Cumulatively these data suggest that glial metabolic 
plasticity is likely concomitant with synaptic plasticity [964, 965], and that astrocytes 
play a central role in coupling synaptic activity to glucose utilization, a central 
physiological principle of brain function that provides a heuristically valid framework 
for experimental studies utilising FDG-PET [965, 993]. 
 
1.9.3.1 Metabolic Impairment in AD 
AD is associated with cortical metabolic deficits and, in particular, significant 
impairments in cerebral glucose hypometabolism (as assessed via FDG-PET) [901-906]. 
Furthermore, the cortical hypometabolism becomes worse as the disorder progresses 
[907-910], and involves regions of the brain associated with the DMN, including the 
posterior cingulate, precuneus, parietal, temporal, and prefrontal brain regions [907, 
994-999].  Regions comprising the hypothetical DMN are normally active during rest 
and tasks with low cognitive demand, but otherwise deactivated [1000].  Functional 
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changes in the DMN correlate with  measures of cognitive performance [1001], and in 
AD, glucose hypometabolism in these regions represents a reliable marker of disease 
status [800, 903, 911-915].  Although one explanation for FDG hypometabolic patterns 
in AD patients reflects neuronal cell loss, the detection of these hypometabolic 
patterns in at-risk persons decades before clinical symptoms of dementia are evident 
[915, 1002, 1003] means that cell loss per se cannot be the root cause [1004].  
Furthermore, in a MRI and FDG-PET study of asymptomatic individuals carrying 
mutations in the PSN1 gene for EOFAD, and normal matched controls, Mosconi et al 
[1005] reported extensive reductions in cortical glucose metabolism in the pre-
symptomatic individuals in the absence of structural brain atrophy, again suggesting 
that cell loss is not a major contributor to low FDG-PET signals.  Indeed, many studies 
have found that cortical glucose hypometabolism accurately predicts subsequent 
decline in MCI, and conversion to AD [915, 1006-1008].  For example, one recent study 
by Toussaint et al [1008], using a large cohort of normal elderly controls, aMCI 
patients, and patients with AD, reported that FDG-PET hypometabolic patterns in 
DMN regions strongly influenced the specificity of the discrimination between 
different stages of AD, progression to MCI, and conversion to AD. These findings are 
consistent with research showing that regional brain hypometabolism is likely a 
consequence of cortical disconnection, the early stages of which can occur in at-risk 
individual’s decades before clinical symptoms of dementia are evident [681, 682, 1009]. 
In addition, although most studies have concluded that APOEƐ4 is not a major factor 
in the magnitude of cortical hypometabolism [1010-1012], a recent study has suggested 
that the E4 allele may be associated with a more global impairment glucose 
metabolism [1013].   
 
1.9.3.2 Amyloid Deposition and Cortical Glucose Metabolism 
The spatial relationship between amyloid deposition and impairments in cortical 
glucose metabolism are not completely understood.  Several studies have shown an 
anatomical overlap between amyloid deposition and glucose metabolism in parieto-
temporal, posterior cingulate and precuneus regions in AD, indicating and early 
metabolic vulnerability in amyloid plaque enriched brain regions [1014-1016]. By 
contrast, amyloid deposition in the frontal cortex, striatum and the thalamus has been 
reported to coincide with relatively spared metabolism [1015].  This suggests that 
metabolic dysfunction may not be driven by amyloid deposition in all brain regions 
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implicated in AD.  Studies have also reported divergent findings with respect to 
associations between amyloid deposition and cortical metabolic dysfunction across 
clinical subtypes. For example, it has previously been shown that patients with EOAD 
show differently distributed glucose hypometabolism in the absence of a regionally 
specific pattern of amyloid deposition [1017].  Furthermore, a recent study by Lehmann 
et al [1018], of EOAD participants and those with other forms of atypical EOAD, has 
reported that hypometabolism patterns differed across AD variants (reflecting 
involvement of specific functional networks), whereas the amyloid patterns were 
generally diffuse and similar across variants. Furthermore, when compared with 
patients with typical AD, one study found that despite similar distributions of PiB 
retention in posterior cortical atrophy, these patients showed reduced FDG uptake in 
occipitotemporal regions suggesting that metabolic impairment rather than Aβ-plaque 
deposition drove the clinical presentation in these patients [1019].  However, a recent 
study by Ossenkoppele et al [1020], of 100 patients with AD and 20 healthy controls, 
reported an increase in amyloid burden via PET-PiB and modest metabolic dysfunction 
in the parietal cortex (FDG-PET) of younger patients with AD.  Parietal amyloid load in 
this study was also found to be related to visuo-spatial functioning in younger patients, 
whilst metabolic impairment in the parietal cortex of patients was related not only to 
visuo-spatial skills, executive function, and attention [1020]. By contrast, in older 
patients, memory performance was associated with metabolic activity in the posterior 
cingulate, suggesting that clinical differences between younger and older patients with 
AD are related not only to topographical differentiation in downstream processes (i.e. 
metabolic dysfunction), but may also originate from distinctive distributions of Aβ 
accumulation [1020].  These findings are consistent with a previous study in non-
demented elderly human subjects which also concluded that traceable Aβ deposition 
in the brain plays an important role in occurrence of neuronal dis-coordination in 
DMN and poor WM [1021].  However, this study found no correlation between DMN 
dis-coordination and glucose hypometabolism [1021].  
Discrepancies between the above studies may reflect differences in cohort 
characterization, sample sizes, or the use of different methods for analysing PiB-PET 
data.  However, the lack of correlation between amyloid deposition and cortical 
glucose metabolism in many studies suggests that fibrillar Aβ deposition may only 
account for a fraction of the clinico-anatomic heterogeneity in AD [1018].  This further 
suggests that processes other than fibrillar Aβ account for the region-specific 
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metabolic impairment in AD [1017].  Among the prime candidates in this regard are 
soluble Aβ oligomers, as cell culture studies have shown Aβ oligomers to impair energy 
metabolism in the brain by decreasing neuronal ATP levels and triggering hexokinase 
(HKI) detachment from mitochondria, thereby decreasing HKI activity in cortical 
neurons [1022].  Indeed, since HKI is a glycolytic enzyme that plays an important role 
in reducing mitochondrial ROS generation and apoptosis in neurons (and other cell 
types) [1023-1025].  Thus, Aβ could induce cortical metabolic function and cell death 
via increased oxidative stress [1022].  This could induce glial senescence, and more 
speculatively, perturb the normal function of astrocytes in meeting the energetic 
demands of neurons.  Indeed, recent research suggests that Aβ does cause alterations 
of astrocytic metabolic phenotype, where they have been shown to impact on neuronal 
viability [1026].  However, observations from other neuroimaging studies show 
conversion to AD in individuals who do not have significant Aβ deposition, but who do 
have cortical glucose hypometabolism [705], suggesting other Aβ-independent 
mechanisms may be responsible.   
 
1.9.3.3 Insulin Resistance and Metabolic Dysfunction in AD 
CNS insulin receptors diverge from their peripheral counterparts both in structure and 
function [1027, 1028].  For example, neuronal insulin receptors are not considered to be 
involved with glucose metabolism [1029], although some research suggests that insulin 
stimulation may lead to a 15% increase in the uptake brain glucose in humans probably 
via an astrocyte-dependent mechanism [1030].  Indeed, using cell cultures containing 
Normal Human Astrocytes (basically human astrocytes which do not derive form 
pathological tissue), Heni et al., have recently shown that human astrocytes are 
insulin-responsive at the molecular level, expressing key proteins for insulin signalling, 
including the insulin receptor β-subunit, insulin receptor substrat-1, protein kinase B, 
and GSK- 3 [1031].  However, whilst Heni et al., reported gliogenesis and cell growth to 
be dose-dependent insulin phenomena in human astrocytes [1031] (a finding consistent 
with a previous study using cell cultures of rodent astrocytes [1032]), neither increased 
glucose uptake, nor lactate secretion appeared to depend on insulin stimulation [1031].  
However, findings from rodent astrocyte-enriched cultures [1033, 1034], and some 
human clinical studies [1030] have produces inconsistent results with respect to the 
role of insulin stimulation in mediating glucose uptake and lactate secretion.  
Nevertheless, in line with previous findings [1034, 1035], Heni et al., did report that the 
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process of glycogenesis was insulin-dependent in human astrocytes in a manner 
similar to other glycogen-storing cell types [1031]. In aggregate, these results are 
consistent with the view that gliogenesis and glycogenesis are insulin dependent 
phenomena in human and rodent brain tissue, although there may be species 
differences with respect to the process of brain glucose uptake and lactate secretion.  
Together with the fact that fundamental differences between rodent and human 
astrocytes have been reported [1036], it is possible that these differences may explain 
some of the general variation between mice and men [1036].  Nevertheless, although 
speculative, insulin resistance or insulin deficiency may still impact upon the process 
of neuro-metabolic coupling in humans if astrocytic glycogenesis is impaired.  
Furthermore, the increased proliferation of astrocytes seen with higher insulin levels 
may suggest that those with hyperinsulinaemia could have greater numbers of 
astrocytes [1031], although this has not currently been verified.  However, given the 
drop in responsiveness to normal physiological levels of insulin in other bodily tissues, 
it is perhaps more likely that insulin deficiency or insulin resistance results in fewer 
astrocytes (or greater numbers of senescent astrocytes). Although not directly relevant 
to this thesis, astrocyte senescence would be worth further investigation as differences 
in cerebral functions between lean and obese persons has been reported in the 
literature [1037], and could represent an additional cause of cortical hypometabolism 
in at-risk and early-stage AD patients. 
 
1.9. 4 An ti-apo pto tic  Mechan isms  and  Neurogenesis  
Apoptotic mechanisms inhibited by insulin/IGF stimulation include the ‘inhibitor of 
Bcl-2’ (BAD), Forkhead Box O (FoxO), GSK-3β, and nuclear factor kappa B (NF-κB) 
[894]. Wnt proteins form a family of highly conserved secreted glycoproteins that act 
as regulatory signalling molecules for cell-to-cell interactions during developmental 
embryogenesis, as well as in the adult brain, experience-dependent synaptic plasticity 
[1038, 1039] via the regulation of acetylcholine receptor translocation to synapses 
[1039]. Wnt proteins bind to receptors of the ‘Frizzled’ and ‘lipoprotein receptor-
related protein’ (LRP) families on the cell surface;  via several cytoplasmic relay 
components these proteins activate beta-catenin (β-catenin), which then enters the 
cell nucleus and forms a complex with T-cell factor 1 to activate transcription of Wnt 
target genes [1040].  In the absence of Wnt proteins these target genes remain silent 
[1040].  GSK-3β is known to regulate Wnt signalling by phosphorylating β-catenin 
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thereby targeting it for ubiquitin and/or proteosome-mediated degradation [1040]. 
Both insulin and IGF-1 have equal potential to inhibit apoptosis in cells that are 
normally responsive to either IGF-I or insulin [1041].  Insulin/IGF resistance and/or 
deficiency of these, has been hypothesised to impact these functions in AD [897].  
 
1.9.4.1 IGF-1 resistance and Neurogenesis 
IGF-1 signalling is crucial for normal brain development, as well as the proliferation, 
survival, and differentiation of each of the major neural lineages, neurons, 
oligodendrocytes, and astrocytes, as well as possibly neural stem cells [1042].  
Moreover, IGF promotes the function of fibroblast growth factor 2 (FGF2), which has 
an important role in maintaining neural stem cells in the undifferentiated state; it also 
plays a major role in activating the stem proliferation [1043-1047].  The sub-granular 
zone (SGZ) of the hippocampal DG, and sub-ventricular zone (SVZ) of the lateral 
ventricles, are two of the few brain regions that display regular neurogenesis 
throughout life [1048]. Whereas in the SGZ, stem cells differentiate into hippocampal 
DG granule cells, in the SVZ of the lateral ventricles the newly produced neurons 
migrate through the rostral migratory stream to the olfactory bulb where they become 
interneurons (see reviews, [1049, 1050]).  Neuronal differentiation is initiated when the 
NeuroD1 gene is activated by paracrine Wnt3 produced by astrocytes [1051-1053].  
NeuroD1 is a transcriptional factor that directly activates the insulin gene [1054-1056], 
and neuroD1-gene-deficient mice are known to lack the hippocampal DG region — a 
phenotype which causes a fatal functional impairment of the nervous system [1056, 
1057]. Neonatal DT1 has been linked to homozygous mutations in the NeuroD1 gene as 
well as neurological abnormalities that included cerebellar hypoplasia, learning 
difficulties, sensory-neural deafness, and visual impairment [1058].  
 In aggregate, the above findings indicate a critical role of NeuroD1 in both the 
endocrine pancreas, and the CNS [894]. Although the initial claim in the 1960s that 
new neurons are critical for learning and memory [1059] is still controversial, 
subsequent analyses at the cellular, circuitry, system and behavioural levels over recent 
years has generated mounting evidence in favour of adult-born neurons providing a 
critical role in hippocampal and olfactory bulb functions (see reviews, [1060, 1061]). 
Indeed, from a functional point of view, hippocampal neurogenesis is considered to 
play an important role in structural plasticity and network maintenance with the 
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adult-born neurons likely delivering a unique processing capacity to pre-existing 
circuitry as opposed to merely replacing dying granule cells [1050].  
 
1.9.4.2 Negative regulators of neurogenesis  
As a biological process, neurogenesis is dynamically modulated by various 
physiological, pathological and pharmacological stimuli [1049, 1050].  Neurogenesis in 
the brain decreases with age (see review, [1062]), an effect that likely reflects an age-
related decrease in Wnt3 protein and the number of Wnt3-secreting astrocytes [1053].  
This suggests that the regulation of paracrine factors (or growth and differentiation 
factors), play a critical role in aging and neurogenesis [1053, 1062].  However, research 
in animals suggests that exercise may rescue impaired neurogenesis in the 
hippocampus of aged mice by increasing the de novo expression of Wnt3 [1053]. Other 
factors which serve as negative regulators of adult neurogenesis in the brain, and 
hippocampus in particular, include inflammation induced by injuries, 
neurodegenerative diseases and irradiation [1063], and insulin resistance [894].  
Indeed, the hippocampus contains substantial amounts of immunoreactive insulin and 
insulin receptors [1064], while hippocampal neurons have been shown to release 
insulin under depolarizing conditions which then participates in memory processing 
through activation through its tyrosine kinase activity receptor (Tyr) kinase activity 
[899]. However, whilst insulin receptor-defective mice have been reported to develop 
cognitive impairments [1065], brain/neuron-specific insulin receptor knockout 
(NIRKO) mice have been reported to exhibit intact learning and memory despite a 
complete loss of insulin-mediated activation of phosphatidylinositol 3-kinase (PI3K), a 
loss of inhibition of neuronal apoptosis [1066], markedly severe neuronal insulin 
resistance, and reduced phosphorylation of Akt and GSK3β that leads to substantially 
increased phosphorylation of protein Tau [1066]. Nevertheless,  whilst NIRKO mice 
develop an impaired sympathoadrenal response to hypoglycaemia [1067], these mice 
retain roughly 5% of their brain insulin receptor protein, with IGF-1 receptors 
unaffected [1066].  Furthermore, the insulin receptor and insulin-like IGF-1 receptor 
are structurally similar, with both found at the cell surface as heterotetramers that 
once activated, can phosphorylate and/or interact with the same intracellular protein 
substrates (including members of the insulin receptor substrate family) to activate 
many of the same downstream signalling molecules (including phosphatidylinositol 3-
kinase PI3K) [1068, 1069].  Thus, it is possible that NIRKO mice are not IGF-1 resistant, 
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and that intact signalling through the IGF-1 receptor is able to functionally compensate 
for the loss of neuronal insulin receptors in this model.   
Research in insulin-deficient rodents with streptozotocin (STZ) induced diabetes 
typically display learning and memory deficits [1070-1072], as well as impaired cell 
proliferation in the adult hippocampal DG [1073] due to a glucocorticoid-mediated 
mechanism [1074].  Indeed, glucocorticoids such as cortisol are increasingly recognized 
as having an important role in the pathophysiology of insulin resistance [1075-1079], 
and are associated with memory impairment in many AD patients [1080], as well as 
being predictive of hippocampal atrophy and memory deficits in AD patients [1081], 
and aged persons [1082].  Glucose tolerance also progressively declines with age in 
humans and is often accompanied by insulin resistance and a high prevalence of T2D 
[1083].  Indeed, glucose intolerance correlates with learning and memory deficits as 
well reduced vigilance and attention [1084], and numerous longitudinal studies have 
confirmed an association between T2D and cognitive impairment [1071, 1085], 
particularly in old age [1086, 1087] where it serves as a risk factor for AD [1088]. 
However, whilst T1D is also associated with cognitive impairments in humans, at least 
one longitudinal study of patients with T1D has failed to find substantial evidence of 
long-term declines in cognitive function despite relatively high rates of recurrent 
severe hypoglycaemia [1089].  However, given the fact that AD and T2D are also 
associated with insulin/IGF resistance [897], raised cortisol levels [897, 1090], and 
aberrant inflammation [752, 1091], it is perhaps not surprising that altered hippocampal 
DG neurogenesis has been reported in both conditions [897, 1092]). Indeed, 
dysfunctional neurogenesis resulting from subtle disease manifestations likely 
exacerbates early neuronal vulnerability to pathological processes common to AD 
[1092].  On the other hand, enhanced neurogenesis has been linked to environmental 
stimuli, physical activity, trophic factors and some cytokines — all of which may 
represent a compensatory response and thus, an endogenous brain repair mechanism 
[1092].  Whilst these factors can potentially enhance cell proliferation in the early 
stages of neurodegeneration, research conducted in animals has suggested that 
survival of newly generated neurons is progressively impaired in AD as pathological 
processes continue [1093]. 
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1.9. 5 Ro le  of  Insu lin  in  Plasticity  Processes  
Insulin acts as a neuropeptide in the brain to regulate food intake, body weight, mood, 
cognitive function, memory, neuronal survival and synaptic plasticity [1094, 1095].  
Indeed, the intranasal insulin administration has been associated with a number of 
positive effects on the brain, including improving learning and memory (particularly 
verbal memory), mood stabilizing effects in patients with AD and healthy volunteers 
[1096-1099].  The effect on memory in human AD patients [1100], and healthy males 
[1101] is also independent of changes in peripheral glucose levels.  The positive effect of 
intranasal insulin administration on learning and memory has also been observed in 
diabetic and non-diabetic mice [1102, 1103].  Indeed, insulin signalling in the limbic 
system and hypothalamus has also been shown to be particularly important for spatial 
memory in rats [899, 1104, 1105].  
The effects of insulin on cognition (particularly learning and memory) has also been 
supported by animal studies which show that insulin modulates the concentrations of 
neurotransmitters crucial for synaptic plasticity in the brain, promoting both 
excitatory glutamatergic and inhibitory transmissions mediated by gamma-
aminobutyric acid (GABA)’ [1106, 1107], as well as acetylcholine [1108].  In addition, cell 
culture research conducted in neurons and Xenopus oocytes expressing recombinant 
NMDARs, suggests that insulin potentiates NMDARs via delivery of new channels to 
the plasma membrane [1109].  Because insulin and insulin receptors are localized to 
glutamatergic synapses in the hippocampus, this suggests that insulin-regulated 
trafficking of NMDARs may play a role in synaptic transmission and plasticity, 
including LTP [1109].  Indeed, this is consistent with research showing that insulin 
enhances NMDAR-mediated synaptic transmission at hippocampal CA1 synapses [1110], 
as well as the regulation of AMPA receptor endocytosis to cause LTD of excitatory 
synaptic transmission in the hippocampus and cerebellum [1111-1113].  Recent research 
has also shown that neurons and synaptic plasticity in the hippocampus of mice 
lacking the insulin receptor substrate protein 2 (IRS-2) exhibit significant deficits in 
NMDA receptor-dependent synaptic plasticity [1114], and cumulatively these results 
suggest viable mechanisms for the underling memory and learning deficits associated 
with impairments in neuronal insulin signalling.  Other research indicates that insulin 
may also play a regulatory role in the synthesis of the norepinephrine transporter, 
thereby modulating activity in CNS noradrenergic pathways [1115].  Clearly, in addition 
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to Aβ levels, insulin resistance and insulin deficiency have the potential to contribute 
to the further disrupt plasticity processes in the AD brain [891, 897]. 
 
1.9. 6 Tau  and  Aβ Pathology  
Tau is inappropriately hyperphosphorylated in AD by several proline-directed kinases, 
(including GSK-3β) [88], as well as increased activation of cyclin-dependent kinase 5 
[1116]  and c-Abl kinases [1117], leading to its misfolding and self-aggregation into the 
paired helical filaments found in NFTs, dystrophic neurites, and neuropil threads [1118].  
Furthermore, besides fibrillar tau, pre-fibrillar tau (tau oligomers) can also aggregate 
[720], where in a similar manner to Aβ oligomers they contribute to 
neurodegeneration by causing synaptic and loss and neuronal death [719].   Combined 
with a dysfunctional ubiquitin-proteasome system [1119], the inflammation-driven 
process of ubiquitination of hyper-phosphorylated tau [1120] further causes its fibrillar 
accumulation, oxidative stress, and ROS generation —all of which promote neuronal 
apoptosis, mitochondrial dysfunction, and necrosis in AD [1121].  Since tau gene 
expression and phosphorylation are normally regulated by insulin and IGF stimulation 
in the brain [1122, 1123], impaired tau gene expression due to reduced insulin and IGF 
signalling [1124] and insulin deficiency (i.e. effective trophic factor withdrawal),  has a 
number of pathological consequences in AD that include a failure to generate 
sufficient quantities of normal soluble tau protein (i.e. it accumulates as hyper-
phosphorylated insoluble fibular tau instead), and attendant exacerbation of 
cytoskeletal collapse, neurite retraction, and synaptic disconnection [897].   
Insulin resistance mediated impairments in energy metabolism have been linked to 
oxidative stress in AD and subsequently, the generation of ROS, DNA damage, and 
mitochondrial dysfunction, since all of these drive pro-apoptosis, pro-inflammatory, 
and pro-APP and Aβ cascades [897].  The concept that brain insulin resistance (with 
attendant oxidative stress and neuro-inflammation), promotes Aβ accumulation and 
toxicity is supported by experimental data [897].  For example, it is known that insulin 
stimulation normally accelerates the trafficking of Aβ from its point of origin at the 
trans-Golgi network to the plasma membrane, where insulin then stimulates its 
extracellular secretion [1125] and degradation by its IDE [1126, 1127].  Central insulin 
resistance/deficiency could in principle collapse this insulin-dependent means of 
degrading monomeric Aβ, allowing it to accumulate in the brain and oligomerise 
[1128].  Indeed, along with insulin/IGF and their concordant receptors [897], neuronal 
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IDE expression in post-mortem tissue obtained from AD are found to be reduced in 
the hippocampus [116, 117], and animal research conducted in transgenic mouse models 
containing APP mutations associated with FAD, has indicated reduced expression of 
IDE in the hippocampus due to raised glucocorticoid levels, and associated  increase in 
Aβ levels [1129].  This is further supported by additional animal research which has also 
shown that IDE responds to Aβ accumulation in the brain [113], and mice with a 
homozygous deletion of IDE have elevated endogenous brain Aβ [114, 115].  However, 
whilst in the cortex IDE protein levels normally diminish with of age, paradoxically 
cortical IDE expression in AD brain tissue is found to be elevated [118], although 
longitudinal studies have not been conducted in this respect.  These differential results 
for IDE in AD remain unexplained.  However, whilst it is evident that insulin-
independent factors are  involved in the expression of IDE in the cortex, IDE 
expression itself may not be optimal in its capacity to degrade extracellular oligomeric 
Aβ [109], particularly if the oligomers form via intracellular pathways [64, 66].  More 
speculatively, it may also be the case that the increased IDE expression in the AD brain 
is a reflection of something akin to "IDE-resistance", where like T2D, higher IDE levels 
reflect a physiological rebalancing mechanism to bring escalating levels of Aβ back 
within an acceptable range.  Indeed, rising Aβ levels may themselves reflect a similar 
phenomenon in some PiB+ persons, where the "Aβ-resistance" may reflect gene 
polymorphisms that result in reduced antioxidant capacity of the peptide in the face of 
early redox imbalance and oxidative stress.  Furthermore, in some individuals who 
perhaps exhibit early glial senescence, the raised Aβ levels may be sufficient to cause 
central insulin resistance and thus the development of AD [897] (see next section). 
Conversely, it may also be the case that some PiB+ persons who do not develop AD are 
just simply ‘resistant’ to the detrimental effects of chronically high concentrations of 
Aβ [1130].  Again, although not directly relevant to the experiments detailed in chapters 
3 and 4 of this thesis, it would be interesting to see if glial senescence is one of the 
factors which differ between PiB+ and PiB- phenotypes. 
 
1.9. 7 C auses  o f in sulin  Resistance/ Deficienc y  in  AD 
Although the cause of cerebral insulin/IGF resistance in AD remains unclear, they 
likely reflect various mechanisms, none of which are likely to be mutually exclusive.  
Here I will mention two of the main factors which are considered to have a role in the 
induction of insulin resistance in AD, T2D and soluble Aβ oligomers. 
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Peripheral insulin/IGF resistance are defining features of T2D [242, 1131, 1132], as well  
as many cases of AD [890].  However, although these two diseases share some clinical 
and biochemical features suggestive common pathogenic mechanisms [1133, 1134], the 
correlation between T2D and AD [246, 1135] has yielded paradoxical results as not all 
studies have confirmed the association (e.g. [249]).  Whilst this may possibly reflect co-
morbid factors such as cerebrovascular complications and APOE genotypes [1136, 1137], 
findings in human post-mortem studies have also reported no significant increase in 
AD diagnosis among diabetics [1138], nor any significant differences in the densities of 
Aβ-plaques and NFT pathology in subjects with T2D compared with normal aged 
controls although peripheral insulin resistance is more common in AD than with 
normal aging [1139].  Thus, although diabetes is a risk factor for AD and other dementia 
T2D, these results indicate that in isolation T2D is unlikely to cause AD [897].  
However, experimental mouse and rat models of chronic high fat diet feeding and diet 
induced obesity with associated T2D, do exhibit deficits in spatial learning and 
memory [1140, 1141].  However, whilst experimental obesity with T2D also causes mild 
brain atrophy with brain insulin resistance, neuro-inflammation, oxidative stress, and 
deficits in cholinergic function [1142, 1143], an important qualifier about these studies is 
that the associated brain abnormalities were typically modest in severity, and devoid of 
NFTs [897]. Therefore, observations both in humans and experimental models suggest 
that while obesity or T2D can be associated with cognitive impairment, mild brain 
atrophy, and a number of AD-type biochemical and molecular abnormalities in brain, 
(including insulin resistance and oxidative stress), they support the contention that in 
isolation they do not cause significant AD pathology [897].  Indeed, research 
conducted in transgenic mouse models of APP mice suggests that diet-induced insulin 
resistance likely promotes and aggravates a range of pre-existing pathologies linked to 
AD, including amyloidosis and neuroinflammation [1144-1148].  One mechanism by 
which brain insulin resistance, oxidative stress, neuro-inflammation, and cell death 
can be generated in AD is via disruption of the liver-brain axis, which in T2D can 
involve the transfer of toxic lipids (including ceramides) across the BBB [890, 948].   
 
1.9.7.1 Aβ oligomers as a Cause of Insulin Resistance 
Current evidence also suggests a role for the abnormal interplay between soluble Aβ 
oligomers and insulin signalling in the brain.  Soluble Aβ oligomers inhibit insulin 
signalling [1149], and aside from their effect on plasticity and deterioration of synapse 
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function, composition, and structure leading to their loss [65].  A recent study by Zhao 
et al [1150] using mature cultures of hippocampal neurons has also reported that 
extracellular Aβ oligomers bound specifically to dendrites, leading to neuronal 
oxidative stress and a rapid but substantial loss of neuronal surface insulin receptors.  
Although the impact on IGF-1 receptors was not assessed in this study, removal of 
dendritic insulin receptors  was associated with increased receptor immunoreactivity 
in the cell body, indicating the ectopic redistribution of receptors and subsequently a 
muted neuronal response to insulin (as measured by evoked insulin receptor tyrosine 
autophosphorylation) [1150].   
A subsequent study by De Felice et al., [1151] using mature cultures of hippocampal 
neurons, has reported that soluble Aβ oligomers bind to synaptic sites on the dendrites 
of neurons, causing oxidative stress, and the removal of insulin receptors.  
Furthermore, that the down regulation of plasma membrane insulin receptors via a 
mechanism sensitive to calcium calmodulin-dependent kinase II (CaMKII) and casein 
kinase II (CK2) inhibition, occurred prior to the Aβ-mediated loss of dendritic spines 
[1151].  However, most importantly this study also showed that insulin prevented these 
effects; moreover, that rosiglitazone (an insulin-sensitizing drug used to ameliorate 
insulin resistance in T2D patients), enhanced the protective effects of insulin by 
preventing the loss of insulin receptors from dendritic plasma membranes, and thus 
the loss of synapses [1151]. Although the molecular identity of the synaptic binding sites 
for Aβ oligomers remain to be determined, they did not bind directly to insulin 
receptors in this study, nor did they compete with insulin for binding to insulin 
receptors [891, 1151].  Moreover, since insulin failed to block the binding of Aβ 
oligomers to dendrites in the presence of the insulin receptor tyrosine kinase inhibitor 
AG1024, it indicates an insulin signalling–dependent mechanism [1151].  Indeed, aside 
from its possible impact on causing the internalisation of insulin receptors (which 
within normal physiological limits may well be a natural regulatory mechanism), Aβ 
oligomers may also modulate other membrane proteins, including NMDAR by 
reducing their cell surface density [1152, 1153],  and thus by implication their 
participation in nominal neuronal communication [891].  Therefore, it is plausible that 
Aβ oligomers may interact with specific (but so far undetermined) membrane-bound 
protein complexes that contain these receptors, which are then internalized via an 
unknown mechanism [891].  At the very least, the neuroprotective effect of 
rosiglitazone in the De Felice et al. study indicates that it requires specific membrane 
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protein components as well as insulin receptor-mediated intracellular signalling events 
[1151].  Recent research using cultured primary cortical rat neurons also suggests that 
rosiglitazone increases dendritic spine density and rescues spine loss caused by 
APOEƐ4 in primary cortical neurons [1154].  Although the above findings were reported 
after the experimental work for this thesis was conducted, they do support the rational 
for the use of insulin sensitizers in ameliorating components of AD pathology in 
preclinical mouse studies. This will be discussed further in section 1.9.8. 
Two major conclusions can be drawn from the above studies. First, that the early 
neuronal damage in AD associated with Aβ oligomers may in part be triggered by the 
Aβ-related internalization of insulin receptors and a concomitant decrease in insulin 
signalling leading to insulin deficiency [891]. Second, that the effects of stimulating 
insulin signalling in neuronal cell cultures, supports the wider rational for a potential 
neuroprotective strategy involving insulin sensitizers an a therapy in AD (see next 
section).  However, intracellular Aβ oligomers can also compromise insulin/IGF 
signalling in the brain by interfering with the association between phosphoinositide-
dependent kinase 1 (PDPK1) and RAC-alpha serine/threonine-protein kinase (AKT1) to 
preclude AKT1 activation (key components of the insulin signalling cascade) [1155] (see 
review in, [891]). Indeed, Aβ peptides are generated intracellularly [1156], but can also 
be taken up into cells from an extracellular source [1157], and it is not clear which 
source of Aβ or Aβ-oligomers plays the pivotal role in mediating detrimental effects on 
neurones and insulin signalling, although it is possible that both scenarios are 
compatible with biological reality.  For example, both targets (one being an 
extracellular Aβ-binding site on neuronal dendrites, the other an intracellular 
interaction between PDK and AKT), could be relevant to AD and Aβ, since Aβ 
oligomers could act via both pathways to impair insulin signalling [891].  Thus, it is 
uncertain which of these pathways is targeted by the therapeutic impact of improving 
insulin signalling.  However, the fact that insulin treatment or activation of its 
downstream signalling pathway reduces intracellular Aβ production and increases its 
extracellular secretion by increasing competition between insulin and Aβ for IDE 
[1126], suggests that intracellular Aβ is more likely to be the key target of the insulin-
mediated protective effect [891].  This is further supported by recent animal data 
showing that targeting intracellular Aβ by a specific γ-secretase inhibitor (or by 
immunotherapy) at an early stage of the disease can prevent synaptic dysfunction in 
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mouse models of AD [1158].  However, γ-secretase inhibitors and immunotherapy have 
failed to deliver quantifiable cognitive benefits clinically [412, 1159].   
 
1.9. 8 PP AR-γ Insulin  Sensitizers:  A  Treatment  for  AD? 
The findings discussed in this section provide a mechanistic explanation for why 
concentrations of insulin well as their receptor mediated signalling, are all markedly 
reduced in the AD brain [891, 897].  However, they also show that the vulnerability to 
Aβ-oligomers can be reduced or possibly even mitigated, by the use of intranasal 
delivery of insulin [894, 948, 1095-1097], as well as treatment with insulin sensitising 
compounds such as rosiglitazone.  These are considered to mediate their beneficial 
effects in the periphery [1160] and CNS [1161], via the activation of the peroxisome 
proliferator-activated receptor-gamma (PPAR-γ).   
 
1.9.8.1 PPAR-γ Receptors and Thiazoladinediones 
PPARs represent a steroid hormone super family of ligand-inducible transcription 
factors that are expressed in fat cells, cells of the liver, muscle, heart, and inner wall 
(endothelium) and smooth muscle of blood vessels [1162].  As such, PPARs act as lipid 
sensors, enhancing insulin sensitivity by modulating whole body metabolism in 
response to dietary lipid intake, as well as the stimulation of mitochondrial function, 
and reduction of inflammatory responses [1163-1169]. There are three classes of PPARs, 
PPAR-α, PPAR-δ/β, and PPAR-γ, all of which are expressed in the adult brain, although 
PPARδ is most abundant, followed by PPAR-γ (see review, [1161]).  PPAR-α is expressed 
in the hippocampal CA1 and dentate gyrus regions.  The δ/β isoform is highly 
expressed in the dentate gyrus and CA1-3 regions of the hippocampus, and the γ 
isoform is expressed weakly in the brain but is present in the hippocampal dentate 
gyrus [1170].   
In the periphery PPAR-γ is mainly expressed in adipocytes, where they regulate 
genes involved in adipocyte differentiation, fatty acid uptake and storage, and glucose 
uptake [1162]. PPAR-γ is bound and activated by several naturally occurring 
compounds, such as the eicosanoids 9- and 13-hydroxyoctadecadienoic acids [1171], and 
more recently nitroalkenes (i.e. nitrated lipids) [1172]. In addition, several high-affinity 
synthetic PPAR-γ agonists have been synthesized, including the thiazolidinedione 
(TZD) class of compounds [1173], or which Rosiglitazone and pioglitazone are the most  
popular in research settings, and have been developed for commercially (pioglitazone, 
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Actos; rosiglitazone, Avandia) for clinical use as insulin sensitizers in patients with 
T2D [1160].  However, TZDs have been shown to improve insulin sensitivity and 
glycemic control in diabetic individuals [1160], the mechanism of action is uncertain.  
Two popular mechanisms have been elucidated and have experimental support.  
Firstly, research has shown that at the insulin receptor level, rosiglitazone increases 
insulin sensitivity as the result of two convergent mechanisms: increased insulin 
receptor expression and insulin receptor activation [1174].  These effects were 
associated with a 40% increase in insulin-stimulated glucose uptake as a result of 
increased GLUT4 translocation to the plasma membrane in adipocytes, which 
happened without changes in the expression of GLUT4 at the mRNA or protein level 
[1174].  Additional evidence shows that rosiglitazone may improve insulin resistance in 
vivo by normalizing GLUT-4 protein content in adipose tissue, and increasing GLUT-1 
in skeletal muscle and fat [1175].  Second, adipose tissue is also a source of free fatty 
acids and adipokines such as adiponectin and resistin [1176, 1177], and may have a role 
in preventing the development of insulin resistance [1178, 1179].  The production of 
adiponectin is decreased in obesity and subjects with T2D and coronary artery disease 
[1180], as well as women with polycystic ovaries [1181-1184].  Rosiglitazone stimulates 
adipocyte differentiation to adipocytes in which adiponectin is secreted leading to an 
increase in its blood plasma concentration [1185-1188].  Adiponectin improves glucose 
transport into cells and thus insulin sensitivity [1189, 1190].  Rosiglitazone has been 
shown to improve insulin sensitivity in patients with T2D, and impaired glucose 
tolerance via a mechanism that is probably related to changes in adiponectin 
production and adiponectin index [1191-1193].  Furthermore, adiponectin has also been 
shown to have anti-inflammatory properties [1194], and may be the mechanism by 
which TZDs are known to inhibit inflammatory cytokine production and thereby the 
development of atherosclerosis [1195].  However, the anti-inflammatory properties of 
rosiglitazone have also been linked to its direct activation of the PPAR-γ receptor and 
the down-regulation of early inflammatory response genes [1196]. 
TZDs have also been shown to promote mitochondrial function via PPAR-γ co-
activator 1 family of proteins, and ATP production [1197, 1198], and inhibit pro-
inflammatory gene expression via inactivation of NFkB-dependent promoters [1165, 
1199].  Furthermore, this class of drugs has also been shown to reduce β-secretase 
activity [1197, 1200], as well as promote cortical spine density (via the PPAR-γ receptor) 
[1154].  Although little is known about the physiological role(s) of PPAR-δ in the brain 
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[1161], resent studies have also shown that agonists for this PPAR isoform can reduce 
amyloid toxicity in vitro [1201], reduce Aβ-plaque deposition and astrogliosis as well as 
increase the expression of neprilysin and IDE in APP mutant mice [1202]. Recent 
studies have also suggested PPAR-α may be an important regulator of cholesterol 
trafficking in macrophages [1203]. Thus, TZDs appear to mediate a diverse range of 
actions in the CNS, including those which may mitigate amyloid pathology, making 
them potentially useful as therapeutic agents for treating cognitive impairment in AD. 
 
1.9.8.2 PPAR agonist treatments in AD 
In addition to the cell culture research already mentioned, rosiglitazone has been 
shown to improve cognitive performance (i.e. learning and memory) and/or ameliorate 
pathological indices related to inflammation, insulin resistance, and phospho tau/Aβ, 
in range of experimental animal models [1164, 1167, 1204-1210], as well as different APP 
mutant models [1129, 1200, 1202, 1211-1217].  Indeed, similar effects have also been 
reported with pioglitazone [1218-1230].  However, all of these studies have reported 
beneficial results, with only one study [1231], reporting negative outcomes in animals.   
Thus, the majority of studies all support PPAR-γ as being a viable therapeutic target in 
AD [1166].  This rational is further supported by research demonstrating that many 
non-steroidal anti-inflammatory drugs (NSAIDs), which include ibuprofen, have a 
protective effect against developing LOAD [1232, 1233], and activate PPAR-γ [1234].  
In terms of human studies with TZDs, the PPAR-γ agonist rosiglitazone (Avandia) 
has been most widely studied in human clinical trials, where in sharp contrast to 
animal studies, its effects in clinical trials undertaken with human AD patients have 
been mixed.  A preliminary trial of rosiglitazone, 4 mg daily, vs placebo in 30 subjects 
with mild AD or aMCI showed better scores on tests of delayed memory and selective 
attention after 6 months of rosiglitazone treatment [1235].  A subsequent double-blind, 
randomized, placebo-controlled study of rosiglitazone in 511 patients over 24 weeks 
revealed no significant improvement in the treated group overall; however, improved 
cognition (Assessment Scale-Cognitive: ADAS-Cog) was observed in a subset of 
patients who did not possess an APOEε4 allele [1236].  More recently, a multi-centre 
randomized proof-of-concept clinical trial has been undertaken by GlaxoSmithKline 
(GSK) pharmaceuticals (the makers of Avandia), that applied FDG-PET for evaluation 
of metabolic therapy with an extended release version of rosiglitazone (rosiglitazone-
XR) in 80 patients with mild-to-moderate AD [1237] over a 12 month period.  Whilst 
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active treatment was associated with a sustained but not statistically significant trend 
from the first month with respect to an early increase in whole brain glucose 
metabolism,  neuroimaging data indicated that active treatment did not lead to a 
significant decrease in the progressive decline in brain glucose metabolism [1237]. 
Furthermore, the rates of brain atrophy were similar between active and placebo 
groups, and measures of cognition (as assessed by the mini mental state Exam, ADAS-
Cog, and the Clinicians' Interview-Based Impression of Change – Plus), also did not 
suggest clear group differences [1237].  Thus, whilst rosiglitazone was associated with 
an early increase in whole brain glucose metabolism, this was not associated with any 
biological or clinical evidence for slowing progression over a 1 year follow up in the 
symptomatic stages of AD [1237].  These results are consistent with the findings of two 
other phase 3 studies which evaluated the efficacy and safety of rosiglitazone in an 
extended release form (2 mg, or 8 mg) over a 48 week period as an adjunctive therapy 
to on-going acetylcholine esterase inhibitor treatment in 485 patients, and treatment 
in 496 patients adjunctive to donepezil [1238].  No statistically or clinically relevant 
differences between treatment groups were observed on the a priori primary endpoints 
in these studies, including the cognitive assessment via the ‘Alzheimer's Disease 
Assessment Sub Scale’, and ‘Clinical Dementia Rating’ scale [1238].  Also, consistent 
with the known profile of rosiglitazone treatment at 8 mg, both studies reported 
adverse events related to edema, although there was no evidence of an interaction 
between treatment and APOE status  [1238].  
One potential explanation of the limited efficacy of rosiglitazone is its poor 
bioavailability to the CNS. Although rosiglitazone passes the BBB, it undergoes active 
efflux through P-glycoprotein–dependent transport, limiting its concentration in the 
brain [1239], although pioglitazone has demonstrated CNS penetration and relevant 
biological activity in a transgenic mouse model of AD [1221].  However, this does not 
explain the apparent discord between the animal data evaluating the impact of these 
drugs on cognition (see next section and Chapter 2).  Coupled with the disappointing 
results of treatment trials based on the amyloid hypothesis [1240] and yet the 
seemingly overwhelmingly positive results from animal studies of these treatments 
[412, 766], the discrepancy between human and animal studies demands urgent 
attention. Yet, it is of interest that a prospective randomized, open-controlled study of 
32 patients with mild to moderate AD (26 patients) or MCI (6 patients), treated with 
pioglitazone (30 mg daily, n=15), or not (n=17, control group), recently reported that 
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pioglitazone resulted in cognitive and metabolic improvements in patients with AD 
and MCI with diabetes [1241].  Although these results require verification in a larger 
double-blind, randomized, placebo-controlled study, it does suggest that peripheral 
insulin resistance and or T2D may be a determining factor in the efficacy of TZDs in 
the treatment of AD.  Furthermore, since none of the large phase 3 clinical trials so far 
reported with rosiglitazone were set up to track clinical changes according to whether 
individuals had concordant T2D or peripheral insulin resistance, and it is possible that 
a positive effect could have been masked in this patient population.   
 
1.9. 9 Summary  of  Strategy  and  Hypothesis  
This thesis details experiments aimed at examining the impact of rosiglitazone on 
cognition and amyloid pathology in a popular transgenic mouse model.  The mouse 
model used for these studies is generally known as Tg2576, and overexpress a genetic 
construct that contains a mutated form of the human APP (hAPP) gene associated 
with FAD kindreds [1242]. As a result, transgenic mice over-produce hAPP and 
consequently Aβ —a process that leads to the age-related development of amyloid 
pathology and cognitive deficits [1242].  Whilst not all clinical symptoms in AD 
patients find their parallel in such models, by using a variety of behavioural tasks it has 
been possible to observe some behavioural impairments in animals that exhibit 
similarities to those observed in AD patients [1243].  In addition, and importantly for 
this thesis, these mice have also been reported to develop spontaneous insulin 
resistance with age [1129, 1244] (see section 2.3.1.3).  
The behavioural experiments detailed in this thesis (see Chapter 3) all use a dual 
treatment strategy.  In the first set of experiments, a late intervention strategy was 
used to examine the impact of rosiglitazone on cognition and amyloid load in adult 
mice when drug administration was initiated at a point in adulthood when significant 
amyloid pathology, synaptic deficits, and behavioural impairment would already be 
expected in transgenic mice [1242, 1245, 1246]. Although Tg2576 mice are not 
considered to have AD, this strategy has some common ground with clinical studies in 
humans.  For example, some studies have delivered rosiglitazone to patients with mild-
to-moderate AD when pathological changes are established [1236, 1238, 1247].  
However, whilst clinical studies evaluating the effectiveness of rosiglitazone in AD 
patients have reported variable results,  pre-clinical studies conducted in Tg2576 have 
been more supportive and reported consistent findings suggesting that rosiglitazone 
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can ameliorate at least some cognitive and pathophysiological changes in hAPP mice 
when amyloid pathology is already established [1129, 1212, 1244].  However, it is 
important to point out, that the primary study upon which this thesis is based was 
conducted by Pedersen et al [1129]. In that study, rosiglitazone had only been 
administered to adult mice aged 8 months or older when amyloid pathology and 
synaptic deficits are already well established in Tg2576, and did not extend beyond a 6 
month drug administration period.  Critically, apart from the assessment of the impact 
of rosiglitazone on Aβ40 and Aβ42 levels, the behavioural assessment of these mice 
was limited to a de novo 8-arm radial maze task used to assess WM and reference 
memory errors.  This is important because it is unclear whether rosiglitazone had a 
selective or wider range impact on cognition in the same animal model.  Thus, in the 
first course of experiments, this thesis reports the outcome of late-intervention 
experiments following longitudinal administration of rosiglitazone from 8 months of 
age.  Chapter 3 details the impact of late-intervention experiments on established age-
related cognitive deficits across multiple domains (see Chapter 3).  The behavioural 
battery used for this was comprised of tasks covering typical phenotypic changes in 
Tg2576 such as spatial and object recognition memory, as well as changes related to 
anxiety.  Post sacrifice tissue analysis relating to late-intervention experiments can be 
found in Chapter 4, and relates specifically to the Elisa assessment of total amyloid 
load derived from single brain hemispheres, and Elisa assessment of plasma 
adiponectin protein levels (for drug penetrance in relation to an established 
physiological marker associated with PPARγ agonism). Based on the findings from 
Pedersen et al., [1129], the hypothesis was that longitudinal treatment with 
rosiglitazone would reverse an acknowledged spatial working memory deficit in 
Tg2576 mice, as well as reduce Aβ42 levels.  None of the subsequent studies using 
rosiglitazone in Tg2576 by Denner et al., [1212], and Rodriguez-Rivera et al., [1215]) have 
reported outcomes for the impact of rosiglitazone on behavioural impairments across 
multiple cognitive domains with longitudinal (chronic) drug-administration.   
At the time of its inception, the effects of chronic rosiglitazone on behavioural 
impairments in Tg2576 from an early age prior to the appearance of significant 
amyloid pathology were unknown.  Indeed, apart from the current thesis, this is still 
the case as none of the subsequent studies in Tg2576 using rosiglitazone [1212, 1215] 
have addressed this issue, despite the fact that concerns have subsequently been raised 
by one pre-clinical study [1215], that rosiglitazone may have a limited therapeutic 
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window for ameliorating cognitive impairment in adult transgenic mice.  Thus, in a 
second course of experiments, this thesis reports the outcome early-intervention 
experiments, all of which investigate the impact rosiglitazone on age-related cognitive 
deficits across multiple cognitive domains (using the same battery of tasks used in late-
intervention experiments) following continuous dosing with rosiglitazone from 5 
months of age (see Chapter 3).  At this time amyloid and synaptic pathology would be 
minimal in these mice, and some measures of cognition would be comparable between 
transgenic and non-transgenic mice [1245, 1246].  The hypothesis in this course of 
experiments was that rosiglitazone should delay the onset of age-related cognitive 
deficits in transgenic drug-treated mice.  Although it was not possible to conduct 
assessment of total amyloid levels for the early-intervention experiments, Chapter 4 
details an experiment which assessed the impact of longitudinal rosiglitazone 
administration on the Aβ-related loss of dendritic spines in the hippocampal dentate 
gyrus.  This has not been examined by any of the previous studies using PPAR 
treatments in preclinical mouse models of APP over-expression.   
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2. ANIMAL MODELS  IN  PRE-CLINICAL  AD  RESEARCH  
 
2.1 INTRODUCTION   
This thesis deals the preclinical assessment of rosiglitazone monotherapy, and details 
in Chapters 3 and 4 the various experimental manipulations undertaken with a popular 
transgenic (TG) mouse model of mutated human APP (hAPP) constructs associated 
with FAD kindreds.  TG mice are widely used to model human diseases, and 
commonly involve the overexpression of a particular protein.  Of these TG models, 
those that overexpress hAPP constructs are among the most frequently used and 
extensively characterised models in AD research.  This chapter discusses the relevant 
necessary background information in relation to TG models. Since it is not possible 
here to provide an in-depth review of this rapidly expanding area of research, the 
reader is directed to several published reviews on the subject [42, 1248-1250].  This 
chapter will focus on hAPP mutants, and in particular, the particular model used in 
this thesis for experimental manipulations. Section 2.2 firstly summarises the major 
hAPP models used in AD-related pre-clinical research before in section 2.3 discussing 
the pathophysiological phenotypic changes associated with the Tg2576 model, which is 
the model of choice for the PPAR-γ intervention experiments detailed in Chapters 3 
and 4.  Section 2.4 then summarises the previously published research relating to the 
effects of rosiglitazone administration on cognition and other pathological indices 
related to Aβ in Tg2576.   
The Tg2576 model was selected due to four main factors.  First, Tg2576 expresses 
aspects of early-stage neuropathology and behavioural deficits which mimic some of 
those found in AD patients. As such, Tg2576 is widely considered to be a credible 
model of amyloid-induced pathology present in the very earliest stages of AD.  Second, 
Tg2576 represents one of the most thoroughly characterised of all the hAPP mouse 
models, with fairly robust and in some cases age-related cognitive and behavioural 
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deficits [1245, 1246, 1251-1253] suitable for examining putatively therapeutic 
interventions.  Third, some studies indicate that male TG mice may have a 
vulnerability for developing spontaneous peripheral insulin resistance with age [1129, 
1244], such that these mice may provide us with a unique opportunity to examine more 
closely the specific conditions and the mechanisms by which insulin sensitizer’s 
impact on measures of AD-related pathology at a very early stage of the process.  
Indeed, a number of studies using different hAPP models have reported that aspects of 
peripheral insulin resistance may drive or significantly complicate AD-related 
pathology in mice [1144, 1146, 1244, 1254, 1255], and that rosiglitazone ameliorates some 
of these factors and leads to cognitive improvement in Tg2576 [1129, 1215, 1244], and 
other hAPP mouse models [1213, 1214, 1216].  Thus, investigating factors which could 
impact on the development of pathological alterations early-on in the disorder is of 
considerable importance clinically, as well as in terms of understanding disease 
mechanisms. Four, that the onset and development of pathology and behavioural 
deficits in this model are compatible with aims of this thesis.    
 
2.2 TG  MO DELS  REPRODUCING  AMYLOID DEPOSITION  
TG modelling has been actively pursued on the basis of the ACH in AD research and 
has taken advantage of mutations in the APP, PS1 and PS2 genes that cause FAD [38-
41]. Modelling is most often pursued in mice, for which the techniques of genetic 
modification have been particularly well developed.  There are, however, a great many 
TG and knock out rodent models used in AD research, as well as viral vector driven 
models [1256], many of which express bi- and tri-genic constructs [40].  Together these 
models mimic a range of AD-related pathologies, although none fully replicates all the 
symptomatic and pathological changes associated with the human disease [42].  
However, the failure of hAPP models to faithfully reproduce NFT pathology and 
neurodegeneration leave a question mark over the primacy of Aβ in both initiating and 
continuing to drive the pathological cascade in AD [705].  Thus, critics argue that most 
of these transgenic models are based on over-expression of exogenous APP, which does 
not apply to AD in humans [1257, 1258].  For instance, Robakis [1257] argues that since 
APP is metabolized to a large number of derivatives besides Aβ, some of which are 
reported to be neurotoxic (e.g., C-terminal fragments), disruptions of behaviour 
observed in these animals cannot unambiguously be explained by the soluble Aβ 
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oligomers.  Nevertheless, despite these limitations the majority of these models have 
contributed significant insights into the pathophysiology of AD, and in particular, the 
effects of Aβ species in pathogenic cascades.  Indeed, hAPP mouse models have been 
widely used in the preclinical testing of potential therapeutic modalities, and have 
played a pivotal role in the development of current Aβ-related immunotherapies for 
AD, some of which remain in clinical trials [42].  Thus, TG mouse modes will continue 
to play central roles in preclinical research related to AD.   
 
2.2. 1 Singl e,  Do uble  and  Triple  ‘3xTG’  models  
The first mouse models to develop Aβ-plaque pathology were generated by expressing 
human APP containing mutations associated with early-onset AD. Thus, in 1995 Games 
and colleagues published the first transgenic mouse (PDAPP) that over-expressed a 
minigene construct encoding human APP transgene associated mutation (V717F) 
[1259]. The platelet derived growth factor-β (PDGF) promoter was used in this model 
to drive the transgene containing V717F because, despite its name, it was known to be 
highly expressed in the central nervous system and to drive strong expression of 
exogenous transgenes in neurons [38]. PDAPP mice exhibited an age-dependent 
amyloid deposition in the brain along with thioflavin-S–positive plaques, including 
those resembling neuritic plaques with dense cores that were highly reminiscent of 
those seen in human AD. Dystrophic neurites, reactive astrocytes, and activated 
microglia were also found near these plaques, and the process was age-related in that 
plaque deposition was minimal at 6 months of age but readily apparent by 9 months, 
increasing dramatically by 12 to 15 months [1260].  Although PDAPP mice did not 
develop the NFTs or cell loss reminiscent of human AD, they were subsequently shown 
to develop age-related learning defects [1261] and synapse loss [1262].  Only a few years 
after the development of PDAPP, Ashe et al. [1263] taking a relatively similar approach 
published their Tg2576 (APPswe) model.  The Tg2576 mouse line is now freely 
available, and is among the most studied TG models in AD research.  Subsequently, 
many additional lines of mice expressing mutant human hAPP have been reported as 
developing similar amyloid pathology and cognitive deficits [1264-1266].  
Double mutant mouse models have been developed which cross hAPP mutant mice 
with those expressing mutant PSEN1 transgenes (PSAPP mice).  Such mice show 
accelerated amyloid deposition [1267-1269], largely due to the increase in Aβ42 
production mediated by PSEN1 mutations [1270, 1271]. The pathology seen in hAPP and 
 95 
 
PSAPP transgenic mice includes diffuse amyloid deposits as well as plaques containing 
fibrillar Aβ that resemble those found in human AD [1259, 1263, 1268, 1269].  
Furthermore, the neuritic-type plaques in these transgenic mice are likewise 
surrounded by dystrophic neurites with associated reactive gliosis [1272-1274].  
However, despite the robust amyloid deposition observed in APP and PSAPP 
transgenic mice, none of these models develops the widespread neuronal loss 
associated with human AD [1272, 1275], although astrocytic apoptosis has not been 
extensively studied in these models. Both neuronal cell loss and robust tau pathology 
(NFTs and neuropil threads) are also absent in mice expressing hAPP and PSAPP alone 
[38].  APP and PSAPP transgenic mice do develop vasocentric dense Aβ-plaques with 
associated structural microvascular damage and BBB abnormalities similar to those 
found in CAA [1276].  This type of pathology is largely absent in PDAPP mice [42].  In 
summary, the common pathological features of the PDAPP and Tg2576 mice (along 
with similar models), are the production of elevated Aβ levels, the formation of Aβ-
plaques, dystrophic neurites, and gliosis.  In addition, other neuropathological, 
electrophysiological, and neurochemical changes have also been found in these mice 
similar to those seen in AD patients [40].   
When double mutant mouse models are combined with a phospho-MAPT tau 
mutation isolated from FTD kindreds, these so called triple 3xTG mutant mice display 
a much wider range of neuropathologies common to human AD (see review, [1250]), 
including dystrophic neurites surrounding neuritic plaques and more extensive NFT 
pathology and neuronal cell loss [1259, 1263, 1269].  For example, the 3xTG model 
harbouring the PS1M164V, APPswe, and TauP301L mutations, typically displays an age-
related progression of pathology that shows a regional distribution pattern of 
neurophysiological lesions similar to that seen in human AD patients, as well as Aβ 
deposits that precede tau pathology [1277].  In addition, behavioural deficits and 
synaptic dysfunction in this mouse model develops around 4 to 6 months, with NFT 
development (which occurs at a later age) associated with early intracellular Aβ 
deposition at 3 months [1277, 1278]. Nevertheless, none of the 3xTG models fully 
reproduce all of the pathological features of human AD [1279].  However, these x3TG 
models combine multiple genetic constructs from both FAD and FTD-17 in 
combinations that are not normally found in humans.  Thus, the ultimate relevance of 
these models to human AD can be questioned [1280].  No-where is this more 
important than in the field of therapeutics in relation to immunomodulation targeting 
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the aggregating proteins Aβ and tau.  This type of AD therapy is currently being 
assessed in many transgenic mouse models, and promising findings in animals have 
led to clinical trials in humans [770].  However, as mentioned in the introduction, 
there  is a discrepancy between results obtained in TG murine models and those of on-
going clinical trials [1281], highlighting the general limitations of these models.  This is 
not helped by the lack of a commercially available animal model for SAD, although this 
is not one of the aims of the current thesis. 
 
2.3 PHENOTY PIC AL  CHARACTE RISTIC S  OF  TG2576  MICE  
Tg2576 mice overexpress hAPP harbouring the double hAPP mutation K670M/N671L 
related to FAD in Swedish kindreds (hAPPSwe), on a hybrid background strain of 
C57Bl/6J with Black 6 Swiss James Webster (B6SJL) [1263].  Tg2576 mice use a hamster 
prion protein promoter in order to drive strong expression of the hAPPSwe transgene.  
This model was created by microinjecting the human APP695 gene containing the 
double mutation K670N, M671L into B6SJLF2 zygotes using a hamster prion protein 
cosmid vector (basically, plasmid vectors that contain cos sites which circularizes the 
DNA in the host cytoplasm).   The resultant mice from founder line 2576 were 
backcrossed to C57BL/6. In March 1999 Taconic Farms (Germantown, NY) received 
stock of Tg2576 from the Mayo Foundation [25], wherehence hemizygous males were 
backcrossed with C57BL/6NTac for derivation by embryo transfer. This colony is 
maintained by mating hemizygous male mice with B6SJLF1 female mice.  Taconic 
received stock of Tg2576 from the Mayo Foundation in March 1999 [1282], wherehence 
hemizygous males were backcrossed with C57BL/6NTac for derivation by embryo 
transfer. The colony is maintained by mating hemizygous male mice with B6SJLF1 
female mice. Since this time, the Tg2576 model has been made widely available to 
research institutions for non-profit research purposes enabling the formation of 
multiple Tg2576 mouse colonies, one of which is maintained by Professor M.A. Good, 
Department of Psychology, at Cardiff University.   
Tg2576 mice express hAPP at levels more than 5-fold above the levels of the 
endogenous mouse APP [1263].  Because the APPswe mutation occurs close to the APP 
β-secretase processing site, it leads to increased β-secretase mediated cleavage and 
increased production of Aβ40 and Aβ42 with age [1263].  Soluble Aβ levels begin to 
increase from approximately 4 to 5 months of age in these mice; they become 
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significant by 6 to 7 months [1245, 1263, 1283-1285].  Between 6 to 10 months of age, 
insoluble forms of Aβ start to increase exponentially, a process that is associated with a 
slight reduction in soluble forms [1283].  Like PDAPP mice, Tg2576 mice show a robust 
age-related increase in Aβ in multiple brain regions, including the frontal and 
temporal cortices, and temporal-limbic regions such as the entorhinal cortex, 
hippocampus, presubiculum and subiculum, although the cerebellum is not 
significantly affected [1263, 1272, 1285, 1286].  By 9 to 10 months of age, there is 
significant deposition of Aβ, including as thioflavin-S–positive plaques similar to those 
found in AD [1263, 1287], gliosis, dystrophic neurites, abnormal tau-phosphorylation, 
and behavioural impairments [1283, 1288-1290].  However, whilst diffuse plaques are 
fairly abundant, the neuritic-like plaques in this model are not evident until around 12 
to 23 months of age [1245, 1291].  Concordant with this, plaque associated microgliosis 
becomes evident from around 10 months of age, with reactive astrocytes present at 18 
months [1245, 1272, 1273, 1292].  Accordingly, Tg2576 mice also show an inflammation 
response that includes the up-regulation of inflammatory markers such as IL-1β, TNF-
α, Cyclooxygenase-2 (COX-2), complement protein C1q, and chemoattractant protein-1 
[1293].   Neuroinflammation can be attenuated by the administration of non-steroidal 
anti-inflammatory drugs such as ibuprofen [1294, 1295], which is a PPAR-γ dependent 
effect [1295].  Significant structural but not physiological changes in cortical neurons 
have been reported in 12-month-old Tg2576 mice [1296], including increased dendritic 
lengths and volumes.  However, extensive NFT pathology, neurodegeneration, and cell 
loss (including the loss of cholinergic neurons), is absent in this mouse model [1272, 
1273, 1297, 1298], leading some to suggest that Tg2576 mice may model the pre-clinical 
aspect of AD [804, 1299].   Section 2.3.1 discusses the physiological phenotype of 
Tg2576. Since synaptic loss and metabolic impairments are the most directly relevant 
to this thesis, these are considered in most detail.  Section 2.3.2 then briefly introduces 
the cognitive phenotype of Tg2576.  However, in order to prevent unnecessary 
repetition of material, much of the detail relating to components of most relevance to 
the behavioural experiments used in this thesis, are reserved until Chapter 3.  
 
2.3. 1 Ph ysiolo gical Phenotype  
2.3.1.1 Factors Related to Synaptic Loss 
In Aβ-depositing mice it is known that "hyperactive" neurons in the hippocampus are 
found exclusively near Aβ-plaques, and appear to be due to a relative decrease in 
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synaptic inhibition as a result of soluble Aβ [82].  Although it is unclear how soluble 
Aβ may cause the heightened activity of these neurones, one theory is that it boosts 
synaptic glutamate in the hippocampus [82, 83].  Indeed, since plaque formation is 
itself associated with a transient drop in the concentration of soluble Aβ isoforms 
[1300], it is possible that this may allow any remaining soluble Aβ species to enhance 
neuronal activity via its ability to act as a regulator of release probability at 
hippocampal synapses [84].  However, since the majority of Aβ is considered to be 
neuronal in origin [53-56], this may then lead to even more soluble isoforms being 
produced, which subsequently cause the localised loss of synapses and depressed 
synaptic output typical of higher concentrations of the peptide Aβ.  Thus, hippocampal 
neurons near plaques may "rev-up" before they eventually become hypo-active. There 
are however, likely to be multiple ways by which soluble Aβ species affect neuronal 
and synaptic activity, all of which have implications for network dysfunction [83].   
Golgi-stained sections of human AD hippocampus and cortex reveal a significant 
decrease in dendritic spine density in many brain regions when compared to age 
matched controls [1301], and recent studies suggest that a failure in synaptic function 
underlies memory deficits in AD and ageing (see reviews, [1302, 1303]).  Synapse 
dysfunction and age-related loss of dendritic spines also occur in mouse APP models 
(see reviews, [1304, 1305]), and correlate well with the earliest signs of cognitive 
impairment [1245, 1301, 1306, 1307]. Learning and memory impairments in Tg2576 mice 
in the absence of overt sensory or motor deficits also suggest that the hippocampus is 
functionally affected in APP overexpressing mice [1262, 1263], more of which will be 
discussed latter in relation to Experiments 1 in Chapter 3.  Given the status of the 
hippocampus as a model system in studies of structural and functional neuro plasticity 
[833], most studies looking at the loss of dendritic spines in hAPP mice have focused 
on this brain region, and more specifically, the dentate gyrus and CA1 region.  
However, whilst most agree that spine density (number of spines per summed unit 
length of dendrite) is significantly decreased in the hippocampi of TG mice [1245, 1308-
1312], the differences may be less obvious in other brain regions with age [838, 1303].    
 The Effect s of  Agin g on  Syn aptic  Loss 
The loss of dendritic spines from the brain in Tg2576, particularly in the hippocampus, 
is a central component of the pathological phenotype of these mice.  As such, this is 
critically important in Experiment 7 of Chapter 4, which assesses spine densitity in the 
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hippocampal dentate gyrus. The molecular layer of the dentate gyrus is one of the 
earliest regions to show age-related amyloid deposition and synapse loss in Tg2576 
mice [1260, 1308, 1313]. Jacobsen et al. (2006) were amongst the first to report this 
[1245], where in 4 but not 2 month old TG mice, showed a significant decrease in spine 
density in the outer molecular layer of the hippocampal DG. This was also the time 
frame in which LTP deficits and contextual fear memory impairment emerged.  
Moreover, these deficits coincided with an increase in the ratio of pre-fibular Aβ42 and 
Aβ40, and remained stable between the ages of 12 to 18 months by which time, 
neuritic-like plaques and significant increases in reactive astrocytes and microglia were 
also observed [1245].  Using stereological methods at both the light and electron 
microscope level, Dong et al. [1308] reported similar findings in Tg2576 mice. Here, 
reduced synapse density (pre and post-synaptophysin-positive boutons) in the outer 
molecular layer of the DG was observed at both 6 to 9 months, and 15 to 18 months of 
age.  A significant decrease in synapse density was also observed in layers II and III of 
the entorhinal cortex at 15–18 months of age [1308].  Moreover, decreases in synapse 
density were correlated with proximity to compact Aβ-plaques, providing evidence of a 
spatial relationship between synapse loss and neuritic-like plaques at the ultra-
structural level in Tg2576 mice [1308].  However, this finding has not been confirmed 
by later studies [1303]. 
That soluble Aβ is likely the harbinger of synaptic loss in APP mutants is supported 
by several in vitro studies that have demonstrated oligomeric aggregates of Aβ 
reducing the number and/or length of dendritic spines in hippocampal neurons [1152, 
1314, 1315]. Aβ oligomers generated in vivo reduce spine density in CA1 pyramidal 
neurons [1312], although the loss of spines and synapses is variable [1308, 1310-1312].  
Using a Golgi-stain and light microscopy, Lanz et al. [1310] examined stretches of apical 
dendrites from five randomly selected completely filled CA1 pyramidal neurons in both 
PDAPP (between the ages of 2 and 11 months), and Tg2576 mice (between 2 and 20 
months of age).  This study reported that in the hippocampal CA1 region, both PDAPP 
mice and their wildtype (WT) littermates exhibited significant dendritic spine loss due 
to both age and hAPP overexpression, with both groups of mice exhibiting a significant 
loss of spines after the age of aged 2-months [1310].  Indeed, the genotype-dependent 
difference in spine density in the PDAPP mice was greatest at 2 months of age (17%), 
this was reduced to 8.8% by 5 months of age, and by 11 months no statistical difference 
in spine density was evident between the two genotypes, despite well-developed 
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plaque pathology [1310].  Like the PDAPP mice, Tg2576 mice also exhibited dendritic 
spine loss in CA1 hippocampal region due to both age and mutant hAPP 
overexpression, although a significant interaction between these variables was not 
detected [1310].  From 2 to 4.5 months of age, only the TG group showed a significant, 
albeit small reduction in spine density (6%), with the largest age-dependent loss 
occurring in both TG and WT groups between the ages of 4.5 and 11 months (18 to 19%) 
[1310].  No further reductions in CA1 spine density were observed between 11 and 20 
month-old mice of either genotype, and overall from 2 to 20 months, aging produced a 
23–26% loss of dendritic spines [1310].  Unlike PDAPP mice, the youngest age group of 
Tg2576 mice did not exhibit the largest decrease in spine density due to the APP 
transgene.  Rather, by 4.5 months a 16% reduction in spine density was observed in TG 
mice compared to age-matched WT littermates, which increased to 14% by the age of 11 
months although at 20 months both TG and WT mice had similar dendritic spine 
density in the CA1 region [1310].  This finding is consistent with the results of Dong et 
at al., (2007), who reported no significant genotypic differences with respect to CA1 
dendritic spine density in 15 to 20 month old TG2576 and WT littermate mice, [1308].  
These results are interesting for a variety of reasons.  Firstly, they suggest that the 
synaptic loss in APP mutants develops in both the DG and CA1 long before overt Aβ-
plaques are formed, confirming doubts with respect to a causal link between insoluble 
amyloid deposits, structural abnormalities of neurons and cognitive impairments [1310] 
(but see [1308].)  In addition, the fact that genotypic differences in CA1 spine loss are 
nullified by increasing age [1310], suggests that some regions of the hippocampus may 
react differentially to the effects of Aβ as well as normal age-related processes.  
The synaptic pathology in the hippocampus and in particular the DG of Tg2576 
mice, probably underpins most of the spatial memory impairments observed in this 
mouse model, although this is speculative.  As mentioned earlier, Jacobsen et al. [1245], 
has reported that Tg2576 mice exhibit an accelerated age-related decline in synaptic 
density in the DG region of the hippocampus, a process that was accompanied by a 
decline in basal AMPA receptor-mediated synaptic transmission, a deficit in the 
induction of LTP, and impairment in a contextual fear conditioning task prior to 
significant Aβ-plaque deposition.  Indeed, the data from this study indicates that the 
perforant path input from the entorhinal cortex to the DG is compromised both 
structurally and functionally in Tg2576 mice, and this pathology manifests as memory 
defects before significant plaque deposition [1245]. These findings are further 
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supported by Chapman et al. [1316], who have previously shown that aged Tg2576 mice 
exhibit normal fast synaptic transmission and short term plasticity, but are severely 
impaired when it comes to in-vitro and in-vivo LTP in both the CA1 and DG regions of 
the hippocampus.  Indeed, the disruption of LTP in this study also correlated with 
impaired performance in a spatial working memory task [1316]. As discussed 
previously, the primary pathogenic mechanism considered by most to be responsible 
for mediating these deleterious changes on hippocampal synapses and plasticity 
processes, are soluble Aβ oligomers.  Indeed, one such species of this type Aβ*56, has 
been suggested as the primary oligomeric form that mediates synaptic changes and 
memory impairments in these mice [1317].  Evidence supporting this relates to a 
previous study by Lesne et al. [804], which reported that a transient reduction in 
Aβ*56 occurs in Tg2576 mice between 11.9 and 12.4 months of age when the rates of 
accumulation of insoluble, fibrillar Aβ are transiently elevated, but memory function 
(as assessed via a spatial memory task) is intact.  Indeed, it was only when levels of 
Aβ*56 were not reduced, that memory function was impaired in Tg2576 mice [804].  
Although longitudinal studies of Aβ*56 in Tg2576 mice are lacking, it is possible that 
other periods of low Aβ*56 occur with advanced age, which may help to explain 
discrepant findings in the literature with respect to reports of intact spatial memory in 
aged TG mice despite significant Aβ pathology [1285].  Tg2576 mice have also been 
shown to exhibit age related impairment in a variety of Pavlovian tasks, including 
contextual fear conditioning (conditioning to a particular context), and cued fear 
conditioning (conditioning to a cue such as a tone) [1245, 1318-1320]. Both the spatial 
memory and cued/contextual fear conditioning impairments are consistent with the 
hypothesis that hippocampal processing and its interaction with the amygdala, is 
aberrant in aged Tg2576 mice [1320], probably as a result of synaptic/plasticity changes 
[1245, 1321]. 
 Microanatomy of  Single Den drit ic  Sp ines in  TG2 576 
Region-specific changes in the microanatomy of single dendritic spines over time have 
also been assessed in Tg2576 and other APP mutants [1311, 1312]. Middei et al., [1311] 
studied eight fully impregnated (randomly selected) hippocampal CA1 pyramidal 
neurons, or dorsolateral striatum (DLS) spiny neurons in Tg2576 and WT littermates 
aged between 3 and 15-months.  This study reported that in each region, all mice 
showed a global reduction in the size of spines as a function of age. However, ageing 
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mutants exhibited smaller spines with shorter necks on CA1 pyramidal neurons, but 
larger spines with longer necks on DLS spiny neurons compared to their age-matched 
wild-type controls [1311].  Since robust synaptic strength is a feature of spines with large 
heads and long necks allowing accumulation of activated synaptic proteins [1322], the 
authors suggested that ageing-related alterations in size of DLS spines were likely a 
compensatory mechanism aimed at maintaining “procedural” abilities in these mice, at 
a time when cognitive abilities dependent on intact hippocampal function are 
compromised [1311].  On the other hand, the presence of spines with short necks and 
small head areas is a prominent feature that correlates with the hippocampal synaptic 
plasticity and/or basal synaptic transmission deficit in TG mice [1288, 1323], as well as 
episodic-like memory impairment [1324, 1325].  However, in contrast to other studies, 
age-related changes were exacerbated in TG mice relative to aged WT mice [1311].  
  
2.3.1.2 Oxidative Stress and Metal Dyshomeostasis 
Although not central to the research aims of this thesis, oxidative stress and metal 
dyshomeostasis are important pathophysiological components of the Tg2576 
phenotype. Similar to AD patients, Tg2576 mice exhibit oxidative stress prior to 
significant Aβ deposition [1286, 1326, 1327], the latter of which also occurs with metal 
dyshomeostasis, since deposition of Cu, Zn and Fe metals are found in areas of amyloid 
plaque pathology [1328, 1329].  Furthermore, the degree of oxidative stress in Tg2576 
mice has been shown to increase with age and correlate with the developmental 
pattern of β-secretase activity and Aβ-plaque formation [1327].  Interestingly, 
behavioural stress (via restraint stress) has also been shown to exacerbate both 
metabolic oxidative stress and other pathological hallmarks in these mice, which may 
result in an increase in corticosteroid levels [1330].  Although the increase in oxidative 
stress in these mice is usually attributed to redox interactions and increasing levels of 
soluble Aβ [873], studies assessing the temporal relationship between oxidative stress 
and soluble Aβ oligomers in Tg2576 mice are currently lacking.  Presently therefore, 
the available evidence is consistent with the proposal that like human FAD sufferers, 
Tg2576 animals may overproduce a human form of Aβ that is less efficient at its 
antioxidant role [882], and a mutated form of hAPP that induces metal dyshomeostasis 
[862].  Although not directly related to the experiments detailed in this thesis, it would 
be interesting to see if murine levels of Aβ are up-regulated at a time of acute oxidative 
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stress as a possible compensatory response, or if these mice develop significant 
numbers of senescent glial cells with age as a result of oxidative stress.   
Research suggests that therapeutic treatment of Tg2576 mice with antioxidants may 
mitigate oxidative stress and/or other pathological features associated with AD [1326, 
1331, 1332].  However, studies of antioxidant treatments in AD patients have been rather 
disappointing [1333, 1334], placing the pathogenic role of oxidative stress in AD (at least 
as a treatment target in diagnosed patients) in doubt [1335]. Various transition metal 
chelators have also been trialed as possible treatments in Tg2576 mice and other APP 
mutants, and have frequently reported positive results [1336-1339].  To date several 
chelating agents have been investigated for their potential to treat neurodegeneration, 
and a series of 8-hydroxyquinoline analogues show the greatest potential for the 
treatment of these diseases in humans (see review, [1340]). However, developing 
chelators capable of crossing the BBB that are safe for humans poses significant 
challenges, although the approach is promising (see review, [1341]).   
 
2.3.1.3 Spontaneous Insulin Resistance 
Central to the justification for using rosiglitazone monotherapy in Chapter 3 of this 
thesis is research suggesting that Tg2576 mice spontaneously develop insulin 
resistance with age.  Pedersen et al [1129, 1148, 1244] have probably provided the 
greatest single contribution to understanding the metabolic deficits in adult male 
Tg2576 mice in this context.  In their initial study, this research group showed that TG 
mice exhibit increased sensitivity to physiological stressors, which was associated with 
aberrant  hypothalamic-pituitary-adrenal (HPA) function, and regulation of blood 
glucose levels [1148].  Indeed, dysfunction of the stress responsive HPA axis is also 
evident in AD patients [1342].  More specifically, Tg2576 mice exhibited severe 
hypoglycaemia and death following food restriction, as well as sustained elevation of 
plasma glucocorticoid levels and hypoglycaemia following restraint stress [1148].  By 8 
months of age male Tg2576 mice were reported to have lower basal serum insulin 
concentrations and exhibited a delayed insulin-induced reduction in blood glucose 
levels relative to WT counterparts, although basal levels of blood glucose and % 
glycosylated haemoglobin were both found to be similar between the two groups of 
mice [1244].  However, following an overnight fasting regime, TG mice were 
subsequently shown to have a greater rise in serum corticosterone levels as well as an 
excessive reduction in serum insulin concentrations [1244].  Furthermore, by 13 months 
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of age, Tg2576 mice became hyperinsulinemic suggestive of spontaneous peripheral 
insulin resistance, an effect that was prevented by the chronic oral administration of 
rosiglitazone starting at 9 months of age [1244].  Moreover, because insulin serum and 
glucocorticoid concentrations were maintained in transgenics at levels observed in WT 
mice following an overnight fast, these results provided evidence for a possible 
relationship between insulin resistance, impaired regulation of insulin and glucose 
levels, and aberrant stress responses in Tg2576 mice [1244].  As accumulation of soluble 
Aβ had been linked to memory deficits in Tg2576 mice, [841, 1284], Pedersen et al., 
suggested that insulin resistance in Tg2576 may contribute to cognitive dysfunction 
observed in these mice by increasing Aβ burden [1129].  In essence, the raised 
glucocorticoid levels in TG mice may have caused the deletion of insulin signalling 
components in the brain thereby initiating insulin resistance.  Rational for this was 
based on experiments by Buren et al. [1343], who showed that in cultured adipocytes, 
raised glucocorticoid levels deleted components of the insulin signalling pathway 
leading to peripheral insulin resistance. Crucially, because IDE is up-regulated by 
insulin in neuronal cells [1344], Pedersen et al., hypothesised that central insulin 
resistance (involving insulin deficiency), would reduce IDE expression, and thus, cause 
a relative increase in Aβ levels that could lead to impaired learning and memory in TG 
mice [1129].  Indeed, because cortisol was previously reported to cause a reduction in 
the levels of IDE, and moreover, a specific increase in the levels of Aβ42 (but not Aβ40) 
in the brain [1345], a similar outcome was predicted in Tg2576 mice. Furthermore, by 
chronically administering rosiglitazone to TG mice, Pedersen et al., hypothesised that 
both central and peripheral insulin could be normalised along with IDE deletion, 
resulting in a reduction of Aβ42 and thus, improvement of learning and memory [1129].  
Pedersen et al. tested their hypothesis in adult male Tg2576 mice and WT-littermates 
using a novel 8-arm radial maze task [1129], the results of which will be discussed in 
section 2.4. 
Rodriguez-Rivera and colleagues [1215], have also reported age-related peripheral 
glucose-regulatory abnormalities and hyperinsulinemia in adult Tg2576 mice 
suggestive of peripheral insulin resistance.  However, another group [1144], have found 
no convincing evidence for spontaneous peripheral insulin resistance in female Tg2576 
mice.  Whilst these discrepant results with female Tg2576 mice remain without 
resolution, studies in humans have shown that the sex steroid hormone estrogen may 
be protective against metabolic syndrome by contributing to the maintenance of 
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insulin sensitivity; estrogen deficiency can lead to development of T2D and insulin 
resistance in women [1346]. Taken in aggregate, current data suggest that peripheral 
glucose-regulatory abnormalities and hyperinsulinemia (both proxies for probable 
insulin resistance), may spontaneously develop in male Tg2576 mice [1129, 1148, 1215, 
1244], but the spontaneous appearance of these physiological impairments in female 
TG mice is more uncertain [1144].  Further studies are required to robustly confirm the 
presence of an insulin resistant phenotype in male Tg2576 mice, and resolve discrepant 
data with respect to such impairment in female TG, although this is not addressed in 
the current thesis.  In addition, it is interesting to note that, in contrast to the 
characteristic hypometabolism seen in AD patients, a recent study by Luo et al. [1347], 
using a combination of FDG-PET and functional fMRI in Tg2576 mice aged 7 and 19 
months of age, has reported the presence of ‘hypermetabolism’ with respect to cortical 
glucose utilisation at the 7 month time point, which could not be accounted for by 
changes in vascular compliance.  However, this hypermetabolic activity decreased with 
age such that, 19-month-old TG mice did not differ in terms of their cortical glucose 
utilisation from age matched WTs [1347].  These data are incompatible with central 
insulin resistance being present in TG mice, although this does not preclude the 
possibility that components of it may have been present in some brain regions (i.e. IDE 
hypo-function for example). However, the initial hypermotabolism revealed in this 
study may be an adaptive change to the overproduction of Aβ [1347], and could reflect 
aberrant behaviour in astrocytes, which in Tg2576 mice, have been shown to exhibit an 
age-related synchronous hyperactivity and long-range calcium waves [1348].  The 
extent to which these effects alter neural activity in rodents akin to the DMN is 
unknown; this is not addressed further in this thesis.  
 Diet  Ind uced Insulin Resistan ce 
Peripheral insulin resistance can be induced in rodents via dietary-induced obesity, a 
process which involves the chronic consumption of a high fat diet (see review, [1349]). 
This is much closer to the clinical situation as diet-induced obesity is a major pre-
disposing risk factor for T2D in man.  However, whilst dietary-induced obese animals 
exhibit moderate elevations in plasma insulin levels compared to control animals fed 
standard rodent chow, they do not typically develop diabetes (hyperglycaemia) [1349]. 
Both plasma glucose and insulin levels are increased following a glucose challenge i.e. 
the obesity is associated with impaired glucose tolerance and insulin resistance.  Ho et 
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al. [1144], were amongst the first to investigate dietary-induced obesity in Tg2576. In 9 
month old female TG mice, they discovered a high-fat diet led to increased levels of 
Aβ40 and Aβ42 peptide generation that corresponded with increased γ-secretase 
activities, decreased IDE activities (decreased IDE expression and activity), increased 
deposition of Aβ into plaques, and behavioural impairment in a spatial water-maze 
task relative to normal-glycemic TG mice.  Furthermore, Ho et al., also observed a 
functional decrease in cortical insulin receptor-mediated signal transduction in the 
insulin-resistant TG mice, although in control studies no detectable alteration in total 
insulin receptor expression was found in the cerebral cortex of insulin-resistant Tg2576 
mice relative to normal-glycemic TG mice [1144].  However, further exploration of the 
apparent inter-relationship of insulin resistance to brain amyloidosis revealed 
decreased insulin receptor autophosphorylation and reduced PI3K/pS473-AKT/Protein 
kinase-B (PKB) levels in the cortex. This was interesting for two reasons.  First, 
AKT/PKB has been associated with an inhibitory role of on GSK-3α activity, the latter 
of which has been shown to promote Aβ peptide generation [1350].  Indeed, GSK-3α 
and pS9-GSK-3β phosphorylation (an index of GSK activation), positively correlated 
with the generation of brain C-terminal fragment of APP in the Ho et al., study [1144], 
which the authors noted provided a valuable index of γ-secretase activity in the brain 
tissue of insulin-resistant TG mice relative to normal-glycemic Tg2576 mice.  Second, 
these results are also consistent with recent research suggesting that intracellular-Aβ 
oligomers in neurons can inhibit insulin receptor signalling in part by interfering with 
the association between phosphoinositide-dependent kinase (PDK), and AKT1, 
precluding AKT1 activation and eliminating the normally neuroprotective benefit of 
insulin [1155].  Indeed, given the aforementioned fact that total insulin receptor 
expression in the cerebral cortex was found in the Ho et al., study to be statistically 
comparable between insulin-resistant Tg2576 mice relative to normal-glycemic TG 
mice [1144], it suggests that this may have been the means by which functional insulin 
receptor deficits and thus, cognitive impairment was mediated in insulin-resistant 
Tg2576 mice.  However, the authors could also not exclude the possibility that changes 
in body fat may have disregulated estrogen balance in these mice, possibly leading 
cognitive changes [1351], and insulin resistance [1346].  Another study conducted with 
female Tg2576 mice and WT-littermates fed a high fat diet [1146], has reported that 
whilst caloric intake of high-fat-diet-fed TG mice were similar to that of normal diet-
fed TG or WT mice during 4 to 8 weeks (wk) of age, it increased sharply at 12 wk, and 
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went up further at 16 wk, which paralleled changes in the level of Aβ40 and Aβ42 in 
the brain of these mice and was associated with abnormal feeding behaviour with time.  
Indeed, the hypothalamus of high-fat-diet-fed TG mice had a significant decrease in 
the expression of the anorexigenic neuropeptide, brain-derived neurotrophic factor, at 
both the mRNA and protein levels [1146].  These findings suggest that the increased Aβ 
in the brain of high-fat-diet-fed Tg2576 mice is associated with reduced brain-derived 
neurotrophic factor expression, which led to abnormal feeding behaviour and 
increased food intake, resulting in obesity and insulin resistance in these animals[1146].  
Moreover, limiting food intake in high-fat fed TG mice by pair-feeding a caloric intake 
identical with that of normal diet-fed mice, completely prevented the obesity and 
insulin intolerance of high fat-fed TG mice [1146], further supporting concerns on the 
potentially adverse long-term effects of allowing ad lib food access by default to most 
laboratory animals [1352].  
 Finally, chronic consumption of sugar in calorically sweetened beverages in 
humans is also a risk factor for obesity, as well as insulin resistance [1353], although 
much of the research in this aria has involved animal research conducted with hAPP 
mouse models other than Tg2576.  For example, using the APPswe-PSEN1 model, Cao 
et al. [1254] have reported that a chronic 25-wk ad lib consumption of a 10% sucrose-
sweetened water in TG (but not WT) mice form the age of 2 months, was sufficient in 
~8 month old mice to induce increased body weight, glucose intolerance, 
hyperinsulinemia, and hypercholesterolemia, although frustratingly, this study did not 
report the sex of the mice used.  Furthermore, these changes in TG mice were 
associated with the exacerbation of spatial memory impairment (as assessed via the 
Morris water maze test), and a 2 to 3-fold increase in insoluble Aβ-protein levels and 
deposition in the brain, although steady state levels of IDE did not significantly change 
in these mice, whereas there was a 2.5 fold increase in brain murine APOE levels [1254].   
In aggregate, these results confirm two things.  First, compared to WT littermates, APP 
mice have vulnerabilities for developing peripheral insulin resistance with age when 
the right environmental variables co-exist.  Second, the development of peripheral 
insulin resistance in these mice can further exacerbate pre-existing amyloid 
pathologies, which may promote central insulin resistance.  A similar exacerbation of 
amyloid pathology and decrease in central insulin signalling is also observed in TG 
mice which contain the double hAPP Swedish and London mutations (APPSWE-LONDON), 
which also have a streptozotocin induced form of insulin-deficient diabetes [1145]. 
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2.3. 2 Behaviou ral  ph enotype  of  Tg257 6  
Any credible model of AD should ideally display not only key pathological 
characteristics of the disease, but also as many of the behavioural characteristics of the 
disease as possible, at least to the extent that this is realistic in a non-verbal animal.  
Whilst not all clinical symptoms in AD patients find their parallel in animal models, by 
using a variety of behavioural tasks it has been possible to observe some behavioural 
impairment’s in animals that exhibit similarities to those observed in AD patients 
[1243].  As such, behavioural tasks are usually sub-divided into groups according to the 
type of memory process being tested.  In general these fall into those assessing spatial 
memory, contextual memory (including episodic-like memory tasks), and those which 
examine working memory/novelty/loco-motor activity (see reviews, [1354, 1355]).  The 
cognitive processes assessed by particular tasks within these categories can be 
differentially affected by the pathology in Tg2576 mice across the animal lifespan [1245, 
1246, 1288, 1325, 1356]. Although the behavioural phenotype of Tg2576 mice also 
includes aspects of BPS [1250, 1252], most experimental studies fixate on cognitive 
impairments, and in particular, memory impairments.  Spatial memory impairments 
and behavioural changes related to anxiety and object recognition are phenotypic 
features associated with Tg2576 mice, and are discussed in the introductions to 
individual Experiments in chapter 3.  
 
2.4 PRE-CLINIC AL  STUDIES  USING  RO SIGLITAZONE   
Several studies have now been published on the effects of rosiglitazone treatment in 
Tg2576 and reported beneficial effects on learning and memory as well as a reduction 
in pathophysiological components related to insulin resistance and hAPPSWE over-
expression [1129, 1212, 1215, 1244].  This section briefly summarises these studies.  
However, particular emphasis is placed on the study by Pedersen et al. [1129], as this 
provides the primary impetus for the experimental work detailed in chapters 3 and 4.  
  
2.4. 1 Tg2576:  Stu dies  by  Ped ersen  and  Collea gues  
However, these studies, only Pedersen et al. [1129], has reported the effects of 
rosiglitazone on cognition and Aβ-protein levels in adult Tg2576 mice following 
continuous administration of the drug over a period of several months.  Having 
previously reported that dietary supplementation with rosiglitazone normalized the 
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insulin responsiveness of male Tg2576 mice [1244], this research group sought to test 
their hypothesis that increasing peripheral insulin sensitivity would improve the 
spatial learning and memory abilities of Tg2576 mice [1129]. Using a novel 8-arm radial 
maze task, Pedersen et al. determined the effects of rosiglitazone on the spatial 
learning and memory abilities of male Tg2576 mice using the following experimental 
design: Tg2576 mice subjected to a standard rodent diet supplemented with 
rosiglitazone (TG-R) at a concentration of 30 mg/kg, Tg2576 mice subjected to an un-
supplemented (control) diet (TG-C), and wild-type mice subjected to an un-
supplemented (control) diet (WT-C). The mice were placed on their respective diets 
beginning at 9 months of age, and by monitoring food intake and body weights over 
several weeks, they were able to determine that the TG-R mice were dosing themselves 
with rosiglitazone at ∼4 mg/kg/day, a figure consistent with their previous findings 
[1244]. The initial behavioural testing was carried out when the mice were ∼13 months 
of age, and had been subjected to their respective diets for ∼15 weeks (roughly 3.4 
months). Pedersen et al. reported that there was a significant attenuation of learning 
and memory deficits in the TG-R mice compared to TG-C counterparts, with TG-R 
mice exhibiting an improvement in spatial working and reference memory across test 
days similar to WT-C mice [1129].  In contrast, the TG-C mice made a consistent 
numbers of errors throughout the testing period, and did not exhibit improvement 
[1129]. These results suggested that rosiglitazone reversed the spatial learning and 
memory impairment Tg2576 mice.  
In terms of the physiological measures, Pedersen et al. determined that 
rosiglitazone prevented abnormally high serum corticosterone levels from being 
reached in TG-R mice that had been fasted overnight [1129]. Because their behavioural 
paradigm involved repetitive overnight fasting that initiated abnormally high 
glucocorticoid levels in TG mice [1244], they hypothesized that abnormal regulation of 
glucocorticoid levels would contribute to the spatial learning and memory deficits of 
Tg2576 mice via a mechanism of lower IDE levels and concordant increase in Aβ-
protein.  The impaired performance of TG-C mice were found to correlate with higher 
levels of serum corticosterone relative to the levels found in TG-R and WT-C R mice 
[1129]. After ∼19 weeks on rosiglitazone, Pedersen administered TG-R mice metyrapone 
(a drug that blocks glucocorticoid production).  As a result, the beneficial effect of 
rosiglitazone on cognition was abolished [1129].  Since rosiglitazone was not considered 
to penetrate the BBB [1236, 1244], these data were interpreted by authors as evidence 
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for a significant role for peripheral insulin sensitivity in cognition [1129].  Finally, 
Pedersen et al. determined if rosiglitazone attenuated known glucocorticoid-induced 
changes in the brain. These studies were carried out on mice that had been sacrificed 
at ∼16 months of age, following rosiglitazone administration for ∼7 months. Pedersen 
et al. reported a statistically significant reduction in the IDE mRNA levels in the 
dentate gyrus, CA2/3, and CA1 regions of the hippocampus in TG-C versus WT or TG-R 
mice, although there were no reported differences in IDE mRNA levels among the 
groups in the frontal cortex [1129].  However, in TG-R subjects, rosiglitazone did not 
affect overall Aβ-plaque burden (thioflavin-S staining), nor did it significantly affect 
Aβ40 levels, although this study did report a significant reduction in the levels of Aβ42 
in the frontal cortex of TG-R subjects versus TG-C mice [1129].  Pedersen et al. 
considered that due to the normalisation of glucocorticoid levels, rosiglitazone  could 
have improved hippocampal IDE levels and ameliorated the frontal cortex IDE hypo-
function in TG-R mice via increased insulin binding to its receptor and/or insulin 
receptor expression [1129].  However, the authors conceded that in TG-C mice, reduced 
uptake of insulin into the brain (itself a consequence of peripheral insulin resistance in 
humans [1357]), could have also contributed to the reduced levels of IDE observed in 
these studies [1129].  Thus, the beneficial effects of rosiglitazone on the TG learning 
and memory abilities (as well as the effects on IDE), could have been due to increased 
uptake of insulin into the brain independent of its effect on glucocorticoid levels [1129].   
A striking outcome of the Pedersen studies is the discovery that fasting serum 
corticosterone levels in the Tg2576 mice were twofold higher than in control animals 
and furthermore, that this effect could be fully reversed by rosiglitazone treatment 
[1129, 1244].  This is of major significance given the well-documented detrimental 
effects of excess corticosteroids on cognition [1358], although glucocorticoids are 
necessary for normal learning and memory in human populations [1359].  However, 
since chronically raised glucocorticoid levels have been associated with antagonism of 
insulin actions and thus, over time the subsequent development of insulin resistance 
[1075] it provides a mechanistic (albeit provocative) explanation for the beneficial 
cognitive effects of rosiglitazone that does not depend on the drug gaining access to 
the brain.  Nevertheless, several components of the work by Pedersen et al. [1129] 
demand critical appraisal, not least of which are concerns over the design and thus 
validity of the de novo behavioural task used in this study to assess spatial learning and 
memory (this is discussed in detail in section 3.3.6.1).  There are also problems with the 
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conceptual framework suggested by Pedersen et al. Firstly, the authors correctly 
acknowledge that IDE indiscriminately degrades both monomeric Aβ42 and Aβ40 
[1360], meaning that the selective reduction of Aβ42 in their study suggests a protease 
other than IDE was most likely responsible for this effect [1129].  Indeed, despite the 
recovery of IDE mRNA levels in the hippocampus of TG-R mice, this was not the 
location where a reduction in fibrilar Aβ42 was observed.  A reduction of Aβ42 levels 
was only observed in the frontal cortex of TG-R mice, where IDE mRNA levels did not 
differ from other groups and the activity of IDE was reported to be less in TG-C mice 
[1129].  Whilst these data support earlier work showing that IDE hypo-function can 
contribute to the accumulation of fibrilar Aβ AD [1361, 1362], they fundamentally 
undermine the hypothesis that reduced IDE expression would in itself, lead to an 
increase in fibular Aβ, and thus memory impairment by this means.  The authors also 
do not address why if raised glucocorticoids were responsible for the loss of IDE, 
activity of the enzyme was only significantly reduced in the frontal cortex [1129] despite 
the considerable expression of the glucocorticoid receptor in the hippocampus, and 
the established role of the latter in providing feedback to the HPA-axis [1363].  Thus, 
the exact relationship between the elevated glucocorticoid levels, IDE, and insulin 
resistance in the transgenic mice is unclear.  Furthermore, whilst the pattern of IDE 
expression by Pedersen et al. [1129], is consistent with results obtained from human AD 
post-mortem tissue in that levels of neuronal IDE are reduced in the hippocampus [116, 
117], they differ from the human studies in that IDE levels are typically elevated in 
cortical regions in AD patients [118].  Consistent with human clinical data, Leal et al. 
[114] reported a plaque-associated overexpression of IDE in the cerebral cortex of 16 
month old Tg2576 mice with the peak of IDE expression in these mice coinciding with 
a sharp accumulation of soluble Aβ and massive Aβ deposition into plaques.   
 
2.4. 2 Tg2576:  Stu dies  by  Other  Research  Groups  
Two additional studies have reported effects on cognition (learning and memory) as 
well as on pathophysiological markers in Tg2576 [1212, 1215], but following a much 
shorter drug administration time.  Using a contextual fear conditioning task, these 
studies determined the effects of rosiglitazone maleate (Avandia®, GlaxoSmithKline) 
pulverized into standard rodent diet at 30 mg/kg, on the learning and memory abilities 
of male Tg2576 mice as well as a group of WT littermates.  Across both studies, mice in 
drug-treated groups received access to rosiglitazone for a 1 month period before 
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behavioural testing and subsequent sacrifice.  In the first study, Rodriguez-Rivera et al. 
[1215], used the Tg2576 model to test the hypothesis that cognitive improvement in a 
contextual fear conditioning task would result following 1 month of PPARγ agonism 
with rosiglitazone, and would correlate with peripheral gluco-regulatory status. 
Rodriguez-Rivera et al. exposed Tg2576 mice and WT littermates to rosiglitazone 
initiated prior to, coincident with, or after the onset of peripheral gluco-regulatory 
abnormalities in TG mice aged  4, 8, and 12 months, respectively. Whereas in TG mice 
aged 5 months-old (peripheral gluco-regulatory abnormalities absent), and 13 months 
old (peripheral gluco-regulatory abnormalities present), rosiglitazone did not illicit 
improvement in a contextual fear conditioning paradigm after one-month treatment 
despite the drug reversing the peripheral gluco-regulatory abnormalities in the 13 
month old mice, the drug did reverse the associative learning and memory deficits as 
well as peripheral gluco-regulatory abnormalities in 9 month old Tg2576 mice [1215].  
These results suggested that the drug mediated cognitive improvement in this group 
did not correlate with peripheral gluco-regulatory abnormalities per se, but probably 
reflected age-dependent mechanistic differences underlying cognitive decline in this 
mouse model [1215]. Unfortunately, the impact of rosiglitazone treatment on total Aβ 
levels (which would have increased in the 13 month old mice) was not determined.   
A subsequent study by Denner et al. [1212], administered rosiglitazone or control 
no-drug to 8 month old Tg2576 mice WT littermates (male and female).  This study 
reported that regulation of hippocampal PPAR coincided with the extracellular signal-
regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signalling following 
rosiglitazone mediated cognitive improvement in TG mice using a contextual fear 
conditioning task [1212].  Furthermore, in the hippocampal PPAR  transcriptome of the 
Tg2576 mice, the authors found significant overlap between peroxisome proliferator 
response element (PPRE)-containing PPAR target genes and cAMP response element 
(CRE)-containing ERK/MAPK CREB target genes [1212].  Using quantitative mass 
spectrometry and bioinformatics on the hippocampal dentate gyrus, this study then 
identified many proteins related to synaptic plasticity and memory formation that 
were induced concomitant with rosiglitazone-mediated cognitive rescue and activation 
of PPAR and ERK2, and that these actions were reversed when hippocampal PPAR was 
pharmacologically antagonized, revealing a coordinate relationship between PPAR 
transcriptional competency and phosphorylated ERK that is reciprocally affected in 
response to chronic activation, compared with acute inhibition of PPAR [1212]. Thus, 
 113 
 
the authors of this study concluded that the hippocampal transcriptome and proteome 
induced by cognitive enhancement with rosiglitazone harnesses a dysregulated ERK 
MAPK signal transduction pathway to overcome AD-like cognitive deficits in Tg2576 
mice [1212]. This meant that whilst the PPAR signalling system may not be crucial for 
normal cognition, it can intercede to restore neural networks compromised by AD-like 
pathophysiological processes.   However, these effects in Tg2576 mice have not yet 
been replicated, and the impact of treatment on IDE or total Aβ levels was again, not 
determined.  In addition, the consumption of feed was not reported in the Denner et 
al. study, so it is not possible to say what daily dose of compound the mice were 
receiving.  Nevertheless, the authors argued that these rosiglitazone-mediated effects 
are consistent with a growing body of research which suggests that rosiglitazone is able 
to cross the BBB in small quantities where it is able to activate CNS PPARγ [1165, 1239, 
1364-1367], an effect which occurs in addition to its effects on glucocorticoid levels. 
Finally, both the Denner et al. [1212] study and that of Rodriguez-Rivera et al. [1215], 
included a WT control that was also administered rosiglitazone, and reported no 
adverse effects following 1 month of exposure.  However, the effects of longer WT 
exposure to rosiglitazone have not been reported.  This is of potential importance 
clinically, as not all AD patients have T2D, or indeed, peripheral glucose abnormalities. 
Finally, it remains an open question as to whether rosiglitazone has varied effects on 
performance in different cognitive domains in Tg2576 mice, and indeed other mutant 
APP mouse models. Currently, no studies have reported whether  rosiglitazone has 
effects across multiple cognitive domains within the same study; most evaluating 
rosiglitazone have been ‘one trick pony’s’ with respect to the assessment of memory.  
Thus, one of the aims of the current thesis is to assess rodent cognition in behavioural 
experiments (see Chapter 3) several cognitive domains, including spatial working 
memory, and anxiety. 
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Study Age (months)/ Dose Rosiglitazone 
(RSG)/ Mode of Delivery 
Sex  
(M/F) 
Methods Main Findings 
Pedersen et al.,  
(2004) 
30 mg/kg in Diet. Dosing with RSG at 9 
Months (MO), for 4 MO.  Tested at 13 MO. 
M Serum corticosterone levels: 
enzyme immunoassay kit; Serum 
insulin levels: Rat Insulin ELISA 
kit. 
At 8 MO, TG mice had lower basal serum insulin concentrations and delayed insulin-
induced reduction in blood glucose levels relative to WT mice. Basal levels of serum 
corticosterone were similar between genotypes but overnight fasting caused a greater rise in 
serum corticosterone levels and an excessive reduction in serum insulin concentrations in TG 
mice.  Deficits were absent in 13 MO RSG treated mice.  Conclusion: Evidence for 
relationship between spontaneous insulin resistance, impaired insulin/glucose levels, and 
aberrant stress responses in TG mice.  
Pedersen et al.,  
(2006) 
30 mg/kg in Diet. Testing at 13 MO after 15 
weeks of RSG dosing, and then again at 14 MO 
(on diet for 19 weeks (wks).  Final testing at 16 MO. 
M 8-arm radial maze task. Enzyme 
immunoassay (corticosterone); 
Rat Insulin ELISA (insulin); Aβ 
ELISA (Aβ40 and Aβ42) 
After 15 wks of RSG, recovery of spatial and working memory deficits was seen in 13 MO 
TG mice.  However, no difference between groups when TG control mice were given short-
term administration of the drug metyrapone at 14 MO. Evidence that increasing insulin 
sensitivity reduces Aβ load and improves the spatial learning and memory abilities of TG 
mice.  
Rodriguez-Rivera et 
al., (2011) 
30 mg/kg in Diet. TG mice assessed after 1 
month treatment with RTZ initiated prior to, 
coincident with, or after, onset of peripheral 
gluco-regulatory abnormalities (4, 8, and 12 
MO)  
M and F Fear conditioning, Glucose 
Tolerance Test, Fasted insulin 
measurement (endocrine 
multiplex assay) 
Whereas 5- MO and 13 MO TG did not gain cognitive improvement after one-month 
treatment with RTZ, 9 MO TG mice exhibited reversal of associative learning and memory 
deficits.  Peripheral gluco-regulatory abnormalities were improved in 9 and 13 MO TG with 
RTZ treatment; RTZ treatment had no effect on the normal glucose status of 5 MO TG mice. 
Conclusion: RTZ-mediated cognitive improvement does not correlate with peripheral gluco-
regulatory abnormalities per se, but reflects the age-dependent mechanistic differences that 
underlie 
Denner et al. (2012) 
 
 
30 mg/kg in Diet. RSG Dosing started at 8 
months, tested at 9 MO. 
M and F Fear conditioning In the hippocampal PPARγ transcriptome, overlap between PPAR response element-
containing target genes, and ERK-regulated cAMP response element-containing target 
genes. Within the TG dentate gyrus proteome, RSG induced proteins with structural, energy, 
biosynthesis and plasticity functions.  RSG-mediated augmentation of PPARγ and ERK2 
activity during TG cognitive enhancement reversed when hippocampal PPARγ was 
pharmacologically antagonized.  Conclusion: hippocampal transcriptome and proteome 
induced by cognitive enhancement with RSG harnesses a dysregulated ERK MAPK signal 
transduction pathway to overcome AD-like cognitive deficits in TG mice. 
Table 2.1: Major studies in Tg2576 using Rosiglitazone 
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2.4. 3 PP AR-γ Studies  Using Other  hAPP  Models  
Several studies have investigated the use of rosiglitazone in APP mouse models other 
than Tg2576, which may shed light on the mechanisms underpinning CNS metabolic 
dysfunction, as well as the means by which rosiglitazone may have a beneficial effect 
on these pathologies.  Escribano et al. [1214], have shown that APPSWE-IND mice also 
exhibit significant disruption to the HPA axis, whereby the hyper-secretion of 
glucocorticoids by 10 months of age results in a significant increase in their plasma 
corticosterone levels compared to WT littermates [1214].  Likewise, Escribano et al. 
have shown that rosiglitazone reversed an object recognition deficit in APPSWE-IND mice 
(which overexpress hAPP with the Swedish K670N/M671L and Indiana V717F familial 
AD mutations under control of the PDGF promoter) aged ~13 months, as well as 
reduced glucocorticoid levels (particularly corticosterone levels) [1214].  However, 
because rosiglitazone also reversed an object recognition deficit in young APPSWE-IND 
mice in this study when glucocorticoid levels were not increased, it suggests that the 
preventive effect of rosiglitazone on memory impairment cannot always be attributed 
to a plasma corticosterone lowering action [1214].  Indeed, PPAR-γ agonists are not 
reported to have analogous effects on glucocorticoids in humans [1368].  However, 
some studies have reported a possible relationship between the signalling associated 
with PPAR-γ activation and the glucocorticoid receptor [1369, 1370].  Furthermore, 
intra-hippocampal injection of the glucocorticoid receptor antagonist RU38486 in 
mice [1371], or in rats with glucocorticoid receptor gene deletion [1372], caused 
impairments in performance on avoidance and spatial memory tasks.   Moreover, in 
APPSWE-IND mice it is apparent that the overexpression of APP and/or the presence of 
APP-derived fragments is sufficient to induce alterations in hippocampal 
glucocorticoid receptors independently of plasma corticosterone levels, a process 
which rosiglitazone reverses at different ages (again independently of glucocorticoid 
levels) [1214].  These results suggest that mutant hAPP mice manifest memory decline 
along with an early and lasting reduction of glucocorticoid receptors in the brain and 
hippocampus in particular - a process which rosiglitazone appears to reverse [152].  
Indeed, in doing so, the drug may restore physiological control of the HPA axis to the 
benefit of learning and memory [1214].  However, this mechanism may require 
rosiglitazone to be freely available in the brain; since its bioavailability to the CNS is 
poor [1239], there may be insufficient drug in the brain to drive these glucocorticoid 
receptors effects. 
 116 
 
Finally, it is interesting to note that whilst studies of rosiglitazone treatment in 
Tg2576 mice have not affected Aβ-plaque burden (by thioflavin-S staining), or Aβ40 
levels [1129], another study by Yan et al. [1230] has reported that pioglitazone caused a 
statistically significant reduction in Aβ40 but not Aβ42 in the brains of Tg2576 mice.   
(again Aβ-plaque burden was not affected).  However, in mice that express the double 
Swedish and Indiana hAPP mutations (APPSWE-IND), rosiglitazone treatment has been 
shown to not only ameliorate a recognition and spatial memory impairment, but also 
reduce Aβ burden in the brain where it almost completely removes the abundant Aβ-
plaques observed in the hippocampus and entorhinal cortex of 13-month-old 
transgenic mice, as well as reduce the number of neuropil threads containing 
phosphorylated tau [1213]. This shows that thiazolidinedione’s such as rosiglitazone 
may have markedly differing effects on AD-like pathology in different APP mouse 
models.  Recently, research has suggested that rosiglitazone, and lithium treatment 
may, in a TG mouse model that co-expresses APPswe and the exon 9 deletion of the 
PSEN1 gene (APPSWEPSN1), mediate their beneficial effects on memory, Aβ-plaque 
burden and phospho-tau, by activating Wnt signalling in the brain [1216]. This 
mechanism possibly involves the increase in β-catenin, and inhibition of GSK-3β [1216]. 
Whether activation of this pathway occurs in Tg2576 mice is uncertain, as is the reason 
for why these drugs exert varying effects across different APP mouse models.   
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Study Age/Dose/ Mode of Delivery Sex (M/F) Methods Main Findings 
Escribano et al., 
(2009) 
5 mg/kg per day RSG administered orally to 1.5 
MO APPswe-Ind mice for 10 weeks to prevent the 
cognitive impairment apparent in 4-MO Tg mice.  
In other studies, beginning at 9 months of age, 
hAPPswe-ind mice were daily treated for 4 weeks 
with rosiglitazone, at the same dose or with the 
vehicle. Age-matched non-transgenic also received 
the vehicle. 
Unknown Object recognition.  Histological assessment of 
damage by staining with thionine (Nissl 
staining).  Free floating tissue sections 
comprising the hippocampal formation were 
processed for immunohistochemistry 
(glucocorticoid receptor).  Plasma 
corticosterone levels (enzyme immunoassay 
kit). 
In mutant mice it was found that memory impairment in the object recognition 
test was prevented and reversed by chronic RSG treatment. An early down-
regulation of glucocorticoid receptors GR occurred in the hippocampus that 
was not related to elevated plasma corticosterone levels, but was prevented by 
RSG. In parallel with behavioural studies, rosiglitazone also normalized GR 
levels in older animals. This effect may contribute to explain the attenuation of 
memory decline by PPARγ activation in an AD mouse model.  No impairments 
were observed in the WT mice receiving RSG. 
Escribano et al., 
(2010) 
We treated 9-month-old transgenic mice by oral 
gavage with rosiglitazone maleate as a suspension 
in sterile water at a dose of 5 mg/kg/day or with 
vehicle for 4 weeks prior to testing (object 
recognition). Groups of animals underwent spatial 
reference learning in the Morris Water Maze test 
after 4 and 16 weeks of treatment. 
M Object recognition; Morris Water Maze test. 
Cortical Aβ42 and Aβ40 levels were measured 
by using a sensitive sandwich ELISA kit. For p-
tau staining, slides were treated with methanol 
and H2O2 to inhibit endogenous peroxidase 
activity, followed by blocking with 3% milk in 
TBS. 
Chronic treatment with RSG facilitated Aβ clearance. RSG reduced Aβ burden 
in the brain and almost completely removed the abundant Aβ-plaques observed 
in the hippocampus and entorhinal cortex of 13-month-old transgenic mice. In 
the hippocampus, neuropil threads containing phosphorylated tau were also 
decreased by the drug. RSG switched on the activated microglial phenotype, 
promoting its phagocytic ability, reducing the expression of prion 
inflammatory markers and inducing factors for alternative differentiation.  The 
decreased amyloid pathology may account for the reduction of p-tau-
containing neuropil threads, and for the rescue of impaired recognition and 
spatial memory in the transgenic mice. 
Toledo and 
Inestrosa (2010) 
9-month-old APPswe/PSEN1 were administered 
intraperitoneal (IP) injections of lithium chloride 
daily (3 mequiv. kg-1 IP, daily), dissolved in saline 
serum, or with rosiglitazone (3mgkg-1) in sterile 
water by oral gavage. Control treatments included 
IP injections of saline solution or maleate in sterile 
water by gavage (0.45mgml-1). 
Unknown Morris water maze Training was conducted up 
to 10 trials per day for a total of 4 days, until 
the criterion of 3 successive trials with an 
escape latency of < 20 s was met. 
Immunohistochemical procedures (Aβ-plaque 
quantification)/ Astroglial GFAP intensity.  
Immunoblotting (synaptic proteins). 
Both RSG and Lithium Chloride significantly reduced (1) spatial memory 
impairment induced by amyloid burden; (2) Aβ aggregates and Aβ oligomers; 
and (3) astrocytic and microglia activation. They also prevented changes in 
presynaptic and postsynaptic marker proteins. Finally, both drugs activate Wnt 
signalling shown by the increase in b-catenin and by the inhibition of the 
GSK3. Conclusion: lithium and rosiglitazone, possibly by the activation of the 
Wnt signalling pathway, reduce various AD neuropathological markers. 
O'Reilly and 
Lynch (2012) 
6mg/kg/day in 50 ul administered in maple syrup. 7 
MO APPswe/PSEN1 mice, on diet for 2 wks prior 
to testing and 2 wks during testing. 
Unknown 
Reported 
Morris Water Maze. 
Aβ ELISA (Aβ40 and Aβ42) 
Accumulation of Aβ was accompanied by deficit in the reversal phase of 
learning in the Morris Water Maze, and that treatment with Rosi for a 4 week 
period, attenuated these changes. 
Table 2.2: Major studies in other APP mouse models using Rosiglitazone 
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3. BEHAVIOURAL  EXPERIMENTS  
 
3.1 INTRODUCTION  
HE AIM of the experiments in this chapter was to evaluate the changes in 
behaviour in adult male Tg2576 mice that might arise from continuous 
rosiglitazone treatment over a period of several months.  Historically, the 
genesis of the programme of research detailed in this thesis originates from the need to 
further clarify the impact of rosiglitazone in adult male Tg2576 mice following the 
controversial 2006 publication of research by Pedersen et al. [1129].  It is important to 
clarify that, at that time no other study had yet been published on the impact of 
rosiglitazone in hAPP mutants, and only limited human clinical data was available —
all of which was generally supportive of a beneficial effect of this drug in patients with 
early to moderate AD [1235, 1236].  As such, the overall lead hypothesis for this thesis 
was that rosiglitazone should ameliorate age-related learning and memory deficits as 
well as pathophysiological changes associated with the hAPP transgene in TG mice.  
However,  subsequent to the 2006 publication or research by Pedersen et al., two other 
pre-clinical studies have been published which have also investigated the impact of 
rosiglitazone treatment on cognition and other pathophysiological measures related to 
hAPP over-expression in Tg2576 [1212, 1215].  As most of the experiments described in 
this thesis have investigated issues that have not been addressed by these recent 
studies, the results reported herein still make an original and timely contribution to 
our understanding of the impact of rosiglitazone on behaviour and amyloid load in 
adult male Tg2576 mice. 
The experiments detailed in this thesis used animals that are subject to procedures 
classified as “Mild”. The relevant ethical approval had been obtained from the Local 
Ethical Review Committee (Cardiff University), and permission from the Genetic 
Modification Safety Committee and the Home Office.  Since one of the primary 
T 
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objectives of this study was to determine the impact of using PPAR-γ treatments to 
modify aspects of AD-related neuropathology and behavioural impairment, no other 
alternative to the use of TG mice was deemed viable.  As stated earlier, the main 
disadvantage of the Tg2576 model is the lack of NFT development and neuron loss. 
However, this model does provide an excellent opportunity to assess the impact of 
therapeutic interventions on the pathology and behavioural changes associated with a 
theoretically early stage of AD pathogenesis and one of the leading putative cause(s) of 
AD: insulin resistance.  Behavioural variability in female Tg2576 has been reported in 
several tasks [1356, 1373, 1374], likely occurring as a function of the estrous cycle [1351].  
This is particularly true with respect to cognitive measures such as spatial memory in 
rodents [1351], as well as assessment of pathophysiological measures such as blood 
plasma insulin levels, and dendritic spine density in the DG of the hippocampus [1375, 
1376], particularly in rodents [1377]) (see Chapter 4).  Whilst the pharmacodynamics of 
many PPAR-γ compounds such as rosiglitazone are considered the same in clinical 
populations irrespective of sex [1378, 1379], variations in performance and physiology 
due to oestrogen could potentially confound the interpretation of any drug effects on 
behavioural performance or the physiological parameters being measured. For this 
reason, only male Tg2576 mice and WT littermates were used in the experimental 
studies detailed in this thesis.  
 
3.2 STRATEGIES  AND  HYP OTHESIS  
None of the pre-clinical studies assessing the impact of rosiglitazone in Tg2576 mice 
have used a battery of cognitive and behavioural assessments covering multiple 
domains [1129, 1200, 1212, 1215, 1244].  Thus, it is unclear if rosiglitazone has a selective 
or wider range benefit on cognition in these mice.  To address this issue, Experiments 
1-4 in this chapter, comprise a battery of behavioural tasks that cover established 
phenotypic cognitive and other behavioural changes in adult Tg2576 mice.  
Experiment 1 involved the use of the T-maze forced choice alternation task (T-maze 
FCA task), a well-characterised and hippocampus-dependent test of rodent spatial 
working memory [1246, 1288, 1380].  Experiments 2 and 3 respectively then detail other 
behavioural phenotypes inTg2576 mice related to non-conditioned anxiety: the 
elevated plus maze (EPM) and marble burying task [1381, 1382].  Both of these tasks are 
popular methods of assessing anxiety-like behaviours in rodents [1383]. Experiment 4 
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then involved the assessment of behavioural changes related to object recognition.  
This involved the use of a de novo recognition task the design and rationale for which 
was based on the published research of Good and Hale [1384]. A detailed rationale and 
methodological procedures relating each of the above behavioural tasks can be found 
in the appropriate sections of individual experiments.  Each of the above behavioural 
experiments is divided into two treatment strategies: a late intervention strategy and, 
an early-intervention strategy (see below).  Finally, Experiments 5, 6 and 7 are detailed 
in Chapter 4, and report post sacrifice biochemical/physiological measures.  Although 
Experiment 5 has data corresponding to the late and early-intervention conditions, due 
to time and financial constraints, it was not possible to do this for Experiments 6 and 
7.  As a result, these latter experiments relate to the late-intervention and early 
intervention strategies respectively. 
 
3.2.1.1 Late-Intervention Strategy 
Neuronal and behavioural deficits in Tg2576 mice appear to be established in a time-
dependent manner, and can be temporally clustered into early deficits observed in 4- 
to 5-month-old animals, and late deficits that occur in animals after the age of 6-8 
months [1245].  Early onset deficits in TG mice occur at ~4 months of age and include a 
decrease in hippocampal spine density in the DG, LTP, in vivo memory as measured by 
contextual fear conditioning task, and an increase in the ratio of Aβ42 compared to 
Aβ40 [1245]. Late deficits observed include spatial working memory impairment in 
tasks such as forced choice T-maze alternation [1288, 1385], which generally emerge 
between 6–8 months of age [1246, 1385].  At this time, insoluble forms of Aβ are 
increasing exponentially [1284, 1291], and hippocampal synaptic pathology is well 
developed [1245].  The initial studies in Tg2576 by Pedersen et al [1129, 1244], as well as 
most subsequent studies using this mouse model [1212] (but see [1215]), have 
administered rosiglitazone to adult mice aged 8 months or older when amyloid 
pathology and synaptic deficits are already well established. However, although all 
these have reported beneficial effects on learning and memory, the publication of 
research by Pedersen et al. [1129, 1244], has been controversial [1166].  Thus, further 
clarification of the impact of rosiglitazone in adult male Tg2576 mice was required.  To 
achieve this, in the first set of experiments involve a late intervention strategy (LINS) 
in which chronic rosiglitazone administration took place from the age of ~9 months 
through to 18 months old (see figure 3.1).    Following initial pre-drug conformation of 
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a cognitive phenotype at 8 months of age, it was predicted on the basis of findings 
from Pedersen et al. [1129, 1244], that rosiglitazone administration would then reverse 
this age-related cognitive and other behavioural deficits observed in male Tg2576 mice, 
as well as lower amyloid load.  
 
 
Figure 3.1: Summary of LINS Design. Key: MO= Month Old; RSG = Rosiglitazone.  TG and 
WT mice were allocated to one of four experimental groups at ~9 MO [TG-non-drug (TG-N), 
TG-Rosiglitazone (TG-R), WT-non-Drug (WT-N) and WT-rosiglitazone (WT-R)] following 
completion of the pre-drug stage of Experiment 1 (this experiment was comprised of three 
stages see Figure 3.3), which assessed spatial working memory via the T-Maze FCA 
paradigm.  Following the conclusion of Experiment 1 at 13 MO, the mice received 
Experiments 2 and 3 after a short break (Elevated Plus Maze and the Marble Burying task 
respectively), both of which assessed non-conditioned anxiety and behavioural disinhibition.  
The behavioural battery concluded with Experiment 4, which assessed memory for object 
recognition and object location. Following the sacrifice of the mice at the age of ~18 months, 
Experiments 5 and 6 were conducted.  Experiment 5 assessed adiponectin protein levels 
from terminal blood plasma samples, whilst Experiment 6 assessed total Aβ levels (soluble + 
insoluble) extracted from homogenates of single brain hemispheres. 
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3.2.1.2 Early-Intervention Strategy 
Some pre-clinical studies have raised concerns that rosiglitazone may have a limited 
therapeutic window for ameliorating cognitive impairments in adult hAPP mice [1215, 
1386]. For example, as discussed in chapter 2, Rodriguez-Rivera et al. [1215], used the 
Tg2576 model to test the hypothesis that cognitive improvement in a contextual fear 
conditioning task would result following 1 month of PPARγ agonism with rosiglitazone 
and would be correlated with peripheral gluco-regulatory status. Rodriguez-Rivera et 
al. reported that whilst in TG mice aged 5 months-old and a separate cohort of TG 
mice aged 13 months, rosiglitazone did not elicit learning and memory improvement 
despite reversing peripheral gluco-regulatory abnormalities in the 13 months old mice.  
However, rosiglitazone treatment did reverse both peripheral gluco-regulatory 
abnormalities and associative learning and memory deficits (contextual fear 
conditioning) in 9 month old Tg2576 mice [1215].  These results are consistent with 
those of Nicolakakis et al. [1386], who using a different hAPP mouse model reported 
that in TG mice started on the PPARγ agonist pioglitazone at ~14 months for 6–8 
weeks, physiological changes occurred (normalised glucose uptake in response to 
neuronal activity and attenuated astroglial activation), in the absence of  recovery of a 
spatial memory deficit in these mice.  Taken together these studies suggest that in 
order to be maximally effective, PPARγ agonists may have to be administered early, 
prior to the occurrence of significant amyloid pathology and synaptic deficits.  
However, to date none of the published studies conducted in Tg2576 mice have 
reported the impact of the drug on the appearance of late-stage age-related cognitive 
deficits following continuous administration of the drug from an early time point when 
amyloid and synaptic pathology in TG animals would be expected to be minimal [1242, 
1245] and some measures of cognition would be comparable between transgenic and 
non-transgenic mice [1246].  Thus, in a second course of experiments, this thesis 
reports an early-intervention strategy (EINS) to investigate the impact of rosiglitazone 
administration on the established appearance of age-dependent cogitative deficits in 8 
month old TG mice following continuous drug administration from the age of 5 
months (see figure 3.2).  It was predicted that rosiglitazone would delay the onset of 
age-related cognitive and behavioural deficits in adult TG mice.  In each experiment, 
the result of experimental manipulations is presented chronologically: LINS data is 
presented first, followed by ENIS.  To avoid repetition, discussion material related to 
each is reserved until after the presentation of both LINS and EINS results.   
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Figure 3.2: Summary of EINS Design. Key: MO= Month Old; RSG = Rosiglitazone. TG and 
WT mice were allocated to one of four experimental groups at 5 MO: TG-non-drug (TG-N), 
TG-Rosiglitazone (TG-R), WT-non-Drug (WT-N) and WT-rosiglitazone (WT-R), and run 
through the same battery of behavioural tasks used in the LINIS condition. However, in order 
to address potential concerns on T-Maze FAC performance due to the order in which this task 
and the anxiety tests were given to mice in the LINIS condition, the presentation of tasks was 
counterbalanced in ENIS such that anxiety related assessments were conducted first 
(Experiments 2B, 3B), followed after a short break by T-Maze testing (Experiment 1B) and 
then object recognition (Experiment 4B).  
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3.3 EXPERIMENT  1:  SPATIAL  WORKING  MEMORY 
3.3. 1 Introduction  
PATIAL MEMORY is assessed in rodents by a variety of means, but most 
commonly via the T-maze, Y-maze, Morris water maze, radial arm maze, radial 
arm water maze, and   Circular platform tasks such as the Barnes maze [1387].  
All of these tasks measure a range different memory types in rodents, including 
‘reference’ and ‘working’ memory. Reference memory can be thought of as retained 
information that is useful across all exposures to the task (i.e., on any day of testing).  
In the Morris water maze, for example, reference memory involves subjects learning 
the location of a fixed position platform or reward over the course of the test (e.g. a 
trial-independent representation), with successful completion of the task requiring 
amongst other things, the use of LTM in the process of navigating to the ‘goal’ location 
[1388].  In rodents, working memory is usually considered to relate to a representation 
of an object, stimulus, or spatial location that is typically used within a trial (such as T-
maze forced-choice alternation), but not between sessions, to guide behaviour [1389].  
 
3.3.1.1 Spatial Memory Impairment in Tg2576 
Most studies have found that Tg2576 mice older than 14 months have significant 
memory impairment, although disagreement exists with respect to the exact time 
these deficits first become evident [1242, 1251, 1253, 1284, 1289, 1356, 1390].  Hsiao et al. 
[1242] reported that that in 9–10 month TG mice (sex not reported), spatial memory 
impairment was revealed via decreased alternation in a Y-maze paradigm, and 
impaired performance in a Morris water-maze task, whereas there was no deficit in 
these tasks at 2–6 months of age.  This is broadly consistent with a study by Barnes et 
al. [1246], which reported that in male Tg2576 mice, deficits in a T-maze spatial 
navigation task generally emerges at approximately 6–8 months of age.  Indeed, this 
study showed that whilst mutant male mice were able to process both intra-maze and 
extra-maze stimuli, they exhibited a deficit in forming an allocentric representation of 
their environment [1246].  It is of interest that during this time period, the production 
of insoluble and soluble forms of Aβ in cortical and hippocampal areas is increasing 
[1284, 1291]. However, using equal numbers of males and females, King and Arendash 
[1356] failed to find any overall TG deficit on Morris water-maze acquisition and 
retention from 3 months to 19 months.  This finding was consistent with the outcome 
S 
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of a previous study [1391], which reported that the combined data from equal numbers 
of aged males and females failed to deliver a significant TG deficit in either Y-maze 
alternation, water maze acquisition, passive avoidance, or active avoidance testing 
between the ages of  3 to 9 months old.  However, results from other tasks in this study 
revealed substantive behavioural deficits in TG mice that were gender-dependent and 
sometimes progressive in nature.   Thus, between 3 and 9 months of age, a progressive 
spatial impairment was observed in a circular platform task by TG males, as was a 
progressive deficit in visible platform testing for all TG animals [1391].  Other 
transgenic effects included both impaired water maze retention and circular platform 
performance in 3 month old TG females.  This later effect was responsible for an 
overall (males + females) TG deficit in circular platform performance at 3 months of 
age [1391]. Further, sensorimotor testing revealed that TG males were more active in 
both open field and Y-maze at 3 months of age [1391].  Nevertheless, Westerman et al. 
[1284], reported that in Tg2576 mice aged between 4 and 25 months (sex not reported), 
a deficit in the Morris water-maze started to appear at around 6 months, whereas 
Ognibene et al. [1252]  found that in TG mice (sex not reported) spatial memory 
impairment was shown in the Y-maze at 7–12 months.  Spatial memory impairments 
have also been found in Tg2576 mice prior to 6 months when the brain is typically free 
of amyloid plaques and deposits [1356, 1391, 1392], providing one reason for seeking an 
early intervention strategy in Tg2576 mice. Thus, whilst not all studies have confirmed 
spatial memory defects in Tg2576 mice, those which have tend to report that they do 
not normally appear before 6 months but are usually present by 9 months.   
Part of the variability in these studies is that the hAPP transgene may have 
interacted with sex differences in some spatial memory and other behavioural tasks. 
Additional factors which may have affected behavioural performance of mice in some 
tasks, including differences in the genetic background in Tg2576 and WT mice, and in 
particular the proportion of SJL background strain [1381].  Using in-bread strains also 
increases the risk of inadvertently “breeding in” unfavourable behavioural traits and/or 
physical defects which may affect behavioural performance. For example, the retinal 
degeneration Pde6brd1 (RD) mutation can be a major pitfall in behavioural studies 
using Tg2576 mice bred on a B6:SJL genetic background as this can potentially 
compromise tests of spatial memory and recognition memory processes [1393].   
A previous study by Pedersen et al. in adult male Tg2576 has suggested that 
rosiglitazone is able to reverse the spatial memory deficit [1129], and is supported by 
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findings in other hAPP mouse models [1216, 1217].  In addition, rosiglitazone has also 
been shown to reverse a spatial memory deficit in aged rats fed a high fat diet [1211].  
However, with the exception of Pedersen et al. [1129], all these studies have used the 
Morris water maze to assess spatial cognition.  The Morris water maze is a classic task 
for testing spatial memory in rodents, and is acknowledged to be dependent on intact 
hippocampal function [1394-1396].  Indeed, the Morris water maze task was used in the 
original study characterizing the Tg2576 mouse [1242].  However, there are other 
popular ways of assessing spatial memory in rodents, and if rosiglitazone does reverse 
the spatial memory impairment in Tg2576 mice, it should do so whatever standard 
measure of rodent spatial memory is used.  
 
3.3.1.2 T-Maze Forced Choice Alternation 
T-Maze Forced choice alternation (FCA) and left-right discrimination tasks using the 
T-maze have been widely used to assess working memory [1389], and reference 
memory [1383, 1397, 1398], respectively in rodents.  These tasks are based on the 
premise that animals have evolved an optimal strategy to explore their environment 
and obtain food with a minimum effort [1389, 1397].  Furthermore, in the absence of 
food-deprivation, a simple T maze can be used as described to assess spontaneous 
alternation, and is based on the willingness of rodents to explore a new environment 
[1397] (i.e. they prefer to visit a new arm of the maze rather than a familiar arm). All of 
these tasks are relatively easy to administer and depend on intact alternation 
behaviour [1398].  Damage to the hippocampus causes severe a spatial memory deficit 
[453], and the T-maze FCA version is widely considered to be dependent on intact 
hippocampal and prefrontal function in rodents [1380, 1396, 1399].  Indeed, the T-maze 
FCA task has been shown to be sensitive to the hAPPSWE mutation in an age-dependant 
manner [1246], probably as a function of its sensitivity to Aβ-related hippocampal 
dysfunction [1385]. A transgene-related impairment in the T-maze FCA task has been 
reported from the age of 8 months in Tg2576 mice [1246], as well as in TG mice aged 12 
and 16 months [1246, 1251, 1288].  Furthermore, the likelihood of detecting significant 
impairment in Tg2576 mice relative to age-matched controls has been found to be 
highest with the use of T-maze FCA and the radial arm water maze tasks compared to 
other popular methods of assessing spatial memory in rodents [1400].  For all of these 
reasons the T-maze FCA task was considered a suitable means of assessing the effects 
of rosiglitazone treatment on spatial working memory in the present study.   
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3.3.1.3 Experimental Design 
Experiment 1A (LINS) aimed to assess spatial working memory in adult male Tg2576 
mice and WT littermates using the T-Maze FCA paradigm between the ages of 8 to 13 
months. It was expected that Tg2576 mice would show a persistent deficit on this task 
throughout this time [1246, 1251, 1385].  This experiment consisted of three stages: a 
single pre-drug stage and two post-drug stages (see figure 3.3).  All three stages 
involved the application of a separate T-maze FCA task.  The pre-drug stage was 
conducted when mice were aged between 8 and 9 months.  The objective here was to 
provide confirmation of phenotype on the T-maze FCA task.  Following the 
completion of the pre-drug stage, groups of TG and WT mice were immediately 
allocated to drug-treated or non-drug treated conditions and started on their 
respective diets (see section 3.3.2.1).  Post-drug 1 took place 1o days after the start of 
drug regimens, when the mice were aged between 10 and 11 months.  The objective in 
this stage was to check for any early drug effects as this had not been determined in 
the original Pederson study [1129] upon which the current thesis is based.  However, 
subsequent studies have reported effects on learning and memory in Tg2576 mice 
following 4 weeks of continued drug administration [1212, 1215].  Mice were then re-
tested at post-drug 2 after ~3 months exposure to experimental diets. This stage took 
place when the mice were aged between 12 and 13 months (see figure 3.1).  The aim of  
Experiment 1B (EINS) was to assess if rosiglitazone exhibited a protective effect in 
relation to the age-related T-maze FCA impairment in 8 month old Tg2576 mice 
following continuous access to the drug from the age of 5 months.  In both 
interventions, the same drug groups and controls were used, with the mice run in 
pseudorandom order across several staggered replications of no more than 18.   
 
Figure 3.3 Experiment 1A.  Starting with a pre-drug (no RSG) assessment at 8 MO, the mice 
were allocated to one of four experimental groups: TG-non-drug (TG-N), TG-RSG (TG-R), 
WT-non-Drug (WT-N) and WT-RSG (WT-R).  Spatial working memory was then re-assessed 
at Post-drug 1after 10 days on RSG, and again at Post-drug 2 after ~3 months RSG 
administration. 
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3.3. 2 Methods  and  Apparatus  
3.3.2.1 Animals and Drug Administration 
All mice were maintained on a 12-h light/dark schedule (lights off at 1500 hours), with 
ad libitum access to food comprised of standard pelleted rodent chow laboratory chow 
(RM1 Rodent, Expanded Pelleted, SDS, England), or the powdered equivalent (RM1 
Rodent Expanded Ground, SDS, England).  With the exception of Experiment 1, which 
required male mice to be water deprived for 22 hours prior to testing in order to 
maintain motivation to find a sucrose reward, all mice received ad libitum access to 
water.  Where mice were water deprived they were maintained at 85% of free feeding 
weight, and weighed daily in order to ensure good general health. All behavioural 
experiments began at 09:00 each day during the light phase, and were completed in 
full compliance with the U.K. Animals (Scientific Procedures) Act 1986, and Home 
Office (United Kingdom) guidelines. The running order of mice during behavioural 
experimentation was counterbalanced for genotype and diet.   LINS Experimen ts   
Animals used in LINS Experiments used 68 experimentally naive heterozygous male 
Tg2576 mice and 47 non-transgenic WT littermates (cohort 1), all of which were 
purchased from Taconic (Taconic Farms, Germantown, NY).   Tg2576 mice contain a 
hamster prion protein promoter in their DNA insert in order to drive strong expression 
of the hAPPSwe transgene.  This model was created by microinjecting the human 
APP695 gene containing the double mutation K670N, M671L into B6SJLF2 zygotes 
using a hamster prion protein cosmid vector. The resultant mice from founder line 
2576 were backcrossed to C57BL/6. In March 1999 Taconic Farms (Germantown, NY) 
received stock of Tg2576 from the Mayo Foundation [25], wherehence hemizygous 
males were backcrossed with C57BL/6NTac for derivation by embryo transfer. This 
colony is maintained by mating hemizygous male mice with B6SJLF1 female mice.  
Taconic received stock of Tg2576 from the Mayo Foundation in March 1999 [1282], 
wherehence  hemizygous males were backcrossed with C57BL/6NTac for derivation by 
embryo transfer. The colony is maintained by mating hemizygous male mice with 
B6SJL F1 female mice. Animals belonging to cohort 1 were received in the laboratory at 
the age of 2 months from Taconic Farms (USA), where they were initially housed in 
standard plastic mouse cages in same genotype groups of three or four.  Each cage 
contained wood shaving bedding and cardboard tubes to provide some environmental 
 129 
 
enrichment.  The mice had been ear punched by Taconic Farms for identification prior 
to their arrival.  At the age of 4 months all mice were singularly re-housed in standard 
mouse cages and their pelleted food exchanged for the powdered equivalent in 
preparation for experimental studies. Behavioural testing of mice from cohort 1 took 
place between the ages of 8 to 17 months.  Cohort 1 mice were then immediately 
sacrificed at 18 months, and the necessary tissues harvested for biochemical analysis.  
The resulting tissue samples were labelled and stored at -20°C until further use. 
Independent genotyping of mice from cohort 1 were confirmed by GSK via a 
subsequent Aβ ELISA analysis following termination.  The rationale for this was that 
any WT mice in the sample would produce a null result in the ELISA, as they 
contained no Aβ-plaques. Whilst this was an unusual means of confirming the 
genotype of these mice, it did establish that the mice had been assigned to the correct 
groups based on their genotype at receipt.   
Drug Administration: Two previous studies have assessed the impact of 
rosiglitazone in WT mice [1212, 1215], and reported no significant impact of the drug on 
behavioural performance or peripheral gluco-regulatory mechanisms, although the 
impact of chronic exposure to the drug in WT littermates has not been determined. 
LINS Mice were allocated to drug-treated or non-drug treated groups and started on 
their respective diets between the ages of ~8-9 months after the completion of each 
pre-drug replication of Experiment 1A.  Mice were allocated to experimental groups 
according to their mean pre-drug performance so that within genotype performance 
was matched across drug-treated and control groups (this would make post-drug 
performances easier to interpret). TG mice allocated to drug-treated conditions 
received powdered lab chow supplemented with research grade drug compound, 
either the partial PPAR-γ agonist GW855266X (TG-B, n=12) at 30mg/kg, PPAR-delta 
agonist GW610742 (TG-A, n=12) at 10mg/kg, or rosiglitazone at 10mg/kg (TG-R, n= 12).  
TG mice allocated to the control condition received un-supplemented powdered lab 
chow (TG-N, n=12).  WT mice in the control condition also received un-supplemented 
powdered lab chow, whereas WT mice allocated to a drug-condition received 
powdered lab chow supplemented with rosiglitazone at a concentration of 10 mg/kg 
(WT-R, n=12).  The decision to include a WR-R control was justified on the basis of 
pharmacokinetics and pharmacodynamics as both can differ among genetically 
engineered lines. Thus, the WT-R control provided a means by which target drug 
effects could be validated in relation to adiponectin levels, which should be similarly, 
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elevated across all PPAR treated groups (see chapter 4).   TG-A and TG-B groups were 
run with the experimenter blind to the identity of the compound as part of an 
outsourced pilot study for GSK, the results of which were not intended to be 
disseminated as part of this thesis. Behavioural testing of TG-A and TG-B groups was 
abandoned midway through Experiment 1A due to concerns over the poor tolerability 
of these compounds in the mice. As a result, both these groups were dropped from the 
study and are not considered further here (these conditions are mentioned here 
merely for completeness).  All mice were maintained on their respective treatment 
regimens until sacrifice.  All PPAR compounds were supplied by GSK pharmaceuticals, 
Harlow UK.  
 EINS Experim ents  
The Tg2576 model has been made widely available to research institutions for non-
profit research purposes, enabling the formation of multiple Tg2576 mouse colonies, 
one of which is maintained by Professor M.A. Good, Department of Psychology, at 
Cardiff University.  The animals used in EINS Experiments were derived from this 
colony, and were comprised of 24 experimentally naive heterozygous male Tg2576 
mice and 25 non-transgenic WT littermates (cohort 3), all of which were specifically 
bred from the colony maintained by Professor Mark Good at Cardiff University.  The 
Tg2576 line was originally established by crossing a C57Bl/6j x SJL F3 founder twice 
into C57Bl/6j [1288]. Overexpression of the transgene was maintained in subsequent 
generations by crossing heterozygous Tg2576 to a C57Bl/6j x SJL F1 line, with each 
generation possessing differences in the relative %age of each of these background 
strains.  It is estimated that the relative contributions are ~59% to 88% of C57Bl/6j; 
12% to 41% of SJL [1288].  This cohort of mice was generated by pairing male 
heterozygous Tg2576 mice with female C57Bl/6j x SJL F1 mice, with the resulting 
offspring being either heterozygous Tg2576 mice possessing the mutation, or 
homozygous Tg2576 wild-type (WT) mice, at a ratio of roughly 50:50. Fifteen days after 
birth, the mice were ear-marked for identification (mouse ears are not normally 
thinned out sufficiently for ear punching before this time), and <0.05cm of distal the 
tail section was taken as a tail-biopsy for subsequent genotyping and PCR analysis (see 
chapter 4 for details) in order to determine genotypic status. Tail biopsies (<0.05cm) 
were removed using ethyl chloride local anaesthetic and a silver nitrate pen to seal the 
incision, with tissue samples stored at -20°C until further use.  Following PCR 
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genotyping, at approximately 6 weeks of age, litters were weaned into standard plastic 
mouse cages of same-sex same-genotype littermate groups of 2 to 4 mice.  At the age of 
4 months all male mice were singularly re-housed in to standard plastic mouse cages 
and their pelleted food exchanged for the powdered equivalent. Female mice were 
maintained on the pelleted food as these were not used in primary studies. 
 Drug Administration:  As stated previously, the TG and WT mice in the ENIS 
experiments were all allocated to experimental drug and non-drug groups at the age of 
~5 months.  The groups chosen were representative of those used in the LINIS 
condition except for the TG-A and TG-B groups. Thus, TG and WT mice allocated to 
the rosiglitazone condition received powdered lab chow supplemented with research 
grade rosiglitazone at a concentration of 10 mg/kg (TG-R, n=12; WT-R, n=13), whereas 
mice allocated to control groups again continued to receive un-supplemented 
powdered laboratory chow (TG-C, n=12; WT-C, n=12).  As indicated in figure 3.1, mice 
in the EINS condition were maintained on their respective treatment regimens until 
sacrifice between the ages of 12 and 13 months.  The necessary tissues were then 
harvested for biochemical analysis, with tissue samples again labelled and stored at -
20°C until further use. Terminal tail biopsies (<0.05cm) were taken for independent 
genotyping (see chapter 4). 
 Prep ar at ion of  Exp erimental  Diet s an d Gen otypin g 
Batches of lab chow dosed with PPARγ compound were prepared according to GSK 
standards.  In brief, appropriate amounts of drug were weighed using an analytical 
weighing machine, and then added to a small amount of 1kg of powdered diet, and 
thoroughly mixed for 30 seconds using a standard coffee grinder.  The contents from 
the grinder were then transferred to the remainder of the 1kg batch of feed, and mixed 
for a further 30 minutes in a standard food mixer.  This ensured that the drug was 
distributed equally throughout the feed.  Several batches of 1Kg drug supplemented 
diet were prepared in advance, and stored in a fridge at 2°C until required.  All drug-
supplemented diet was replaced in mouse food hoppers every 3 days to ensure no stale 
compound was consumed by the mice.  For each mouse, the average daily food 
consumption was calculated over several weeks during periods of ad lib food and water 
access in order to determine the degree of consumption and thus, self-dosing in drug 
groups.  Daily intakes, adjusted for body weight, were derived by dividing average 
intakes by the average body weight, and then multiplying the result by 30g (the 
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approximate weight of an adult mouse).  Daily food consumption was approximately 
the same in each group across both interventions, ranging from ~4.5 to 6.3 ± 0.1 
g/day/mouse. This meant that TG-R and WT-R mice were dosing themselves between 
approximately 4.5 mg/kg/day, to 6.3 mg/kg/day.  The lower band of these figures was 
comparable with a previous report in Tg2576 using a similar delivery method [1129]. 
 
Genotyping Procedure 
Tissue biopsies from mice were genotyped using the polymerase chain reaction (PCR) 
molecular biology technique in order to determine which mice harboured the human 
double APPswe mutation. PCR selectively amplifies specific deoxyribonucleic acid 
(DNA) regions exponentially for measurement using gel electrophoresis. In the in-
house protocol used here, specific oligonucleotide primers were used to selectively 
amplify the nucleic acid sequence coding the 63 APPswe transgene.  The selective DNA 
amplification in PCR occurs through enzymatic replication, and utilises the repeated 
thermal cycling of a DNA sample containing multiple reagents that include DNA 
polymerase, deoxynucleoside triphosphates (dNTPs) and oligonucleotide primers. 
Please see section 3.3.2.1 for details of mice used for genotyping procedures. 
Methods: In preparation for the PCR DNA was first digested and extracted from the 
tissue samples. Defrosted tissue samples were digested by incubating in 600μl of TES 
cell lysis buffer (1M Tris HCl Buffer pH 8.0, 0.5M EDTA pH 8.0, 10% SDS, dH20) at 55°C 
for 20 minutes. Following this 1.5μl of 25mg/ml Proteinase K (Sigma, Cat. P2308) was 
applied to each sample, vortexed, and incubated overnight at 55°C.  DNA was then 
extracted by adding 200μl of 5M ammonium acetate, which was vortexed and 
centrifuged for 10 minutes at 14,000 rpm to pellet the proteins. 650μl of supernatant 
was removed carefully so as not to dislodge the pellet, and transferred into 600μl of 
molecular biology grade isopropanol. This solution was mixed using inversion and 
centrifuged for 2 minutes at 14,000 rpm. The supernatant was discarded, and 150μl of 
ice cold 70% molecular biology grade ethanol was applied to the DNA-containing 
pellet, and then centrifuged for 2 minutes at 14,000 rpm. Following a repeat of the 
latter process, the supernatant was then removed and the samples dried at 37 °C until 
the ethanol was evaporated. DNA was re-suspended in 60μl of TE buffer (1M Tris HCl 
pH 8.0, 0.5M EDTA pH 8.0, dH20) and incubated overnight at 55°C. PCR was then 
carried out on the DNA samples within 24 hours or stored at-20°C until use. 
 133 
 
PCR analysis:  1 μl of DNA sample was added to 24μl of master mix to make a 25μl 
solution. The samples and master mix were maintained on ice during this process. 
Master mix was prepared using 2.5μl 10x reaction buffer, 1.25μl 50mM MgCl2, 1.25μl 
10mM dNTPs, 0.25μl Primer 1501 (50 pmol), 0.25μl Primer 1502 (10 pmol), 0.25μl Primer 
1503b (10 pmol), 1.5μl BIOTAQ Red DNA Polymerase (1μg/μl) and 16.75μl nuclease-free 
MilliQTM water (Millipore, USA). The DNA polymerase 10x reaction buffer and MgCl2 
were supplied in BIOTAQ Red DNA Polymerase kit (Bioline, Cat. BIO-21041). The 
oligonucleotide primers 1502 (5’ 600bp) and 1503b (5’ 450bp), were then used to 
amplify the APPswe transgene, while primer 1501 (5’ 600bp) amplified the endogenous 
murine prion protein (PrP) with primer 1502. The 25μl solution for each sample was 
vortexed and centrifuged for 6 seconds at 4000rpm.  Each sample was placed into the 
PCR cycle machine alongside one positive TG control (1μl of previously confirmed TG 
DNA, plus 24μl master mix), one negative WT control (also 1μl of previously confirmed 
WT DNA, plus 24μl master mix), and one blank control (comprised of 1μl nuclease-free 
water plus 24μl master mix). The blank control was a necessary means of detecting any 
potential contamination. The PRC cycler was programmed to carry out APPswe 
transgene amplification through initialisation at 72°C for 2 minutes followed by 36 
cycles of: 1) denature at 94°C for 1 minute, 2) anneal and amplify at 62°C for 1 minute, 
and 3) incubate at 72°C for 2 minutes for elongation, with 2 seconds added to the 
elongation step per cycle.  Samples were then maintained at 4°C in the PRC cycler until 
collected for electrophoresis.  
Gel electrophoresis of DNA. Gel electrophoresis was used to separate out each of the 
DNA amplification products. A 17-tooth-combed 1.5% agarose gel was made using 3g 
NuSieve® molecular grade agarose (Fisher scientific, Cat. BMA50091) in 200ml of TAE 
buffer (40 mM Tris base, 1 mM EDTA pH 8.0, 0.01% v/v glacial acetic acid, dH2O) with 
20μl of SYBR® Safe DNA gel stain (Invitrogen, Cat. S33102). Once set the gel was placed 
into a RunOne system® gel tank with TAE buffer, then 10μl of DNA marker, 8μl of each 
sample and 8μl of each control was applied into separate tooth-comb slots. The DNA 
marker was made from the following: 10μl of ‘DNA Marker’ (Promega, Cat. G3161); 2μl 
"Orange G solution" (comprised of 0.25% Orange G, and 15% Ficoll in MilliQTM 
water).  This was then vortexed thoroughly, and centrifuged for 10 seconds at 
4000rpm.  The gel tank was then run at 100V for approximately 20 minutes in order to 
drive the electrophoresis process. Results were obtained by observing and image of the 
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gel under UV light.  A representative example of a gel electrophoresis can be seen in 
Appendix 2. 
 
3.3.2.2 Apparatus 
The T-Maze was constructed from three arms made of clear Perspex, each of which 
measured 9 cm wide and 13 cm high.  The floor of the maze was made from brown 
melamine wood.  The start arm was 52 cm long, with each of the goal arms measuring 
26 cm long. The maze apparatus was housed in a quiet testing room on top of a green 
felt-covered table that was 92 cm high (see figure 3.4).  The testing room was well 
illuminated and contained a variety of extra-maze cues (posters and laboratory 
benching). Guillotine doors were used to block the start and goal arms. Mice ran for a 
reward of 50 µl of 10% sucrose solution in tap water, which was placed in a food-well at 
the end of each goal arm.  The arms of the maze were wiped down with a 1:20 dilution 
of Mr Muscle® glass cleaner with water, and dried with paper towelling, prior to 
placing each mouse in the apparatus. The experimenter wore surgical gloves 
throughout the experiment to reduce odour contamination as this could inadvertently 
provide a cue to animals during trials.  
 
Figure 3.4: T-Maze apparatus insitu. 
 
3.3.2.3 Behavioural Procedures 
Mice received an initial habituation phase comprised of one 5 minute trial per day for 3 
consecutive days, during which all arms of the maze were open and sucrose reward 
was placed only in the food wells. If the reward was not consumed within 5 minutes, 
the mice received a further 5 minutes in the T-maze. Mice were then tested over 8 
consecutive days and received 6 pairs of runs per day, each of which was no more than 
a maximum of 10 minutes duration. On the first run of each trial (sample run), both 
goal arms were baited. However, a removable opaque Perspex door blocked access to 
one of the arms.  The mouse was released from the start box and allowed to enter the 
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open goal arm and consume a sucrose reward (~50 µl 10% sucrose) for 10 seconds 
before being removed and replaced in the start box. A response was defined as an entry 
when the rear of the body (excluding the tail), passed the entrance to the arm. The 
maze (including both goal and non-goal arms) was then cleaned to obscure any 
potential intra-maze odour cues. On the second run of each trial (choice run), which 
followed within 5-10 sec of the first run, both goal arms were now open and the mouse 
was rewarded for correctly choosing the previously unvisited arm (now the only arm to 
contain a reward).  If an incorrect choice was made, the entrance to the arm was 
blocked by a Perspex door and the mouse left in the non-baited arm for 15s before 
being returned to its home cage. The location of the sample arm (left or right) was 
varied pseudo randomly across the session such that mice received three left and three 
right presentations, with no more than two consecutive trials with the same sample 
location in each session. The order of left and right presentations was counterbalanced 
across days, and in the case of the LINS, across experimental stages, with mice run in 
squads of 8 in each replication so as to maintain an inter-trial interval (ITI) of 
approximately 21 min. In both the habituation and testing stages, mice were 
transported to the test room in individual home cages and acclimatised to the room for 
10 minutes prior to each habituation and testing session taking place.   
Scoring and Exclusion Criteria:  During testing, T-maze performance was calculated 
as a %age of correct trials (successful alternations) of the six trials conducted per day. 
Mice were excluded from analysis due to morbidity/mortality, or if they spent more 
than three consecutive trials where they failed to move from the start position in the 
T-maze for the first 5 minutes (non-responsiveness).  Based on this criterion, in 
Experiment 1A, 20 TG mice (TG-C, n=3; TG-R, n=3; TG-A, n=8; TG-B, n=6), and 5 WT 
mice (WT-C, n=2; WT-R, n=3) were excluded from cohort 1 due to mortality; 1 TG (TG-
C), and 2 WT mice (WT-C, n=1; WT-R, n=1) were excluded for non-responsiveness. 
Although the mortality rate in Tg2576 is generally known to be greater over the first 12 
month of life, the mortality rate in Experiment 1A seems particularly high, and is 
driven primarily by the high numbers of mice lost in the TG-A and TG-B conditions.    
Thus, excluding TG-A and TG-B groups, the total numbers of mice in Experiment 1A 
were as follows: 17 TG mice (TG-C, n=8; TG-R, n=9), and 18 WT (WT-C, n=10; WT-R, 
n=8).  In Experiment 1B, none of the mice were excluded due to mortality or non-
responsiveness. Thus, the total numbers of mice in Experiment 1B were as follows: 24 
TG mice (TG-C, n=12; TG-R, n=12); 25 WT mice (WT-C, n=12; WT-R, n=13).  Although 
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one can see that strictly speaking, the rate of mortality is not comparable in the LINS 
and ENIS conditions, excluding the TG-A and TG-B groups in the LINIS condition, this 
could just have been chance as housing conditions and care remained the same across 
both cohorts of mice.  
 
3.3.2.4 Statistical Analyses  
All statistical analysis were carried out using an analysis of within-subjects variance 
(ANOVA) using the statistical package IBM SPSS Statistics v.21.00, with an alpha value 
(p) <0.05, taken as being statistically significant.  Each of the three stages of 
Experiment 1A had previously been analysed as separate ANOVAs, each of which 
involved the 8 days of performance data being arranged in and analysed as, four test 
blocks, each of which contained the number of correct trials calculated across 2 days of 
testing.  However, for the purposes of this study, Experiment 1A was analysed as a 
single three-way repeated measures ANOVA of the form: Genotype (TG or WT) and 
Treatment (drug-treated, or non-drug treated) as between-subject factors, and Stage 
(mean number correct choices calculated across the 8 days of testing) as the within-
subject factor. The conclusions of this analysis were the same as that achieved via the 
separate blocked analysis of each stage, and in an overall ANOVA, there was no effect 
of block, and no interactions involving this factor (max F).  However, since Experiment 
1B was comprised of a single stage, the data was analysed as a three-way repeated 
measures ANOVA of the form: Genotype and Treatment as between-subject factors, 
and Block (4 test blocks, each containing the number of correct trials calculated across 
2 days of testing), as the within-subject factor.  Following significant interactions, tests 
of simple main effects were carried out using MANOVA syntax as described in Kinnear 
and Gray [1401] (p. 295, 350).  Sidak correction was used for all multiple comparisons in 
order to guard against making Type 1 errors [1401].  In aggregate, these measures follow 
the conventional means for reporting statistical analysis in the sciences (p.373, [1402]).   
ANOVA Assumptions: The assumptions of each ‘within-subjects’ ANOVA were also 
tested within the statistical package, and included tests for normality, homogeneity of 
variance, and sphericity. Normality was tested using the Shapiro-Wilk test; if this 
assumption was found to be violated (p<0.05), then the kurtosis value was checked.  A 
perfect normal distribution will have a kurtosis value of ‘3.0’, with skewness close to ‘0.’ 
Kurtosis is positive if the tails are "heavier" than for a normal distribution (i.e. right 
‘positive’ skewed distribution), and negative if the tails are "lighter" than for a normal 
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distribution (i.e. left ‘negative’ skewed distribution). If kurtosis is less than 3 it is 
platykurtic (flatter), and the lower it is, the flatter the distribution will be.  If kurtosis is 
more than 3 it is classed as leptokurtoc (more peaked), with higher values representing 
a more ‘pointed’ distribution. Whilst ANOVA can tolerate data that is non-normal 
(skewed or kurtotic distributions) with only a small effect on the Type I error rate, 
platykurtosis can have a profound effect when group sizes are small [1401].  Thus, if 
platykurtosis was present, the ANOVA result was reported only after appropriate 
transformation of the data, or by using the less powerful non-parametric statistical 
tests (NPTESTS) which do not require the assumption of normality (see below).  The 
assumption of homogeneity of variance was tested within SPSS by using Levene’s test 
of equality of error variances.  If this assumption was found to be violated (p<0.05), 
then non-parametric tests were used.  However, if on these occasions the results of the 
non-parametric tests (see below) were of the same pattern of significance as reported 
by the parametric tests,  the ANOVA result would be reported as ANOVA has been 
shown to be accurate despite violation in these circumstances [1401].  Finally, the 
assumption of sphericity was also tested in SPSS by using the Mauchly’s test of 
sphericity. If this assumption is violated (p<0.05), then an epsilon correction is 
normally reported as the Greenhouse-Geisser result in the SPSS output table.  
However, if the Greenhouse-Geisser did not differ numerically from the value in 
‘sphericity assumed’ then the latter was reported in order to prevent sections becoming 
un-wieldy due to stating partial degrees of freedom.  If testing whether performance 
was above chance level in each group, one sample t-tests were used (appropriate for 
the number of conditions compared, the type of sample, and type of data). 
Non-parametric tests:  Since non-parametric tests are generally considered to be 
less powerful than parametric methods, these types of test were used when no 
parametric test was valid. The Mann-Whitney-U test was used in relation to a 
between-subjects design involving two independent groups, or the Kruskal-Wallis test 
(equivalent to the one-way ANOVA) for the comparison of data from more than two 
independent groups.  However, since the Kruskal-Wallis test is an omnibus tests that 
cannot tell you which specific groups are significantly different from each other, 
determining which groups differed was accomplished by using an appropriate post-hoc 
test adjusted for multiple comparisons. Within IBM SPSS Statistics, the NPTESTS 
procedure offers the option of stepwise post hoc tests if the Kruskal-Wallis test is 
significant.  The Wilcoxon signed-rank test was considered as appropriate test in 
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relation to a within-subjects design involving a one off comparison between two sets of 
scores from the same group (i.e. equivalent to the dependent t-test).   
 
3.3. 3 Results  
3.3.3.1 Experiment 1A: LINS Analysis Stage s 1-3  
Figure 3.5 shows the mean percentages of correct choices for mice in stages 1-3 of the 
T-Maze FCA task (the mean percentage of correct choices per test block in each stage 
can be found in Table 3.1). Inspection of this figure suggests that overall, Tg2576 were 
significantly impaired relative to WT controls in the FCA task in each stage, with no 
significant treatment effects.  Thus, rosiglitazone agonism for approximately 3 months 
failed to reverse the spatial working memory deficit revealed by the T-Maze.  
Inspection of this figure also suggests that despite a reduction in the accuracy of WT 
drug-treated mice across post-drug stages, this was not significant. This description 
was confirmed by ANOVA of the form:  Genotype and Treatment as between-subject 
factors, and Stage, as the within-subject factor (see section 3.3.2.4).  This showed a 
main effect of Stage F(2,60)=6.808, p=0.002, a main effect of Transgene, F(1,30)=28.701, 
p=<0.001, a no significant effect of Treatment F<1, a significant two-way interaction of 
Stage by Genotype F(1.30)=1.886, p=0.040, no significant two-way Stage by Treatment 
interaction F<1, and no significant Stage by Genotype by Treatment interaction 
F(2,60)=2.205, p=0.119.  Tests of between-subjects effects showed a non-significant 
Treatment by Transgene interaction F(1,30)=1.211, p=0.280.    A follow-up test of simple 
main effects for the significant Stage by Genotype interaction revealed that TG mice 
were impaired relative to WT mice in each stage of the experiment: Pre-drug, 
F(1,30)=7.381, p=0.011; Post-Drug 1, F(1,30)=24.125, p=<0.001; Post-drug 2, F(1,30)=31.561, 
p=<0.001.     
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Figure 3.5: LINS T-Maze (Experiment 1A): Means (±S.E.M) with asterisk denoting 
significance at the 0.05 level. Dotted line represents chance levels of performance.   
 
Table 3.1: LINS T-Maze (Experiment 1A): Mean percentage of correct choices per test block 
in each stage (each test block is the mean of 2 days data).  As one can see from the data in 
this table, the means of both TG groups remain similar throughout all three stages of 
Experiment 1A indicating that there is likely to be no significant effect of rosiglitazone 
treatment on spatial working memory.  Although this also remains the case for both WT 
groups, it is evident that there is more variability in the group means between drug-treated 
verses non-drug treated mice.  Whilst this could indicate a mild but non-significant) negative 
drug effect, this could also just reflect natural variability in performance. 
Stage/Group Test Block 1 
% Correct 
Test Block 2 
% Correct 
Test Block 3 
% Correct 
Test Block 4 
% Correct 
Pre-Drug M SEM M SEM M SEM M SEM 
TG-C 60.42 6.63 68.75 5.84 75.00 6.10 72.92 7.17 
TG-R 63.89 6.51 61.11 5.73 75.93 5.63 75.00 6.05 
WT-C 65.74 5.63 76.85 4.77 86.11 4.81 91.67 3.67 
WT-R 64.58 4.38 70.83 2.23 85.42 5.84 91.67 2.23 
Post-Drug 1         
TG-C 59.38 5.98 66.67 4.72 77.08 6.25 76.04 6.38 
TG-R 66.67 4.17 69.44 4.17 70.37 6.82 82.41 7.01 
WT-C 85.19 4.56 86.11 4.39 94.44 2.78 93.52 1.85 
WT-R 86.46 3.84 88.54 2.70 95.83 2.23 89.58 2.61 
Post-Drug 2         
TG-C 60.42 3.43 71.88 4.71 63.54 5.21 66.67 3.52 
TG-R 72.22 4.39 75.00 3.11 73.15 6.02 71.30 6.23 
WT-C 83.33 3.93 81.48 1.85 94.44 1.96 94.44 2.41 
WT-R 73.96 5.55 81.25 3.78 82.29 6.58 87.50 6.86 
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3.3.3.2 Experiment 1B: EINS 
Figure 3.6 shows the mean performance of mice in the early-intervention group (see 
Table 3.2).  These mice were given a single T-Maze FCA task (scores expressed as mean 
percentage of correct choices) following continuous drug administration from the age 
of 5 months.  Inspection of this figure suggests that a significant overall transgene 
effect is once again evident indicating that continuous rosiglitazone administration 
from the age of 5 months did not delay the onset of the forced-choice alternation 
impairment. This description was confirmed by ANOVA with Genotype and Treatment 
as between-subject factors, and Block (4 test blocks, each containing the number of 
correct trials calculated across 2 days of testing), as the within-subject factor. This 
showed a main effect of Block F(3,135)=10.726, p=<0.001, a main effect of Transgene, 
F(1,45)=6.504, p=0.014, a main effect of Treatment F(1,45)=6.504, p=0.014, no significant 
two-way interaction of Block by Genotype F(3,135)=2.611, p=0.054, a significant two-way 
Block by Treatment interaction F(3,135)=10.726, p=0.001, and no significant Block by 
Genotype by Treatment interaction F(3,135)=1.613, p=0.189. There was no significant 
two-way Treatment by Transgene interaction F<1.  A follow-up test of simple main 
effects for the significant Block by Treatment interaction revealed no significant 
differences between non-drug treated mice and drug-treated mice during any of the 
four test blocks: Test Block 1, F<1, p=0.846; Test Block 2, F(1,30)=1.916, p=0.176; Test 
Block 3, F<1; Test Block 4, F<1.  The mean percentage of correct choices per test block 
can be found in Table 3.2. In aggregate, these results suggest that continuous dosing 
with rosiglitazone from 5 months of age was insufficient to prevent the onset of TG 
behavioural impairment on the forced choice alternation task.  
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Figure 3.6: LINS T-Maze (Experiment 1B).  Mean %age of correct choices. Overall TG mice 
are still significantly impaired to WT mice. Values are means ±S.E.M with asterisk denoting 
significance at the 0.05 level.  Dotted line represents chance levels of performance.   
 
Table 3.2: EINS T-Maze (Experiment 1B): Mean percentage of correct choices per test 
block (each test block is again the mean of 2 days data). As one can see from this table, the 
means of both TG groups again remain similar throughout all three stages of Experiment 1B 
indicating that there is no significant effect of rosiglitazone treatment on spatial working 
memory.  Although this also remains the case for both WT groups, there is again evidence for 
variability in the WT-R group means relative to the WT-C mice.  Again, this could indicate a 
mild (but non-significant) negative drug effect on spatial working memory. 
 
3.3 .4 Discussion  
The results of Experiment 1A and 1B both indicate that the performance of adult 
Tg2576 mice remains significantly impaired relative to that of WT-C mice irrespective 
of when the treatment regimen is initiated.  These findings lend further support to 
previous studies showing that adult Tg2576 mice are impaired in the T-maze FCA task 
[1246, 1251, 1288, 1385], although they also show that after ~3 months continuous 
rosiglitazone administration, the drug was unable to reverse or delay the age-related 
Group Test Block 1 
% Correct 
Test Block 2 
% Correct 
Test Block 3 
% Correct 
Test Block 4 
% Correct 
 M SEM M SEM M SEM M SEM 
TG-C 57.64 3.76 56.25 3.86 70.14 4.29 69.44 3.75 
TG-R 55.56 4.02 54.86 7.21 61.11 6.10 57.64 6.52 
WT-C 62.50 3.91 84.72 3.05 90.28 2.87 92.36 1.91 
WT-R 67.31 5.12 69.23 3.70 69.87 6.23 74.36 6.22 
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spatial working memory deficit in TG mice revealed via the T-maze FCA task.  These 
results contrast with several studies in the scientific literature, which have all reported 
that rosiglitazone can restore or enhance aspects of hippocampal function known to 
deteriorate in middle-aged rats [1403], aged rats [1207], models of T2D [1210], and 
perhaps most importantly, hAPP mouse models [1214, 1216, 1217]. For example, there are 
reports that rosiglitazone can enhance learning, hippocampal place cell activity, and 
synaptic plasticity in middle aged rats [1403], and in the hAPPSWE-IND model, reverse 
hippocampal glucocorticoid receptor down-regulation [1214],  as well as removal of 
abundant amyloid plaques in adult TG mice [1213].  However, none of these dramatic 
effects on hippocampal function, have been observed in Tg2576, although studies have 
reported beneficial effects of rosiglitazone on ameliorating spatial memory deficits 
[1129], and learning and memory impairments associated with other behavioural tasks 
considered to involve recruitment of the  hippocampus [1212, 1215].  Thus, although we 
have not studied hippocampal function on a neurophysiological level (i.e. synaptic 
plasticity and glucocorticoid receptor levels), comparison with the behavioural 
findings of some of the above studies are warranted, although this will largely be 
restricted to findings in Tg2576 relating to spatial memory, as these are the most 
relevant here. I should also be briefly comment on the observation that across both 
interventions, WT-R mice showed a persistent trend towards impaired performance 
relative to WT-C mice, although this was not significant within the 3 month 
administration period. This finding is consistent with those reported by other studies 
using much shorter drug administration times [1212, 1215].  However, it will be of 
interest to the reader to see how in the current study, this profile changes drastically in 
WT mice with continued administration of the drug over a longitudinal period. 
 
3.3.4.1 Comparisons with Other Studies 
Pedersen et al [1129] have studied the effects of continuous rosiglitazone 
administration in male Tg2576 mice. This study assessed spatial memory via a de novo 
8-arm radial maze task [1129], and reported that the drug reversed a spatial learning 
and memory impairment in TG mice. Importantly, Pedersen et al. used a drug 
concentration of 10 mg/kg mixed with standard rodent laboratory chow, and delivered 
to animals in pelleted form for ~3.4 months. It is worth mentioning that this delivery 
method may have made it difficult to determine how much compound was actually 
reaching the mice (and indeed, how often it was replenished to avoid consumption of 
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stale compound), since it is possible that concentrations of the drug may have been 
unequal across food pellets.  This is why in the current study we chose to use 
powdered diet, as this allowed us greater control over the delivery process (see 
protocol for experimental diets).  In addition, unlike the current study, Pedersen et al. 
did not report any independent physiological parameters showing that the drug had 
achieved systemic circulation (i.e. adiponectin levels as in the current study).  
Nevertheless, it is noteworthy that the range of self-dosing reported in our study was 
not only comparable to that reported by Pedersen et al. [1129], but greater.  Thus, 
although one possible reason why we did not observe a reversal of the spatial working 
memory deficit in the T-Maze is that the TG-R mice may have needed longer on the 
compound, as in both early and late-intervention experiments, mice had only received 
access to the compound for ~3 months before T-maze FCA testing was terminated.  
However, this explanation is unlikely for two reasons.  First, the higher range of dosing 
in the current study would most likely have cancelled out the effects of a slightly 
shorter administration period.  Second, one recent study has reported significant 
recovery of memory deficits in Tg2576 mice using a concentration of 10 mg/kg after 
only 1 month of continuous rosiglitazone administration [1215], a finding supported by 
other studies also using short duration administration periods of rosiglitazone in 
different hAPP mouse models [1216, 1217]. 
There are concerns over the experimental design of the de novo 8-arm radial maze 
task used to assess spatial learning and memory in the Pedersen et al. study [1129].  In 
short, the mice were initially placed in the central hub of the maze with all doors 
closed. All doors were then simultaneously opened when 4 arms were baited by an 
automatic pellet feeder. Four of the arms were consistently baited with 20 mg food 
pellets (1, 2, 4, and 7), whereas the other 4 arms were never baited.  In addition to 
extra-maze cues (a door and computer), intra-maze cues included small pieces of 
white tape placed proximal to the floor of the baited arms. The mice were then allowed 
to continue exploring until all four baits in the food troughs had been consumed or 
until 5 min had elapsed. This procedure was repeated such that mice were subjected to 
4 runs per day.  During training (2 days) the mice were only allowed access to the 
baited arms, whereas during testing (3 days), the mice were allowed access to all 8 
arms.  The number of reference memory errors (entering an arm that was not baited), 
and working memory errors (entering an arm containing food that was previously 
entered), were recorded.  Pedersen et al. observed that TG-R mice exhibited spatial 
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working and reference memory abilities similar to WT mice, with continued 
improvement across test days [1129].  By contrast, TG-C mice made consistent numbers 
of errors throughout the testing period, and did not exhibit improvement across these 
measures.  The difficulty with this is that the nature of the cues controlling the 
performance of mice is uncertain meaning that it is impossible to determine what 
aspect of behaviour rosiglitazone modified the TG mice, or indeed, the nature of the 
neural systems engaged by the task.  This leaves open the question of whether 
rosiglitazone was affecting spatial memory in this study or some other component of 
performance such as general arousal, motivation/impulsivity, or habituation processes.  
For example, during the test phase it is unlikely that mice entering un-bated arms 
provided a fair measure of ‘reference memory’.  Since these arms would most likely 
have appeared as novel spatial locations to the mice they would have encouraged 
further exploration.  Thus, as no food was ever placed at these locations, one would 
predict that normal mice would habituate to them across the test days leading to 
progressively fewer entries.  So, instead of measuring ‘reference memory’, entries into 
unabated arms may have measured short-term habituation to novel spatial locations.  
Although the FCA task also measures short-term habituation, unlike the Pedersen et 
al., study, the spatial location of the food varies systematically across trials between the 
left and right sides of the apparatus.   
Two studies conducted with other hAPP models have also reported that 
rosiglitazone administration has a beneficial effect on spatial learning and memory 
[1216, 1217].  Toledo et al. [1216] reported that in 9 month old APP/PS1 mice given a 
daily gavage treatment of ground rosiglitazone maleate in a suspension in sterile water 
for 12 weeks (Avandia; concentration =3mgkg-1), the drug reversed a spatial memory 
impairment in a modified Morris water-maze task, reduced Aβ aggregates and Aβ 
oligomers, as well as reduced astrocytic and microglia activation. In addition, Toledo et 
al. also showed that rosiglitazone prevented changes in presynaptic and postsynaptic 
marker proteins and activated a Wnt signalling pathway, the latter of which may have 
been responsible for mediating the positive effects in relation to reducing 
neuropathological markers associated with hAPP [1216].  However, it is of interest that 
the authors of this study do not report the numbers of male verses female mice used.  
This is of potential importance, because after 12 weeks of treatment, ‘high variability’ 
was observed between TG mice and WT-littermates on a standard Morris water maze 
task, with no clear difference emerging among any of the groups of animals [1216].  
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Thus, it is possible that this variability may in part have been due to changes in the 
oestrous cycle in female mice (if any were used), although incomplete reporting of 
experimental details makes this impossible to know for sure. In order to overcome the 
behavioural variability, Toledo et al. moved to a ‘training-to-criterion’ version of the 
Morris water maze[1216], which in in PDAPP mice had previously been shown to 
measure memory flexibility [1261], and exhibit greater sensitivity to hippocampal 
dysfunction [1261, 1404].  In brief, mice were trained to escape to a hidden platform 
inside a circular pool filled with lukewarm opaque water, and surrounded by salient 
distal objects mounted on walls of the test room. When a mouse reached a criterion of 
three consecutive trials with an escape latency of <20s, the platform was switched to a 
new location of 4 possible candidates, and the animal was retrained.  Memory 
flexibility was measured by the number of trials needed to reach criterion at each 
location. Since mice were required to learn a series of successive spatial locations one 
at the time, it has been suggested that this task, may be an efficient means of reducing 
within-group variability —a major conundrum in behavioural neuroscience [1405]. 
Using this procedure, Toledo et al. [1216] found a significant difference between drug-
treated verses non-drug treated TG mice, with the former showing a reversal of the 
deficit in the number of trials required to reach the escape criterion at each of the four 
platform locations.  It is possible that in this instance, the lower drug concentration 
used by Toledo et al. would have produced a mild drug effect that only a more 
sensitive test of spatial memory was able to detect.  However, the fact that a genotypic 
difference was not found in the standard Morris water maze task makes this uncertain.  
In principal this issue could have been tested in the current study by taking a second 
measure of spatial memory.  This could have involved using the water maze task or an 
adapted version of a plus maze experiment in which mice are trained to find 
consecutive goal locations from multiple release points within the maze.   
Finally, a recent study by O’Reilly and Lynch [1217] has also reported that in 7 
month old female hAPP/PS1 mice and WT littermates, rosiglitazone maleate (Alpha 
Technologies, Ireland) at a concentration of 6mg/kg/day in 50µl of maple syrup for 2 
weeks prior to behavioural testing, was sufficient to reverse the TG deficit in spatial 
memory.  The study by O’Reilly and Lynch [1217] contains an obvious confound in that 
female mice were used to assess spatial memory and yet no attempt was made to check 
where the mice were in relation to their oestrous cycle at the time of testing.  
Nevertheless, the discrepancy between the findings from the current study, and those 
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from hAPP/PS1 mice, remain to be fully explained, although comparisons are 
complicated by the fact that the dynamics of hAPP pathology may be different in these 
models compared to Tg2576, and indeed, vary even with the same mouse model 
depending on the relative proportions of SJL F1 background [1374]. 
 
3.3.4.2 Factors Possibly Affecting the Outcome of Experimental Measures 
Aside from the issues already discussed, two further other issues may potentially have 
contributed to the null findings in the present study.  First, one could question the 
logic for supplying potentially diabetic TG mice with a sucrose reward during 
behavioural trials, particularly since in other hAPP mouse models the intake of 10% 
sucrose-sweetened water has been shown to induce insulin resistance and exacerbate 
memory deficits and amyloidosis [1254].  However, these effects are only observed with 
chronic ad libitum access [1254], which does not apply to the current experiment.  
Thus, consumption of the sucrose solution probably had a negligible effect on the 
overall performance of the mice.  Second, it is possible that retinal degeneration due to 
the Pde6brd1 (RD) mutation may have affected T-maze performance in some mice 
[1393], but particularly the TG mice as Aβ pathology has also been linked to retinal 
degeneration in several hAPP mouse models [1406-1408]. However, it has been argued 
that Tg2576 mice show impaired spatial memory irrespective of retinal degeneration 
status [1406]. Whilst mice are able to use an allocentric representation to solve the T-
Maze [1246], something that retinal degeneration could have potentially perturbed, 
mice and rats have been shown to solve the T-Maze via a number of different ways 
[1389, 1409, 1410], including with a sense of direction [1410].  Thus, to some extent, any 
visual problems could have been compensated for by the mice using non-visual types 
of information. The fact that despite any potential problems due to visual deficits, 
majority of WT mice (unlike most TG mice) were still able meet criterion across 
experimental stages, suggests that WT mice at least are able to use such information to 
acquire the task. 
 
3.3.4.3 Late Intervention Rosiglitazone: Did we intervene too late? 
In the remainder of this discussion, I want to briefly return to addressing some of the 
major findings of this experiment in relation to some theoretical concerns, and wider 
implications of using rosiglitazone to treat AD-like pathologies.  Chief amongst these is 
the issue of whether or not administering rosiglitazone to adult mice (and indeed aged 
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humans) at a time when amyloid pathology is already well advanced in the brain is 
essentially, a late-intervention strategy that is ‘too late’.  In this regard, the findings 
from Experiment 1A are most consistent with those of Nicolakakis et al. [1386], who 
reported that in hAPP transgenic mice started on PPARγ agonist pioglitazone at ~14 
months of age, physiological changes occurred (i.e. normalised glucose uptake in 
response to neuronal activity, and attenuated astroglial activation), in the absence of a 
recovery in the spatial memory deficit in these mice [1386].  Indeed, similar results 
have also been obtained with rosiglitazone in Tg2576 by Rodriguez-Rivera et al. [1215], 
who reported that rosiglitazone agonism for a 4 week period prior to behavioural 
testing led to the drug reversing peripheral gluco-regulatory abnormalities in 9 month 
old, and 13 month old Tg2576 mice, but only reversing learning and memory deficits in 
the 9 month old TG mice.  It is interesting to note that Rodriguez-Rivera et al. used a 
contextual fear conditioning paradigm to assess memory in animals, and did not report 
the numbers of male and female mice used in their study.  Although it is therefore 
possible that the failure of the drug to reverse learning and memory deficits in the 13 
month old TG mice may have, as the authors themselves noted, reflected age-
dependent mechanistic differences underlying cognitive decline in Tg2576 [1215], it is 
also possible that contextual fear learning may have been affected by differential 
activation of ventral hippocampal extracellular signal-regulated kinase between male 
and female mice [1411].   Both these studies show that it is possible to affect 
components of the pathological cascade common in AD without necessarily achieving 
cognitive improvement.  Indeed, these findings mirror the inconsistency in the human 
clinical data as although some human clinical trials have reported rosiglitazone 
monotherapy to have beneficial effects on learning and memory in patients with mild-
moderate AD has [1235, 1236], no significant effects of the drug have been reported in 
more recent phase 3 clinical data in patients with mild-to-moderate AD [1237, 1238].  
This is despite the drug apparently eliciting an early increase in whole brain glucose 
metabolism [1237].  Indeed, across the human literature [412, 770, 771] and pre-clinical  
literature[1215, 1386], the conclusion seems to be that in order to be most effective 
PPARγ agonists may have to be targeted at the earliest preclinical stages of the disease.  
This is difficult to do in humans because it is currently not possible to reliably say 
which patient with aMCI will progress to AD from those who will not [311, 314, 1412].  
Finally, it is worth mentioning that one of the possible reasons for why we report 
null findings with respect to spatial memory impairment compared to prior reported 
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studies in the scientific literature, is the differential activation of common neural 
structures.  For example, a number of studies now suggest that brain regions such as 
the hippocampus can be differentially activated by behavioural tasks [510, 686], and 
that diverse behavioural effects may result when selective disruption occurs to 
particular hippocampal sub-regions.  There is robust evidence for at least two distinct 
functional domains, although neuroanatomical, and neuropsychological studies 
suggest this may be an underestimate (see [686, 1413]).  Selective lesion studies show 
that the hippocampus is functionally subdivided along the septo-temporal axis into 
dorsal and ventral regions, each associated with a distinct set of behaviours [686]. 
Dorsal hippocampus has a preferential role in certain forms of learning and memory, 
notably spatial learning, but ventral hippocampus may have a preferential role in brain 
processes associated with anxiety-related behaviours [686, 1413] (see introduction to 
Experiment 2).  Thus, although speculative at this point, it is possible that depending 
on the fine distribution of PPARγ receptors in different brain regions, it may be the 
case that the weak CNS penetrance of rosiglitazone will only be sufficient to selectively 
affect certain functional domains within structures such as the hippocampus, whilst 
leaving others impaired.  Whether or not a cognitive effect is seen will depend on how 
any given task functionally activates a particular brain region that may (or may not) 
have been affected on a physiological level by the drug in question.  Indeed, this poses 
one possible reason for why it is that physiological changes may not necessarily be 
translated into cognitive improvement.  Likewise, the same could apply to any possible 
neuroprotective functions of a drug when it is delivered early before significant 
amyloid pathology takes place in the brain.   
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3.4 EXPERIMENT  2:  NON-CONDITIONED  AN XIETY  (EPM)  
3.4. 1 Introduction  
3.4.1.1 The Elevated Plus Maze 
A number of different tests are available for assessing anxiety in experimental animals, 
and rodents in particular. These tests are classically divided into conditioned and 
unconditioned tests. Unconditioned tests are based on the natural aversion of rodents 
to novel environments, which evoke a conflict between the animals exploratory and 
fear/defensive behaviours [1414].  Examples of popular non-conditioned tests of anxiety 
include the elevated plus maze (EPM), the marble burying task, and the forced swim 
test [1383]. Conditioned aversive tasks include the Pavlovian fear conditioning 
procedure, which assess learning and memory for associatively conditioned stimuli. 
Non-conditioned anxiety tests have certain advantages over conditioned tests, 
including being inexpensive and simple to apply because they require no previous 
training period, are based on the spontaneous behaviour of animals, and use a natural 
stimulus to induce anxiety states [1415].   
The EPM is designed such that a cross-shaped platform is raised above floor level, 
with two arms constructed with high walls along the both sides (i.e. the ‘closed’ arms), 
whilst the remaining two arms have no enclosing along their sides (i.e. ‘open’ arms). As 
a result, this apparatus has physical properties such as height and lack of protection, 
that are believed to induce anxiety-like responses in rats [687, 1416], and mice [1383].  It 
is therefore considered an ethologically valid measure of anxiety in these animal 
species.  Anxiety is reflected in the tendency for ‘normal’ mice to prefer spending more 
time exploring the ‘safer’ closed arms of the apparatus relative to the more risky ‘open 
arms’ [1417].  Thus, time spent in the open arms is a valid index of anxiety-like 
behaviour in rodents, including behavioural disinhibition [1418].  To put it another 
way, the EPM task is considered to have face value or ‘construct validity’ in terms of 
this and related behaviours (see below) being observable dependent variables in 
measuring an unobservable construct, such as anxiety and disinhibitory behaviour in 
rodents  [1419].  This is further supported by the fact that anxiogenic drugs have been 
shown to reduce time spent on the open arms whereas anxiolytic drugs having the 
opposite effect (i.e. increasing the time spent on the open arms) [1420].  Related 
behavioural indices in this task also include the number of crossings between arms, or 
arm entries [1383].  These can also be used as ways of evaluating locomotor activity, 
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anxiety reactions and behavioural disinhibition [1383, 1421].  In addition, a number of 
ethological measures can also be used to assess anxiety reactions and behavioural 
disinhibition in the EPM, including head dipping (i.e. exploratory behaviour), stretch-
attend postures (i.e. risk-assessing behaviour) and the degree of self-grooming (also a 
measure of behavioural disinhibition) [1419].  However, all of the behavioural measures 
mentioned above can also be affected (to a greater or lesser degree) by mouse strain 
differences, particularly with respect to locomotor activity [1422].  Nevertheless, 
anxiolytic drugs have been shown to alter patterns of exploratory activity in rodents by 
increasing the number of entries into (as well as the amount of time spent in) open 
arms of the EPM [1423-1425].  Thus, the EPM is a well characterised test for evaluating 
anxiety/disinhibitory behaviour in rodents [1383], and is used to assess these 
behaviours in the current study.   
 
3.4.1.2 Anxiety and Behavioural Disinhibition in Tg2576 
The neurological basis of emotional disturbances and BPS in AD is thought to reflect 
pathology in the MTL (particularly structures such as the amygdala and hippocampus), 
as well as frontal lobes [341, 1426].  Tg2576 mice similarly show pathology in these same 
brain regions [1242, 1291], suggesting that these mice likely exhibit a behavioural 
phenotype that includes emotional disturbances as well as some behavioural 
characteristics reminiscent of BPS in AD.  However, these may not always correlate 
with amyloid deposition. For example, Jacobsen et al  [1245] have detected an early 
decrease in spine density in the outer molecular layer of the hippocampal DG 
beginning as early as 4 months of age, which by 5 months coincided with a decline in 
LTP (following perforant path stimulation), and impairment in contextual fear 
conditioning task.  At this time significant amyloid pathology is absent in TG mice 
[1245].  These results are in agreement with the findings from other studies [1427-1431], 
which have reported impaired fear conditioning to context and/or auditory cues in fear 
conditioning paradigms in Tg2576 mice.  Several previous studies have also used the 
EPM and other tests to assess anxiety in Tg2576 mice [1252, 1381, 1382, 1390, 1391], and 
have revealed a phenotypic tendency for this model to display reduced 
anxiety/disinhibited behaviour.  For example, although there are no published reports 
of behaviour in the EPM at an age earlier than 7 months, in 9 month old, and 17 month 
old Tg2576 mice and WT littermates, it has been reported that there is a greeter 
propensity for TG mice to spend increased time in the open arms as well as making 
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more open arm entries relative to WT mice [1382, 1390]. These results suggest that 
Tg2576 mice are less anxious/more disinhibited than WT mice.  As such, these 
tendencies are referred to here as genotypic ‘target’ behaviours. In addition, using the 
EPM, 9 month old Tg2576 mice have also been shown to exhibit abnormal responses to 
unconditioned aversive or anxiogenic stimuli (e.g. by spending significantly more time 
visiting the open arms and making more entries into these open arms than controls 
[1382]).  However, it is important to also mention the findings of Ognibene et al. [1252], 
who have reported that both these target behaviours in the EPM are non-significant 
trends in Tg2576 mice between the ages of 7 to 12 months.  However, Ognibene et al., 
did  report a number of other measures consistent with reduced anxiety in Tg2576 
mice, including increased head dipping, less stretch-attend postures and increased 
self-grooming in the EPM, as well as preferential exploration of exposed regions of an 
open-field arena indicative of a disinhibited phenotype  [1252].   Taken in aggregate, 
these studies are consistent with the view that TG2576 mice display behavioural 
responses associated with reduced anxiety and behavioural disinhibition, although it is 
evident that other factors can modify these behaviours, including most obviously 
background strain [1381]. 
Currently, no studies have reported outcomes for the assessment of rosiglitazone 
treated Tg2576 mice on the EPM task.  However, rosiglitazone has been reported to 
reverse a contextual fear conditioning impairment in 9 month old Tg2576 mice, but 
not in mice aged 5, and 13 months of age (sex unreported) [1215]. Rosiglitazone has also 
been shown to reverse a contextual fear conditioning impairment in 20 month old 
male F344 rats [1207], although it had no effect hippocampal interleukin-1beta (IL1β) 
levels, markers of oxidative damage, or NMDA receptor expression.  Thus, in order to 
assess the impact of rosiglitazone on non-conditioned anxiety as assessed by the EPM, 
in Experiment 2A (LINS), mice were given a single exposure to the EPM at ~13 months 
following a 2 day rest period after the conclusion of Experiment 1A.  In Experiment 2B 
(EINS), mice received a single exposure EPM task at the age of ~8 months. 
 
3.4. 2 Methods  and  Apparatus  
3.4.2.1 Animals and Drug Administration 
Experiment 2A (LINS) used the mice from Cohort 1, which had previously undergone 
Experiment 1A. Experiment 2B (EINS) used the mice from Cohort 3 which were 
experimentally naïve (this because the order of spatial and anxiety experiments were 
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reversed in the ENIS condition).  Please see section 3.3.2.1 for details of housing and 
drug administration. 
 
3.4.2.2 Apparatus  
The EPM was constructed from two open arms, each measuring 8cm wide x 50cm long, 
which ran from north to south, and two enclosed arms, measuring 8cm wide x 50cm 
long and 15cm high, running from west to east (see figure 3.7). The plus maze platform 
was elevated 90cm from the floor via a vertical black frame, and had a white laminate 
wood floor supported laterally by a black metal frame. The walls forming the enclosed 
arms were comprised of mat black coloured Perspex, with open arms containing an 
extremely short (1cm tall) clear Perspex walls to help prevent falls. The maze was 
placed inside a wooden arena (102cm2 and 43cm height) with a sawdust-covered floor 
to cushion the mouse in the event of a fall. The apparatus was located in quiet and 
brightly illuminated room comprised of multiple environmental cues, including 
shelves and a computer system.  A camera was mounted on the ceiling and connected 
to a DVD player and monitor to ensure all sessions were recorded.   A camera was 
attached to the ceiling directly above the maze, which was connected to a computer, a 
television monitor and video recorder (VCR). The camera input was used to visualise 
the maze activity on the television monitor, and each session was recorded using the 
VCR.  Noldus® Ethovision tracking software on the computer was utilised to collect 
data using the camera input by manual scoring (see Scoring and Statistical Analysis). 
 
 
Figure 3.7: EPM Apparatus. Left: The apparatus insitu. Right: A WT mouse exploring one of 
the open arms. 
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3.4.2.3 Behavioural Procedures 
Testing in Experiment 2A and 2B took place over a single day, with mice transported to 
the test room in their individual home cages. Prior to the start of each trial, the EPM 
was cleaned thoroughly with a 1:20 dilution of Mr Muscle®, and the VHS video 
recording equipment was activated. The mouse was placed in the centre platform of 
the EPM facing a left-hand closed arm, after which the experimenter withdrew to the 
computer station at the edge of the room.  The animal tracking software (Noldus© 
Ethovision) was then started, with the experimenter observing the behaviour of the 
mouse on the monitor, manually scoring as appropriate (see scoring Criteria). In the 
rare event that a mouse fell from the open arms, the animal was retrieved from inside 
the arena and placed back onto the centre platform of the EPM as previous. Each 
animal was given one session of five minutes (300 seconds) duration in the maze with 
free-access.  When the session had expired, the animal was removed from the maze 
and placed back into its home cage prior to being returned to the holding room. 
Scoring and Exclusion Criteria: Mouse behaviour within the EPM apparatus was 
scored manually using the Noldus© Ethovision software. Here, mice were scored for 
two measures: (i) the mean time spent in the open and the closed arms; (ii) the mean 
number of entries into the open and the closed arms. Each arm was assigned a specific 
letter on the computer keyboard, which was pressed upon entry into and exit from 
each arm.  An arm entry was defined as when all four paws of the mouse passed the 
entrance of the arm, and an arm exit was defined as when all four paws crossed outside 
the arm.  This criteria is comparable to that previously reported by Lalonde et al. 
[1390], and Ognibene et al. [1252]. Using this methodology, Noldus® Ethovision 
software automatically calculated the total duration spent in each arm and the total 
number of entries into each arm. The accuracy of this scoring method was checked for 
the first 3 mice tested per session.  No further mice were excluded from the analysis 
due to mortality, although one WT mouse (from WT-C), was removed from the 
Experiment 2A due to a non-fatal injury which temporarily impeded its mobility. In 
addition, in Experiment 2B, 1 TG mouse (TG-C) met criterion for non-responsiveness 
(spending the whole 5 minutes at the start location). Thus, the total numbers of mice 
run in Experiment 2A were 18 TG mice (TG-C, n=9; TG-R, n=9), and 18 WT (WT-C, 
n=9; WT-R, n=9). In experiment 2B, the total numbers of mice run were as follows: 24 
TG mice (TG-C, n=12; TG-R, n=12), and 25 WT mice (WT-C, n=12; WT-R, n=13).   
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3.4.2.4 Statistical Analysis 
Raw data for each of the frequency and duration measures were analysed by 3-way 
ANOVA, which had Genotype and Treatment as the between-subject factors and Arm 
(open or closed) as the within-subject factor.  Using IBM SPSS Statistics v.21.00 
software with an alpha value (p) <0.05, taken as being statistically significant Any 
significant ANOVA interactions and non-parametric analysis were conducted as 
previously indicated in Experiment 1 (see section 3.3.2.4).  As well as analysing the raw 
data, both the duration and frequency data in each experiment were converted into a 
preference ratio (PR).  For the duration data the ratio was calculated for preference for 
spending time in open arms: = time spent in open arms/time spent in both open and 
closed arms. PRs above 0.5 indicate that the mouse was spending more time in the 
open arms than in closed arms.  For the frequency data the preference ratio was 
calculated for making entries into open arms: = entries into open arms/Total number 
of entries). PRs above 0.5 indicate that the mouse was making more entries into open 
than closed arms.  Analysis of PRs is less subject to the influence of individual 
variability in both duration data frequency of entries; it provides a measure of the 
extent of discrimination between the open and closed arms of the apparatus.  All PRs 
were analysed by 1-way ANOVA, with PR: (Duration Open Arm, Frequency Open Arm 
Entries), as the dependent variable, Genotype and Treatment as factors.   
 
3.4. 3 Results   
3.4.3.1 Experiment 2A: LINS Mean  Time Sp ent  in Op en and C losed Arms 
Figure 3.8 shows the mean duration spent in the open and closed arms of the EPM.  
Inspection of this figure shows that there are no significant differences between any of 
the groups, although there is a tendency for WT mice spending more time in closed 
verses open arms of the apparatus (the TG mice slightly favour the open compared to 
closed arms).  This description was confirmed by 3-way repeated measures ANOVA 
with Arm (duration spent in open and closed arms), Genotype, and Treatment as 
factors.  This showed a non-significant effect of Arm F(1,32)=0.933, p=0.341, a non-
significant effect of effect of Transgene, F(1,32)=2.194, p=0.148, a non-significant effect 
of Treatment F(1,32)=1.614, p=0.439, a non-significant two-way interaction of Arm by 
Genotype F(1,32)=2.806, p=0.104, a non-significant two-way Arm by Treatment 
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interaction F(1,32)=0.398, p=0.533, and a non-significant three-way interaction of Arm 
by Genotype by Treatment interaction F(1,32)=0.049, p=0.827. Tests of between-
subjects effects showed that overall there was a non-significant two-way Treatment by 
Transgene interaction F(1,32)=1.157, p=0.290. In the absence of any significant 
interactions, no further statistical analysis was performed using the raw data.  PRs 
were calculated for time spent in open arms (see Table 3.3).  Despite this showing a 
trend towards TG mice spending more time in the open arms relative to WT mice, this 
was non-significant.  A one-way univariate ANOVA confirmed this, with PRs (for time 
in open arms) as the dependent variable, and Genotype, and Treatment as factors.  
This showed a non-significant effect of Genotype F(1,32)=2.554, p=0.120, a non-
significant effect of Treatment F(1,32)=0.358, p=0.554, and a non-significant Genotype 
by Treatment interaction F(1,32)=0.017, p=0.898.  
 
Figure 3.8:  LINS EPM (Experiment 2A).  Mean duration spent in open and closed arms.  
There are no significant transgene differences between groups with respect to the time spent 
in open verses closed arms of the EPM, and no significant effects of drug treatment. Values 
are means ±S.E.M.   
 PR (Open Arms) 
LINS Group M SEM 
TG-C 0.50 0.08 
TG-R 0.53 0.08 
WT-C 0.37 0.05 
WT-R 0.42 0.07 
 
Table 3.3:  PR (duration) data for LINS EPM (Experiment 2A).     
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Mean  Fr equ ency of  Entries into Op en an d C losed  Arm s 
Figure 3.9 shows the mean frequency of entries into open and closed arms of the EPM.  
Inspection of this figure shows that there is no overall transgene effect with respect to 
the number of entries into open verses closed arms of the apparatus, or any significant 
differences due to rosiglitazone treatment. This description was confirmed by repeated 
measures ANOVA with Arm (frequency of open and closed arm entries), Genotype, 
and Treatment as factors. This showed a main effect of Arm F(1,32)=14.518, p=<0.001, a 
non-significant effect of effect of Transgene, F(1,32)=0.007, p=0.933, a non-significant 
effect of Treatment F(1,32)=0.007, p=0.933, a significant two-way interaction of Arm by 
Genotype F(1,32)=4.422, p=0.043, a non-significant two-way Arm by Treatment 
interaction F(1,32)=0.380, p=0.542, and a non-significant three-way interaction of Arm 
by Genotype by Treatment interaction F(1,32)=1.332, p=0.257. There was a no 
significant Treatment by Genotype interaction F(1,32)=1.804, p=0.189.  
A follow-up test of simple main effects for the significant Arm by Genotype 
interaction revealed that TG mice made significantly more entries to open arms 
compared to closed arms F(1,32)=17.482, p=<0.001, whereas in WT mice the difference 
between the frequency of entries into open verses closed arms was non-significant 
F(1,32)=1.458, p=0.236.  Thus, whilst this within genotype comparison confirmed the 
target behaviour in TG mice consistent their exhibiting a disinhibited phenotype, the 
seemingly poor discrimination in the WT mice between arms meant that the WT 
target behaviour of making more entries into closed arms verses open could not be 
confirmed.  However, a between genotype comparison did show that WT mice made 
more entries into closed arms compared to TG mice F(1,32)=4.793, p=0.036, although 
no transgene effect was evident with respect to open arms F(1,32)=1.068, p=0.309.  It is 
likely that larger mean for WT-R open entries likely contributed to the lack of a 
transgene effect with respect to open arm entries.  
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Figure 3.9:  LINS EPM (Experiment 2A). Mean frequency of open and closed arm entries.  
Values are means ±S.E.M with asterisk denoting significance at the 0.05 level.   
 
PRs were calculated for the number of open arm entries (see Table 3.4).  Inspection 
of this table suggests that there are no significant differences beyond an overall effect 
of genotype with TG mice making more arm entries than WT counterparts.  A one-way 
ANOVA confirmed this interpretation, with PRs (total number of entries into open 
arms) as the dependent variable, and Genotype, and Treatment as factors.  This 
showed a significant effect of Genotype F(1,32)=5.417, p=<0.026, a non-significant effect 
of Treatment F=<1, and a non-significant Genotype by Treatment interaction 
F(1,32)=1.710, p=0.200.   
 
 PR (Open Arms) 
Group M SEM 
TG-C 0.66 0.03 
TG-R 0.61 0.06 
WT-C 0.50 0.02 
WT-R 0.56 0.05 
Table 3.4:  LINS EPM (Experiment 2A).  Open Arm Entries PRs (frequency data).    
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3.4.3.2 Experiment 2B: EINS Mean  Durat ion Spen t in Open an d Closed  Arms 
Figure 3.10 shows the mean duration spent in the open and closed arms of the EPM for 
the early-intervention experiment.  Inspection of this figure suggests that overall TG 
mice spent more time in open arms relative to WT mice, although this likely being 
driven by the large response in the TG-N group.  This description was confirmed by 3-
way repeated measures ANOVA with Arm (duration spent in open and closed arms), 
Genotype, and Treatment as factors.  This showed a non-significant effect of Arm 
F(1,44)=0.012, p=0.915, no significant effect of effect of Transgene, F(1,44)=0.069, 
p=0.794, no significant effect of Treatment F<1, no significant interaction of Arm by 
Genotype F<1, no significant two-way Arm by Treatment interaction F=<1, and a 
significant three-way interaction of Arm by Genotype by Treatment interaction 
F(1,44)=6.242, p=<0.005. There was a non-significant two-way Treatment by Genotype 
interaction F(1,44)=1.451, p=0.235.   
A follow-up test of simple main effects for the significant Arm by Genotype by 
Treatment interaction revealed that TG-R and WT-R mice did not differ with respect 
to the time spent in open arms F(1,44)=1.964, p=0.168, or closed arms F(1,44)=0.596, 
p=0.444.  However, TG-C mice did spend significantly more time in open arms 
compared to and WT-C mice F(1,44)=6.538, p=0.014, whereas time spent in closed arms 
was not significant F(1,44)=2571, p=0.116.  Thus, genotypic target behaviours were 
confirmed in TG-C mice when compared to WT controls.  Indeed, within genotype 
comparisons showed that TG-C mice also spent significantly longer in the open arms 
compared to TG-R mice, F(1,44)=5.704, p=0.021, with the time spent in closed arms 
non-significant: F(1,44)=2.136, p=0.151.  This suggests that rosiglitazone may have 
modified some component of anxiety/disinhibition in the TG-R mice.  By contrast, 
WT-C mice did not differ significantly from WT-R in either the time spent in open 
arms F(1,44)=2.488, p=0.122,  or closed arms F<1, suggesting that the drug did not 
significantly affect performance.  Finally, within group comparisons showed that 
neither of the TG or WT groups showed a significant bias for time spent in open verses 
closed arms of the apparatus, although this was close with respect to the TG-C group: 
TG-R: F(1,44)=1.150, p=0.289,  TG-C: F(1,44)=3.717, p=0.060; WT-R: F<1,  WT-C: 
F(1,44)=1748, p=0.193.  PRs were also calculated for time spent in open arms (see Table 
3.5).  Inspection of this table suggests that there is a tendency towards TG mice 
spending more time that WT mice in the open arms of the apparatus, although this is 
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not likely to be significant.  A one-way univariate ANOVA confirmed this, with PRs as 
the dependent variable, and Genotype, and Treatment as factors.  This showed a no 
significant effect of Genotype F(1,47)=2.053, p=0.159, n0 significant effect of Treatment 
F<1, but a significant Genotype by Treatment interaction F(1,47)=6.146, p=0.017.  A 
follow-up test of simple main effects for the significant Genotype by Treatment 
interaction confirmed the findings in the raw analysis, revealing that compared to WT-
C mice, the TG-C group spent more time in open arms of the apparatus, F(1,44)=7.344, 
p=<0.005, whereas neither of the drug treated groups differed significantly from each 
other on this measure, F<1.  Within genotype comparisons then showed that TG-C 
mice spent significantly more time in open arms relative to TG-R mice F(1,44)=4.537, 
p=0.039, whereas the difference between both WT groups was again, non-significant 
F(1,44)=1.851, p=0.181.  Therefore, TG-C mice are more disinhibited than WT-C mice, 
and rosiglitazone significantly reduces a component of the target behaviours in the 
TG-R mice.   
 
 
Figure 3.10:  EINS EPM (Experiment 2B).  Mean duration spent in open and closed arms.  
Values are means ±S.E.M with asterisk denoting significance at the 0.05 level.   
 
 PR (Open Arms) 
Group M SEM 
TG-C 0.69 0.08 
TG-R 0.44 0.10 
WT-C 0.37 0.07 
WT-R 0.53 0.08 
Table 3.5:  EINS EPM (Experiment 2B).  Open Arms PR (duration data). 
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Mean  Fr equ ency of  Entries into Op en an d C losed  Arm s 
Figure 3.11 shows the mean frequency of entries into open and closed arms of the EPM.  
Inspection of this figure shows that there is an overall transgene effect, although the 
direction of this differs between genotypes.  WT mice make significantly more entries 
into closed arms, whereas WT mice make significantly more entries into open arms.  
This is pattern is likely driven by the fact that unlike both drug-treated groups, the 
distribution of entries in non-drug-treated conditions shows a significant selection 
bias, with TG-C mice making more entries into open arms than closed, and WT-C mice 
making significantly more entries into  closed arms than open.  This interpretation was 
confirmed by an ANOVA with Arm, Genotype, and Treatment as factors.  This showed 
revealed no significant effect of Arm F<1, no significant effect of effect of Genotype, 
F<1,  no significant effect of Treatment F(1,44)=2.792, p=0.102, but a significant Arm by 
Genotype interaction F(1,44)=11.536, p=<0.01, no significant Arm by Treatment 
interaction F<1, but a significant Arm by Genotype by Treatment interaction 
F(1,44)=6.657, p=<.05. There was no significant Treatment by Genotype interaction F<1.    
A follow-up test of simple main effects for the significant Arm by Genotype by 
Treatment interaction revealed that whilst the number of open arm entries was non-
significant between non-drug treated groups, F(1,44)=3.263, p=0.079, WT-C mice did 
make significantly more entries into closed arms than TG-C mice, F(1,44)=4.189, 
p=0.047.  Thus, although this analysis shows that the genotypic target behaviour was 
not confirmed in the TG-C mice (i.e. that they make more entries into open arms than 
WT mice), the behaviour of the WT mice was consistent with their exhibiting a more 
anxious/less disinhibited phenotype. TG-R and WT-R mice also did not differ with 
respect to the number of open arm entries F<, or closed arm entries F<1.  Nevertheless, 
within genotype comparisons did show that TG-C mice made more entries into open 
arms than TG-R mice, F(1,44)=4.330, p=0.043,  although the number of entries into 
closed arms was non-significant: F<1.  By contrast, WT-C mice did not differ 
significantly from WT-R in either the number of entries into open arms F<1, or closed 
arms F(1,44)=2.748, p=0.105.  Again, this suggests that rosiglitazone had modified some 
component of the disinhibited TG phenotype, but had a negligible effect on WT mice.  
Finally, whilst neither nether of the drug-treated groups showed a significant bias 
towards making more entries into one type of arm or another TG-R: F<1, WT-R: F<1, 
both non-drug treated groups did show a bias with TG-C mice making significantly 
more entries into open compared to closed arms, F(1,44)=9.679, p=<.05, and WT-C 
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mice making more entries into closed arms compared to open arms F(1,44)=7.187, 
p=0.010.  Thus, within the non-drug control groups, significant arm biases were found 
in relation to the number of arm entries that were entirely consistent with genotypic 
target behaviours.  
 
Figure 3.11:  EINS EPM (Experiment 2B).  Mean frequency of open and closed arm entries.  
Values are means ±S.E.M with asterisk denoting significance at the 0.05 level. 
 
PRs were also calculated for the number of open arm entries (see Table 3.6).  In line 
with expected genotypic preferences, this did confirm that in the non-drug treated 
groups TG mice showed a significant preference for making more entries into open 
arms relative to closed than WT mice.  This interpretation was confirmed by an 
ANOVA, with PRs as the dependent variable, and Genotype, and Treatment as factors.  
This showed a significant effect of Genotype F(1,44)=4.704, p=0.036, a non-significant 
effect of Treatment F(1,44)=1.832, p=0.183, and a significant Genotype by Treatment 
interaction F(1,44)=8.180, p=0.006.  A follow-up test of simple main effects for the 
significant Genotype by Treatment interaction revealed that TG-C mice made 
significantly more entries into open arms compared to WT-C mice, F(1,44)=12.138, 
p==<.01, although the PRs for drug-treated groups did not differ statistically, F<1.  
Furthermore, and of considerable interest, a within genotype analysis showed that TG-
R mice made significantly fewer entries into open arms compared to TG-C mice, 
F(1,44)=8.521, p=<.05, whereas the difference between both WT groups was not 
significant F(1,44)=1.185, p=0.282.  This confirmed that rosiglitazone had reduced some 
component of anxiety/disinhibition in the transgenic mice. 
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 PR (Open Arms) 
Group M SEM 
TG-C 0.66 0.04 
TG-R 0.42 0.07 
WT-C 0.38 0.04 
WT-R 0.46 0.06 
Table 3.6:  EINS EPM (Experiment 2B). Open Arm Entries PRs (frequency data).    
 
3.4. 4 Discussion   
During Experiment 2 mice were scored in the EPM according to two popular 
characteristics thought to correspond to anxiety and behavioural disinhibition in 
rodents: the total time spent in the open verses closed arms of the EPM apparatus, and 
the number of entries made into each of these arms.  I will first discuss each of these 
measures in relation to the control (non-drug) treated mice before discussing in 
further detail the interesting findings in relation to rosiglitazone and its impact on 
both of these measures in the early-intervention group.   
 
3.4.4.1 Evaluation of Experimental Controls 
It is undoubtedly the case that across both late and early-intervention experiments, 
there is evidence to support the view that TG mice display disinhibited behaviours in 
the EPM, although this is most convincing for the early-intervention group.  In 
Experiment 2A, no significant differences were found between with genotypes with 
respect to either the time spent in open and closed arms, or the number of entries into 
these arms (although weak trends in the direction of target behaviours are seen).  
Thus, in terms of target behaviour open arm entries, in the late intervention study TG 
mice are no more anxious or disinhibited than WT mice.  However, the fact that 
compared to TG mice, the WT mice did make significantly more entries into closed 
arms, suggests that WT mice were the more anxious.  Indeed, it is also apparent that 
unlike WT groups, both TG groups do show a significant bias in their arm selections, 
making more open arm entries than closed.  This does suggest that some component 
of anxiety/behavioural disinhibition was present in TG mice that may have been 
absent in the WT mice (or at least, not present to the same degree).  In Experiment 2B 
(early intervention) the situation is considerably different; both target behaviours were 
confirmed in non-drug treated controls.  Thus, TG-C mice spent significantly more 
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time in open arms compared to WT-C mice, and made significantly more open arm 
entries than WT-C mice, although this latter finding was only evident when a 
preference ratio was calculated for the number of open arm entries divided by the total 
number of open and closed entries. Indeed, non-drug treated mice in both genotypes 
also displayed significant within group preferences, with TG-C mice making more 
entries into open verses closed arms, and WT-C mice showing the opposite preference.  
Both of these findings are consistent with previous studies using the EPM which show 
that TG mice display a disinhibited phenotype relative to WT mice (i.e. make more 
open arm entries and spend more time in the open arms [1381, 1382, 1390]).  However, 
like the current study, not all studies have reported finding a significant genotypic 
difference with respect to these measures in the EPM [1252, 1381], although other 
measures have been reported which suggest that TG mice are comparatively 
disinhibited compared to WT controls [1252].  This suggests that a number of factors 
could affect the performance of mice in the EPM task.   I will briefly summarise these. 
 Fa ctor s Possib ly Affect in g EPM Perf orman ce  
With the exception of one study [1381], most studies have not reported the ratio of 
male to female mice used in experiments.  The levels of oestrogen are known to 
influence anxiety related behaviours in humans [1351], as well as rodents (e.g. [1432, 
1433]).  Indeed, the numbers of female mice used is particularly important in the 
context of Tg2576 [1434] and other hAPP models [1435, 1436] where it has been 
reported that sex and/or endocrine factors (particularly those associated with reduced 
oestrogen signalling) strongly modulate cerebral β-amyloidogenesis in hAPP-
transgenic mice leading to more extensive amyloid pathology than in age matched 
males.  Thus, it is possible that some studies which have reported a significant 
genotypic difference with respect to the duration spent in open and closed arms, have 
used a higher proportion of female mice where oestrogen signalling happened to be 
transiently low.  However, since this is not the case in the current study this cannot be 
considered a suitable explanation for why the findings in controls were more robust in 
the early-intervention data. 
It is possible that variation in the genetic backgrounds of various TG2576 colonies 
used in studies may be responsible for some of the variance in reported outcomes 
relating to the EPM.  For example, Lassalle et al. [1381], have investigated spatial 
memory and anxiety in  Tg2576 mice relative to 3 genetic backgrounds of TG2576 
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differing by their genetic heterogeneity (homozygous verses heterozygous) and strain 
of origin (C57BL6, CBA, B6SJL F1) after only one generation backcrossing.  Whilst 
Lassalle et al. report a significant transgene effect in terms of the time spent in the 
open-arms by TG mice relative to WT littermates, this difference is less pronounced in 
the B6SJL background in which WT mice also spend much time in the open-arms 
[1381] (note: the number of arm entries in this study was not assessed).  That said, both 
the Tg2576 colony in Cardiff maintained by Professor Mark Good, and the mice 
purchased from Taconic [1282], originate from the same B6SJL background strain, 
although it is possible that small variations in the genetic makeup of these animals 
may have been responsible for the differential late, and early-intervention results.  
Indeed, it is possible that genetic differences in the late-intervention cohort could have 
reduced the sensitivity threshold of the EPM task, making it more susceptible to other 
factors. Finally, there are two methodological issues that could explain why the late-
intervention data was not as robust as was the case in the early-intervention cohort. 
First, Experiment 2A (LINS) had fewer mice.  Given that there were weak trends in the 
direction of target behaviours, fewer mice may have made the experiment more 
susceptible to individual variation responses that the PRs could not fully correct.  
Second, the mice in Experiment 2A were older (~13 months at test) than mice in 
Experiment 2B (~8 months at test). Whilst age may be one factor which could may 
changes in the behaviour of WT mice on a range of tasks [1437], limited evidence 
suggests that compared to mice with a predominant C57BL6 background, TG2576 and 
WT mice from a predominantly B6SJL F1 background may be less resilient to the 
effects of aging across some cognitive measures [1284, 1356].  However, this has not 
been investigated with respect to emotional behaviours in Tg2576 mice and WT 
littermates, particularly at the 13 month old time point. Indeed, whilst one study has 
reported a significant difference in 17 month old Tg2576 mice in some genetic 
backgrounds with respect to the total duration of time spent in open and closed arms 
[1381], the frequency of arm entries has not been assessed.  Some research also suggests 
that anxiety measures in younger mice are less susceptible to pre-test conditions 
compared to the same variables in adults [1438].  Again, although this does not appear 
to have been systematically studied in Tg2576, since the mice in Experiment 2A had 
received prior exposure to searching for food in a similar apparatus (i.e. the T-maze), it 
is possible that that this may have reduced the sensitivity EPM to genotypic differences 
in the older mice. Indeed, the mice in Experiment 2B were not only younger adults, but 
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also experimentally naive.  Nevertheless, the results of both interventions do support 
the view that TG mice exhibit less anxiety/greater behavioural disinhibition than WT 
both in young adult mice, and older mice. 
 
3.4.4.2 Impact of Rosiglitazone on Anxiety and Disinhibition  
Although the impact of rosiglitazone on anxiety and behavioural disinhibition is 
unknown, rosiglitazone has been shown to improve contextual fear conditioning in 
aged rats [1403], demonstrating that the drug may (in non-TG mice at least), affect 
some components of emotional memory in adult mice. However, it is evident from the 
results of the late-intervention experiment that there are no significant drug effects in 
any of the groups with respect to the primary methods of assessing anxiety and 
behavioural disinhibition in ~13 month old Tg2576 mice, in the EMP task despite being 
on the compound for between ~5-to-6 months. As such, the results of Experiment 1A 
are consistent with those of Nicolakakis et al. [1386], in that delivering PPARγ 
compounds to adult mice when amyloid pathology is well under way does not 
necessarily result in rescue the behavioural phenotype of hAPP mice.  However, it is 
also apparent that in Experiment 2A the target behavioural effects in the EPM task 
were much weaker, and not conclusively incompletely demonstrated in controls.   
Thus, without confirming the behavioural phenotype in control mice, it is not possible 
to say anything further about what impact rosiglitazone might have had in ~13 month 
old mice.  The results of Experiment 2B (EINS) confirm both sets of target behaviours 
in the TG and WT non-drug treated controls.  Furthermore, unlike Experiment 2A, 
continuous rosiglitazone administration from the age of 5 months did significantly 
reduce the amount of time TG-R mice spent in open arms of the apparatus relative to 
same genotype control, as well as the number of entries into open arms of the 
apparatus.  However, the drug did not seem to ‘restore’ the within group closed arm 
bias seen in the WT-C mice (although in WT-C mice this was only significant in 
relation to the number of entries into closed verses open arms). Thus, the current 
study is the first to report that when delivered early, rosiglitazone does affect the 
performance of TG mice in the EPM task.  However, as to what component of the task 
the drug had affected, and what its mechanistic basis might be given the findings of 
experiment 1B, is more uncertain.  In the final part of this discussion therefore, I will 
address these issues. 
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Doe s Ro sigl itazon e Mak e TG mic e Mor e Anx ious? 
Only two parameters were used in this study to detect differences in anxiety in the 
EPM. These parameters were the time spent in the open sections, and the number of 
open arm entries [1383].  Indeed, in this study, the number of entries into arms was 
probably the most sensitive of these parameters for assessing levels of anxiety and 
behavioural disinhibition across both cohorts of mice. This fits with several studies 
which have reported that Tg2576 mice have increased levels of locomotor activity in 
the EPM [1382] and other similar tasks [1439-1441].  Indeed, since at least some 
instances of clinical anxiety have been linked to hyperactivity of the septo-
hippocampal system [1442].  For example, hyperactivity of this system has been linked 
to increased negative association of stimuli with a consequential increase in anxiety 
when the stimuli are subsequently presented [1442].  Thus, the hippocampal pathology 
observed in Tg2576 [1245, 1251, 1263, 1308, 1310] most likely explains the disinhibited 
phenotype of these mice.  However, not all studies have found activity levels in Tg2576 
to necessarily increase/decrease in the EPM in accordance with the traditional anxiety-
like parameters such as the time spent in open and closed arms of apparatus [1441].  In 
this context, it is important to note that the number of entries in the EPM (and similar 
tasks), is a focus of considerable discussion, primarily because it is unclear as to 
whether this parameter is an ‘activity index’ (i.e. locomotor activity), or an ‘anxiety 
index’ [1441]. Indeed, studies have used increases or decreases in the frequency of 
entries parameter in the EPM and other similar tasks (i.e., elevated zero maze), as 
either anxiety or activity differences [1443-1446].  One possible reason for these 
contradictory interpretations is that entries parameter is only partially related to 
anxiety levels [1441].  For example, as a parameter of anxiety, the time spent in the 
open sections of the EPM can be affected by the number of entries, and is important to 
distinguish whether the differences observed in mice are therefore related to anxiety or 
activity levels [1441]. 
In order to address the above issues, Heredia et al. [1441], have recently proposed a 
new index of anxiety that they refer to as “Time by Entries” (TbE). This new parameter 
adjusts for the influence of activity on time in the open section of an elevated Zero-
maze, although the principles can also be applied to the EPM.  Heredia et al. used the 
following formula:  
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   = Time in Open Section Number of Open Arm Entries 
 
The square-root was used in order to maximize differences at low levels of activity, and 
minimize differences at high levels of activity or ‘hyperactivity’, and is based on the 
theoretical function of square-root as a half of parabola with a vertical directrix [1441]. 
If the entries increase (i.e. when an animal crosses the open section rapidly and 
continuously), this parameter minimizes the effect of the high levels of activity over 
time spent in the open section.  Since time in the open section increases when there 
are high activity levels, Heredia et al. were able to re-evaluate the time spent in the 
open section of the maze by controlling for high activity levels with the TbE parameter.   
In addition, because TbE is a correction of time in an open area, it must be interpreted 
as the time spent in the open area [1441].  Thus, a high TbE rating is indicative of low 
levels of anxiety, while low TbE rating is indicative of high levels of anxiety [1441]. 
Using TbE in relation to the zero maze, Heredia et al. have assessed how individual 
housing, handling procedure and interaction between individual housing and handling 
procedure affect the baseline anxiety in Tg2576 mice and WT littermates [1441].  
Tg2576 mice were randomly assigned to two experimental groups: 1) individually 
housed, unhandled, and 2) individually housed and handled. Heredia et al. reported 
that the handling procedure in wild type animals did not show any consistent effect on 
anxiety-like behaviour levels if the animals were not individually housed [1441].  With 
respect to Tg2576 animals, individually housed/handled Tg2576 mice were less anxious 
than the individually housed/unhandled animals, and Tg2576 handled animals showed 
a reduction in activity levels compared to the Tg2576 unhandled animals [1441]. 
Comparing Tg2576 mice with their WT controls, the results of Heredia et al. suggest 
that Tg2576 mice are less anxious than WT animals. But, after calculating TbE index, 
their results did not show significant differences for this parameter, and therefore, it 
was concluded that significant differences in time spent in the open section by Tg2576 
mice are primarily mediated by the activity levels of this group [1441]. This means that 
differences in time spent in the open section between individually housed/unhandled 
Tg2576 mice and individually housed/unhandled wild type mice, were not due to 
differences in anxiety-like behaviour per se, but rather, reflected differences in activity 
levels [1441], probably as a consequence of the generally acknowledged hippocampal 
pathology in TG mice.  One should say at this point, that in terms of the current study, 
whilst the mice from cohort 1 and 2 were all individually housed from a young age, 
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they were handled frequently by animal technicians (as part of husbandry and 
maintenance procedures), as well as by the researcher conducting the experiments, so 
effects should have been the same across both cohorts. 
 One has to wonder now, what the results would be if the TbE index is applied to 
the data in Experiments 2A and 2B. This data is summarised in Table 3.7.  A 
subsequent comparison of the figures obtained for the TbE index in both the LINS and 
EINS EPM experiments were subjected to statistical analysis using a 1-way univariate 
ANOVA, with TbE as the dependent variable, and Genotype, and Treatment as 
factors. 
 LINS TbE 
(Exp. 2A) 
EINS TbE 
(Exp.2B) 
Group M SEM M SEM 
TG-C 25.98 4.01 13.51 2.08 
TG-R 36.45 4.72 7.64 1.50 
WT-C 25.17 4.21 8.09 1.05 
WT-R 24.53 4.00 10.66 1.01 
Table 3.7:  Group TbE Scores for EPM.  Experiment 2A/B.    
 
This showed that in both experiments there were no significant differences any of the 
groups.  LINS:  no significant effects of Genotype F(1,32)=2.248, p=0.144, of 
Treatment F(1,32)=1.388, p=0.256, or a Genotype by Treatment interaction 
F(1,32)=1.714, p=0.200.  Similarly, EINS: no significant effect of Genotype F(1,47)=0.23, 
p=0.727, of Treatment F(1,47)=0.27, p=0.870, or a Genotype by Treatment 
interaction although this was close, F(1,44)=3.349, p=0.074.  Both of these results are 
consistent with the findings of Heredia et al. [1441], and suggest that levels of anxiety 
were approximately similar across all groups in both experiments, with differences in 
time spent in the open section not reflecting differences in anxiety-like behaviour per 
se, but rather, differences in activity levels.   
What else could explain the fact that rosiglitazone did, in the EINS data at least, 
significantly impact on performance in the EPM task?  It is possible that the drug 
modified some motivational component of TG behaviour, leading to lower activity 
levels. If true, such a change has not been previously reported in the scientific 
literature, and does not in any case explain why a similar effect was absent in the late-
intervention cohort. It is also possible that the drug may have in the EINS cohort, 
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prevented some component of hippocampal pathology in the TG mice such that this 
may have reduced the levels of hyperactivity.  Indeed, the role of the ventral 
hippocampus in emotional processing is considered to be distinct from that of the 
amygdala (which is associated specifically with fear), as well as distinct from the role of 
dorsal hippocampal regions involved with spatial memory functions [80[686].  In this 
respect, Gray and McNaughton's theory of the septo-temporal axis [1447], can in 
principle, incorporate these apparently distinct hippocampal functions, and provide a 
plausible unitary account for the multiple facets of hippocampal function [686].  Thus, 
although speculative, it is at least plausible that rosiglitazone may have had an impact 
on some component of the ventral hippocampal function whilst leaving the dorsal 
regions either untouched, or if there were any physiological changes, maybe they were 
of insufficient magnitude to significantly impact upon spatial memory function as 
assessed via the T-Maze FCA task.  Indeed, it is possible that amyloid pathology had 
progressed too far in the LINS cohort, for the drug to make a difference in either 
region, despite the fact that these 13 month old mice had received rosiglitazone 
agonism for ~5 months.  Thus, in this case, it would appear that the late-intervention 
therapy really was ‘too late’ to make a significant difference.  However, as stated 
earlier, it is also possible that variation between the cohorts in terms of the degree of 
SJL F1 background may also have had an impact on the pattern of results obtained. 
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3.5 EXPERIMENT  3:  MARBLE  BURYING 
3.5. 1 Introduction  
Marble burying behaviour has been a popular test of neophobia in rodents, where 
historically it has been used with mouse models of anxiety [1383, 1448]. This task is 
widely considered to tap into species-typical defensive reactions of rodents to 
spontaneously bury unfamiliar stimuli [1449].  Furthermore, marble burying is 
sensitive to the administration of anxiolytic and antipsychotic drugs, which are 
normally used to treat anxiety disorders or obsessive-compulsive disorder [1448, 1450].  
Indeed, administration of such drugs in rodents has been shown to result in a 
reduction in burying behaviour in mice [1451-1453].  Currently, only one study has 
reported assessment of Tg2576 mice on the marble burying task.  Using female Tg2576 
mice and WT littermates aged 12.5, and a separate cohort of female mice aged 23 
months, Deacon et al. [1374] reported no significant differences in marble burying 
between genotypes.  The performance of male Tg2576 mice on this task has not been 
reported in the literature, and there are no reports investigating the effects of 
rosiglitazone on this measure of anxiety.  It is worth just recapping that the anxiety 
tasks were counterbalanced across both LINIS and ENIS conditions, and were given to 
mice second in the LINIS condition, and first in the ENIS condition.  Thus, in 
Experiment 3A (LINS), mice were given a single exposure to the EPM at ~13 months 
following a 2 day rest period after the conclusion of T-maze FCA testing (Experiment 
1A).  In Experiment 3B (EINS), the EPM task was delivered to 8 month old mice, 
exactly 2 days after the conclusion of  the EPM testing (Experiment 2B).   
 
3.5. 2 Methods  and  Apparatus  
3.5.2.1 Animals and Drug Administration 
Experiment 3A (LINS) used mice the mice form cohort 1, which had previously 
undergone the T-maze and EPM task. Experiment 3B (EINS) used the mice from 
Cohort 3.  These mice had received exposure only to the EPM.  Please see section 3.3.2.1 
for details of housing and drug administration. 
 
3.5.2.2 Apparatus  
Each marble burying arena was composed from a large white polycarbonate cage base 
41cm long, 24.5cm wide and 12.5cm tall, filled with a level compact layer of sawdust 
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6.5cm deep (see Figure 3.12). Twenty mixed-colour glass marbles (1.5cm diameter) were 
placed on top of the sawdust layer equally distanced apart in a 4-column by 5-row 
arrangement. In comparison to a grouped-marble arrangement, this arrangement 
forced the mice to encounter the marbles more frequently, and prevented an 
alternative avoidance response rather than burying the aversive stimuli (see [1454]).  A 
transparent Perspex lid 41cm long, 27cm wide and 1cm thick was placed securely on 
top of the cage base to prevent the mouse from escaping the arena. The lid was placed 
in a central position allowing for a 1.25cm gap either side for ventilation. Four marble 
burying arenas were placed on a table elevated 121cm from the floor, allowing 4 mice to 
be tested during one 30-minute session. A camera was attached to the ceiling directly 
above the arena to allow viewing and recording for documentation using a monitor 
and VCR. Each marble burying arena was photographed for documentation using a 
digital camera at the end of each session. 
 
 
Figure 3.12: Marble burying apparatus. (Left) Initial setup of marbles. (Right): Typical WT 
result obtained after 30 minutes (non-buried marbles are displayed in transparent circles). 
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3.5.2.3 Behavioural Procedures 
This test was given as a one day procedure. Each mouse received a single trial 
comprised of 30 min in a cage with a clear Perspex lid placed over the top to prevent 
escape (a small gap was present at the top and bottom of the lid to allow air 
circulation).  When the session had expired, the animals were removed from the maze 
and placed back into their home cages prior to being returned to the holding room.  
The number of marbles buried was then recorded (see scoring method below), and the 
sawdust renewed for each session.  Marbles were cleaned thoroughly with a 1:20 
dilution of Mr Muscle® prior to being placed in each box.  The experimenter wore latex 
surgical gloves at all times throughout the experiment, and all behavioural trials were 
recorded onto VHS video.  Mice were run in the sequence as occurred in Experiment 1. 
 
3.5.2.4 Scoring and Statistical Analysis 
Using the criteria used in previous studies [1454], a buried marble was defined as a 
marble covered at least two thirds of their depth by sawdust.  Thus, an unburied 
marble was over one third visible on the surface of the sawdust layer.  No further mice 
were excluded from the analysis due to morbidity/mortality, and none of the mice met 
criterion for non-responsiveness (in this case, spending the whole 30 minutes at the 
start location). Thus, the total numbers of mice run in Experiment 3A were 18 TG mice 
(TG-C, n=9; TG-R, n=9), and 19 WT (WT-C, n=10; WT-R, n=9). In Experiment 3B, the 
total numbers of mice run were as follows: 24 TG mice (TG-C, n=12; TG-R, n=12); 25 
WT mice (WT-C, n=12; WT-R, n=13).  Since the dependent variable in this experiment 
had only one level, each Experiment was analysed by a single 2-way univariate 
ANOVA, which had Marbles Buried as the dependent variable, and Genotype; 
Treatment as factors.  All statistical analysis were conducted using IBM SPSS Statistics 
v.21.00 software with an alpha value (P) <0.05, taken as being statistically significant. 
Significant ANOVA interactions and non-parametric analysis were conducted as 
previously indicated (see section 3.3.2.4).     
 
3.5. 3 Results   
3.5.3.1 Experiment 3A (Late Intervention) 
Figure 3.13 shows the mean number of marbles buried for each group in the marble 
burying task.  Inspection of this figure shows that there is a significant transgene 
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effect, with WT mice burying more marbles than WT mice.  However, there are no 
significant drug effects in either genotype.  This description was confirmed by ANOVA, 
which had Marbles Buried as the dependent variable, and Genotype; Treatment as 
factors.  This showed a significant effect of Genotype F(2,33)=4.322, p=<.05, no 
significant effect of Treatment F<1, and no Genotype by Treatment interaction F<1. 
 
 
Figure 3.13: LINS Marble burying task (Experiment 3A). Mean %age of marbles buried for 
each group.  Values are means ±S.E.M with asterisk denoting significance at the 0.05 level. 
 
3.5.3.2 Experiment 3B (Early Intervention) 
Figure 3.14 shows the mean percentage of marbles buried for each group in the marble 
burying task.  Inspection of this figure shows that there is a significant transgene 
effect, with WT mice burying more marbles than WT mice.  However, there are no 
significant drug effects in either genotype.  This description was confirmed by two-way 
univariate ANOVA, which had Marbles Buried as the dependent variable, and 
Genotype; Treatment as factors.  This revealed a significant effect of Genotype 
F(1,44)=14.328, p=0.001, no significant effect of Treatment F(1,45)=1.259, p=0.268, and 
no significant Genotype by Treatment interaction F<1.  
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Figure 3.14: EINS Marble burying task (Experiment 3B). Mean percentage of marbles 
buried for each group.  Values are means ±S.E.M with asterisk denoting significance at the 
0.05 level. 
 
3.5 .4 Discussion   
The results of both Experiments 3A (mice aged 13 months) and 3B (mice aged ~ 8 
months), show a significant transgene effect, with WT mice burying significantly more 
marbles than TG mice. This contrasts with the findings reported by Deacon et al. 
[1374], where no genotypic differences between either young (3 month old) or adult 12 
month old) Tg2576 mice and WT littermates.  There are three major factors which may 
help to may explain these discrepant findings.  First, Deacon et al. assessed TG and WT 
mice at 3 months of age, and a separate cohort of mice aged 12 months of age.  In both 
instances, female mice were used.  This is potentially of significance because previous 
research has shown that progesterone and/or estrogen can influence impulsivity 
and/or fear in female rodents [1455-1457], and administration of estrogen and/or 
progesterone to ovariectomized rats decreases anxiety behaviours in the open field and 
EPM tasks [1456].  Consistent with this, research conducted in naturally cycling rats 
has shown when tested on a marble burying and conditioned fear tasks, rats in 
behavioural estrus showed less impulsive burying and freezing behaviour than 
diestrous rats [1458].  Indeed, when ovariectomized rats were administered 
progesterone, estrogen or vehicle, progesterone or both estrogen and progesterone, 
were found to decrease impulsive burying and freezing behaviour compared to vehicle 
[1458].  Thus, these results suggest that progesterone and/or estrogen may mediate 
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components of impulsive and/or avoidant behaviour in rodents, although these effects 
have not been verified in naturally cycling mice in the marble burying task.  However, 
it seems reasonable to suggest that in the Deacon et al. study, behavioural estrus may 
have overlapped with the application of the marble burying task, such that the WT 
mice would have likely showed less impulsive burying behaviour than would have 
occurred in diestrous mice.  Given that that in the current study, the results of 
Experiment 3 clearly show that TG mice bury less marbles anyway, behavioural estrus 
in some or all of the squads of mice tested in the Deacon et al. study could have 
accounted for the null finding.  Second, methodological differences could also account 
for the discrepant findings.  Deacon et al. used only 12 marbles, in contrast to the 20 
marbles used in the methodology reported in the current experiment [1374]. This lower 
number of marbles may have further reduced their ability to detect genotypic changes 
in female Tg2576 mice.  Third, strain differences were reported by Deacon et al. [1374], 
which may have also accounted for the differing results in the current study.  More 
extensive research is required to characterise the performance of Tg2576 mice from 
different background strains before any firm conclusions can be drawn.   
Most behavioural scientists would probably agree that marbles, by nature, are likely 
to be non-aversive to mice, something Njung’e and Handley [1454] confirmed in 1991 
by showing that mice did not avoid the marble-containing side of a two compartment 
box.  Thus, it is unlikely that either mice or rats are necessarily in a state of anxiety 
when faced with the sudden appearance of marbles in their environment.  Indeed, 
whilst mouse marble burying has historically been used as a screening model for the 
detection of anxiolytics [1459], with benzodiazepine receptor agonists such as rapid-
onset diazepam or chlordiazepoxide found to decrease the number of marbles buried 
[1460-1462], non-anxiolytic compounds such as classical antipsychotics, anxiolytics, 
psychostimulants, and certain classes of antidepressants (see review, [1449]) have also 
been found to modulate marble burying behaviour [1451, 1453, 1459, 1463].  This 
suggests that the predictive validity of this procedure for anxiety may be limited.  
Indeed, subsequent research has shown that mouse marble burying behaviour whilst 
genetically regulated, is not correlated with other anxiety-like traits in mice nor 
stimulated by novelty [1464].  Rather, it now appears to reflect a repetitive behaviour 
that persists/perseveres with little change across multiple exposures [1464].  In this 
way one can probably explain why considering the fact that TbE analysis of data in 
Experiment 2 showed that levels of anxiety were statistically comparable across groups, 
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marble burying behaviour nonetheless was found to differ significantly between 
genotypes in both the LINS and ENIS marble burying experiments. However, given the 
range of factors which can seemingly disrupt marble burying behaviour, one has to 
admit to the apparent uncertainty with respect to the likely neural mechanisms 
engaged by the marble burying task. Of key importance in this regard is whether the 
behaviour is a response of rodents to the presence of marbles [1449, 1465], or a non-
intended consequence of digging behaviour [1462, 1466].  For example, marbles may 
appear buried due to mice engaging in digging behaviour in the general vicinity [1448].  
Perhaps the most reasonable approach is to assume that marble burying simply 
measures species-typical digging behaviour [1448] that may in part be dependent on 
intact hippocampal function [1467]. Indeed, one interpretation of marble 
burying/digging is that it will likely be modified by any agent affecting hippocampal 
function, including the benzodiazepines and 5-HT active compounds [1447, 1468], 
although given that psychostimulants can also inhibit marble burying [1459, 1463], it is 
likely that brain regions other than the hippocampus are also involved in regulating 
this  species-typical behaviour. Nevertheless, given the disruption to the hippocampal 
circuitry in Tg2576 mice, this may partly explain why the digging behaviour is 
disrupted in Tg2576.  Furthermore, since burrowing/digging behaviour is not directly 
related to learning and memory, it cannot reliably predict changes in such aspects of 
cognition, although it may involve other aspects of cognition such as executive 
function or attention [1374].  
Given these considerations, and the uncertainty as to whether or not rosiglitazone 
had modified some component of hippocampal function, it perhaps comes as no 
surprise that the drug did not modulate marble burying behaviour in either of 
Experiments 2A or 2B.  However, having assessed mobility of mice in an empty arena 
prior to the marble burying task being run, could potentially have informed this issue.  
Nevertheless, the reasons for TG mice burying fewer marbles than WT is not likely to 
be a simple matter of the former being more active (i.e. they stop more infrequently 
than WT mice to dig).  Furthermore, given the wide range of substances that can 
seemingly modulate marble burying behaviour, reducing locomotor activity (if indeed 
that is what rosiglitazone did in Experiment 2A), would be no guarantee that ‘normal’ 
marble burying behaviour would have been restored in the TG mice. 
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3.6 EXPERIMENT  4:  OBJECT  RECOGNITION  MEMORY 
3.6. 1 Introduction  
Object recognition memory is the ability of many animal species to discriminate the 
familiarity of previously encountered objects [1469].  As such, behavioural tasks such as 
delayed nonmatching-to-sample (DNMS) and spontaneous object recognition (SOR) 
for assessing object memory in non-human primates and rodents, have proved 
invaluable as animal models of specific aspects of human memory processes [1469].  
Indeed, these tasks constitute the core means by which animal models can successfully 
access many key aspects of MTL amnesia first characterised in patient HM [525, 534].  
Since it is impossible to do justice to the vast literature on this subject in the limited 
space available in this chapter, the reader is directed to the following reviews [500, 525, 
1470].  This section briefly outlines the SOR task and some of its variants, as these are 
now common behavioural tests used to measure object recognition in animals, and 
rodents in particular.  A de novo version of the SOR task is used to assess object 
recognition memory in the current study, specific details of which are summarised at 
the end of this section. 
 
3.6.1.1 Spontaneous Object Recognition Tasks 
The spontaneous object recognition task originates from the work of Ennaceur and 
Delacour [1471], and exploits the natural tendency of rodents to explore novel stimuli 
in preference to familiar stimuli. Typically, the SOR task is run in an open field arena, 
although recent efforts to address certain controversial aspects of the literature have 
prompted the introduction of a novel Y-shaped apparatus for testing SOR [1472] (these 
are not considered here). In the open field test, the spontaneous loco-motor or 
exploratory activity of mice is usually studied in circular or square arenas, which vary 
in size depending on the experiment concerned and whether the environment is 
divided into distinct quadrants or sections [1355].  The SOR paradigm is similar in 
principle to the DNMS task.  A single SOR trial consists of sample and choice phases, 
separated by a variable retention delay [525]. In the sample phase, the rodent is 
introduced into the testing apparatus, which contains two identical junk objects (A1 
and A2). The rodent is allowed to freely explore these objects for a limited amount of 
time before being removed from the apparatus. At the end of the retention delay, the 
animal is reintroduced to the apparatus, which now contains a triplicate copy of the 
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sample object (A3) and a novel object (B) to which the animal has had no prior 
exposure. Under normal circumstances, rodents will preferentially explore the novel 
object in this choice phase, and this behaviour is taken as the index of recognition of 
the familiar sample object [525].  For this reason, the SOR task is sometimes referred to 
as Novel Object Recognition task (NOR) [1473], as a means of differentiating it from 
other variants which assess spatial memory (see below).  SOR is also known as the 
visual paired comparison (VPC) task in studies with humans and monkeys [1469].  
Because SOR uses the natural exploratory behaviour of animals, unlike DNMS it does 
not require a pre-training phase (i.e. reward-based learning of the non-matching-to-
sample rule).  Aside from the advantage of allowing object recognition to be studied in 
a more natural manner without the potential complications of interpretation 
introduced by nonmatching-to-sample acquisition (or motivational considerations), 
the task is much quicker and simpler to run than DNMS [1473].  Furthermore, by 
varying the length of the interval between sample and test phases, SOR tasks can be 
used to assess either LT or WM processes [1474].   Indeed, the task is incredibly 
versatile in its simplicity.  With slight modifications for example, the SOR can be used 
to assess object-in-place memory (see figure 3.15).  In the spontaneous Novel Location 
Recognition task, the index of stimulus recognition is this time taken to be a measure 
of the greater time spent exploring a familiar object that has switched its spatial 
location in the choice phase [1474].  In this instance, the natural propensity of rodents 
is to spend more time exploring the familiar object that has been moved to a different 
location, versus the familiar object that remains in its previous location [1474].  For all 
of these treasons, SOR tasks have often become the test of choice for behavioural 
neuroscientists.  As a result, SOR tasks have contributed greatly to our current 
understanding of the neurobiological basis of object recognition memory [525], as well 
as the interactions of multiple brain regions (perirhinal cortex, hippocampus and 
medial prefrontal cortex) mediating object-in-place memory [498, 1475]. 
 
3.6.1.2 Recognition Memory in Adult Tg2576 Mice 
Probably the most systematic contribution to understanding object recognition 
memory in Tg2576 mice using SOR analogues has been undertaken by Good and 
colleagues. In their initial study with male and female mice, Hale and Good [1253], 
used a standard square shaped arena to assess object novelty, recency discrimination, 
and object-location memory in Tg2576. Using a standard two-item object array and 
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delays between the sample and test stages of up to 2 minutes, 30 minutes and 24hrs, 
this study found that 14-month old Tg2576 mice were able to detect novel objects as 
well as age-matched WT mice [1253].  In addition, TG mice also exhibited a normal 
recency effect by exploring less the object most recently encountered compared to an 
object encountered earlier in a trial [1253].    
 
 
Figure 3.15: Two-trial SOR tasks. (Top panel) ‘Novel object’ Recognition.  (Bottom Panel)  
Novel Location Recognition.   
 
Consistent with studies of visuospatial recognition memory in AD patients Hale and 
Good showed that Tg2576 mice were impaired in detecting a change in the relative 
positions of an array of four familiar objects [1253].  In this test, object-location 
memory was assessed by using a procedure previously devised by Dix and Aggleton 
[1476] in which rats were firstly familiarised to a set of four objects (square 
configuration), in the centre of a square arena. Then following a retention delay, 
subjects were given a choice phase in which two identical copies of the sample objects 
had been exchanged across diagonal spatial locations (i.e. topological transformation), 
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while the remaining copies of sample objects stayed in the same locations as previous 
[1476]. Dix and Aggleton suggested that whilst standard novel location tasks involving 
the relocation of familiar objects to novel positions may reflect memory for the spatial 
organization of objects in the arena, only the modified object-location task described 
above would require memory for specific object-location associations. Thus, the results 
of the Hale and Good suggested that adult TG mice are impaired in forming a 
representation of the spatial organization of objects in an arena, but not impaired in 
discriminating familiar from novel items per se [1253].   
In order to further investigate the extent to which the hAPPswe mutation 
selectively disrupts processes specific to memory for location (as opposed to object 
identity), Good and Hale [1384] undertook a further study of object recognition 
memory with a cohort of 16 month old male Tg2576 mice.  In order to determine 
whether the size of the object array interacted with object recognition memory in 
Tg2576 mice (i.e. made object novelty detection harder), object novelty and object–
location tasks both used a four-item object array.  In line with their previous findings, 
Good and Hale showed that adult Tg2576 mice retained normal object novelty 
discrimination [1384], although in contrast to their previous paper this was only 
examined using a two minute retention interval (it remains possible that novelty 
discrimination may have been impaired with longer delays).  Also consistent with their 
previous study, Good and Hale found that Tg2576 mice displayed impaired memory for 
the location of objects when 2 objects out of 4 underwent diagonal topological 
transformation [1384]. Good and Hale also tested spatial novelty in subjects by using a 
manipulation that involved moving two familiar objects to novel locations that had not 
been previously occupied by any of the objects. This manipulation involved changing 
the metric relationships between the objects and the arena walls for two displaced 
objects, whilst the remaining objects were positioned in the same locations as 
previous. Of importance here is the fact that subjects were counterbalanced across two 
different sample array configurations. If animals were allocated to an expanding array 
condition, the objects were initially presented in the centre of the arena and then, 
during the choice trial, two objects were moved to the corners of the arena. If on the 
other hand subjects were allocated to the contracting array condition, the objects were 
initially presented in the four corners of the arena and then during the choice trial, two 
objects were moved to the centre of the arena. Interestingly in this experiment both 
control and Tg2576 mice preferentially explored the familiar objects moved to 
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previously unoccupied (novel) locations [1384].   In order to test the generality of their 
findings, Good and Hale used a spatial novelty manipulation that kept the metric 
properties of the array (i.e. object–object distance and shape of the landmark array) 
consistent between the sample and test trial. Again, the results of this experiment 
showed that both control and Tg2576 mice preferentially chose to explore familiar 
objects when they were moved to previously unoccupied locations [1384].  
Overall, these results indicate that aged Tg2576 mice are able to form 
representations of the identity of objects as well as exhibit memory for the spatial 
organization of objects in an arena. In contrast, conjunctive memory for specific 
object–location associations is severely impaired in aged TG mice [1384].  Such 
conjunctive processes are the very basis of episodic memory for "what," "where," and 
"when" in humans, as well as similar processes in other animal species [367].  Indeed, 
using similar methodology to their previous studies with female and male mice, Good 
et al. [1324] have shown that TG but not WR mice aged 10-12 months old are impaired 
when it comes to forming an integrated memory of the spatio-temporal context in 
which objects were presented. These results demonstrate that male and female wild-
type, but not APP-mutant, mice are able to form an "episodic-like" memory of the 
spatio-temporal properties of objects supporting the hypothesis that aberrant APP 
processing contributes to impairments in event memory [1324]. In a recent review, 
Palmer and Good [1321], summarised converging evidence from animal and human 
studies which suggests that an early target of amyloid pathology is synaptic activity in 
the DG (dentate gyrus)/CA3 network which probably disrupts pattern separation 
processes required for the formation of episodic memory.   
 Support ing Studies of  Rec ogn ition Memory  in hAPP Mice 
A study by Ognibene et al. [1252], with 7-12 month old Tg2576 mice (sex un-reported) 
has also reported findings consistent with those of Good and Hale [1253].  In this study 
the object recognition task was comprised of seven consecutive stages (each 5 minutes 
in duration), each of which was separated by a three minute retention interval.  In the 
first stage subjects were habituated to an empty circular open field arena.  In stages 2-4 
subjects were then familiarised to five objects placed in the centre of the arena, such 
that four objects formed a square, with the fifth object at its centre.  Throughout stages 
2-7 the frequency and the time spent exploring objects were measured for each subject.  
During stages 5-6, the central object then exchanged places with one of the peripheral 
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ones, a topological manipulation similar to that used by Good and Hale [1253].  In stage 
7 one of the five familiar objects was then substituted with a novel object. The results 
of Ognibene et al. showed that whilst object novelty detection was comparable across 
TG and WT groups, Tg2576 mice failed to discriminate displaced objects and were 
therefore impaired in forming a representation of the spatial organization of objects in 
the arena [1252]. These results corroborate the findings of Good and Hale [1253].  In a 
subsequent longitudinal study Middei et al. [1325], further assessed object novelty and 
object-location memory in adult and aged Tg2576 mice (sex not reported).  Whilst this 
latter study also utilised the seven-stage object recognition task, the procedure was 
modified at stages 5-6 to examine object-place memory by moving two familiar objects 
to different spatial locations, a manipulation similar to the spatial novelty 
manipulation used by Good and Hale [1384].  However, it is important to note that 
whilst Good and Hale moved two familiar objects to two novel (previously 
unoccupied) locations in the choice trial, the study by Middei et al., only re-positioned 
one of the two spatially displaced objects to a novel location, as the second displaced 
item was moved to a position that had previously contained the first displaced object 
[1325].  Using this modified scheme Middei et al., tested mice first at 7 months and 
then again at 14 months of age.  Middei et al. showed that seven month old Tg2576 
mice failed to explore objects that had changed spatial location, although along with 
WT controls, TG mice showed a normal preference for object novelty [1325].  However, 
at 14 months of age, both controls and Tg2576 mice displayed behavioural 
abnormalities because both groups failed to react to objects that had been displaced, 
or object novelty [1325].  In considering the differences between this study and that of 
Good and Hale [1384], it is interesting to note that Good and Hale used a four-item 
array, whereas Middei et al. used a five-item array [1325], the latter of which may have 
placed extra cognitive demands on older subjects, perhaps accounting for why 14 
month old transgenic and WT mice failed to discriminate spatially shifted objects, as 
well as novel from familiar objects.  An additional factor may have been that some 
aged subjects may have developed subsequent visual impairments related to the effects 
of age on genetically pre-disposed retinal degeneration processes (see [1406]).  
SOR paradigms have been used by several groups to test object novelty detection in 
hAPP mice including the Tg2576 model, and reported contrasting results with that of 
the studies discussed thus far. For example, Taglialatela et al. [1477], found that using a 
two object array, object novelty discrimination was intact in 5 month old Tg2576 mice 
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(males and females) when subjects were tested following a two-minute retention 
period, but was impaired when testing took place after 4 hours, and 24 hours.  The 
authors of this study addressed the fact that their results contrast with the findings of 
Good and Hale [1253], and suggested that the discrepancy is possibly due to the latter 
having a higher proportion of the SJL background in there mice [1477].  This is 
plausible because differences in background strain are known to make a difference to 
the cognitive phenotype of Tg2576 mice [1381].   Studies using other mouse models of 
hAPP over expression have also revealed deficits in object novelty detection.  For 
example, a recent study by Simón, et al. [1478] used a two-item object array in a box 
shaped arena to assess object novelty detection in 2, 4 and 8 month old hAPPSWE-IND 
mice, and reported that object novelty detection was intact in transgenic and 
littermate controls when subjects were aged 2 months, but impaired in hAPPSWE-IND 
mice at 4 and 8 months of age. Whilst this study also apparently used Tg2576 mice in 
behavioural studies, frustratingly the authors do not clearly indicate which behavioural 
tests had been undertaken with Tg2576 mice and when [1478].   
Escribano, et al. [1214], have used a standard SOR task to evaluate object novelty in 
hAPPSWE-IND mice that received oral rosiglitazone at a dose of 5 mg/kg per day starting 
at 1.5-month-old mice for a total of 10 weeks. Rosiglitazone rescued object novelty 
detection in hAPPSWE-IND mice at 4 and 10 month of age (following 4 weeks of drug 
administration [1214].  Whilst it was unfortunate that this study did not examine 
whether rosiglitazone therapy modified Aβ levels, the authors did provide 
immunohistochemical evidence that linked the restorative effects of this drug to 
prevention of an early decrease in hippocampal glucocorticoid receptors. In untreated 
mice this decline coincided with the onset of behavioural deficits [1214].  In a 
subsequent study [1213], Escribano et al., confirmed the restorative effects of 
rosiglitazone on object-novelty detection, but also showed that the drug facilitated Aβ 
clearance by reducing plaque burden in the brain, as well as reducing the number of 
neuropil threads containing phosphorylated tau [1213].  Furthermore, rosiglitazone 
treatment led to activation of microglia, promoting phagocytic ability, and reducing 
the expression of pro-inflammatory markers [1213]. This study provides further insights 
into the mechanisms for the potentially beneficial effect of rosiglitazone on amyloid 
pathology and cognitive deficits. Importantly for this thesis, the effects of rosiglitazone 
on recognition memory in Tg2576 mice, has not been examined. 
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3.6.1.3 Experiment Rationale and Design 
In experiment 4 object recognition memory was assessed in Tg2576 and WT 
littermates using a de novo SOR (called the ‘Cross of Changes’ or ‘COC’).  Two versions 
of this task are used in this thesis.  First there is the Absolute Novelty version of the 
COC task, where in the choice trial mice have to discriminate two different novel 
objects within a segmented open field arena from two familiar objects appearing in the 
same spatial locations as per the sample trial (see Figure 3.16a).  Since Tg2576 and WT 
mice have been shown to exhibit comparable preferences for object novelty in both 2 
and 4 item arrays [1253, 1324, 1384], it was predicted that Tg2576 and WT mice should 
similarly exhibit a comparable preference for object novelty in the Absolute Novelty 
task.  In the second version of the COC task, in the choice phase mice are required to 
discriminate between two different but familiar objects occurring in the same locations 
as per a previous, and the same novel object that appears in two familiar spatial 
locations.  This generates a potential spatial mismatch during the test for the novel 
stimulus in a way that the absolute novelty task does not (see Figure 3.16b).  Thus, the 
second version of the COC task is referred to as Spatial Mismatch task.  
 
Figure 3.16: COC Task. (a): Spatial Mismatch version.  This shows the typical setup, with 
letters different denoting the placement of different objects.  Red circles represent the 
diagonal plane in containing the novel object. (b): Absolute Novelty version.  Red circles again 
represent the diagonal plane in containing the different novel objects.  As can be seen, the 
direction of the switch in both versions of the COC task are counterbalanced across test days, 
with different objects being used of separate days.  Note:  although we are primarily 
interested in object novelty in these tasks, the familiar objects involve regency effects.    
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 Although none of the SOR paradigms currently reported in the literature have 
involved the placement of the same novel object in two different spatial locations 
simultaneously, it seems reasonable to assume that ‘recognition’ in the context of the 
Spatial Mismatch task, would likely require the hippocampus for encoding and short-
term recall of specific object-location associations [487, 1475]. Indeed, research in rats 
has previously shown that individual hippocampal neurons develop responses to 
specific stimuli in the places where they have differential significance [495]. Thus, in 
the Spatial Mismatch task, the differential significance with respect to the novel object 
could be reflected in separate familiar/novel discriminations taking place in both the 
top and bottom horizontal axis of the apparatus generating a greater net amount of 
exploration time with respect to the novel object relative to both familiar objects.  
Given that an early target of amyloid pathology in Tg2576 is synaptic activity in the DG 
(dentate gyrus)/CA3 network (see review by Palmer and Good [1321]), and the fact that 
specific object-place associations are disrupted in Tg2576 [1384], one hypothesis would 
be that although TG and WT mice can detect object novelty, only the WT mice should 
be able to respond to the differential significance of the novel object given its 
mismatched spatial locations, and thus generate a greater net amount of exploration 
time relative to the summed response to familiar objects.  Thus, Experiment 4A (LINS) 
involved mice being given the Spatial Mismatch Novelty COC task between the ages of 
16-17 months.  By this time the mice had been on compound for between ~8-to-9 
months.  It is important to say that an initial pilot experiment for the relative novelty 
task had been conducted with a separate cohort of ~12 months old non-drug treated 
Tg2576 mice and WT littermates prior to its use in Experiment 4A.  However, there 
was insufficient time to run the Absolute Novelty task with the LINS cohort due to a 
prior agreement with GSK to conclude behavioural studies in order to honour the 
agreed time-table for completing the necessary biochemical analysis (much of which 
required pre-booking of equipment and staff resources at GSK, Harlow).  
In Experiment 4B and 4C (EINS), mice were given both versions of the COC task 
between the ages of ~10 and 12 months of age.  The Relative Novelty task (Experiment 
4B) was given to mice first, followed two days later by the Absolute Novelty version 
(Experiment 4C).  The two day gap between these tasks was used in order to ensure 
that animals remained sensitive to object novelty, as mean contact time with objects 
tends to decrease in TG and WT groups across test days.   
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3.6. 2 Methods  and  Apparatus  
3.6.2.1 Animals: and Drug Administration 
Experiment 4A (LINS) used mice from cohort 1, which had previously undergone the 
T-maze and both anxiety related tasks. Experiment 4B and 4C (EINS) used the mice 
from Cohort 3.  These mice had received exposure to both anxiety tests first, followed 
by the T-Maze.  Object recognition assessment was the last behavioural experiment 
conducted with both cohorts.  Please see section 3.3.2.1 for details of housing and drug 
administration. 
 
3.6.2.2 Apparatus  
Open Field: How location is defined within the context of this experiment was an 
important consideration.  For example, most object-location SOR paradigms use an 
un-partitioned open field arena in which particular target locations are primarily 
usually intended by researchers to be distinguishable on the basis of intra-maze and/or 
extra-maze cue(s). Furthermore, because in general each target location within an un-
partitioned arena is often visible to subjects from any other position in the apparatus, 
one may consider that the ability to resolve multiple locations may vary according to 
how salient the cues are from different positions and the degree to which cues 
themselves span multiple areas. In order maximise the ability of the mice to form 
sufficiently robust representations of locations within an apparatus, in Experiment 4 
animals received exposure to objects in a novel open field rectangular arena (83 cm x 
58 cm x 35 cm), where the internal space was partitioned into four separate 
compartments of approximately equal size by means of internal walls (each the same 
height as the perimeter wall) that formed a plus configuration. Distinct extra maze 
cues were distinguishable from each compartment, with transit between internal 
compartments accomplished via 2 internal doorways (each 15 cm high and 15 cm wide) 
located at the bottom of each internal partition where it joined the perimeter wall (see 
figure 3.19a). The outer walls, floor and internal partitions of the arena were all 
constructed from commercially available (5mm) white foam card (see Figure 3.17.a).  
The arena was located on top of a table 50 cm from the floor, in the centre of a (novel) 
quiet testing room that contained a variety of extra-maze cues, including posters on 
the walls, and a computer.  Finally, the middle of each arena contained a circular 
object zone (see Figure 3.17.b), each of which measured 10cm in diameter.  This was 
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marked out on the floor with black permanent marker, with the centre point of each 
zone clearly delineated by a small cross.  Via a camera suspended from the ceiling 90 
cm above the arena mid-point, each object zone was transposed onto to a computer 
monitor (RISC-PC), before the floor of the arena was covered with approximately 2 cm 
of aspen wood chip bedding.  These transposed object zones would be used to score 
object-mouse interactions (see method).  
Recording equipment and Objects: The camera was attached to a Panasonic video 
recorder (Secaucus, NJ, Model Number NV-MV20), the computer monitor, and PC 
(Acorn Computers, Cambridge, England). All behavioural sessions were recorded onto 
VHS video, and the movement of animals tracked via Ethovision software (Noldus, 
Wageningen, Holland).  Objects were obtained from a variety of sources, and were 
constructed from materials that could not be easily gnawed by the mice, and were 
nonporous (e.g., toddler proof reinforced plastic).  The shape and size of objects varied 
in order to make them as geometrically interesting and distinct as possible.  All objects 
were free standing and mounted onto the blank side of marble effect dominoes (1cm 
thick) in order to make them hard to displace by the mice (see figure 3.17 c).  None of 
the objects exceeded the boundary of an object zone, and none were taller than 20 cm.  
All objects were of a proportion that made it difficult for the animals to climb or rest 
on during the experiment, and each was represented in quadruplet. 
 
 
Figure 3.17: Object Recognition Arena. (a): Left: The arena insitu. Top right: A TG mouse 
exploring one of the objects. Bottom Right: A view of one of the objects used in experiments 
from the perspective of a mouse. (b) Right: Objects insitu within the object zones.  Left: A 
closer view of the one of the object zones showing the centre marking. (c) Some of the 
objects used within the apparatus for object recognition studies. 
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3.6.2.3 Behavioural Procedures 
The Spatial Mismatch and Absolute Novelty tasks were both four day procedures.  
Each task involved two days of habituation (each day = 1 ten minute trial), immediately 
followed by two consecutive test days.  Each test day involved a 10 minute sample trial, 
followed ~2 minutes later by a 10 minute choice trial.  Both Tasks utilised the same 
habituation method. Mice were run in four staggered replications, with each 
containing no more than 12 mice.  Each replication contained mice representative of all 
experimental conditions, and as always were run with the experimenter blind to 
genotype and condition.  Within each replication, the mice were run in squads of 6.  
Mice were transported to the testing room 30 minutes before the start of testing in 
order to habituate.  During this time the mice remained in their home cages in order 
to maintain familiarity with kin (mice were arranged in the holding room in the order 
in which they were run during experiments).  At the start of each day of 
experimentation, the video recorder was started in the test room, and left to fun 
continuously. This prevented errors in relation to forgetting to initiate recording 
during individual trials. The recorder was checked periodically to ensure that it 
remained on, and tapes renewed as necessary to ensure complete coverage. 
Habituation Days:  On the first habituation day, mice were exposed to the arena in 
devoid of any objects.  The mice were placed into the corner of a chamber facing the 
perimeter wall, and allowed to freely explore each of the chambers for 10 minutes. The 
start chamber chosen for each mouse was counterbalanced across groups and session. 
When the habituation session had expired, the mouse was removed from the 
apparatus and placed into its home cage before being transported back to the animal 
holding room.  Before the next trial was initiated, any mouse droppings were removed 
from the arena, and the woodchip surfacing agitated in each compartment in order to 
disrupt any odour trails left by the previous occupant. On the second habituation day, 
the woodchip surfacing was brushed aside to reveal the circular object zones in each 
chamber.  One set of identical objects were then placed directly over the centre point 
for the top-left (TL) and top-right (TR) zones (i.e. A, A¹), whilst a different set of 
identical objects were placed over the centre point for the bottom-left (BL) and 
bottom-right (BR) zones (i.e. B, B¹).  All objects were placed facing outwards into the 
arena.  The marble bases of each object were then re-covered with wood chip so that 
neither bases nor object zones were visible.  If necessary the wood chip covering 
adjusted so that it was distributed approximately equally in each compartment.  
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During each habituation trial, a mouse was placed into the corner of the chamber 
diametrically opposite to one used on day-1 (again facing the perimeter wall), and 
allowed to explore for 10 minutes.  With the experimenter secreted behind a canvas 
screen to prevent any visual disruption to subjects, the computer tracking software was 
started and used to record the movements of the animal.  Exploratory behaviour 
manually scored by the experimenter (see scoring and statistical analysis). When the 
session had expired, mice were removed from the arena as previous.  The objects were 
then removed from the arena and immersed in dilute Mr. Muscle cleaner (1:20 dilution 
in water), and dried with a clean cloth. Fresh (identical) copies objects were then 
replaced in each of the object zones as previous. Prior to the start of a trial the 
woodchip flooring was agitated in each compartment to disrupt odour trails.  Stock 
objects were always kept out of the line of sight of the mice. 
Sample and choice trials (Spatial Mismatch Novelty): For the sample and choice 
trials, the same basic procedure was used as in the habituation stages, except that now 
three object types were used (see Figure 3.16a).  In the sample trial each mouse was 
presented with two copies of an object in the top and bottom zones as per the 2nd day 
of habituation. The subject was then placed into the corner of a chamber diametrically 
opposite to the one that was used on the second habituation day as previously 
described, and allowed to explore for 10 min. The experimenter then retreated behind 
a canvas screen prior to starting the tracking software and scoring the exploratory 
behaviour of the mouse recorded (see scoring and statistical analysis).  When the trial 
had expired the subject was removed from the arena and placed back in its holding 
cage. During a subsequent 2 minute interval, all objects were removed from the arena 
and cleaned as previous. Fresh copies of the sample objects were replaced in the object 
zones as previous, except that now, one object in each set was replaced with a copy of 
the same novel object such that the change always took place across diametrically 
opposite locations i.e. TL: A, TR: C; BL: C, BR: B. The mouse was then placed back into 
the arena in the same position as used in the sample trial, and allowed to explore for a 
further 10 min. The animal’s exploratory behaviour was again scored.  When the choice 
trial was over, the mouse was placed back into its holding box and transported back 
into the animal holding room.  All objects were then removed from the arena, washed 
as previous, and then fresh copies used to set up the arena for the next sample trial.  
Again, wood chip covering was agitated as previous, and adjusted so that it remained 
equally distributed in each compartment.  All mice received 2 consecutive days of 
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testing on each trial type, with different sets of objects used on each day. The type of 
object used in the sample phase, the type used as a novel cues, and the left–right 
positioning of the novel cues, were each counterbalanced between groups and across 
days.  Although on any one test day subjects were placed into the same corner on both 
the sample and test, the corner of entry was counterbalanced across days. Thus, across 
both days of testing each subject experienced placement in a chamber during a choice 
trial where the novel object had, and had not been placed.  The experimenter wore 
latex surgical gloves at all times throughout the experiment to prevent odour 
contamination of the apparatus/objects.  
Sample and choice trials (Absolute Novelty Task- Experiment 4C only): At the end of 
the relative novelty task, the animals received a 2-day break before commencing the 
absolute novelty task. The same basic methodology was used as previous, except that 
during choice phases, two different novel objects were placed in 2 different but familiar 
locations (see figure 3.16b). The type of objects used in the sample phase, the type used 
as a novel cues, and the left–right positioning of the novel objects, were each 
counterbalanced between groups and across days.  All behavioural sessions were 
recorded onto VHS tape and scored as previous (see below).  
 
3.6.2.4 Scoring and Statistical Analysis 
Each object had been previously been assigned a specific scoring zone on the computer 
monitor and black and white observation monitor both of which matched the size and 
position of the corresponding object zones on the arena floor (as relayed by the camera 
suspended in the ceiling above the apparatus). A separate button a keyboard computer 
was used to identify each object zone on the monitor screen, and pressing the relevant 
key signified the beginning or end of investigative behaviour. Object exploration was 
therefore defined as the time an animal spent attending to objects within the zone 
boundaries [1471].  In addition, object exploration was also scored if an animal made 
head/whisker contact with an object in transit as this was taken to represent velocity 
based wiskering [1479].  Object exploration was not scored if the animal was in contact 
with but not facing the object or if it sat on the object, or used it as a prop to look 
around or above the object.  EthoVision recorded the total exploration time for each 
target zone, and signified the end of the trial.   
Mice were excluded from this experiment if they died prior to completing both 
sample and choice phases across the two test days, or if they had any mobility related 
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injuries or other health related issues which might otherwise affect their performance 
in this task. Mice were also excluded if they met criterion for non-responsiveness, 
which in this case, involved any animal, on either of the sample trials, failing to move 
from the start position for the entire duration of the trial, or failing to explore the two 
sets of sample novel objects for 5 seconds or less. This reduced the risk of any choice 
trial responses from being unfairly influenced by either low object contact times, or 
incomplete representation of both sets of sample objects. One additional criterion 
came into effect specifically for object recognition tests, and involved assessment of 
the repetitive spinning behaviour which can affect some mice (most commonly TG). 
On any given trial, any mice that exhibited a tendency to spin repetitively were 
excluded from behavioural trials if the spinning behaviour lasted for longer than 10 
seconds on more than one occasion at the boundary of a scoring zone, as this would 
otherwise artificially inflate some object contact scores.  Why some mice spin in this 
manner is not well understood, but it may be an unfortunate side-effect of continued 
inbreeding. Although spinning behaviour was observed in some mice in both 
experiments, it was not severe enough to meet criteria for exclusion and in most 
instances took place outside the vicinity of the scoring zone.  No further mice were 
excluded from the analysis of Experiment 4A due to any of the above criteria.  
However, in order to maintain as robust a non-drug control as possible, two additional 
age-matched WT mice were added to the WT-C group (these mice belonged to a 
different cohort, and had received prior exposure to the T-Maze, and EPM) in order to 
maximise numbers. Thus, the total numbers of mice run in Experiment 4A were 18 TG 
mice (TG-C, n=9; TG-R, n=9), and 21 WT (WT-C, n=12; WT-R, n=9).  No mice were 
excluded from the Experiment 4B and 4C due to mortality/morbidity, or repetitive 
circling behaviour.  Two mice (1 TG-R, and 1 WT-C) were excluded for non-
responsiveness.  Thus, in Experiment 4B/4C, the total numbers of mice run were as 
follows: 23 TG mice (TG-C, n=12; TG-R, n=11); 24 WT mice (WT-C, n=11; WT-R, n=13).   
Habituation data in each was only used as a dry run on scoring and for the purposes 
of assessing mice for early exclusion. Analysis of raw contact times for sample and 
choice data were analysed separately by 3-way repeated measures ANOVA.  In order to 
verify that any differences in object contact times between groups was not due to any 
gross changes in locomotor activity per se, the data from across both sample stages was 
analysed by 3-way ANOVA with Day (Total object contact time Day1, and Day 2), 
Genotype, and Treatment as factors. Raw contact times from across both choice trials 
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were analysed by 3-way ANOVA, which had Genotype and Treatment as the between-
subject factors, and Object (Familiar vs. Novel) as the within-subject factor. To ensure 
interrater reliability, an independent experimenter who was also blind to the animal 
assignments and object contingencies rescored 20% of all test phases from the original 
video footage. The rescored results significantly correlated with the original scores 
(r=.82, p=0.01) indicating robust interrater reliability. To ensure that we were sensitive 
to differences between groups, raw data from across choice trials were also converted 
into a preference ration ratio of the form: time spent exploring novel object(s)/time 
spent exploring all objects. PRs above 0.5 indicate that the mouse is exploring the 
novel object(s) more than the remaining familiar object(s), whereas PR scores below 
0.5 indicate that mice are exploring familiar objects(s) more than the novel object(s). 
PR data was analysed by 1 way univariate ANOVA, with Genotype and Treatment as 
factors.  Finally, independent sample t-tests were used when comparing the PRs of 
each group to chance.  All analysis were conducted using IBM SPSS Statistics v.21.00 
software as previous, with an alpha value (P) <0.05, taken as being statistically 
significant. Any significant ANOVA interactions and non-parametric analysis were 
conducted as previously indicated in Experiment 1 (see section 3.3.2.4).    
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3.6. 3 Results   
3.6.3.1 Experiment 4A (LINS): Spatial Mismatch Task  Samp le Tri al  Data   
Table 3.8a shows the mean contact times in seconds made by WT and Tg2576 mice 
with 2 pairs of novel objects in the sample stages of each test day, in the Spatial 
Mismatch Task.   Inspection of these data indicates that overall, both Tg2576 and WT 
mice explored two sets of novel objects at approximately the same rate across sample 
stages, although all groups showed a decline in contact time with objects across the 2 
sample trials.  This description was confirmed by ANOVA with Day (Total object 
contact time Day1, and Day 2), Genotype, and Treatment as factors. This showed a 
main effect of Day F(1,35)=42.799, p=<0.001, non-significant effect of Genotype  
F(1,35)=1.879, p=0.179, no significant effect of Treatment F(1,35)=0.217, p=1.579, no 
significant Day by Genotype interaction F(1,35)=0.341, p=0.563,  no Day by Treatment 
interaction F(1,35)=0.073, p=0.789, no Day by Treatment by Genotype interaction 
F(1,35)=2.288, p=0.139, or genotype by treatment interaction, F(1,35)=1.240, p=0.273.  
Thus, any differences in object contact times between groups in the subsequent choice 
stages were not likely to be caused by gross changes in object exploration per se.   
 
 
Table 3.8:  LINS Object Recognition (Experiment 4A).  Spatial Mismatch Task (a) Raw 
object contact times for novel objects used in both sample stages. (b) Mean choice trial 
preference ratio for novel objects. 
(a) Sample (Day 1)   
Contact Times (Sec) 
Sample (Day 2)  
Contact Times (Sec) 
Group M SEM M SEM 
TG-C 39.7 4.49 22.9 4.49 
TG-R 33.5 5.34 20.1 5.34 
WT-C 38.4 4.02 26.0 4.02 
WT-R 39.0 4.39 19.6 4.39 
 (b) PR.  Novel Objects 
Group M SEM 
TG-C 0.43 0.04 
TG-R 0.62 0.04 
WT-C 0.67 0.04 
WT-R 0.55 0.04 
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Choice Tri al  Data   
Figure 3.18 shows the mean total object contact times in seconds made by WT and 
Tg2576 mice across choice trials in the Spatial Mismatch Task.  Inspection of this 
figure suggests that a significant transgene effect exists between non-drug control 
groups, with WT-C mice spending more time exploring novel objects compared to TG-
C mice.  However, the total amount of time spent exploring familiar objects remains 
comparable between these groups. No transgene effect exists between drug-treated 
groups; each spends a similar amount of time exploring both classes of object. The 
relative time spent exploring either class of object does not differ between TG groups.  
The aforesaid also applies to the comparison of the relative time spent exploring novel, 
and familiar objects, in both WT groups.  Nevertheless, the exploratory trends vary 
within groups. Whilst the TG-R group, like WT-C mice, appear to spend a greater 
amount of time exploring novel over familiar objects (i.e. they discriminate between 
novel and familiar objects), neither the TG-C nor WT-R groups appear to explore one 
type of object over another.  However, both TG-C and WT-R groups do exhibit trends 
in their exploratory behaviour suggestive of some degree of discrimination taking place 
(PR comparisons will further inform the status of these trends). Thus, rosiglitazone 
primarily seems to have affected the exploratory preferences of drug-treated animals, 
rather than the total time spent exploring a particular class of object per se. 
The above interpretation was confirmed by an ANOVA, with Object, Genotype, and 
Treatment as factors. This confirmed a significant effect of Object F(1,35)=10.588, 
p=0.003, no significant effect of effect of Genotype, F(1,35)=0.878, p=0.355, no 
significant effect of Treatment F(1,35)=0.391, p=0.536, no significant two-way 
interaction of Object by Genotype F(1,35)=3.244, p=0.080, no significant two-way 
Object by Treatment interaction F(1,35)=0.469, p=0.498, and a significant three-way 
interaction of Object by Genotype by Treatment interaction F(1,35)=10.740, p=0.002. 
The Treatment by Genotype interaction was not significant F<1. A follow-up ANOVA 
for the Object by Genotype by Treatment interaction revealed a significant transgene 
effect exists between non-drug control groups, with WT-C mice spending more time 
exploring novel objects compared to TG-C mice, F(1,35)=5.981, p=0.020, although the 
total amount of time spent exploring familiar objects remains comparable between 
these groups F(1,35)=3.016, p=0.091. When compared to WT-C mice, this demonstrates 
a relative impairment in the TG-C mice with respect to total exploration time of novel 
objects.  Despite the trend in the TG-R group for spending more time exploring novel 
 195 
 
objects compared to WT-R mice, any relative difference in total exploration time of 
either class of object is non-significant: Novel: F(1,35)=0.008, p=0.927; Familiar 
F(1,35)=1.471, p=0.233.  Further comparisons show that the relative time spent exploring 
novel and familiar objects did not differ between TG groups: Familiar objects, 
F(1,35)=2.859, p=0.100; novel object, F(1,35)=1.645, p=0.208.  Likewise the relative time 
spent exploring novel and familiar objects did not differ between WT groups: Familiar 
Objects, F(1,35)=2.811, p=0.103;  Novel Objects, F(1,35)=0.493, p=0.487.  In terms of 
within group exploratory preferences, the TG-R group, like WT-C mice, appear to 
spend a greater amount of time exploring novel over familiar objects (i.e. that 
discriminate between novel and familiar objects), TG-R, F(1,35)=6.149, p=0.018; WT-C, 
F(1,35)=18.398, p=<0.01, neither the TG-C or WT-R groups differ statistically in terms of 
their within group preference for exploring one type of object over another: TG-C, 
F(1,35)=1.485, p=0.231; WT-R, F(1,35)=1.590, p=0.216.  However, both TG-C and WT-R 
groups do exhibit trends in their exploratory behaviour suggestive of some degree of 
discrimination taking place (see PRs analysis). Rosiglitazone primarily seems to have 
affected the exploratory preferences of drug-treated animals (i.e. the ratio of time each 
spends exploring one type of object over another), rather than the total time spent 
exploring a particular class of object per se. 
 
 
Figure 3.18:  LINS Object Recognition (Experiment 4A).  Mean contact times the novel 
object, and two familiar objects across both choice stages of the Spatial Mismatch Task. 
Values are means ±S.E.M with asterisk denoting significance at the 0.05 level. 
 
The raw contact time data were converted into a preference ratio as indicated in 
section 3.6.2.4 (see Table 3.8b).  Inspection of this table suggests that TG-C mice are 
significantly impaired relative to WT-C and TG-R groups, and that the WT-R group is 
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impaired relative to the WT-C group.  This description was confirmed by a one-way 
ANOVA with PR as the dependent variable, and Genotype, and Treatment as factors. 
This revealed a main effect Genotype, F(1,35)=6.462, p=0.016, no significant effect of 
Treatment, F<1, and a significant Genotype by Treatment interaction,  F(1,35)=13.154, 
p=0.001.  A follow-up test of simple main effects for the significant Genotype by 
Treatment interaction then revealed that the TG-C group was impaired relative to the 
WT-C group F(1,35)=20.522, p=<0.001, whereas neither drug-treated groups differed 
significantly, F(1,35)=0.549, p=0.464. Further comparisons then showed that compared 
to TG-C mice,  the TG-R group spent significantly more time exploring novel over 
familiar objects,  F(1,35)=9.289, p=0.004, as did WT-C mice in comparison to the WT-R 
group, F(1,35)=4.109, p=0.050.  Finally, in order to test whether groups successfully 
showed above-chance performance on choice trials, the Mean PRs for each group were 
compared to chance levels (i.e. 0.50= no discrimination) using one sample t-tests. This 
statistical analysis revealed that the only the WT-R group failed to perform at above 
chance levels: TG-C, (T(8)=-6.430, p=<0.001; TG-R, (T(8)=2.630, p=0.030; WT-C, 
(T(11)=4.468, p=0.001; WT-R, (T(8)=1.644, p=0.555. These results are important because 
they indicate that the impairment in the TG-C mice is a relative one as these mice do 
discriminate in favour of exploring familiar objects over novel ones.  By contrast, the 
impairment in the WT-R group appears to reflect a more general impairment in 
discrimination between objects as the PR score was not above chance levels (although 
it was close).  In aggregate, these results indicate complex relationships within groups 
with respect to the exploration of objects in the Spatial Mismatch Task.   
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3.6.3.2 Experiment 4B (EINS): Spatial Mismatch Task  Samp le Tri al  Data   
Table 3.9a shows the mean contact times in seconds made by WT and Tg2576 mice 
with sample stage novel objects in the Spatial Mismatch task.   Inspection of these data 
indicates that overall, both Tg2576 and WT mice explored two sets of novel objects at 
the same rate as control mice across both sample stages, although all groups showed a 
decline in contact time with objects across the 2 sample trials.  This interpretation was 
confirmed by a 3 way repeated measures ANOVA with Day, Genotype, and Treatment 
as factors. This showed a main effect of Day, F(1,43)=8.284, p=0.006, no effect of 
Genotype  F<1, no significant effect of Treatment F<1, a no Day by Genotype interaction 
F<1,  no significant Day by Treatment interaction F<1, and no significant Day by 
Treatment by Genotype interaction F(1,43)=0.103, p=0.750.  The genotype by treatment 
interaction was not significant, F<1.  Thus, any differences in object contact times 
between groups in the subsequent choice stages were not likely to be caused by gross 
changes in object exploration per se.   
 
 
Table 3.9:  LINS Object Recognition (Experiment 4B).  Spatial Mismatch Task. (a) Raw 
object contact times for novel objects used in both sample stages. (b) Mean choice trial 
preference ratio for novel objects. 
 
(a) Sample (Day 1)   
Contact Times (Sec) 
Sample (Day 2)  
Contact Times (Sec) 
Group M SEM M SEM 
TG-C 38.4 4.94 29.4 5.08 
TG-R 38.7 3.58 29.3 3.25 
WT-C 35.5 3.65 28.7 3.83 
WT-R 34.4 4.74 31.9 3.95 
 (b) PR.  Novel Objects 
Group M SEM 
TG-C 0.40 0.03 
TG-R 0.69 0.01 
WT-C 0.67 0.02 
WT-R 0.48 0.03 
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Choice Trial  Data   
Figure 3.19 shows the mean total object contact times in seconds made by WT and 
Tg2576 mice across choice trials in the EINS Spatial Mismatch Task.  Inspection of this 
figure suggests that a significant transgene effect exists between non-drug control 
groups, with WT-C mice spending more time exploring novel objects over familiar 
ones compared to TG-C mice, the latter of which seem to show the opposite 
discrimination.  Discounting the likely significant discrimination in the TG-C mice for 
the familiar object, the pattern of responses across groups looks very similar to that 
indicated by Figure 3.18, with Rosiglitazone treatment recovering function in the TG-R 
mice, but having a detrimental effect on discrimination in the WR-R mice as this is the 
only group which does not appear to show a preference for either the novel or familiar 
object.  The total amount of time spent exploring familiar objects again looks 
statistically comparable between groups. The above description was confirmed by a 
ANOVA, with Object, Genotype, and Treatment as factors. This showed a significant 
effect of Object F(1,43)=17.957, p=<0.001, a no significant effect of effect of Genotype, 
F<1, no significant effect of Treatment F(1,43)=3.794, p=0.058, no significant two-way 
Object by Genotype interaction, F<1, a significant two-way Object by Treatment 
interaction F(1,43)=6.089, p=<0.05, and a significant three-way Object by Genotype by 
Treatment interaction F(1,43)=41.090, p=<0.001. The Treatment by Genotype 
interaction was not significant F(1,43)=1.433, p=0.238.    
 
 
Figure 3.19:  EINS Object Recognition (Experiment 4B).  Mean contact times the novel 
object, and two familiar objects across both choice stages of the Relative Novelty Task.  
Values are means ±S.E.M with asterisk denoting significance at the 0.05 level. 
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A follow-up test of simple main effects for the significant Object by Genotype by 
Treatment interaction revealed a significant transgene effect between non-drug 
control groups, with WT-C mice spending more time exploring novel objects 
compared to TG-C mice, F(1,43)=7.815, p=0.008, although the total amount of time 
spent exploring familiar objects remained comparable between these groups 
F(1,43)=2.262, p=0.140. Compared to WT-C mice, this demonstrates a relative 
impairment in the TG-C mice with respect to total exploration time of novel objects.  
No transgene effect exists between the TG-R and WT-R groups with respect to the 
total time spent exploring familiar objects although this was close, F(1,43)=3.929, 
p=0.054,  whereas TG-R mice did spend significantly more time exploring novel objects 
relative to WT-R mice, F(1,43)=4.555, p=0.039. Further comparisons showed that TG-R 
mice spent longer exploring novel objects relative to TG-C mice F(1,43)=16.704, 
p=0.<001, although the relative time spent exploring familiar objects did not differ 
between these groups, F(1,43)=2.811, p=0.232.  Neither WT group differed with respect 
to the time spent exploring novel objects, F<1, although the WT-R group did spend 
significantly more time exploring familiar objects relative to WT-C mice, F(1,43)=5.321, 
p=0.026. Both the TG-R and WT-C groups spent significantly more time exploring 
novel over familiar objects, TG-R, F(1,43)=35.370, p=<0.001; WT-C, F(1,43)=17.171, 
p=<0.01.  Again, WT-R mice did not exhibit a significant bias for exploring novel over 
familiar objects, F<1.  However, unlike Experiment 4A, the raw contact time data did 
establish that the TG-C group spent significantly more time exploring familiar over 
novel objects, TG-C, F(1,43)=6.379, p=0.015 (remember this was only confirmed in the 
PR analysis in Experiment 4A).  These results again suggest that rosiglitazone affected 
the exploratory preferences of drug-treated animals. 
The raw contact time data were converted into a preference ratio as indicated in 
section 3.6.2.4.  This data is displayed in Table 3.9b.  Inspection of this table suggests 
that TG-C mice are significantly impaired relative to WT-C and TG-R groups, and that 
the WT-R group is impaired relative to the WT-C group.  This interpretation was 
confirmed by ANOVA, with Genotype, and Treatment as factors. This revealed no 
significant effect Genotype, F(1,43)=1.804, p=0.186, a significant effect of Treatment, 
F(1,43)=5.108, p=0.029, and a significant Genotype by Treatment interaction,  
F(1,43)=16.287, p=<0.001.  A follow-up test of simple main effects for the significant 
Genotype by Treatment interaction then revealed that again the TG-C group was 
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impaired relative to the WT-C group F(1,43)=41.719, p=<0.001.  However, in contrast to 
Experiment 4A, the WT-R group was significantly impaired relative to the TG-R group, 
F(1,43)=21.204, p=<0.001 (likely as a consequence of the heightened mean novelty 
response in the TG-R group). Further comparisons then showed that compared to TG-
C mice,  the TG-R group spent significantly more time exploring novel over familiar 
objects,  F(1,43)=47.977, p=<0.001, as did WT-C mice in comparison to the WT-R 
group, F(1,43)=16.505, p=<0.001.  Finally, in order to test whether groups successfully 
showed above-chance performance on choice trials, the PRs for each group were 
compared to chance levels (i.e. 0.50= no discrimination) using one sample t-tests. This 
analysis revealed that all groups except the WT-R group made a significant 
discrimination; TG-C, (t(11)=-3.633, p=0.004; TG-R, (t(10)=10.000, p=<0.001; WT-C, 
(t(11)=10.652, p=<0.001; WT-R, (t(12)=-0.457, p=0.656. These results affirm that TG-C 
mice discriminate in favour of exploring familiar objects over novel ones, whereas the 
WT-R group do not discriminate indicating a more systemic impairment in 
discrimination between objects. In aggregate, these results confirm that rosiglitazone 
significantly alters the preference of TG mice in favour of exploring novel over familiar 
objects, whilst it impairing recognition memory more generally in the WT-R mice.   
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3.6.3.3 Experiment 4C (EINS): Absolute Novelty Task  Samp le Tri al  Data   
Table 3.10 shows the mean contact times in seconds made by WT and Tg2576 mice 
with 2 pairs of novel objects in the sample stages of each test day, in the Absolute 
Novelty Task.   Inspection of these data indicates that overall, both Tg2576 and WT 
mice explored two sets of novel objects at the same rate as control mice across both 
sample stages.  However, whilst most groups showed a slight decline in contact time 
with objects across the 2 sample trials, the WT-C mice showed a slight increase. This 
interpretation was confirmed by ANOVA with Day, Genotype, and Treatment as 
factors. This showed a no significant effect of Day F<1, no significant effect of Genotype  
F(1,43)=2.161, p=0.149, no significant effect of Treatment F<1, no significant Day by 
Genotype interaction F<1,  no significant Day by Treatment interaction F<1, and a no 
significant Day by Treatment by Genotype interaction F(1,43)=2.694, p=0.108.  There 
was also no significant genotype by treatment interaction, F<1.  Thus, any differences 
in object contact times between groups in the subsequent choice stages were not likely 
to be caused by gross changes in object exploration per se.  
 
Table 3.10:  EINS Object Recognition (Experiment 4C).  Absolute Novelty Task (a) Raw 
object contact times for novel objects used in both sample stages. (b) Mean choice trial 
preference ratio for novel objects. 
 
(a) Sample (Day 1)   
Contact Times (Sec) 
Sample (Day 2)  
Contact Times (Sec) 
Group M SEM M SEM 
TG-C 32.9 4.51 26.0 3.35 
TG-R 31.4 3.32 28.8 4.33 
WT-C 34.3 6.07 40.7 8.75 
WT-R 41.7 8.79 33.8 2.69 
 (b) PR.  Novel Objects 
Group M SEM 
TG-C 0.58 0.04 
TG-R 0.64 0.03 
WT-C 0.69 0.03 
WT-R 0.53 0.05 
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Choice Tri al  Data   
Figure 3.20 shows the mean total object contact times in seconds made by WT and 
Tg2576 mice across choice trials in the Absolute Novelty Task.  Inspection of this figure 
suggests a significant transgene effect between non-drug control groups, with WT-C 
mice spending more time exploring novel objects compared to TG-C mice.  However, 
the total amount of time spent exploring familiar objects were statistically comparable 
between these groups.  No transgene effect exists between drug-treated groups; each 
spends a similar amount of time exploring both class of object. Furthermore, only the 
WT-C group appears to spend significantly more time exploring novel objects 
compared to other groups.  However, the exploratory trends do differ within these 
groups. The TG-R group, like WT-C mice, show a significant within group preference 
for exploring novel over familiar objects (i.e. they successfully discriminate between 
these classes of objects).  By contrast, neither TG-C nor WT-R groups appear to exhibit 
a significant preference for exploring novel over familiar objects, although the TG-C 
mice are clearly trending in this direction (the PRs will further inform the status of this 
trend).  Overall, these observations suggest that rosiglitazone may have had at most, a 
mild effect on the ability to detect absolute novelty in TG mice, whereas the drug has 
again clearly impaired the performance of WT-R mice.   
The above description was confirmed by a 3 way repeated measures ANOVA, with 
Object, Genotype, and Treatment as factors. This showed a significant effect of Object, 
F(1,43)=23.425, p=<0.001, a significant effect of effect of Genotype, F(1,43)=5.929, 
p=0.019, a non-significant effect of Treatment F(1,43)=0.60, p=0.807, no significant 
Object by Genotype interaction, F<1, no significant Object by Treatment interaction 
F(1,43)=2.333, p=0.134, and a significant Object by Genotype by Treatment interaction 
F(1,43)=6.351, p=0.016. The Treatment by Genotype interaction was not significant, F<1. 
A follow-up test of simple main effects for the significant Object by Genotype by 
Treatment interaction revealed a significant transgene effect between non-drug treated 
mice, with the WT-C group spending more time exploring novel objects compared to 
TG-C mice, F(1,43)=8.287, p=0.006, although the total time spent exploring familiar 
objects remained comparable between these groups F<1. Compared to WT-C mice, this 
again demonstrates a relative impairment in the TG-C mice with respect to total 
exploration time of novel objects.  There was no transgene effect between the TG-R 
and WT-R groups with respect to the time spent exploring novel objects, F<1, or 
familiar objects, F(1,43)=3.917, p=0.054. Likewise, neither TG group differed 
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significantly from each other in terms of the total time spent exploring novel objects, 
F<1, or familiar objects, F<1.  However, the WT-C group did spend significantly more 
time exploring novel objects relative to the WT-R mice, F(1,43)=5.104, p=0.029, 
although neither WT group differed with respect to the time spent exploring familiar 
objects, F(1,43)=1.436, p=0.237.  Within group comparisons showed that only the TG-R 
and WT-C groups spent significantly more time exploring novel over familiar objects, 
TG-R, F(1,43)=6.730, p=0.013; WT-C, F(1,43)=19.849, p=0.<001; WT-R, F<1, although the 
TG-C mice did show a similar but non-significant pattern of response in favour of the 
novel objects: TG-C, F(1,43)=3.353, p=0.074.      
  
Figure 3.20:  EINS Object Recognition (Experiment 4C).  Mean contact times for the 
Absolute Novelty Task. Values are means ±S.E.M with asterisk denoting significance at the 
0.05 level. 
 
Raw contact time data were converted into a preference ratio as indicated in section 
3.6.2.4.  This data is displayed in Table 3.10b.  Inspection of this table again suggests 
that only the TG-R and WT-C groups exhibited a statistically significant preference for 
exploring novel over familiar objects.   This description was confirmed by ANOVA with 
Genotype, and Treatment as factors. This revealed no significant effect Genotype, F<1, 
no significant effect of Treatment, F(1,43)=1.336, p=0.254, and a significant Genotype by 
Treatment interaction,  F(1,43)=7.753, p=<0.01.  A follow-up test of simple main effects 
for the significant Genotype by Treatment interaction then revealed that the PR score 
of both TG groups did not differ significantly, F(1,43)=1.250, p=0.270. The TG-R group 
also did not differ significantly from the WT-R group, although this was close, 
F(1,43)=3.429, p=0.071.  However, WT-R mice were significantly impaired relative to 
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their WT-C counterparts F(1,43)=8.265, p=0.006, suggesting that rosiglitazone had 
detrimentally impacted on the ability of these WT mice to respond to novel objects in 
their environment.  TG-C mice were significantly impaired relative to WT-C mice, 
F(1,43)=4.348, p=0.043. Finally, in order to test whether groups successfully showed 
above-chance performance on choice trials, the mean PRs for each group were 
compared to chance levels (i.e. 0.50= no discrimination) using one sample t-tests. This 
statistical analysis confirmed that only the TG-R and WT-C groups were responding at 
above chance levels in the absolute novelty task:  TG-C, (t(11)=-1.773, p=0.104; TG-R, 
(t(10)=4.183, p=0.002; WT-C, (t(10)=5.590, p=<0.001; WT-R, (t(12)=0.492, p=0.632.  In 
aggregate these results suggest that both TG-C and WT-R mice likely exhibit 
impairment in absolute novelty, although the PR analysis does suggest that unlike the 
WT-R mice, TG-C mice are discriminating to some degree in the expected direction. 
 
3.6. 4 Discussion   
In this experiment object recognition memory was assessed in Tg2576 and WT 
littermates using a de novo COC task.  Two versions of this task were used.  In the 
Absolute Novelty version the choice trial required mice to discriminate two different 
novel objects from two different familiar objects within a segmented open field arena.   
Since Tg2576 and WT mice exhibit comparable preferences for object novelty in 2 and 
4 item arrays [1253, 1324, 1384], it was predicted that TG and WT mice should exhibit a 
comparable preference for object novelty in this task.  In the spatial Mismatch Task, 
the mice were required to discriminate between two different familiar objects, and the 
same novel object appearing in two different spatial locations.  Thus, unlike the 
Absolute Novelty task this generates a potential spatial mismatch during the test for 
the novel stimulus leading to a disruption of specific familiar/novel discriminations in 
both the top and bottom horizontal axis of the apparatus.  This should lead to a greater 
net amount of exploration time with respect to the novel object relative to familiar 
objects.  However, whilst both TG and WT mice can detect object novelty, it was 
hypothesised that only the WT mice should be able to respond to the mismatched 
spatial locations, and thus make a significant bias for exploring novel objects over 
familiar ones.    
It is evident from both Experiments 4A and 4B, that TG-C mice do exhibit 
impairment in the Spatial Mismatch task, although the nature of the impairment in is 
unclear because the mice do make a significant discrimination in favour of familiar 
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objects (this was only confirmed via PR scores in the LINS mice, and reflected in both 
PR scores and raw contact time data in the EINS experiment). The reason for this 
preference in TG mice is unclear.  It could represent random noise. On the other hand, 
it could be a consequence of the experimental design.  For example, TG mice evidently 
can tell that an object is novel (otherwise behaviour would be distributed randomly), 
but in the absence of a robust ability to form specific object place associations in a 
segmented arena, it is possible that they treat the two copies of the novel object as a 
singular entity.  Thus, since both familiar objects are different, these may incur a 
greater overall contact time.  It is of interest that whilst Tg2576 mice are able to form 
representations of the identity of objects (as well as exhibit memory for the spatial 
organization of objects in an arena), conjunctive memory for specific object–location 
associations is severely impaired in aged TG mice [1384].  However, these studies have 
been conducted in an open field non-segmented arena, and it is possible that in the 
Spatial Mismatch Task, specific object–location associations are more vulnerable to the 
APPSWE mutation. 
It is of interest that whatever underpins the TG impairment in the Spatial Mismatch 
task, this is reversed in the TG-R mice both in aged mice (LINS mice were aged 16-17 
months at test), and young adult mice (ENIS mice aged ~10 and 12 months of age).  
Given that it is uncertain as to what the mechanism of ‘impairment’ is in non-drug 
treated TG mice the mechanism for this recovery is unclear in the TG-R mice, 
especially considering that Experiment 1 no improvement in spatial working memory 
was detected in either the LINS or EINS cohorts.  However, in both cases these mice 
had been on compound for much longer when tested in the Spatial Mismatch task, so 
it is possible that a longer period of drug agonism (LINS:~8-to-9 months; EINS 7 
months) may have allowed recovery of some component of hippocampal function.  
This remains untested in TG2576 mice, although in separate studies that I have not 
been able to include in this thesis, I have conducted both versions of the COC task 
with a cohort of 12 month old hippocampal lesion and sham BL6 mice.  In that 
experiment I found that the Spatial Mismatch task was sensitive to hippocampal 
lesion, where the Absolute Novelty Task was not. These results are preliminary, and 
require replication. One should also say that although the effects of rosiglitazone have 
not been studied in Tg2576 mice prior to the current study, the drug has been found to 
significantly impact upon object recognition processes in other hAPP mouse models 
[1213, 1214], although these have used standard 2-item object arrays in a standard 
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rectangular (non-segmented) open field arena.  However, whilst the impact of 
rosiglitazone was clearly unable to rescue the spatial working memory deficit in 
Experiment 1, it is possible that differential changes in this brain region led to an 
improvement of recognition memory.  Likewise the changes induced by the drug in the 
WT-R mice leading to the impairment of recognition memory in both the Spatial 
Mismatch and Absolute Novelty tasks are also uncertain, although Experiment 7 of 
Chapter 4 will discuss this issue in more detail.  
The finding in the current study that TG-C mice were impaired in the EINS 
Absolute Novelty Task was suppressing given that previous research has reported 
‘absolute’ object novelty detection to be intact in Tg2576 mice [1252, 1253, 1324, 1325, 
1384], although others have reported contradictory findings [1477].  Whilst differences 
between studies with may possibly involve differing proportions of the SJL background 
in there mice, it is also possible that the type of open field arena used as well as the 
number of objects used, is also important.  For example, although previous research 
has shown that absolute object novelty is comparable in TG2576 mice and WT 
littermates with 2 and 4 object arrays [1253, 1384], this has not been assessed in an 
apparatus where by its design configurable cues would have been harder to derive for 
the whole object array (such as in the Absolute Novelty Task), and possibly the 
environment was more conductive to forming specific object place relationships (by 
nature of the fact that the arena was segmented into 4 zones, each of which were 
associated with distinct as well as overlapping extra-maze cues.  The novelty 
discrimination may therefore have been harder in the Absolute Novelty task, possibly 
explaining why TG-C mice failed to make an above chance discrimination.  However, 
whether rosiglitazone agonism was responsible for slightly adjusting the TG-R 
response enabling them to make an above chance discrimination is uncertain in this 
experiment remains uncertain.  Thus, it remains possible that rosiglitazone had a 
marginal effect on absolute novelty detection in TG-R mice, or we may just have been 
unlucky with the responses in the TG-C group, such that these mice would most times 
show a significant novelty discrimination in this experiment (indeed, the trend is 
clearly there in the raw contact time data for this group). These findings require 
further investigation and robust verification.  Nevertheless, it is evident that 
rosiglitazone is able to reverse components of object recognition deficit in Tg2576 mice 
although the nature and mechanism of reversal is unknown. 
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3.7 CHAPTER  DISCUS SIO N  
The overall lead hypothesis for this thesis was that rosiglitazone should ameliorate 
age-related cognitive deficits and pathophysiological changes associated with the hAPP 
transgene in TG mice. As discussed in the introduction to this chapter, this was 
primarily based on the controversial publication of research by Pedersen et al. [1129, 
1244].  Here a dual treatment strategy was used to assess the study hypothesis.  In the 
first course of behavioural experiments we sought to determine if chronic rosiglitazone 
agonism from the age of ~8-9 months would reverse specific behavioural deficits in TG 
mice related to spatial working memory (T-Maze FCA), anxiety (EPM and Marble 
burying task), and object recognition memory (Spatial Mismatch task).  At this time, 
insoluble forms of Aβ are increasing exponentially [1284, 1291], and hippocampal 
synaptic pathology is well developed [1245].  The outcome of these studies suggest that 
whilst the drug was unable to reverse the spatial working memory deficit in TG mice, 
or moderate behavioural disinhibition in the EPM task, the drug did significantly alter 
the preference of aged TG mice for exploring two identical copies of a novel object 
placed in two different but familiar spatial locations.  With the exception of the object 
recognition data, these result fit with other research suggesting that administration of 
PPARγ compounds largely do not reverse cognitive deficits in adult Tg2576 mice when 
amyloid pathology is already well developed even if they are able to moderate some  
aspects of the underlying physiological abnormalities in these mice [1215, 1386].  As 
such these findings fit with recent clinical studies in humans [1237, 1238, 1247, 1480].  
However, in these human studies it is of interest that explicit object recognition skills 
were not assessed in patients receiving rosiglitazone or pioglitazone agonism.  None of 
the clinical or pre-clinical research has also indicated serious adverse effects of 
rosiglitazone on cognition, although in preclinical studies none have assessed the long 
term impact rosiglitazone administration.  However, adverse health effects of 
rosiglitazone administration have been reported in the human literature, although 
these are contested (see discussion in [1481]).  On the basis of the results of the LINS 
behavioural experiments, the study hypothesis must be largely rejected, although the 
object recognition data is the one exception. 
In a second course of experiments, this study used an early-intervention strategy 
(EINS) strategy to investigate the impact of rosiglitazone administration on the 
established appearance of age-dependent cogitative deficits in 8 month old TG mice 
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following continuous drug administration from the age of 5 months.  At this time 
significant amyloid pathology and synaptic deficits were absent in TG mice, and it was 
predicted that rosiglitazone would delay the onset of age-related cognitive deficits in 
adult TG mice.  Again we derive inconsistent results on this issue.  Whilst the EPM and 
object recognition data (Spatial Mismatch Novelty in particular) suggest longitudinal 
rosiglitazone agonism from a young age may be sufficient to moderate some 
components of phenotypic changes in Tg2576 mice, it clearly is unable to rescue the 
primary working memory deficit of these mice, or impact upon marble burying 
behaviour, or absolute novelty detection (although the latter may have been mildly 
benefited).  Given the object recognition data for the Spatial Mismatch task in the 
EINS cohort, it would have been of interest to have perhaps re-tested the EINS mice on 
the T-Maze FCA task.  Thus, the hypothesis for the EINS cohort cannot be accepted in 
its entirety and the physiological basis for the beneficial effects of rosiglitazone on TG 
mice are uncertain.  In this respect it will be of interest to evaluate this in the context 
of the final two experiments of this thesis (see Chapter 4). 
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4. PHYSIOLOGICAL  MEASURERS 
 
4.1 INTRODUCTION  
HE AIM of the experiments in this chapter was to  provide physiological 
evidence for the behavioural studies and thus, the study hypotheses  detailed 
in Chapter 3.  The two biochemical measures used in this study use tissue 
samples obtained at sacrifice.  These relate to the assessment of adiponectin protein 
levels from terminal plasma samples (Experiment 5A and 5B), and assessment of total 
Aβ levels isolated from single brain hemispheres (Experiment 6) and the assessment of 
dendritic spine density in the dentate gyrus of the hippocampus form slices of lightly 
fixed brain tissue (Experiment 7). As the rationale for many of these measures has been 
outlined in previous chapters, I will provide a brief summary of the main points for 
each experiment.  
Before discussing Experiments 5-to-7 in detail, I want to address from the outset the 
major limitation of this chapter.  It will be evident from the above that there is an 
absence of important histological validation of the mice used in experimental studies, 
including whether their pathology had developed according to expected timescales. 
The absence of such descriptive information was unavoidable due to financial and 
motivational limitations imposed upon the Author by the commercial partner (GSK).  
However, whilst there is a clear need for these experiments to be conducted in the 
future, it is worthwhile to remember that the major deficit in spatial working memory 
was not recovered in rosiglitazone treated TG mice (see Experiment 1), and that the 
deficit overlapped with that in the TG control mice. Indeed, although this may not 
have been the case with Experiments 2 and 4, the results of Experiment 7 will further 
support the likely view that key pathological physiological changes related to the over-
production of Aβ (loss of dendritic spines) were still very much in evidence in TG mice 
despite chronic exposure to rosiglitazone. In addition to histological validation, there 
T 
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was also a disappointing lack of available funds from the commercial partner to 
support wider exploration of other relevant biochemical markers such as IDE, IGF‐1, 
and GLUT‐4.  These could have widened the scope of possible changes elicited in the 
treatment groups.  Although many of these were among the original aspirations of the 
study, I was unable to follow through with these for the reasons discussed. 
 
4.2 EXPERIMENT  5:  PLASMA  ADIPONE CTIN  LE VELS   
As mentioned previously, the genesis of the programme of research detailed in this 
thesis originates from the need to further clarify the impact of rosiglitazone in adult 
male Tg2576 mice following the controversial publication of research by Pedersen et al 
[1129].  It is notable that whilst the Pedersen et al and several other studies have 
reported beneficial effects of rosiglitazone on the cognitive and/or some pathological 
aspects of the Tg2576 mice [1129, 1212, 1215, 1244], none of these studies has attempted 
to verify the systemic penetration of the drug by looking for its impact on a predictable 
physiological marker other than peripheral glucose responses.  Thus, in this thesis 
both intervention strategies verify the systemic penetration of rosiglitazone by 
validating against terminal plasma adiponectin levels [1208], which should be similarly, 
elevated across all PPAR treated groups. In addition, several studies have also reported 
that adiponectin protein as an anti-inflammatory effect [1194, 1482-1484], something 
which may also confer some measure of benefit to reducing the pro-inflammatory 
profile of Tg2576 mice (this has not been reported in the literature). 
 
4.2. 1 Methods  and  Apparatus  
4.2.1.1 Animals: and Drug Administration 
Experiment 5A (LINS) used mice the mice from cohort 1.  To recap, cohort 1 mice had 
been sacrificed by cervical dislocation between the ages of 18 and 19 months, 
wherehence the necessary tissues harvested for biochemical analysis.  The resulting 
tissue samples were then labelled and stored at -20°C until further use. Experiment 5B 
(EINS) used the mice from Cohort 3.  To briefly recap, these mice were sacrificed 
between the ages of 12 and 13 months and the necessary tissues harvested for 
biochemical analysis in the same manner as above.  In brief, terminal blood samples 
(200 μl) were rapidly obtained by cardiac puncture, and plasma was separated by 
centrifugation (120× g for 20 min) at room temperature and stored individually at 
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−20°C until assay.  Please see section 3.3.2.1 for further details of housing and drug 
administration. 
 
4.2.1.2 Analytical Procedures 
Plasma adiponectin levels were measured using a mouse adiponectin immunoassay 
(RandD Systems, Quantikine Acrp30 kit).  All samples, standards, and controls were 
assayed in duplicate as per the manufacturer’s instructions.  In short, all reagents and 
samples were brought to room temperature before use.  All reagents, standard 
dilutions, and samples were prepared as directed in the product insert. Any excess 
microplate strips were removed from the plate frame and returned to the foil pouch 
containing the desiccant pack.  This was then resealed. 50 µL of Assay Diluent was 
added to each well, followed by 50 µL of Standard, Control, or sample. The plate was 
then sealed (with the attached a plate sealer), and incubated at room temperature for 3 
hours.  After this time had expired each well was aspirated and washed, repeating the 
process 4 times for a total of 5 washes. 100 µL of Conjugate was then added to each 
well. The plate was then covered with a fresh plate sealer, and incubated at room 
temperature for 1 hour after which the plate was aspirated and washed 5 times. 100 µL 
Substrate Solution was then added to each well, and incubated at room temperature 
for 30 minutes. During this stage the plate and contents were protected from light.  100 
µL of Stop Solution was then added to each well.   The plate was then read at 450 nm 
within 30 minutes, with the wavelength set for correction at 540 nm or 570 nm. 
 
4.2.1.3  Statistical Analysis 
Raw data for each of the levels of plasma adiponectin were analysed by 1 way ANOVA, 
which had [Adiponectin] (concentration adiponectin) as the dependent variable, and 
Genotype and Treatment as factors.  All analysis were conducted with IBM SPSS 
Statistics v.21.00 software with an alpha value (P) <0.05, taken as being statistically 
significant Any significant ANOVA interactions and non-parametric analysis were 
conducted as previously indicated in Experiment 1 (see section 3.3.2.4).  Experiment 5A 
was conducted with samples from 15 TG mice (TG-C, n=7; TG-R, n=8), and 16 WT 
(WT-C, n=9; WT-R, n=7).  The differences in numbers of samples compared to the 
previous experiment reflect the inability to obtain sufficient blood samples for analysis 
from some mice. Experiment 5B the total numbers of mice run were as follows: 23 TG 
mice (TG-C, n=12; TG-R, n=12); 24 WT mice (WT-C, n=11; WT-R, n=13).  
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4.2 .2 Results  
4.2.2.1 Experiment 5A: LINS Cohort 
Figure 4.1 shows the mean levels of adiponectin protein levels derived from terminal 
blood plasma levels for the LINS cohort.  Inspection of this figure suggested that 
overall rosiglitazone treated mice displayed significantly higher adiponectin levels 
relative to non-drug treated mice.  This interpretation was confirmed by ANOVA with 
Adiponectin concentration (ng/mg) as the dependent variable, and Genotype, and 
Treatment as factors. This revealed a no significant effect Genotype F<1, a significant 
effect of Treatment, F(1,27)=45.166, p=<0.001, and no significant Genotype by 
Treatment interaction,  F<1. Thus, in the late stage cohort we conclude that the 
delivery method succeeded in the drug reaching systemic penetration. 
 
Figure 4.1:  LINS Plasma Adiponectin Levels (Experiment 5A).  Mean levels of plasma 
adiponectin isolated from terminal blood samples.  Values are means ±S.E.M with asterisk 
denoting significance at the 0.05 level. 
 
4.2.2.2 Experiment 5B: EINS Cohort 
Figure 4.2 shows the mean levels of adiponectin protein levels derived from terminal 
blood plasma levels for the EINS cohort.  Inspection of this figure suggested that again, 
rosiglitazone treated mice displayed significantly higher adiponectin levels relative to 
non-drug treated mice overall.  This interpretation was confirmed by ANOVA with 
Adiponectin concentration (ng/mg) as the dependent variable, and Genotype, and 
Treatment as factors. This revealed a non-significant effect Genotype F(1,45)=1.243, 
p=0.271, a significant effect of Treatment, F(1,45)=70.848, p=<0.001, and a non-
significant Genotype by Treatment interaction,  F<1. Thus, in the early-stage cohort we 
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again conclude that the delivery method succeeded in the drug reaching systemic 
penetration. 
 
Figure 4.2:  EINS Plasma Adiponectin Levels (Experiment 5B).  Mean levels of plasma 
adiponectin isolated from terminal blood samples.  Values are means ±S.E.M with asterisk 
denoting significance at the 0.05 level. 
 
 
 
4.3 EXPERIMENT  6:  TOTAL  AΒ LEVELS   
Several studies have reported that rosiglitazone significantly impacts upon Aβ42 levels 
and or amyloidosis in hAPP mouse models [1129, 1213, 1217].  Since Aβ represents the 
primary instrument of synaptic deficits thought to underlie the behavioural phenotype 
of Tg2576 mice [1245, 1309, 1312, 1321], this study assessed total Aβ levels extracted from 
single brain hemispheres.  Thus, on the basis of Pedersen et al, it was predicted that 
rosiglitazone would lower amyloid levels in the drug-treated Tg2576 mice.  However, 
whilst the assessment of adiponectin levels are applicable to both LINS and EINS 
cohorts, unfortunately time and cost issues limited the assessment of total Aβ levels to 
the LINS cohort only.  In both cases, this assessment involved the use of Enzyme-
linked immunosorbent assay (ELISA).  Since both these measures reflect relatively 
small nature of the adiponectin and Aβ experiments, results relating to these are 
covered in the same discussion. Finally, this chapter also summarises the genotyping 
procedure used as the primary means of establishing the genetic identity of mice used 
in both LINIS and EINS studies. 
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4.3. 1 Methods  and  Apparatus  
4.3.1.1 Animals: and Drug Administration 
Experiment 6 (LINS only) used mice the mice from cohort 1.  To recap, these mice had 
been sacrificed by cervical dislocation between the ages of 18 and 19 months, 
wherehence the necessary tissues harvested for biochemical analysis.  In brief, brain 
hemispheres were extracted fresh and divided along the central sagittal access with a 
scalpel such that the two brain hemispheres were separated.  One hemisphere was 
chosen for the Aβ ELISA analysis.  The remaining brain hemisphere was snap frozen in 
liquid nitrogen for autoradiography (unfortunately cancelled by GSK due to lock of 
funding).  The hemispheres chosen for each condition were counterbalanced across 
mice from within each treatment group to avoid any hemispheric bias.  All tissue was 
stored at -20°C until further use.  Please see section 3.3.2.1 for further details of housing 
and drug administration. 
 
4.3.1.2 Analytical Procedures 
Total human Aβ levels (the soluble and insoluble Aβ protein extracts) expressed by the 
APPswe mutation in Tg2576 mice were quantitatively measured in brain samples  by 
ELISA using commercial colorimetric immunoassay kits for human Aβ40 (Invitrogen, 
Cat.# KHB3482) and human Aβ42 (Invitrogen, Cat.# KHB3442).  This sandwich ELISA 
uses microtiter strips with wells coated with a monoclonal antibody specific for the 
NH2-terminus of human Aβ.  The protocol involved a series of diluted standards of 
known concentration being assayed alongside the experimental samples in order to 
create a standard curve to accurately measure sample concentrations of Aβ40 and 
Aβ42 peptides.  The intensity of the coloured end reaction was then read by a plate-
reader, with the light being directly proportional to the concentration of human Aβ 
present in the sample.  
In preparation of the ELISA, the human Aβ40 and Aβ42 standards were 
reconstituted from powder with standard reconstitution buffer (55 mM sodium 
bicarbonate, pH 9.0), as indicated by the manufacturer, and diluted 1:20 in BSAT-DPBS 
(0.2 g/l KCl, 0.2g/l KH2PO4, 8.0 g/lNaCl, 1.150 g/l Na2HPO4, 5% BSA, 0.03% Tween-20 
in MilliQTM water, pH 7.4). The tissue samples maintained on ice, were also diluted 
1:20 in BSAT-DPBS containing 1:100 protease inhibitor cocktail (Calbiochem, Cat.# 
539134). Serial dilutions of the standards in standard diluent buffer (provided in handy 
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kits) were then made for the standard curve: 500 to 7.81 pg/ml for the Aβ40 standard, 
and 1000 to 15.63 pg/ml for Aβ42 standard. Samples were then diluted further with 
standard dilution buffer in order to make two sample dilutions for the ELISA to in 
order to ensure detection within the standard curve range. The corresponding dilution 
required had been previously piloted because it varies with Aβ type (i.e. soluble and 
insoluble), isoform (i.e. Aβ40 and Aβ42), and with age (Aβ increases with age, and the 
mice used with in this asses were considered elderly). For example, a whole 
hippocampus from 12 month old TG2576 mice aged 12 months, would normally need to 
be diluted 1:400 and 1:800 in order for soluble Aβ to be detected within the standard 
curve range.  Once prepared, 50μl of each diluted standard and sample were applied to 
the antibody-coated microtiter strip wells, in duplicate, with 50μl of rabbit anti-human 
Aβ40 or Aβ42 detection antibody. Following a 3 hour incubation period on a shaking 
plate at room temperature, liquid was then discarded from each well and washed four 
times with working wash buffer (25x concentrate wash buffer 1:24 in deionised water). 
100μl of the secondary antibody (1:100 anti-rabbit Ig’s-HRP 100x concentrate in HRP 
diluent) was then applied to each well using a multi-channel pipette and incubated for 
30 minutes on a shaking plate at room temperature. Following washes (as described 
above), 100μl of stabilised chromogen was then applied to each well, and incubated for 
approximately 20 minutes at 25°C in the dark. This blue-coloured reaction was then 
stopped by applying 100μl of stop solution into each well and the absorbance was 
measured at 450 nm using a colorimeter plate reader (FLUOStar Optima, BMG 
Labtech). Optima 2.0 software directly calculated Aβ concentrations of each sample 
based on the absorbance values relative to the absorbance values of the standard curve 
(based on known concentrations of standard serial dilutions). Only values within the 
standard range were used. Aβ protein concentrations were calculated by taking the 
mean value of duplicates, and expressed as pg of Aβ per μg of protein (this required 
the use of protein concentrations obtained in the BCA assay).  
 
4.3.1.3 Statistical Analysis 
Raw data for each of the estimates of total Aβ levels were analysed by 2 way 
multivariate ANOVA, which had [Aβ isoform] (Aβ40/42), and Treatment as factors.  
All analysis was conducted with IBM SPSS Statistics v.21.00 software with an alpha 
value (P) <0.05, taken as being statistically significant Any significant ANOVA 
interactions and non-parametric analysis were conducted as previously indicated in 
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Experiment 1 (see section 3.3.2.4).  Experiment 6 was conducted with samples from 18 
TG mice (TG-C, n=9; TG-R, n=9), and 21 WT (WT-C, n=12; WT-R, n=9).)  Note:  The 
WT samples were only used to verify genotype (none of these showed any trace of 
human Aβ). 
 
4.3 .2 Results  
4.3.2.1 Experiment 6: LINS Cohort 
Figure 4.3 shows the mean levels of Aβ40 (Figure 4.3 A) and Aβ42 (Figure 4.3 B), both 
of which were derived from single brain hemispheres.   Inspection of this figure 
suggests no significant differences between drug-treated and non-drug treated groups 
with respect to total levels of either Aβ40 or Aβ42. This interpretation was confirmed 
by ANOVA, which had [Aβ isoform] (Aβ40/42), and Treatment as factors.  This gave a 
significant effect of Aβ isoform, F(1,16)=8.742, p=<0.05, a no significant effect of 
Treatment, F<1, and no significant Aβ isoform  by Treatment interaction, F<1.  Thus, I 
conclude that rosiglitazone had no impact upon either Aβ40 or Aβ42 levels. 
 
 
Figure 4.4:  LINS Total Aβ Levels (Experiment 6).  (A) Mean levels of total Aβ40 (B) Mean 
levels of total Aβ42 Both Aβ isoforms isolated from whole single brain hemispheres.  Values 
are means ±S.E.M. 
A 
B 
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4.3. 3 Discussion  
4.3.3.1 Experiment 5: Adiponectin Levels 
As a means of validating against the primary method of drug administration in this 
study, both Experiments 5A and 5B show that rosiglitazone had reached systemic 
penetration in both cohorts of mice.  This is consistent with other studies which have 
found that rosiglitazone increases peripheral levels of this protein [1485-1487].  
Adiponectin is an important adipocyte-derived hormone that regulates metabolism of 
lipids and glucose, and its receptors (AdipoR1, AdipoR2, T-cadherin) appear to exert 
actions in peripheral tissues by activating the AMP-activated protein kinase, p38-
MAPK, PPAR alpha and NF-kappa B [1483].  Indeed, adiponectin has been shown to 
exert a wide range of biological functions that could elicit different effects, depending 
on the target organ and the biological milieu [1483, 1488].  This includes potent anti-
inflammatory effects [1194, 1482]. There is also substantial evidence to suggest that 
adiponectin receptors are expressed widely in the brain and adiponectin levels are 
known to be expressed in regions of the mouse hypothalamus, brainstem, cortical 
neurons and endothelial cells, as well as in whole brain and pituitary extracts [1483].  
However, it should be said that adiponectin signalling in the brain is still poorly 
understood, and the function of adiponectin receptors may well vary depending on 
their location in the brain [1489].   
The impact of increasing adiponectin levels in hAPP mice has not been explored.  
This is of potential significance as anti-inflammatory treatments have been linked to 
beneficial effects in some AD patients [412, 766], and rosiglitazone may impart its anti-
inflammatory effect via peripheral and central mechanisms that involve adiponectin 
signalling, [1164, 1490-1493], although neither of these is likely to be mutually exclusive.  
Anti-inflammatory effects associated with adiponectin have also been reported via a 
heme oxygenase-1-dependent pathway on stellate macrophages (Kupffer cells) [1194].  
The peripheral mechanism at least, probably involves the PPAR-γ-mediated 
production of adiponectin protein (a hormone) in adipose tissue [1482], and it is 
conceivable that any centrally mediated anti-inflammatory role of this protein could be 
beneficial in AD.  However, given the robust increase in adiponectin levels in drug 
treated mice in the present study, it is disappointing that any impact on cognition was 
extremely limited. Indeed, although adiponectin is considered to exert a potent anti-
inflammatory effect, this view is being challenged in light of recent reports of elevated 
levels of this protein in various inflammatory disease states, including arthritis, 
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preeclampsia and end-stage renal diseases [1483].  Indeed, it has been shown that 
adiponectin induces production of the pro-inflammatory mediator IL-6 and activation 
of NF-κB in human synovial fibroblasts and adhesion molecule expression in 
endothelial cells [1484, 1494, 1495].  However, it is not uncommon for many proteins 
such as adiponectin to exert sometimes opposite effects in different tissues (i.e. 
something can be pro-inflammatory or not depending on the circumstances).  Thus, 
raising adiponectin levels could have contradictory effects in AD, and indeed hAPP 
models, (as well as WT mice).   
 
4.3.3.2 Experiment 6: Total Aβ Levels 
Despite the fact that several studies have reported that rosiglitazone significantly 
impacts upon Aβ levels and or amyloidosis in hAPP mouse models [1129, 1213, 1217], the 
finding in the current study  that there was no significant impact of the drug on either 
Aβ40 or Aβ42 levels is disappointing.  Nevertheless, it remains possible that we may 
have reduced the soluble portion of Aβ40/42, although we did not explicitly test this.  I 
have already discussed the inconsistencies with the findings of Pedersen et al [1129], in 
relation to a differential impact of rosiglitazone on Aβ42 but not Aβ4o levels.  
However, it is evident that other studies have also provided contrasting results to the 
current study in relation to the purported effects of the drug on ameliorating insoluble 
aggregates of Aβ [1213, 1217].  These discrepancies may partly reflect methodological 
differences between studies, as well as differences in the amyloid dynamics across 
hAPP models.  However, further investigation is required to in order to clarify this 
issue.  Nevertheless, I have confidence in the findings of the present study that 
rosiglitazone does not impact on Aβ levels in Tg2576 mice, although I cannot be 
certain that some regional differences in amyloid pathology may have existed as a 
result of rosiglitazone agonism (again the assessment method did not allow for 
regional analysis).  If there were some regional differences, this in itself could 
potentially explain the limited impact of rosiglitazone in reversing the cognitive 
phenotype of the Tg2576 mice used in this study.   
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4.4 EXPERIMENT  7:  DENDRITIC  SPINES  DENSITY  
4.4. 1 Introduction   
Dendritic spines are tiny protrusions along neuronal dendrites that constitute the 
major postsynaptic sites for excitatory synaptic transmission in the CNS. These spines 
are highly motile and can undergo remodelling even in the adult nervous system [737].  
Experiments conducted in animals suggest that the extent of spine remodelling is 
correlated with behavioural improvement after learning, implicating a crucial role of 
synaptic structural plasticity in memory formation [738-742].  Furthermore, recent 
research also suggests that a small fraction of new spines induced by novel experience 
together with most spines formed early during development and surviving experience-
dependent elimination, are preserved in order to provide a structural basis for memory 
retention throughout the entire life of an animal [739, 741-743]. Thus, spine re-
modelling and the formation of new synapses are activity-dependent processes which 
provide a structural basis for memory formation [737, 836, 837].   
A loss or alteration of dendritic spines has been described in patients with 
neurodegenerative disorders, including AD [838], where in the latter they are  
considered to be a much better correlate of cognitive impairment in patients than Aβ-
plaque burden (see, [408, 744, 745]).  Mounting evidence from human and animal 
studies suggests both the dysfunction and subsequent loss synapses in AD is mediated 
by diffusible soluble Aβ oligomers [60, 62-65, 408, 409]. Once bound to synapses, Aβ 
oligomers have been found to instigate a variety of pathological processes, including by 
interfering with functional synaptic plasticity processes in the hippocampus [782]. For 
example, at picomolar concentrations naturally secreted soluble Aβ oligomers can 
disrupt hippocampal LTP in acute brain slices and in vivo, where in the latter they have 
been shown in rats to impair the memory for complex learned behaviour [50].  
Disruption of functional plasticity by Aβ oligomers has been shown to include LTD, 
which is promoted rather than inhibited [805, 831].  Thus, in summary, the overall 
impact of oligomers appears to be depressed synaptic output.  However, phospo-tau 
oligomers have also been linked to detrimental effects on neurones and synapses [402, 
403], highlighting that both species of oligomer are attractive therapeutic targets in AD 
[410-412].  On the basis of the amyloid hypothesis, it was predicted that there should 
be a link between Aβ oligomers and synaptic loss in mouse models related to FAD 
kindreds [408, 831, 838].  This prediction has been confirmed [839], as have related 
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predictions that Aβ oligomers cause dysfunctional trafficking of ionotropic glutamate 
receptors and metabotropic glutamate receptors [839, 840].  The concentration of 
soluble Aβ oligomers has been shown to predict synaptic change in AD patients [404], 
and oligomers are known to accumulate with age in all the transgenic models 
examined so far, including mouse, rat, and Caenorhabditis elegans [841-844].  However, 
what promotes oligomer accumulation in SAD remains uncertain, and numerous 
transgenic mouse models overexpressing human APP FAD mutations (sometimes in 
combination with FAD-linked PSEN1 mutations), have shown that these models do not 
generally display NFT pathology or overt neuronal cell loss, thus questioning the 
relevance of these in vitro experimental paradigms [779].   
Transgenic models have become crucial to understanding the role of Aβ in AD 
pathology, as well as for testing novel therapeutic strategies.  However, in order to test 
the effects of candidate therapeutic treatments, it is necessary to recognize the type, 
extent, and onset of pathologies in each model.  In the Tg2576 mouse model (originally 
termed APP 695SWE), amyloid plaques do not develop until 18 months [1242], 
although both LTP deficits in hippocampal CA1 and DG and spatial memory deficits in 
a modified water maze are evident before this, suggesting impaired synaptic plasticity. 
Jacobsen et al., were the first to characterise this across the lifespan of Tg2576 [1245], 
and show that decreased dendritic spine density, impaired LTP, and behavioural 
deficits occurred months before overt plaque deposition at 18 months of age. Indeed, a 
decrease in spine density in the outer molecular layer of the dentate gyrus (DG) was 
found as early as 4 months of age in these mice, and by 5 months there was a 
significant decline in LTP in the DG after perforant path stimulation and impairment 
in contextual fear conditioning [1245]. Moreover, an increase in the Aβ42/Aβ40 ratio 
was first observed at these early ages, although total amyloid levels did not 
significantly increase until ~18 months of age, at which time significant increases in 
reactive astrocytes and microglia were also observed [1245].  Importantly, Jacobsen et 
al., show that the perforant path input from the entorhinal cortex to the DG is 
compromised both structurally and functionally in Tg2576, and this pathology is 
manifested in memory defects long before significant plaque deposition.  Indeed, the 
DG/CA3 network is considered to be central to the proper encoding of episodic 
memory [1496], and  disruption of the CA3/DG pattern of activation in Tg2576 likely 
represents the primary pathophysiological basis for memory impairment in these mice 
[1321]. 
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4.4. 2 Methods  and  Apparatus  
4.4.2.1 Animals and Drug Administration 
Experiment 7 (EINS) used the mice from Cohort 3.  To recap, these mice were 
sacrificed between the ages of 12 and 13 months, and the necessary tissues harvested for 
biochemical analysis.  In brief, the mice were first culled via cervical dislocation and 
checked for dead prior to the heads being decapitated with a sharp scissors. The brains 
were then rapidly dissected and sectioned along the coronal axis on a vibratome into 
250μm slices in 0.1m phosphate buffered saline (PBS) at room temperaturea.  Brain 
slices were collected into a segmented Petri dish containing PBS in its wells.  Following 
collection, PBS solution was removed from each well and replaced with 1.5 % 
paraformaldehyde (PFA) for 10-15 minutes.   Following pre-stain fixing, the PFA was 
removed and each slice washed three times with PBS in preparation for labelling with 
DiD stock solution containing 7.5 µl of DiD crystals dissolved in ethanol (V-22887, 
Molecular Probes, Eugene, OR.) per l ml of PBS. The stock solution was covered with 
silver foil (to prevent photo bleaching) and placed on a generic solution mixer until 
use.  All solutions were at room temperature when used.  
 
4.4.2.2 DiD labelling and mounting 
PBS solution was removed from each well and replaced with 1ml of DiD stock solution.  
The Petri dish was then covered with laboratory cling film, tin foil, and then placed on 
a tissue rocker on low speed for 16-20 hoursb. This method encourages DiD crystals to 
                                                   
a Preparation of fresh slices in ice cold solutions causes many dendritic spines to disappear.  Although spines re-form 
during a recovery period (typically 1hr whilst incubated in ringer solution), research has shown that the new 
expression of spines and spine proteins is abnormal (Kirov, Petrak, Fiala, & Harris 2004; Cheng, Huang, Lin, Chow, 
and Chang 2009).  In addition, in transgenic mouse models such as Tg2576, there may also be potential recovery 
complications due to differences in brain plasticity mechanisms mediating spine recovery.  However, because cutting 
brain slices in solutions at room temperature prevents cold induced spine loss (Bourne, Kirov, Sorra & Harris 2007), 
this potential problem can be avoided.  Finally, pilot data has indicated that profusion fixed tissue does not differ 
quantitatively (i.e. number of cells and spines detected) from fresh tissue cut at room temperature (Anderson J, 
unpublished pilot data). 
 
b Placing the Petri dish in a water bath at 37ºC for 2-3 hours also works.  In this case, heating speeds up dye 
diffusion and gives a slightly deeper penetration of the dye into the brain slice.  However, this method also produces 
more crystal clumping and a higher occurrence of artefact staining, which collectively make confocal imaging 
problematic.  Heating for longer than 2-3 hours was found to give too intense a stain making confocal imaging 
impossible. With a weaker DiD stock solution this method can be used to label cortical neurons, although there 
appears to be more staining artefacts generated with this method. 
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repeatedly wash across the surface of the tissue maximising the total number of 
collisions between different parts of the brain slice and the dye crystals. Although this 
method requires a longer time for dye diffusion along cell membranes, it produces a 
sparse labelling of granule cells whose apical dendrites intersect with or are very near 
the slice surface, with minimal artefacts and dye clumping (i.e. multiple crystals 
settling in fewer positions).   
Following incubation with the DiD stock solution, the tissue was transferred to a 
low intensity lighting lab and washed 3 times in PBS before being  post-fixed in 4% 
PFA for 10-15 minutes to preserve staining and improve tissue stability.  During this 
time the tissue was kept covered with tin foil to prevent dye bleaching.  The PFA was 
then removed and the tissue washed three times in PBS before being mounted onto 
glass microscope slides with the glycerol-based mounting medium Fluromount 
(containing DABCO as an anti-fade reagent; Sigma-Aldrich, USA).   Slides were then 
cover slipped and sealed with clear nail varnish.  All imaging took place within 2 days 
of cover slipping when background staining was minimal. 
 
4.4.2.3 Laser confocal microscopic imaging of cells and image analysis 
Hippocampal granule cells were imaged using Zeiss 510 Meta confocal laser scanning 
microscope (LSM 510 META). All images were taken using the Plan-C-APOCHROMAT 
63 × water immersion lens (1.2 corrected). We used 2048 × 2048 pixels for frame size 
without zooming. A 633 nm Helium/Neon laser (at 5%) was used to visualize 
fluorescence emitted by DiD. The configuration parameters were as follows: (1) filters, 
channel 3 band pass 560–615 nm, (2) pinhole diameter, 108 μm, (3) beam splitters, 
MBS-HFT UV/488/543, DBS1 mirror, DBS2 NFT, DBS3-plate.  Serial stack images of 
randomly stained dendrites were imaged from brain slices with a step size ranging 
from 0.2 to 0.5 μm.  Stack images were imaged if the dendritic segment could be traced 
back to a cell body, with samples obtained from both apical and basal dendrites (this 
ensured we sampled cells from within the granule cell layer).  
Following collection of confocal imaging, all z-stacks were de-convolved with the 
Autoquant X 2.1.1 software (Media Cybernetics Inc., USA) using the blind adaptive 
point spread function (PSF) algorithm to remove noise associated with spherical 
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aberrationc (see, [1497]). All stacks were analysed in black and white.  All de-convolved 
z-stacks were imported into Imaris x64 6.3.1 software (Bitplane AG, Switzerland), and 
the dendritic segments measured in 3D.  Only samples measuring between 70 and 120 
um from the proximal end of the dendrite were used in the analysis.  Each image stack 
was then imported into NeuronStudio x64 0.9.86 software (freely available from 
Mount Sinai School of Medicine, New York, USA), and the dendrite then projected and 
traced in 3D so that the default spine detection and classification module of 
NeuronStudio could be used to count the number of dendritic spines along the length 
of dendrite (see Figure 4.5).  In short this uses a Rayburst-based spine analysis routine, 
a processes which counts and classifies spines into either, Stubby, Thin, or Mushroom 
within concentric 50 μm circles at increasing distance from the soma (Sholl analysis). 
This classification scheme makes use of each spine's head to neck diameter ratio, 
length to head diameter ratio, and head diameter to determine its proper type. An 
operator then inspected each cell, and made minor corrections as needed using the 
NeuronStudio interface.  In order to measure the spine density of the sample the total 
number of spines were then divided by the total length of the dendrite sample 
(micrometers). The NeuronStudio software is a robust programme for and the accurate 
counting of dendritic spines, and unlike other semi-automated methods, has been peer 
reviewed for robustness [1498, 1499].  
 
4.4.2.4 Statistical analyses 
Curvature spine ratios of dendritic segments in the Tg2576 vs Wt groups in the Sholl 
analysis data were compared by 1-way univariate ANOVA with Spine Density as the 
dependent variable, and Genotype, and Treatment as factors. Sidak tests were used 
in tests of simple main effects following significant interactions. The null hypothesis 
for each test was rejected at a threshold of 0.05.  All data are presented as mean ± SEM.  
 
                                                   
c Although application of the blind algorithm on the  complete z-stack produces good results, splitting the stack into 
smaller segments of interest and then applying the deconvolution algorithm works better and reduces the effects of 
overshadowing of more intense stained sections on less intensely stained structures (Anderson J, unpublished pilot 
data).  This may also help ensure that the adaptive PSF is sensitive to changes in z-distance and ensure that spine 
density measurements are as accurate as possible, (e.g. by allowing more spines to be imaged in the z-axis than is 
usually possible).   
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Figure 4.5:  Experiment 7 (Confocal Imaging).  (A) Reconstruction of dendritic spine 
samples in NeuronStudio. Left: a deconvolved stretch of dendrite. Middle: Automated Scholl 
identification of dendritic spines and model tracing of the stretch of dendrite. Right: The model 
tracing and spines without the background image.  (B) Reconstruction of a second sample 
obtained from a WT mouse.  
 
4.4 .3 Results   
Figure 4.6 shows the mean spine density obtained from confocal data stacks of 
segments of mouse apical and basal dendrites bel0nging to hippocampal granule cells 
across treatment conditions.  Inspection of this figure indicates two important 
findings.  First, that TG mice have significantly lower dendritic spine density in the 
dentate gyrus granule cell population relative to the WT-C group, and that 
rosiglitazone does not change this.   Second, that the WT-R mice have significantly 
lower dendritic spine density in the dentate gyrus granule cell population relative to 
the WT-C group, reflecting an impairment that is similar to that observed in the TG 
population.  The above interpretation was confirmed ANOVA, which revealed 
A 
B 
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significant effect of Genotype F(1,130)= 38.034, p=<0.001, a significant effect of 
Treatment F(1,130)= 35.851, p=<0.001, and a significant Genotype by Treatment 
interaction F(1,130)= 45.665, p=<0.001.  A follow –up test of simple main effects for the 
significant Genotype by Treatment interaction revealed that neither of the TG groups 
differed from each other, F<1, with both TG groups exhibiting a significant loss of 
dendritic spines relative to WT-C mice, TG-C verses WT-C, F(1,130)= 84.791, p=<0.001; 
TG-R verses WT-C, F(1,130)= 81.220, p=<0.001.  Further comparisons showed that the 
DG spine density in WR-R group was significantly lower than in the WT-C group, 
F(1,130)= 81.220, p=<0.001, but was not significant when compared to either of the TG 
groups, TG-R verses WT-R, F<1; TG-C verses WT-R, F<1.  These results show that 
chronic rosiglitazone agonism for an approximate 12 month period failed to recover the 
loss of hippocampal DG dendritic spines in TG mice, but did cause a significant loss of 
spines in this brain region in WT-R mice in par with the loss seen in both TG groups.   
 
 
Figure 4.6:  Experiment 7 (Spine Density Results).  (Left) Graph showing mean dendritic 
spine density for each group. (Right) Examples of tissue samples from each group. 
  
4.4 .4 Discussion  
Although the method of staining hippocampal slices in this experiment was novel, and 
lacking in more extensive validation, the results obtained with respect to the reported 
loss of dendritic spines in the dentate gyrus of Tg2576 mice are in line with those 
reported by previous studies using this mouse model [1245, 1308, 1309].  Despite 
encouraging research showing that rosiglitazone may have a protective role on cortical 
dendritic spines [1154], as well as a protective effect on spines by boosting insulin 
signalling [1151], I find that long term rosiglitazone agonism did not significantly 
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recover the Aβ related loss of dendritic spines in the hippocampal dentate gyrus.  
Whilst it is possible that changes in spine density did take place in other regions of the 
hippocampus, and indeed the cortex (these regions were not investigated), I am 
inclined to believe that if these effects exist in vitro they are probably of limited value 
as recovery of the behavioural phenotype in my experiments was limited.  This at least 
is consistent with the larger double blind clinical studies in humans with mild to 
moderate AD which show that Rosiglitazone administration does not recover function 
across a range of cognitive domains [1238, 1247, 1480].   
The surprise finding of significant loss of dendritic spines in the rosiglitazone 
treated WT mice probably goes some way to explain in mechanistic terms why this 
group exhibited impairment with chronic exposure.  Nevertheless, the reasons for this 
are unclear. One possibility is that we induced a hyperisnsulinemic/Hypoglycemic 
state in these mice by providing them with access to diabetic medication when they 
essentially may have had normal blood glucose and insulin levels. In this context it is 
unfortunate that the planned measures of these biomarkers were cancelled due to 
financial restrictions imposed by the commercial partner.  Another possibility is that 
we may have boosted IGF-1 levels in these mice.  At least one previous study has shown 
that IGF-1 promotes Aβ production by a secretase-independent mechanism [1500]. If in 
this effect had occurred in the hippocampus of WT-R mice as a result of chronic 
rosiglitazone treatment, it could have resulted in an increase in murine Aβ levels that 
subsequently had an adverse impact on synaptic function in these mice.    It is 
interesting that both TG rosiglitazone treated groups exhibited an elevation in total Aβ 
levels in Experiment 6, although this was not significant.  The results of Experiment 7 
at least suggest that measurement of murine Aβ may be important when rosiglitazone 
(and indeed other PPARg agonists) are used in preclinical studies using hAPP mutants. 
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5. SUMMARY 
 
NIMAL  studies provide us with a unique opportunity to study the effects of 
therapeutic agents on limited disease mechanisms common to AD in the 
early stages.  This thesis dealt with the preclinical assessment of chronic 
rosiglitazone administration in WT and TG2576 mice.  Tg2576 mice contain the 
APPSWE transgene which results in the overproduction, accumulation and deposition 
of Aβ, neuroinflammation, the loss of dendritic spines in the hippocampal dentate 
gyrus, and learning and memory deficits.  As such, the lead hypothesis for this thesis 
was that in the LINS condition, rosiglitazone should reverse the established age-
related learning and memory deficits and pathophysiological changes (i.e. lower Aβ 
levels).  In the EINS condition, rosiglitazone should prevent the onset of these changes 
when drug administration was initiated from 5 MO prior to significant Aβ pathology 
taking place, as well as prevent the loss if dendritic spines in the dentate gyrus.  
Experiment 1 of this thesis shows that rosiglitazone failed to recover or prevent the 
onset of a robust spatial working memory deficit in TG mice, as revealed by the FCA T-
maze task.  However, in Experiment 2 (EPM), I did show that rosiglitazone was able to 
prevent at least some component of behavioural disinhibition in the TG mice, 
although it did not have the same effect on TG mice in the LINS condition.  Likewise, 
in Experiment 3, the drug did not reverse or prevent the behavioural deficit as revealed 
by the Marble Burying task.  Whilst both Experiments 2 and 3 were intended to assess 
anxiety and behavioural disinhibition, discussions of both experiments address 
concerns that these tasks may measure different things, which in the case of the 
Marble Burying task, still remain unclear.  Finally, in Experiment 4 I also found that 
rosiglitazone did reverse a behavioural impairment related to the detection of a novel 
object that appears in two mismatched spatial locations along with two different 
familiar objects.  It is not possible to say whether or not in the EINS condition the drug 
prevented the deficit because the nominal age at which the TG deficit occurs is 
A
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currently unknown.  Nevertheless, the same result in both conditions indicates that 
rosiglitazone had a robust beneficial effect on object recognition memory in the TG 
mice.  Thus, in summary, although rosiglitazone did not reverse of prevent the onset of 
the spatial memory impairment (the major deficit in these mice), the drug may have 
had a limited impact on reducing behavioural disinhibition and object recognition 
memory.  The limited impact of rosiglitazone in rescuing the behavioural phenotype of 
the TG mice in this thesis supports the contention that in order to be most effective, 
PPAR agonists may have to be delivered to patients early, before significant Aβ 
pathology occurs.  However, this would mean delivering the drug to at risk individual’s 
(i.e. individuals with aMCI) decades before overt dementia symptoms appear.  This is 
problematic for a number of reasons, not least of which because current bio-markers 
are not able to pinpoint with exact certainty those persons who are destined to develop 
dementia from those who will not. Also, the particular age used in the current thesis 
for early drug monotherapy, make a human comparison problematic, as it would likely 
require delivering the drug in childhood.   
In Experiment 5, the significant elevation in murine adiponectin levels show that 
the delivery method for the drug provided an effective means by which rosiglitazone 
could reach systemic penetration.  It is interesting to note that in T2D (which is 
associated with chronic low grade infection), adiponectin levels are typically decreased 
[1178, 1180], with higher levels being associated more with a reduced risk for T2D [1186].  
The status of adiponectin levels in AD is largely unknown, although one research 
group has recently reported that in women, increased plasma adiponectin levels serve 
as an independent risk factor for the development of both all-cause dementia and AD 
[1501].  In this context, an elevation in adiponectin levels could be a sign of that pro-
inflammatory processes have outstripped the natural capacity of the system to deal 
with the infection/damage (i.e. response is maximal, but insufficient to overcome the 
problem).  In addition, some chronic inflammatory conditions may involve a loss of 
anti-inflammatory efficacy.  Either way, the result may be that more anti-inflammatory 
proteins (including adiponectin) have to be produced in order for the system to try 
and keep neuroinflammation in check.  This suggests that in some people at least, a 
form of ‘adiponectin resistance’ could develop.  The results of Experiment 5 in this 
thesis are disappointing in that artificially raising adiponectin levels did not seem to 
translate into a robust rescue of the behavioural phenotype of TG mice.  Nevertheless, 
on first glance, it is not unreasonable to think that the elevations in adiponectin with  
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chronic exposure to rosiglitazone may have been one of the factors responsible for the 
limited restoration of the cognitive phenotype, particularly if it dampened down some 
of the central inflammation processes.  However, recent research has started to 
question whether or not endogenous adiponectin is able to influence CNS pathways, 
particularly since it may not pass the BBB [1489], so it is unclear whether raising 
peripheral levels of this protein would have an impact upon CNS function in Tg2576 or 
an adverse effect in WT mice. Nevertheless, CSF adiponectin has been detected after 
an i.v. injection of full-length adiponectin in C57Bl/6J mice, and that both systemic and 
i.c.v. administration of adiponectin reduced serum glucose and lipid levels and 
decreased body weight [1487]. Indeed, that study was instrumental for suggesting that 
adiponectin could be a centrally acting signalling molecule; a position further 
substantiated by subsequent research showing that peripherally administered 
adiponectin stimulated AMPK in the hypothalamus of mice, to increase food intake 
and decrease energy expenditure [1488]. However, whether endogenous adiponectin 
might have a similar effect in humans is not yet clear.  In addition, the identification of 
adiponectin receptors on brain endothelial cells (and the finding of a modified 
secretion pattern of centrally active substances from BBB cells) does provide one 
mechanism by which adiponectin could conceivably evoke effects on energy 
metabolism [1489].  In summary, the effects of elevating adiponectin levels in hAPP 
models may have limited value, (beneficial in TG, and possibly detrimental in WT), 
require further investigation.   
It is also clear that in this thesis, rosiglitazone not only failed to lower total Aβ 
levels (see Experiment 6), but also failed to prevent the Aβ-related loss of dendritic 
spines in the hippocampal dentate gyrus (see Experiment 7).  This is in spite of 
rosiglitazone having been systemically present from the age of 5 MO. Although a 
number of concessions have been discussed in relation to these findings, they do 
perhaps provide a mechanistic reason for why more robust rescue of the behavioural 
phenotype was not observed.  As such, all of the above findings fit with those reported 
by the most recent large phase 3 clinical trials [1237, 1238], indicating that the drug 
does not significantly impact on dementia symptoms (although object recognition has 
not been robustly assessed). Thus, as far as big Pharma is concerned, rosiglitazone has 
been ‘marked for death’, despite incidental reports of beneficial effects of the drug in 
pre-clinical studies using hAPP models.   
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It is also evident from the experimental studies reported in this thesis that 
administering a drug such as rosiglitazone may have unintended side-effects.  Thus, it 
is clear from the results of the experiments detailed herein, that the chronic exposure 
to rosiglitazone produces a significant behavioural impairment in the WT-R mice.  At a 
pathophysiological level this fact could be reflected in the significant and somewhat 
shocking loss of dendritic spines from the hippocampal dentate gyrus. If this effect 
occurred across multiple brain regions, it would perhaps explain why the effect on 
cognition seemed to be have present to varying degree across all the behavioural 
domains assessed.  Indeed, it is a shame that the study of additional biomarkers were 
cancelled by the industrial partner, as this could have greatly extended the ability of 
this thesis to pin down what had gone wrong in these mice (i.e. was it due to an 
elevation in IGF-1.  Indeed, it would also have been interesting to see if this raised 
levels of murine Aβ.  The only other study to have investigated the pre-clinical impact 
of the drug in WT littermates to Tg2576 mice has reported no adverse side effects, 
although administration of the drug was stopped after 4 weeks [1129, 1244].  One 
wonders if there was unreported data which showed similar results to my own for 
longer administration periods.   I do not know if these detrimental effects would 
transfer to humans (a possibility in some people with aMCI for example), but, if they 
did, it would likely make learning and memory worse in the long-term.  However, no 
adverse effects of the drug have been reported in other non TG rodent models [1165, 
1204-1207, 1209-1211, 1239, 1365-1367, 1403], although these have not included chronic 
exposure in WT mice.  Nevertheless, the findings from this thesis are likely to further 
add to the currently negative profile of this and similar drugs [1481].  In aggregate, the 
results detailed in this thesis do not support the use of rosiglitazone as a viable 
candidate for human trials as full rescue of the Tg2576 phenotype was not achieved.  
Nevertheless, the drug may have limited value as a research tool in pre-clinical studies. 
  Fin al  Though ts  
There are serious challenges ahead for neurodegeneration research and in particular, 
behavioural neuroscience in relation to animal models of specific pathological 
components common to AD.  It is unfortunate that no commercially available model 
exists for SAD.  This is important because within science, one is usually taught that 
arguing from the minority to the majority is bad practice.  And yet, that is in a way, 
what we have to with hAPP models.  Furthermore, whilst most (typical) AD involves 
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progressive amnesia followed by various combinations of focal cortical deficits (e.g. 
aphasia, apraxia, agnosia), and impaired executive function [72], it is of interest that 
the FAD mutations from which most animal models derive (including Tg2576) are 
almost exclusively associated with EOAD where atypical clinical phenotypes are much 
more common.  Indeed, in atypical AD focal deficits other than memory impairment 
can dominate in the early-stages of the disorder, although some types are primarily 
amnesic in nature [72, 73].  In this respect, the clinical phenotype observed in AD 
patients seems to largely reflect the degree to which gross neuropathologies are either 
cortical predominant, or hippocampal predominant [72], although these distinctions 
are seldom considered in relation to TG models deriving from FAD kindreds.  
Incomplete reporting of methodological procedures with respect to the numbers of 
male vs. female mice used in experimental procedures is also a serious concern.  This is 
bad practice and makes interpretation across studies difficult if not impossible in some 
instances.  I also consider that similar stringent conditions should apply to the 
reporting of all pre-clinical studies conducted with hAPP mice, as is the case now with 
most human clinical data.  This would help to reduce the bias towards just reporting 
positive results in the sciences, whilst ‘bottom drawing’ negative or null findings. 
Indeed, this is possibly one contributory reason for why big pharmaceutical led 
projects into neurodegeneration are on the decrease: it has become harder to push 
through to market marginally effective drugs.   
Finally, it is evident that AD is an incredibly complex disorder, to treat.  So far it 
appears resistant to the process of reductionist science.  One feels that the current 
strategy of most pharmaceutical led endeavours to treat the disorder are possibly 
misguided in their over simplicity.  The race to find the next ‘block buster drug’ may be 
an attractive financial incentive, but it can impede progress in targeting certain 
therapies to smaller groups of patients with particular genetic profiles.  Indeed, whilst 
is likely that the treatment of AD will require poly pharmacy, given the high financial 
stakes involved when drugs fail clinical trials, this is not something that most 
commercial companies have the stomach for.   There is also much about the brain we 
have yet to understand.  Currently, trying to cure AD is somewhat like attempting to 
fix a car without knowing how much of the car works. Nevertheless, I have greatly 
enjoyed conducting the research associated with this thesis, and am hopeful that if we 
continue to integrate basic and medical research, real advances in the treatment of 
dementia will eventually be forthcoming. 
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APPENDIX  1 
 
 
Representative photograph of gel electrophoresis showing PCR amplification of DNA 
from Tg2576 and WT mice. Lane 1 = 100bp DNA ladder; Lanes 2, 5, 7, 8, 10, 12 and 14 = 
double band corresponding to amplification of endogenous murine prion protein and APPswe 
transgene, therefore representing TG mice; Lanes 3, 4, 6, 9, 11 and 13 = single band 
corresponding to amplification of endogenous murine prion protein, therefore representing 
WT mice; Lane 15 = Blank (water) control, Lane 16 = Positive control (known TG sample), 
Lane 17 = Negative control (known WT sample). 
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